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MD abstract
The relationship between non transferrin bound iron and iron 
overload in thalassaemia and sickle syndromes
Iron overload is a major cause of morbidity and subsequent mortality in patients 
with thalassaemia major, its effects in thalassaemia intermedia and sickle cell anaemia 
are however less well known. The presence of non transferrin bound iron is well 
described in adult thalassaemia patients but it is unclear as to when NTBI appears and 
what relationship it has to ineffective erythropoiesis and end organ damage.
Data is presented on children with thalassaemia from a five-year prospective 
study showing that NTBI is present early in thalassaemia syndromes and this is probably 
due to ineffective erythropoiesis. In addition results from this study show that there is no 
relationship between markers of oxidative damage and NTBI in early childhood.
Following this a comparison of adult patients with sickle cell anaemia and 
thalassaemia is undertaken looking at NTBI and cardiac iron burdens assessed by MRI. 
The thalassaemia patients at high liver iron burdens have a significant risk of cardiac 
iron loading and when patients with sickle cell anaemia and thalassaemia major are 
matched for liver iron it is seen that cardiac iron loading is not seen in sickle patients and 
this may be because NTBI is lower in this group.
In the last chapter data is presented showing that serum pro-hepcidin is down 
regulated by NTBI, anaemia and erythropoietin in thalassaemia but not sickle 
syndromes. There is no clear relationship between pro-hepcidin and liver iron but 
hepcidin mRNA is down regulated by iron burden supporting the important role of this 
protein in iron regulation.
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Chapter One
The relationship between non transferrin bound iron and iron 
overload in thalassaemia and sickle syndromes
1.1 Introduction: the goals of this thesis
The purpose of the work presented in this thesis is to examine the relationship 
between plasma non-transferrin bound iron (NTBI), iron overload and iron distribution to 
organs in patients with thalassaemia and sickle cell syndromes.
In thalassaemia syndromes, iron overload may result from increased 
gastrointestinal iron absorption or from repeated blood transfusions. Patients with 
thalassaemia intermedia (Tl) may slowly develop iron overload secondary to increased 
gastrointestinal iron absorption, even without receiving blood transfusions. In 
thalassaemia major (TM), iron accumulation occurs more rapidly as a result of repeated 
transfusions from an early age. If inadequately chelated, these patients will develop 
endocrinopathies and cardiac failure from iron deposition in these organs. With the early 
introduction of chelation therapy, these consequences are now less commonly seen in 
TM than previously (Borgna-Pignatti, et al 2004), although patients may still suffer 
serious complications from iron overload such as endocrinopathies and cardiac 
decompensation if inadequately treated (Borgna-Pignatti, et al 1998, Borgna-Pignatti, et
Page 20 of 278
al 2004, Zurlo, et al 1989). The extent to which critical threshold levels of total body iron 
(Olivieri and Brittenham 1997) or the duration of exposure to high iron burdens (Gabutti 
and Piga 1996) or the distribution of iron to different organs contribute to the net effects 
of transfusional iron overload remain unclear. Up until very recently, evidence of iron 
overload was based on tests such as serum ferritin, liver iron content by biopsy, or on 
the effect of iron overload on organ function such as endocrine function, glucose 
tolerance tests and left ventricular function. However with the recent use of Magnetic 
Resonance Imaging (MRI) it has been possible to examine iron distribution and the 
relationship between myocardial and hepatic iron loading. The factors that determine 
iron loading into the heart and endocrine organs in TM remain unclear. A key candidate 
that may be critical in determining the distribution of iron to various organs is plasma 
NTBI. However there have been no studies that examine the relationship between the 
progression of iron overload and NTBI levels in thalassaemia or sickle cell disorders. In 
this thesis, a longitudinal assessment is undertaken in thalassaemia major to see if a 
critical iron burden exists at which plasma NTBI appears.
In sickle cell anaemia (SCA), the relationship between iron overload and 
distribution to organs such as the heart is even less well defined than in TM. In SCA 
ineffective erythropoiesis does not play a major role and, in the absence of blood 
transfusion, iron overload is not seen. However, the management of SCA in recent years 
has increasingly included the use of blood transfusions to prevent and treat 
complications such as stroke, chest syndrome and venous ulcers. This in turn has 
resulted in patients developing significant iron overload, necessitating treatment of some 
patients with iron chelating agents. End organ damage from iron overload is less well 
described in SCA than in TM, even in the context of a high transfusional iron load and 
high hepatic iron loading. It has been suggested that iron may be dealt with differently in 
SCA with more sequestering of iron in the reticuloendothelial system (Walter, et al
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2006). In order to examine this possibility in the thesis, multi-transfused SCA patients 
are matched to thalassaemia patients for liver iron concentration, and relative levels of 
cardiac iron deposition as well as relative NTBI levels compared between these patient 
groups.
The recent discovery of molecules involved in iron regulation such hepcidin have 
provided insight into how both gastrointestinal iron absorption and iron release from 
macrophages is regulated. Theoretically levels of hepcidin could impact on NTBI levels 
and hence on secondary iron distribution by NTBI to various organs in transfusional iron 
overload. The relationship between hepcidin, iron overload and NTBI in patients with 
thalassaemia and SCA has not been compared previously.
Specific questions to be addressed in this thesis are:
1) The age at which NTBI appears in children with thalassaemia syndromes, and 
whether it is present early or develops later in relation to iron overload (chapter 3)
2) The relationship between NTBI and markers of ineffective erythropoiesis and their 
relationship with markers of oxidative damage (chapter 3):
3) A comparison of the relationship between NTBI and iron loading in the liver and 
myocardium in thalassaemia syndromes and sickle cell anaemia (chapter 4)
4) The relationship between hepcidin, iron overload and NTBI in patients with 
thalassaemia and SCA (chapter 5).
Before addressing these specific questions, a brief description of thalassaemia 
and sickle syndromes is given with particular reference to the contrasting ways in which 
iron overload may develop in thalassaemia major, thalassaemia intermedia and sickle 
cell disease.
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1.2 Beta Thalassaemia Syndromes
The thalassaemia syndromes comprise a heterogeneous family of disorders that 
arise from defects in the rate of synthesis of alpha or beta chains that form the globin 
component of haemoglobin.
1.2.1 Pathophysiology
Beta thalassaemia occurs due to reduced or absent synthesis of p chains. This 
results in an excess production of a chains, which cannot form tetramers and therefore 
precipitate in the developing erythroid cell forming large intracellular inclusion bodies. 
These excess chains are very unstable and become associated with the red cell 
membrane and ultimately result in the destruction of the developing erythroid precursors 
in the intra-medullary space by a number of mechanisms including oxidative damage to 
cell membranes and interference with cell division (Rund and Rachmilewitz 1995, Shinar 
and Rachmilewitz 1990).
This premature destruction of erythroid precursors results in the development of 
anaemia due to ineffective erythropoiesis. Those cells that do mature and enter the 
circulation are prematurely destroyed due to the presence of inclusion bodies in the 
splenic microcirculation. Hence the anaemia in thalassaemia syndromes is due to both 
ineffective erythropoiesis and a shortened red cell survival.
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26Variant p haemoglobins such as HbE (p GAG-AAG, glutamic acid -lysine),
when co-inherited with the P thalassaemia mutations can result in thalassaemia 
syndromes of varying severity (Rees, et al 1998).
1.2.2 Classification
Thalassaemia syndromes can be subdivided according to their genetic causation 
or according to their phenotypic presentation. Normal globin production results from 
balanced synthesis of alpha globin from duplicated genes on chromosome 16 and singe 
p genes on chromosome 11. The description below will focus mainly on p globin 
thalassaemia resulting from reduced or absent p globin synthesis, as it is p thalassaemia 
that is studied in subsequent chapters.
Classification according to phenotype
The most commonly used and simplest classification is according to the clinical 
severity of the anaemia. This results in 3 main subdivisions.
• Carriers (single p mutation) of the defect with asymptomatic anaemia 
(Thalassaemia trait)
• Severe transfusion dependant anaemia (Thalassaemia Major; TM): usually 
homozgote or compound heterozygote for p mutations
• Intermediate severity of anaemia that may or may not require transfusion 
support. (Thalassaemia Intermedia, Tl) : genetically heterogeneous (see below)
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Classification of p thalassaemias according to genotype
p thalassaemia mutation can be classified according to amount of globin chain 
that is produced. With some mutations no globin is synthesised and is termed p° 
thalassaemia. In others the globin chain is synthesised but in reduced amounts and is 
known as p+ thalassaemia. The majority of the p thalassaemias tend to be due to point 
mutations rather than deletions. However, because 6 and the duplicated y genes are 
upstream of the p gene, large deletional mutation of the p gene may also involve 
deletions of these genes (e.g. §p thalassaemias). The §p Thalassaemia, ey5p 
Thalassaemia, SThalassaemia, and Hereditary Persistence of Fetal Haemoglobin 
(HPFH) will not be discussed in this thesis as individual disorders but will be discussed 
in so far as their role as modifiers of the thalassaemia phenotype, p like thalassaemia 
syndromes may also result from a compound heterozygous state of a p mutation with a 
p haemoglobin variant that is present in reduced quantities such as Ep thalassaemia 
syndromes.
1.2.3 Genetic basis of p thalassaemias
Over a 1000 mutations affecting the globin genes have been identified to date 
(Clark and Thein 2004) with about 200 of these resulting in p thalassaemia syndromes 
(Flint et at 1998) of varying clinical severity. A variety of mutations can occur in the 
globin genes varying from simple point mutations to large deletions, insertions or 
alterations that result from more than one mutation. The site at which a mutation occurs 
will also affect whether there is an abnormal globin chain, reduced amounts of a normal 
globin chain or no globin chain synthesis. Mutations at one of the promoter sites
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invariably result in reduced production of globin whereas mutations occurring at initiation 
sites will lead to no globin chain production. Splice junction mutations (donor or acceptor 
sites) will result in absent globin production due to abolition of normal splicing. Whereas 
mutations in the consensus splice sites causes reduced normal splicing but will result in 
some globin chain synthesis. Mutations at poly A sites lead by and large to reduced 
production of globin chains. Mutations can occur outside the globin genes leaving the 
genes themselves intact and result in reduced globin synthesis such as deletions of the 
LCR of the globin genes resulting in ey5p° thalassaemia, or deletion of the a globin 
enhancer site, which is at the 3’ end of the a gene.
1.2.3.1 Genetic modifiers of the phenotype
The thalassaemia syndromes are clinically diverse disorders: genetic modifiers 
are known to exist that account for some of the variability seen within any given 
genotype. There are however very complex interactions between environmental and 
other genetic factors that may affect the phenotype of the thalassaemia and much work 
still needs to be done to identify these factors. Certain factors are well known to affect 
the phenotype of the disorder. The primary modifier of the genotype is the site of the 
globin chain defect itself. The secondary modifiers are due to variation in the production 
of HbF, the alpha globin defect and the coinheritance of a p globin chain variant. As 
survival in patients has improved more subtle modifiers of the phenotype have been 
identified and are described as tertiary modifiers (Thein 2004) . Infection with malarial 
parasites in worsening the severity of anaemia particularly in the younger patients can 
be considered a tertiary modifier of the phenotype (Premawardhena, et al 2005). Co­
inheritance of the mutation associated with Gilberts syndrome leads to a higher 
propensity to develop gallstones (Bosma, et al 1995) and can be considered a tertiary
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modifier. The coinheritance of HFE defects in particular the C282Y in thalassaemia 
intermedia is a tertiary modifier of iron loading (Rees, et al 1997).
Osteoporosis is extremely common in thalassaemia syndromes and may be due 
to a combination of factors but workers have recognised associations with the vitamin D 
receptor (VDR)(Dresner Pollack, et al 2000), and Collagen type 1a (COLIA1) gene 
(Perrotta, et al 2000). In this thesis (chapter 5) the role of hepcidin, which is a negative 
regulator of iron absorption, is explored and its role in modifying iron distribution and 
hence iron mediated damage in thalassaemia and sickle syndromes.
1.2.4 Incidence and Frequency of Thalassaemia
The frequency of the alpha and beta globin defects have not been analysed in all 
countries worldwide, primarily due to lack of resources and greater clinical priorities. 
However a number of workers have undertaken these studies in individual countries. 
World wide figures from the WHO suggest that there are 270 million carriers for globin 
gene defects and that 300,000 to 400,000 children are born annually with a severe 
haemoglobin disorder (Weatherall and Clegg 2001). As the socioeconomic 
circumstances improve world wide a greater number of children will survive into 
adulthood and the economic burden of treatment of the haemoglobinopathies will 
increase manifold.
Micro-mapping by individual groups have shown how the frequency of 
thalassaemia or variant haemoglobins such as HbE can vary significantly throughout a 
region often just a few miles apart (Ahmed, et al 2002, Araujo, et al 2003, Old, et al 
2001, Thong, et al 2005). This may be due to social factors as in many south East Asian 
communities, marriages occur within tribal/family group confines and this has resulted in 
a higher gene frequency in specific groups e.g. in Pakistan the frequency of
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thalassaemia trait is 5.4% for the general population (Khattak and Saleem 1992) but on 
family testing based on index cases the incidence was 31% and there was a 25% risk 
that the carrier would be in a marriage at risk of producing an affected child (Ahmed, et 
al 2002); in Oman the carrier rate for the indigenous Arab population is 1-2% (Daar, et al 
1998) but in the Belushi tribe which migrated from the province of Baluchistan (Pakistan) 
the incidence is 10% (Angastiniotis and Modell 1998)
Figure 1.2.4.a World distribution of Thalassaemia Syndromes and HbS
Legend: world distribution if Haemoglobinopathies from Christianson, A. et al. BMJ 
2004;329:1115-1117. credited to the WHO GENOMIC RESOURCE CENTRE
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Figure1.2.4.b Overall distribution of haemoglobin disorders (%carriers) by WHO 
region
Legend: WEATHERALL, DAVID J. Keynote Address: The Challenge of Thalassemia for the 
Developing Countries. Annals of the New York Academy of Sciences 1054 (1 Cooley's Anemia: 
Eighth Symposium), 11-17. doi: 10.1196/annals. 1345.002
Due to migration the prevalence of the TM and Tl has altered in a number of 
countries. In the UK there are approximately 800 patients with TM (Modell, et al 2000). 
The greatest increase in births of thalassaemic children is in the Asian communities and 
predominantly Pakistani families (Modell, et al 2000). The UK distribution of these 
disorders reflects this where large pockets of ethnic minorities settled the thalassaemia 
frequency is greatest (Hickman, et al 1999).
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Figure 1.2.2.4.C Geographical distribution of thalassaemia major and intermedia
in England
Legend: reproduced from (Hickman, et al 1999) Map of England showing the majority of TM and 
Tl births are in London, the Midlands and the north of England. These are the traditional areas 
where migrant families settled.
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1.2.5 A Historical Perspective
The initial description of thalassaemia by Thomas Cooley in 1925 (Cooley and 
Lee 1925) was of 5 children who presented with anaemia, hepatosplenomegaly, 
discolouration of the skin and classical facies. They all had a leukocytosis which was not 
of the leukaemic type but predominantly normoblasts and in 2 patients many reticulated 
cells. There was normal or increased resistance to of red blood cells from these to 
haemolysis by hypotonic solutions. In addition all these children had a classical 
mongoloid facies.
Further publications both in Europe and in the USA defined the complications of 
anaemia in TM. These children usually presented within the first year of life and rarely 
survived beyond the first few years of life. Profound anaemia, failure to thrive, recurrent 
infections, and progressive abdominal distension due to hepatosplenomegaly were 
uniformly described. Those with the severest anaemia would die within the first few 
months of life from cardiac failure and /or infection and those with less severe anaemia 
would start to develop other manifestations of the anaemia such as poor growth and 
venous ulceration. Thrombocytopenia and neutropenia secondary to hypersplenism 
along with associated infective and bleeding complications was also seen.
X ray images of the bones would show cortical thinning, and a ‘moth eaten’ or lace 
like’ appearance, of the intramedullary space in the small bones. The skull X rays were 
the most dramatic with the classical ‘hair on end’ appearance due to expansion of the 
diploic space. Pathological fractures were frequent occurrences. Extramedullary 
haematopoiesis could be seen on chest X rays and some children would go onto 
develop spinal cord paraparesis due to cord compression. As children developed 
beyond the age of 7 years there was evidence of delayed growth and sexual 
development that was thought to be secondary to severe anaemia and possibly the 
siderosis from increased gastrointestinal iron absorption (Weatherall and Clegg 1972).
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The prognosis of children with TM was poor with one of the best descriptions in Man’s 
Haemoglobins by Lehmann and Huntsman (Lehmann and Huntsman 1966) where in 
chapter 15 the attitude to the treatment was described as:
“Somewhat similar to the attitude of the physician treating children with leukaemia".
It was stated that: “it was possible to nurse these children through to the age of 10 or 11" 
and “the condition is so hopeless that attention must be given to the parents and family “.
However, advances were being made in the care of thalassaemic children 
primarily aimed at improving quality of life and included splenectomy and transfusion 
both of which had significant impact on the outcome.
1.2.5.1 History of blood transfusion use
Blood transfusion as a therapeutic measure has only been a practical option 
since the late 1920s as the ability to use blood group typing became more widespread. 
Blood transfusion was used as early as 1665 when transfusions were carried out 
between dogs to confirm that transfusion was safe. Mollison (Mollison 1979) described 
the first blood transfusion to a human that was published by Denis in 1667.
“ When a man who had fallen into a phrensy occasioned by a disgrace he 
received' was transfused calfs blood.
“It was hoped that by its mildness and freshness it would allay the heat and ebullition of
his Bloud’
Over the next few years more animal to human transfusions occurred and the 
outcome was so poor that they were banned by the Paris society of Physicians in 1678. 
James Blundell first performed successful human-to-human transfusions in 1818 and 
during the ensuing years he performed 10 transfusions 5 of which were successful. 
(http://www.bloodbook.com/index.html).
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No real advances occurred in transfusion medicine until 1901 when Karl 
Landsteiner first described agglutination reactions on mixing different blood samples and 
concluded only 2 antigens were needed to explain the 4 groups of people. It was not 
until 1908 that the benefits of cross matching for safe transfusion practice were observed 
and the first matched blood transfusion performed (Race and Sanger 1975) . Over the 
next 10 years anticoagulants were developed which allowed longer storage of blood and 
the British established the first ‘blood depot’ during World War I. The British Red Cross 
instituted the first blood transfusion service in the world in 1926 around the same time as 
the first description of Cooley’s anaemia.
1.2.5.2 Impact of blood transfusion in thalassaemia management
As early as 1925 in Cooley’s original paper one of the children was given 
transfusion:
“The only results in treatment have been with a mixture of spleen and red bone 
marrow combined with administration of hydrochloric acid. One transfusion caused only 
slight transient blood change, and urine examination showed the transfused blood 
underwent rapid haemolysis. A more recent transfusion was followed by a better blood 
picture and less haemolysis”
The use of blood was dangerous and difficult and it was only by the late 1930’s 
that blood transfusions were being used to treat the anaemia in some patients, albeit at 
infrequent intervals, resulting in children surviving longer but still having the majority of 
the manifestations of severe anaemia. Wintrobe’s view on transfusion therapy in 1946 
(Wintrobe 1946) was rather pessimistic stating that
“transfusion is of temporary value".
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It was not until 1964 when Wolman published his data (Wolman 1964) on 
maintaining children with a high mean haemoglobin that the evidence for improved 
survival became clear. The children in Wolman’s study had fewer complications from 
anaemia, better growth and quality of life in the first decade. Over the next few years an 
increasing body of evidence was accumulated supporting a high transfusion regime 
which allowed remarkably good growth, development and health throughout childhood 
(Beard, et al 1969, Piomelli, et al 1969). It was noted that children on high transfusion 
regime had less splenic and hepatic enlargement and the cardiomegaly was less 
marked (Piomelli, et al 1974). Based on the evidence from these and other studies it was 
concluded that high transfusion regimes were desirable in order to maintain good quality 
of life. Weatherall and Clegg (Weatherall and Clegg 1972) in Chapter 9 (Management of 
Thalassaemia) recommended that a pre-transfusion Hb of 10g/dl be maintained at all 
times to ensure a good quality of life with a judiciously timed and well followed up 
splenectomy if necessary, accepting that:
‘At the moment there seems little doubt that iron overload will kill children on any
type of transfusion regime’
Deaths were now no longer occurring in the first decade from severe anaemia 
but increasingly seen in the 2nd decade of life from complications secondary to iron 
overload in the myocardium, in particular sudden cardiac death due to dysrhythmia and 
cardiac failure (Engle 1964). The increasing appearance of endocrinopathies and 
diabetes form iron deposition in other vital tissues (Weatherall and Clegg 1972, Wolman 
and Ortolani 1969) was also becoming more recognised.
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1.2.6 Transfusional iron overload in thalassaemia major
1.2.6.1 Rate of iron loading from blood transfusion
Iron in the average non iron overloaded healthy adult is present to the order of 
around 40-50mg/kg body weight. Most of this is present in the form of haemoglobin 
(30mg/kg) with the remainder divided between myoglobin (4mg/kg), iron containing 
enzymes (2mg/kg), and storage iron in the form of ferritin and haemosiderin. Storage 
iron tends to be between 0 -2000mg and is primarily found in the liver, spleen and bone 
marrow. Dietary iron absorption is approximately 1-2mg per day and this is matched by 
the iron lost through exfoliation of gut mucosal cells, skin cells and those from the urinary 
tract. In women additional iron is lost through endometrial shedding. There is no 
excretory mechanism for iron, and there is only a limited mechanism for modulating iron 
absorption (Conrad, et al 1999).
Iron may accumulate as a result of increased iron absorption thorough the 
gastrointestinal tract or may be iatrogenic via blood transfusions. In the thalassaemia 
syndromes iron overload occurs due to blood transfusions and to some degree 
secondary to increased Gl iron absorption in TM and predominantly via Gl iron 
absorption in the Tl. A unit of red cells, processed from 420 mL of donor blood, contains 
approximately 200 mg of iron (0.47 mg iron/mL of whole donor blood or 1.16 mg iron/mL 
of pure red cells). In splenectomised TM patients, in order to maintain an average Hb of 
12g/dl, they will receive an average of 300 mL of whole blood per kg per annum (range 
200-400 mL whole blood/kg) (Modell 1976). This will equate to approximately 28 mg of
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iron in an adult weighing 70 kg. In non-splenectomised TM patients the transfusion 
requirements are generally higher and this may lead to a greater degree of iron loading, 
however the use of blood transfusion regimens designed to maintain a high mean Hb 
regimen may reduce the extent to which the spleen contributes to an increased blood 
transfusion requirement (Modell 1976). The increased Gl iron absorption results in for a 
further 1-4 mg daily (Pippard and Weatherall 1984), therefore iron will accumulate at a 
rate of 0.4-0.5 mg/kg/day or 28-35 mg/day in a splenectomized adult patient with TM.
1.2.6.2 Clinical effects of transfusional iron overload
The first evidence of severe iron overload was often the failure of the child to go 
into puberty or to complete pubertal development (Modell 1976). The reason for this 
delayed pubertal growth spurt was unclear and growth hormone deficiency was 
excluded as a cause (McIntosh 1976, Zaino, et al 1969). It was not until Landau who 
found reduced gonadotrophins (Landau, et al 1978) and a reduced response to LHRH 
that this axis was considered as a cause for the delayed puberty. Around the same time 
the incidence of other endocrinopathies such as hypothyroidism and hypoparathyroidism 
were documented (Flynn, et al 1976, Lassman, et al 1974). Diabetes was a well 
recognised complication and tended to occur in children with severe iron overload over 
the age of 10 years (Toccafondi, et al 1970). Cardiac iron loading occurred mostly in 
adolescence in the pre-chelation era. The most serious and frequently fatal 
consequence of transfusional siderosis was cardiac failure or dysrythmmia due to iron 
deposition in the myocardium. Those patients who did not die of cardiac failure would by 
late adolescence have developed hepatic cirrhosis. As a result of the advances made in 
transfusion support most patients were surviving into adolescence and then dying of 
complications secondary to iron overload.
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1.2.6.3 Mechanisms of toxicity of iron overload
Iron that is not bound to transferrin or stored within ferritin, causes oxidative 
damage by free radical generation by the Haber- Weiss reaction (Halliwell and
Gutteridge 1990, Olivieri and Brittenham 1997). Hydroxyl radicals (OH*) that are 
released as a consequence of this reaction can then cause lipid peroxidation, oxidation 
of cellular proteins, lipoproteins, nucleic acids, and other cellular constituents (Aust, et al 
1985, Halliwell and Gutteridge 1990). Any cell death that occurs will result in fibrosis and 
loss of organ function and hence the complications of iron overload develop (Aust, et al 
1985, Britton, et al 2002, Fleming and Bacon 2005, Houglum, et al 1990, Junge, et al 
2001). Oxidative damage is thought to be the key reason for the fibrosis and cell death in 
affected organs such as the liver in thalassaemic patients.
It is however, highly likely that a critical iron burden is necessary before damage 
occurs (Olivieri and Brittenham 1997) and quite probable that duration of exposure to 
high iron burdens is also important (Gabutti and Piga 1996). This is probably the reason 
why children developed diabetes around the age of 10 years in the pre chelation era and 
cardiac failure during adolescence. Modern management has resulted in a dramatic 
decline in iron overload associated complications. The primary reason for this decline 
has been the use of chelation regimes to remove the excess iron.
1.2.7 Significance of Non transferrin bound iron in iron overload
Iron exists in human sera as transferrin bound iron, however once transferrin 
becomes fully saturated then free iron is found in the form of non-transferrin bound iron
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(NTBI). NTBI was first identified by Hershko in thalassaemic patients in whose sera 
chelatable iron was measured in the presence of a fully saturated transferrin and when 
thalassaemic sera was added to normal sera the chelatable iron could no longer be 
detected (Hershko, et al 1978). NTBI was then found to occur in other iron loading 
conditions such as haemochromatosis and was linked to oxidative damage (Gutteridge, 
et al 1985).
To date the exact nature of NTBI is undefined and it is thought to be composed 
of a mixture of oligomeric and monomeric complexes of iron with ligands such as citrate, 
phosphate and albumin (Hider 2002). It is probable that the nature of the NTBI varies 
according to the type and degree of iron overload (Breuer, et al 2000). In addition it is 
known that in some iron overload states, patients may have NTBI in the presence of 
unsaturated transferrin (Gosriwatana, et al 1999). It is thought that this type of NTBI is 
inaccessible to transferrin and some NTBI species can cause oxidative damage by free 
radical generation by the Haber- Weiss reaction (Halliwell and Gutteridge 1990, Olivieri 
and Brittenham 1997). In this thesis the relationship between NTBI and markers of 
oxidative damage (malondialdehyde and protein carbonyls) in children who have TM or 
Tl will be presented in Chapter 3.
1.2.8 Iron chelation therapy
By the late 1960’s there was a desperate need for an effective, safe and 
acceptable method for iron removal / chelation. Weatherall and Clegg (Weatherall and 
Clegg 1972) gave a comprehensive review on the status of chelating agents in 1972 
which was relatively pessimistic about the potential benefits:
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1 It takes at least 5 to 10 years to assess any regime designed to reduce mortality 
from iron overload and few physicians have been keen to examine critically a prolonged 
regime which is expensive, painful and probably of marginal benefit”
Work on chelation therapy had been ongoing since the early 1960’s, and the 
development of safe and effective chelation therapy was to prove just as important as 
appropriate blood transfusion support in modifying the natural history of thalassaemia.
1.2.8.1 Desferrioxamine
Desferrioxamine (DFO) was first introduced in the early 1960’s as a chelating 
agent to treat acute iron poisoning (Moeschlin and Schnider 1964, Pittman 1964). It 
belongs to the hydroxamic acid class of chelators and is a hexadentate chelator, able to 
bind 1 ferric iron per molecule. It binds ferric iron with very high affinity producing 
ferrioxamine, which is excreted both in the urine (30-50%) and faeces (Bianco, et al 
1984, Hershko and Rachmilewitz 1978, Pippard 1989, Pippard, et al 1982, Walsh, et al 
1964) It has a relatively short half-life of 5 to 10 minutes in the plasma (Summers, et al 
1988) and it was noted by Sephton-Smith that maximal excretion of iron occurred when 
it was administered as a slow IV infusion (Smith 1962). However there was concern 
about loss of efficacy over time and the potential for achieving a net negative iron 
balance (Modell 1979). A review on chelation therapy in 1969 (Waxman and Brown 
1969) was very downbeat about the benefit of chelator therapy.
It was only when Barry (Barry, et al 1974) published data from a controlled trial 
on iron chelation that the benefits of iron chelation became clear. The study compared 
patients on 6 days a week treatment with 500mg IM DFO and 2G IV with transfusion, to 
a control arm who received no DFO. A significantly reduced iron burden as measured by
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liver iron and ferritin and the lesser degree of hepatic fibrosis was shown in those 
patients who received iron chelation. Follow-up data from this study in 1981 showed that 
of the 9 patients in the treatment arm only 1 had died whereas 6/10 in the control arm 
had died. This is the only placebo-controlled trial on a chelating agent that has been 
published and these results changed significantly the treatment of patients with 
thalassaemia. The short half-life and greater excretion of iron seen with infusions 
prompted a number of workers to assess the efficacy of SC DFO as a treatment option. 
A number of studies were published in 1978 and 1979, which showed considerable 
reductions in ferritin, and liver iron and improvement in liver function tests (Hoffbrand, et 
al 1979, Weiner, et al 1978). Pippard (Pippard, et al 1978b) showed the potential for 
chelation therapy in thalassaemia to alter significantly the prognosis and life expectancy 
when he showed that children treated with subcutaneous infusions of DFO achieved 
negative iron balance.
On the basis of this and other studies showing that urine excretion of 
ferrioxamine increased with concurrent administration of ascorbic acid (Pippard, et al 
1978a, Wapnick, et al 1969) the recommendation was to start chelation with SC DFO as 
12 hr infusions on 5 nights a week as soon as possible in children who were on 
transfusion programmes along with low dose ascorbic acid (Weatherall and Clegg 1981).
However the benefit of chelation therapy in preventing cardiac failure (Wolfe, et 
al 1985) and the role of intensive chelation in patients with established heart failure 
(Aldouri, et al 1990, Cohen, et al 1989) was not established until much later. Since the 
first studies documenting reversal of cardiac failure in thalassaemia patients DFO has 
become the gold standard for treatment of acute cardiac decompensation (Davis, et al 
2004, Davis and Porter 2002).
Despite the very clear benefits of chelation therapy, it is a difficult treatment to 
use and adherence to therapy has been a major issue for both clinicians and patients
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over the last 30 years. Gabutti and Piga (Gabutti and Piga 1996) showed clearly that 
survival was dependant on the frequency of chelation therapy used. Zurlo and Borgna- 
Pignatti (Borgna-Pignatti, et al 2004, Zurlo, et al 1989) showed a reduced frequency of 
complications due to iron overload in patients who had received chelation form an early 
age. In addition survival data from the UK registry (Modell, et al 2000) showed that 
despite good access to chelation therapy the outcome was still poor with over 50% of 
patients dead by the time they reached 35yrs of age. The search for an alternative 
chelator, which is easier to take, has been the goal for many physicians looking after 
patients with thalassaemia.
In the search for an effective oral chelator many were investigated but only a few 
have ever reached clinical studies in humans. I will only discuss the oral chelators that 
are in clinical use currently and how these have affected thalassaemia management.
1.2.8.2 Deferiprone (1,2,-dimethyl-3-hydroxypyridin-4-one, CP20, L1)
Deferiprone is of the hydroxypyridinone class of chelators and was first identified 
as a chelator in the late 1980’s (Kontoghiorghes and Evans 1985, Kontoghiorghes, et al 
1987b). It is bidentate and 3 molecules of deferiprone are required to bind one ferric iron. 
Early studies on humans a mere 2 years after its identification as a chelator of iron 
showed good urinary iron excretion (Kontoghiorghes, et al 1987a). The first study on 
safety was published in 1992 by Al-Refaie (al-Refaie, et al 1992b), who found it to be an 
effective chelator but with significant side effects including neutropenia and significant 
arthropathy. Since that time to the present day there have been many publications on its 
effectiveness and safety (al-Refaie, et al 1995, Kontoghiorghes, et al 1990, Olivieri, et al 
1990). However it is also a difficult treatment to adhere to, because of multiple tablets 
have to be taken three times daily and its significant gastrointestinal side effects. In
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addition the very serious side effects of neutropenia/ agranulocytosis require continuous 
weekly monitoring of blood counts and severe arthropathy which can occasionally be 
destructive (Ceci, et al 2003, Cohen, et al 2000, Maggio, et al 2002).
Recently there has been much debate in the literature on combination therapy 
with deferiprone and DFO because of the relatively poor hepatic iron clearance of 
deferiprone (Caro, et al 2002, Mourad, et al 2003) , and the possibility that deferiprone 
may preferentially clear iron from the myocardium (Anderson, et al 2002, Hershko, et al 
2004, Hershko, et al 2002, Wu, et al 2004).
A fuli discussion of this debate will not be undertaken because clear clinical 
evidence for this in the form of randomised clinical trials is still awaited. There is no 
doubt however that the deferiprone has helped to improve adherence to therapy and 
improved iron burdens in a significant number of patients taking it who were unable to 
adhere to DFO therapy.
1.2.8.3 Deferasirox (ExJade, ICL 670)
Deferasirox is an N substituted bis-hydroxyphenyl-triazole and belongs to a new
class of synthetic tridentate chelators. 2 molecules of Deferasirox bind to one molecule 
of ferric iron. It underwent extensive preclinical animal studies and was found to be a 
potent and selective oral iron chelator. It was well absorbed and tolerated in the phase 1 
and 2 studies (Nisbet-Brown, et al 2003) and 20 to 25mg/kg doses have been found to 
be as effective as DFO with regards to hepatic iron clearance and ferritin values 
(Cappellini, et al 2006, Piga, efa/2004, Porter, et al 2004).
During large phase 2 and 3 studies, side effects which were thought to be 
associated with the drug were skin rash (10%) transient nausea (20%), diarrhoea (20%) 
and abdominal pain and vomiting (15% each). Mild rises in the serum creatinine were 
observed in 30% of patients and these resolved on dose reduction. Serious adverse
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events have been rare and no cases have been reported of arthropathy or 
agranulocytosis. Its impact on survival and adherence is likely to be significant because 
patients who find chelation with DFO difficult or have serious side effects with 
deferiprone will now have the option of once daily oral medication. The long-term impact 
on survival and the incidence of iron-associated complications will become clearer over 
the next 10 years or so.
1.2.8.4 Optimal use of iron chelators
A challenge with the use of any iron chelator is that although excess iron is 
potentially toxic, iron is also required for normal physiological purposes. Hence over 
chelation may result in toxic side effects of iron depletion. From the first reports of falling 
iron burdens with chelation therapy (Barry 1974) to the present day, the understanding 
on safe and effective use of DFO in order to minimise drug related side effects such as 
high tone hearing loss (De Virgiliis, et al 1979), spinal column and growth abnormalities 
(De Virgiliis, et al 1988), night blindness and other complications such as cataracts 
(Bloomfield, et al 1978, De Virgiliis, et al 1988) has increased significantly. It is now rare 
to see major toxicity in newly treated thalassaemia patients. The development of the 
therapeutic index has provided clinicians with a simple method for reducing toxicity and 
still maintaining adequate iron chelation (Porter, et al 1989). The sides effects 
associated with deferiprone require regular neutrophil count monitoring weekly, in 
addition, liver function tests and serum zinc levels should be monitored regularly and 
zinc replacement therapy given if necessary. In patients on combination therapy 
appropriate attention has to given to the side effects of both drugs. The long term 
complications from the use of Deferasirox are not yet clear as patients have not been 
treated for a sufficiently long period. There is however some concern relating to the 
potential for renal impairment.
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1.2.9 Monitoring of Thalassaemia major
Monitoring of young patients to assess for adequate growth and development 
and x rays to assess bone age, the annual auditory and ophthalmic assessments as well 
as the use of bone density scans to assess osteopenia/ osteoporosis have allowed 
clinicians to diagnose problems early and ensure better outcomes for the patients.
Diagnostic tools to look at complications have allowed significant improvements 
in treatments; for example the use of DEXA scans (dual energy x-ray absorptiometry) for 
the diagnosis of osteoporosis in thalassaemia patients (Angastiniotis, et al 1998) has 
allowed interventional therapy with bisphosphonates such as Pamidronate (Chatterjee, 
et al 2003b, Morabito, et al 2002) to help improve bone density. The monitoring of 
myocardial iron overload has always been problematic because of the inter observer 
variability seen with echocardiography (ECHO). The use of MUGA (Multiple gate 
Acquisition /radionucleotide ventriculography) to provide very accurate information on 
the left ventricular ejection fraction has allowed appropriate management decisions to be 
made (Davis, et al 2004). The most significant advance in monitoring of myocardial iron 
load has been made with MRI (Magnetic Resonance imaging) and this will be discussed 
in chapter 4.
Liver iron burden was always traditionally investigated using liver biopsy but this 
is now used less frequently because the MRI techniques used can quantify hepatic iron 
load. Liver biopsy however remains extremely useful, but under utilised, for monitoring 
fibrosis in patients who are infected with hepatitis C secondary to blood transfusion.
The impact of better transfusion practice and the use of appropriate chelation in 
the management of TM has transformed the lives of patients in the northern hemisphere
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in the 80 years since Cooley’s original report. Whereas death was the only outcome for 
severe TM children in the first decade of life, it is now predicted that a child born today 
should expect a good quality of life with relatively few iron associate complications 
(Borgna-Pignatti, et al 2004), to have a family, a career and a near normal life 
expectancy. This however is not the case in many parts of the southern hemisphere 
where children cannot be given safe blood or be maintained on high transfusion regimes 
because of lack of resources and the lack of affordable chelators. In these children all 
the classical features of Cooley’s anaemia are still seen as well as the complications of 
severe iron overload as can be seen in the seventeen year old girl in figure 1.2.9a and 
1.2.9b.
Figure 1.2.9.a Under transfused thalassaemia major patient
Legend: A 17 year old girl with TM in Pakistan, receiving chelation with her blood transfusion 
only. Showing a protuberance of the frontal bones, prominent maxilla and protuberance of her 
teeth .In addition she is jaundiced. Verbal consent was given for the picture to be taken and used.
Page 45 of 278
Figure1.2.9.b Thalassaemic girl aged 17 years
Legend: Same young girl standing with her mother. Note the stunted growth, lack of sexual 
development, and slate grey discolouration of the skin in comparison to her mother.
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1.3 Thalassaemia Intermedia
Tl is a milder form of thalassaemia, which does not require transfusion to 
maintain life. These children grow normally but will have significant anaemia and will 
either be transfusion independent, require blood transfusion occasionally or be on 
regular transfusion regimes at 6 to 12 weekly intervals. Transfused Tl patients are 
described as those requiring less than eight transfusions per annum, if they require more 
than this then they are re-classified as TM patients.
1.3.1 Historical perspective
In 1925 Rietti published the first description of this milder anaemia in the Italian 
medical literature, with similar descriptions of children and adults being published by 
Greppi (1928) and Macheli (1935). It was called the La Malattia di Rietti-Greppi-Micheli 
syndrome. Wintrobe first noted a similar syndrome in 3 Italian families with anaemia and 
splenomegaly in Baltimore (USA) in 1940. Many workers described similar patients in 
the American literature and by 1949 it was clear that La Malattia di Rietti-Greppi-Micheli 
syndrome was a form of thalassaemia intermedia.
These patients lived into adulthood but often developed some of the stigmata of 
Cooley’s anaemia. In 1956 the first patient with HbH was identified when a fast moving 
band was noted on an electrophoretic strip. In 1958 Hb Barts was identified in a 9 month 
old infant, with a blood film suggesting thalassaemia, at St Bartholomew’s hospital. It
became clear soon after these discoveries that haemoglobin consisted of a  and P
Pag© 47 of 278
chains and lack of sufficient production of either of these could cause a thalassaemia 
like syndrome (Weatherall and Clegg 1981).
1.3.2 Molecular and genetic basis of thalassaemia intermedia
The severity of thalassaemia syndromes is determined in general by the 
imbalance of alpha to non alpha (beta +gamma) globin chain synthesis. Factors such as 
the ability of red cells to destroy unpaired globin chains by proteolysis can contribute to 
the severity of the thalassaemia syndrome. While it is on many occasions possible to 
predict a Tl phenotype on the basis of the genotype, such as a homozygous mild beta- 
mutation (such as I VS 1—6), there are a number of modifiers of the phenotype that can 
modulate the genotype such as HPFH or proteolysis of excess unpaired globin.
A Tl syndrome may arise from one or more of the following;
• Homozygote (or compound heterozygote) for mild p thalassaemia mutation
• Homozygote for severe p mutation but persistence of HbF due to;
o Xmn polymorphism 
o HPFH
o Other factors increasing HbF
• Coinheritance of p thalassaemia (heterozygote) and a thalassaemia-like Hb variant such 
as;
o Hb E p thalassaemia
o Hb lepore p thalassaemia
These may result in a TM or Tl phenotype
• Coinheritance of a thalassaemia mutations with homozygous p thalassaemia
o Resulting in decreased globin imbalance from homozygous a p thalassaemia
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• Coinheritance of an extra alpha gene with heterozygous for (3 thalassaemia
o (resulting in increased globin imbalance compared with (3 thalassaemia trait
• Very rarely heterozygote from dominant thalassaemia mutation
1.3.3 Complications associated with thalassaemia intermedia phenotypes
Tl is a clinical diagnosis and covers a wide range of homozygous, compound 
heterozygous and heterozygous genetic defects. The severity of the anaemia is 
extremely variable and some patients present at a relatively young age and require 
intermittent transfusion support, other patients have very mild anaemia and are 
diagnosed in adulthood when a mild anaemia is noted. All patients with Tl can develop 
complications secondary to anaemia. These tend to be more common in the moderate to 
severe Tl patients. These complications are very similar to those described in the TM 
patients with splenomegaly, venous ulcers, and bone abnormalities on x ray being 
commonly seen. Venous ulcers are a frequent occurrence in Tl patients and have been 
described extensively in the literature. To date there is no clear consensus on how best 
to treat these and a range of options have been used including transfusion support, HbF 
modifiers as well as topical treatments.
Thrombosis is a considerable concern in Tl patients and this is more common 
post splenectomy (Atichartakarn, et al 2002) . It is possible this may be associated with 
the underlying coagulopathy (due fragments of red cell membranes) or the long-standing 
hypoxia (Aessopos, et al 2005, Aessopos, et al 2001). Osteopenia and osteoporosis in 
Tl patients are well described (Angastiniotis, et al 1998, Dresner Pollack, et al 2000, 
Mahachoklertwattana, et al 2003) and the optimal management of this is a yet unclear 
although there is some data to suggest that Tl patients have low bone turnover and 
respond poorly to bisphosphonates (Chatterjee, et al 2003a).
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It is well documented that patients with the intermedia syndromes develop iron 
overload secondary to hypoxia which increased gastrointestinal iron absorption (Celada 
1982, Pippard, et al 1979, Pippard and Weatherall 1988). Hitherto the possible 
mechanism for this were unclear but the discovery of iron transporter molecules that are 
involved in regulation of iron absorption such as DCT1 (Gunshin, et al 1997) and the 
discovery of further molecules involved in iron homeostasis such as ferroportin/lregl 
(Abboud and Haile 2000, McKie, et al 2002) and hepcidin (Park, et al 2001) have 
provided some insight into possible mechanisms.
The management of Tl is largely symptomatic and the real advances in 
management are the ability to transfuse and chelate those patients who develop 
complications or have symptomatic disease. The most important advance has been the 
avoidance of splenectomy if possible and to only use this if the spleen is massively 
enlarged or if there are signs of hypersplenism in order to avoid the thrombosis risk and 
the use of anticoagulants in those who are at high risk of thrombotic events.
1.3.4 Mechanisms of increased Iron absorption in thalassaemia intermedia.
Blood transfusion is intermittent or absent in Tl and the increased iron loading is primarily 
due to excess iron absorption. The degree of ineffective erythropoiesis, the extent of erythroid 
expansion and the severity of the anemia all effect the degree of Gl iron absorption. The role 
each factor plays in an individual patient with Tl is difficult to predict. Pippard showed in one 
study that Tl patients absorbed 26-73% of food iron (Pippard, et al 1979). More recently 
Pootrakul examined iron absorption in HbE/p-thalassaemia and found that it varied between 20- 
75% and correlated with plasma iron turnover, transferrin saturation and liver iron concentration 
(Pootrakul, et al 1988). Iron absorption in thalassaemia intermedia can thus be up to 5-10 times 
normal, or 0.1 mg/kg/day (Gordeuk, et al 1987).
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In Tl, the main mechanism of increased iron loading is through increased iron 
absorption from the diet. Increased iron absorption is also seen in TM but the rate of 
iron loading from blood transfusion is at least ten times that which results from iron 
absorption. Other forms of anaemia such as SCA may not be associated with increased 
iron absorption, possibly because ineffective erythropoiesis is not a prominent feature in 
this condition, unlike Tl. A key goal of this thesis is to contribute to the understanding of 
how iron loading and distribution can differ between thalassaemia and sickle disorders. 
This is dealt with in greater detail in subsequent chapters but a description of the factors 
known to regulate gastrointestinal absorption is given here as an introduction to the 
subject.
The amount of iron absorbed per day is tightly regulated in humans and over the 
last few years several key regulators of iron absorption have been identified and their 
roles defined. The first regulator to be identified was the iron transporter DCT1 (divalent 
cation transporter) (Gunshin, et al 1997) which is known to be expressed on the apical 
surface of enterocytes and has also been shown to be responsible for uptake of low 
molecular mass NTBI species in early red cells (Andrews 1999) and is probably 
responsible for the increased uptake that was seen in cardiac myocytes as described by 
Parkes (Parkes, et al 1993).
Following this discovery attention was focused on the basolateral membrane of 
enterocytes and ferroportin (Iregl) was identified (Abboud and Haile 2000, McKie, et al 
2000). Ferroportin is thought to be responsible for the transport of iron out of the 
duodenal enterocyte into the plasma compartment where it is bound to transferrin. Then 
Dcyt b (Duodenal Cytochrome b) was identified by the same group working on 
ferroportin (McKie, et al 2001), it is a ferric reductase that is thought to be responsible for
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the reduction of ferric iron to supply ferrous iron to DCT1 on the apical border of the 
duodenal enterocyte.
The discovery of hepcidin which is a 25 amino acid peptide expressed by 
hepatocytes and was first isolated from human urine by Park et al (Park, et al 2001) has 
been important in providing some insight into regulation of iron homeostasis. The liver 
was found to be the main site for mRNA expression. Hepcidin and its relationship to 
anaemia was noted by Nicholas (Nicolas, et al 2002a) when transgenic mice over 
expressing hepcidin died of severe iron deficiency anaemia soon after birth. The relation 
between anaemia and hepcidin was further defined by Nicholas when mice were 
subjected to anaemia by repeated phlebotomies to induce iron deficiency or exposed to 
phenylhydrazine to induce haemolysis. The phlebotomised mice were found to have an 
80% decrease in hepcidin mRNA even in the presence of normal liver iron stores and 
the haemolytic anaemia mouse model was found to have a 3 fold reduction in the 
presence of an increased liver and serum iron.
Tissue hypoxia secondary to anaemia may therefore play a major role in hepcidin 
regulation and result in increased iron absorption. More recently work by Adamsky et al 
using a Tl mouse that was transfusion independent found reduced liver hepcidin mRNA 
(Adamsky, et al 2004) suggesting that the down regulatory effect of anaemia overrides 
the up regulatory effect of iron overload. Follow up work from this group showed 
decreased hepcidin expression in TM mice (Weizer, et al 2004). In addition on exposure 
of human hepatoma HepG2 cells to human thalassaemic sera they found that hepcidin 
expression was an average of 3 fold lower then that evoked by normal sera. The down 
regulating effect with thalassaemic sera but not with normal sera suggested that there 
may be a upstream factor whose levels may increase in the sera in response to 
ineffective erythropoiesis and that this may override the upregulation of hepcidin in 
response to iron overload. There has been no study looking at the relationship between
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hepcidin, anaemia, iron burden and NTBI in patients with thalassaemic syndromes and 
SCA. In chapter 5 the relationship between iron overload and hepcidin and its 
relationship with NTBI in the thalassaemia syndromes and SCA will be discussed.
1.4 The Sickle Syndromes
1.4.1 Genetic and molecular basis of sickle syndromes.
Sickle haemoglobin (HbS) is caused by a single nucleotide substitution in codon 
6 (GAG to GUG) of the p chain resulting in the insertion of valine in place of glutamic 
acid. There are a number of variant haemoglobins (HbC, HbD Punjab, HbO Arab, Hb 
Lepore etc.) which when co-inherited with HbS result in sickle syndromes. HbS can also 
be co-inherited with p thalassaemia chain mutation causing (Sp Thalassaemia) that 
results in sickle manifestations of varying severity dependant on the type of p 
thalassaemia mutation.
The syndromes can be divided into the following subgroups:
a) Carriers of the sickle haemoglobin are clinically asymptomatic
b) Homozygous sickle cell anaemia
c) Compound heterozygote
Homozygous sickle cell anaemia is a very heterogeneous disorder with some 
patients having severe disease and others mild or moderate disease. HbS can interact 
with other haemoglbins, resulting in a sickle syndrome. The most common are HbC, 
HbO Arab, HbD Punjab, Hb Lepore, and p thalassaemia mutations. HbSC tends to have 
a milder clinical course then HbSS as the haemolysis is less severe but the micro­
occlusive events particularly in the eye tend to be more severe. HbSD Punjab is often of
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a severe phenotype as is HbS OArab whereas HbSE and HbS Lepore are relatively 
milder. The severity of HbSp thalassaemia will vary dependant on the p mutation. Those 
with Sp° thalassaemia will have as severe a sickle disorder as those with HbSS, 
whereas those with Sp+ thalassaemia will have a milder clinical course.
1.4.2 Pathophysiology of sickle cell anaemia
The basic defect resulting in sickling episodes is the formation of rigid deformed 
sickle shaped red cells. The red cells will start to sickle at oxygen saturations below 85% 
and will nearly all have sickled by 38% oxygen saturation. The red cells become 
deformed as a consequence of the crystallisation of HbS within red cells (Bertles and 
Dobler 1969). These cells have increased mechanical fragility and tend to occlude 
vessels in the microcirculation. The stasis that occurs as a consequence of this, results 
in further hypoxia and worsening sickling of the red cells and a vicious cycle develops. 
The tissues distal to the occlusion develops ischemic damage. Vaso-occlusive crises 
typically occur in bone marrow leading to sporadic bone pain. Other tissues affected 
acutely by the sickling process include the lungs (chest syndrome) central nervous 
system (stroke), gastrointestinal and penile tissue.
The sickling process results in shortened red cell survival resulting in a 
haemolytic anaemia but this does not typically require blood transfusion in the steady 
state with Hb values typically between 7 and 9 g/dl. . Blood may be rapidly sequestered 
in the spleen or occasionally liver and the patient will present with worsening anaemia or 
hypovolemic shock. Hyposplenism resulting from repeated episodes of splenic 
ischaemia leads to an increased risk of pneumococcal septicaemia. The chronic effects 
of sickle cell disease may affect many other tissues, such as the kidney (chronic renal
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failure), the retina (proliferative retinopathy), bone (avalcular necrosis of the hip), the skin 
(leg ulceration)(see below).
1.4.3 Incidence and frequency of sickle cell anaemia
The initial distribution of the HbS gene was determined by the frequency of 
occurrence of the mutation and the occurrence of falciparum malaria.
Literature published in the 1940’s defined it as a predominantly negroid disease: 
“A disease essentially peculiar to Negroes, which is characterised by anaemia, 
rheumatoid manifestations, leg ulcers and acute attacks of pain, and is distinguished 
morphologically by peculiar sickle-shaped and oat shaped red corpuscles. ”
(Wintrobe 1946)
By the 1930’s however a number of families had been described in the USA of 
Greek, Italian and Sicilian ancestry who also had SCA, however this was assumed to be 
due to ’’ancestral Negroid blood” . As can be seen from figure 1,4.4a the incidence of 
distribution of SCA had been quite well documented by the early 1950’s.
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Figure 1.4.3a Distribution of sickle cell anaemia in the old world
Legend: Figure from Dacie JV, The haemolytic anaemias: part 1 Congenital anaemias. The 
distribution of Sickle cell anaemia in the Old World. In the early descriptions SCA was thought to 
be a predominantly Negroid disorder (Dacie 1960)
The distribution of sickle has changed significantly world wide due to migration. 
In the UK Hickman recently documented the frequency and distribution of SCA. There 
are approximately 10,000 patients in the UK with SCA and approximately 178 
births/annum (Hickman, et al 1999).
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1.4.3.a Geographical distribution of SCA in England
Legend: reproduced from Hickman (Hickman, et al 1999) the majority of SCA births are in London 
and the midlands. These are the traditional areas where migrant families settle
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14.4. Historical perspective of sickle cell anaemia
Herrick first identified sickle cells in 1910 when he published an article called
“Peculiar Elongated red blood corpuscles in a case of severe anaemia”
The patient was a 20 year old Negro who was a dental student in Chicago and 
gave no history of rheumatism or other joint trouble. This first case report described the 
abnormal morphology of the erythrocytes but the description of ‘sickle cell anaemia’ was 
not used for the disorder until Mason introduced the term in 1922. The carrier state or 
trait was identified in the parents of patients with SCA by 1923 by Taliaferro and Huck 
(Dacie 1960). Patients usually presented within the first year of life with anaemia or 
painful crisis often associated with a febrile course. There would be rheumatic pains and 
jaundice. These crises were described as thrombotic crises due to agglutination of the 
erythrocytes (Weatherall and Clegg 1981). Wintrobe gave a classical description of 
patients with SCA in his textbook describing them as:
“underweight, the trunk is short, the extremities long, the body habitus linear with 
comparatively narrow hips and shoulders”.
Wintrobe commented in his textbook Clinical Haematology (Wintrobe 1946) that 
the majority of children would die in the first decade of life and few would survive to the 
3rd decade. Death was usually due to intercurrent infection especially tuberculosis, 
cardiac failure due to haemorrhage or thrombosis and renal failure. Gallstones 
(Washburn 1911) were recognised as a problem and death due to shock precipitated by 
the rapid removal of sickled red cells from the circulation was also documented 
(Sydenstricker 1924a). By 1960 Dacie in the second edition of his authoritative textbook 
on haemolytic anaemias, vaso- occlusive crises were described clearly along with 
osteomyelitis (Hodges and Holt 1951) , sickle stroke (Sydenstricker, et al 1923),
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pulmonary infarcts (Graham 1924), the risk of death if anesthetised, and the inability to 
concentrate urine (McCrory, et al 1953). However SCA was still described it as a 
disease predominantly of childhood (Dacie 1960). By the early 1980’s however, our 
understanding of SCA was very similar to the present day. The prognosis had altered 
somewhat by this time and this was predominantly felt to be dependant on the socio­
economic circumstances of the patient. The management of acute and chronic 
complications of SCA have changed significantly and the use of blood transfusions has 
become more widespread.
1.4.5. Complications of SCA that may require blood transfusion.
A detailed description of all the complications of sickle cell disease and their 
management is beyond the scope of this chapter, the aim of which is to focus on 
conditions where repeated blood transfusion may result in iron overload. Below the 
common complications of SCA for which blood transfusion may be required are 
discussed.
1.4.5.1. Neurological complications
Stroke was recognised in early reports (Sydenstricker, et al 1923) and a review 
by Hughes in 1940 (Hughes, et al 1940) defined the clinical syndrome as occurring 
mainly in children below the age of 10 years, the frequency of recurrence and the 
resultant hemiplegia and convulsions. Further reviews have improved our understanding 
of sickle stroke syndromes and the pathology behind them. Management of the acute 
stroke syndrome with blood transfusion improved clinical outcomes (Sarnaik, et al 1979) 
but it was not until transcranial Doppler (TCD) was used to monitor cerebral flow in
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children that significant improvement has occurred in identifying children at high risk 
(Adams, et al 1998b). This was a benchmark study (known as the STOPI study) and had 
considerable impact on patient management. The very important conclusion from this 
study was that patients with TCD greater than 200 cm/s should receive blood transfusion 
to reduce the risk of stroke. The cooperative study on sickle cell disease also identified 
other five other risk factors important in cerebral infarction risk assessment such as 
recent and frequent chest syndromes, low haemoglobin, recent transient ischemic attack 
and high blood pressure. In the very young children, dactylitis, high WBC count and 
significant anaemia were important predictors of severe outcomes (Ohene-Frempong, 
et al 1998). Children with raised TCDs should be started on transfusion programmes 
aiming for a HbS% of 30% or less as primary prevention. However around 60% of 
children with abnormal TCDs do not develop stoke even in the absence of transfusion 
(Abboud and Atweh 2006).
More recently silent infarcts have been noted on 17% of sickle children (Kinney, 
et al 1999). Management of this is unclear but is being evaluated in a clinical trial 
(Kirkham, et al 2006) looking at the use of prophylactic blood transfusion.
Role of blood transfusion:
There are significant uncertainties as to when it is safe to stop blood transfusion 
in children who have has a stroke syndrome and are receiving blood as secondary 
prevention with conflicting reports in the literature (Rana, et al 1997, Wang, et al 1991). 
In children receiving blood transfusions for primary prevention the STOPI I study showed 
that if transfusions were stopped once TCDs had reversed into the normal range, these 
reverted to abnormal values and there was a high risk of stroke (Adams and Brambilla 
2005). Not all children with raised TCD’s however go onto have a stroke syndrome and 
these children are facing long term transfusion programmes with the need for chelation
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therapy for iron overload. There is a clear need for a more precise risk assessment for 
sickle stroke syndromes.
1.4.5.2. Acute chest syndromes (ACS)
Chest syndromes can be precipitated by a number of conditions such as 
pulmonary emboli or chest infections and has been the subject of two large studies the 
CSSCD (Vichinsky, et al 1997) and the MACSS (Vichinsky, et al 2000). The syndrome is 
often not recognised early enough and hence many large centres have devised 
protocols for the management of this. Evidence of acute respiratory distress with 
tachycardia, hypoxia and a chest X ray showing pulmonary infiltrates should act as a 
precipitant for exchange transfusion (Vichinsky, et al 2000) and respiratory support 
either in intensive care or on the ward. Most patients with ACS will receive exchange 
transfusions or less frequently top up transfusions to help improve the Hb and oxygen 
carrying capacity. Many case reports have been described in the literature but in the 
largest series by Wayne (Wayne, et al 1993) 32 of 35 patients had rapid improvement in 
oxygenation and good clinical outcomes. The positive impact on outcomes of blood 
transfusion on ACS has resulted in many clinicians considering it for use in the 
prevention of recurrences in patients with severe or repeated episodes. This is primarily 
due to concerns that recurrent ACS may contribute to chronic pulmonary failure, 
pulmonary hypertension and cor pulmonale (Collins and Orringer 1982, Powars, et al 
1988), however the effect of blood transfusion on prevention of these late pulmonary 
outcomes is unknown because this has not been studied formally. Hydroxyurea has 
been found to be beneficial in prevention of recurrent ACS (Charache, et al 1995).
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1.4.5.3. Priapism
Priapism was originally noted as a complication of SCA by Diggs and Ching 
(Diggs and Ching 1934). Reviews published in the 1960s identified that priapism tended 
to affect the younger patients and a diverse range of treatments were ineffective (Sousa, 
et al 1962). More recent data (Emond, et al 1980) suggested that priapism is more 
frequent then previously thought and occurred in 40-50% of patients above the age of 
20 years, and there are two distinct types ( stuttering and acute).
Treatment for priapism continues to be difficult and there is limited and 
contradictory data on transfusions and possible complications such as ASPEN 
syndrome (Siegel, et al 1993) (Baruchel, et al 1993, Miller, et al 1995, Rackoff, et al 
1992). Intracavernosal injections with alpha agonists such as etilefrine or phenylephrine 
(Muruve and Hosking 1996, Virag, et al 1996) have helped improve outcomes to some 
degree. However a significant number of patients will proceed to surgery to create 
shunts and eventually to insertions of penile prostheses to help treat priapism (Maan, et 
al 2003, Sadeghi-Nejad and Seftel 2002).
1.4.5.4. Aplastic crisis
This was first recognised as a complication in 1950 (Singer, et al 1950). 
Classically the syndrome presents with symptoms of a recent upper respiratory tract 
infection followed by a rapid fall in haemoglobin and a reticulocytopenia. Spontaneous 
recovery occurs within 5 to 10 days and provided the anaemia is not too severe 
managed conservatively. Occasionally transfusion support is needed in which case the 
slow administration of one or two transfusions aimed at raising the hemoglobin by 2-3
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g/dL over four to eight hours, should be sufficient to improve the clinical condition of the 
patient until spontaneous recovery occurs.
The association with parvovirus was first recognised by Pattison (Pattison, et al 1981).
1.4.5.5. Splenic sequestration
This was first recognised as a complication in SCA by Tomlinson (Tomlinson 
1945) and was found to be the most common cause of death in early life (Rogers, et al 
1978). The disorder is of varying severity from mild splenic enlargement and a slight fall 
in Hb to severe hypovolemic shock (Topley, et al 1981). The early recognition of splenic 
sequestration crises in children has helped to reduce the mortality form this complication 
(Emond, et al 1985). It has now become part of routine management to teach parents to 
recognise splenomegaly and the signs and symptoms of sequestration crisis. This has 
resulted in a much improved survival in patients (Lee, et al 1995). Management remains 
transfusion support primarily in the acute setting. Chronic blood transfusion support may 
reduce the risk of recurrent sequestration crises, reduced splenomegaly and 
hypersplenism but it does not ultimately prevent the need for splenectomy. It may 
therefore have a role in delaying splenectomy in children until they are over 5 years of 
age.
1.4.5.6. Surgery
SCA patients have a high risk of post-operative complications and about a 1% 
mortality rate whist undergoing surgical procedures such as cholecystectomy (Koshy, et 
al 1995), the most frequent complication being ACS. Koshy et al showed that sickle 
complications were reduced by about sixty percent in those patients who had peri­
operative transfusions in low risk procedures. Despite this however the peri-operative 
use of blood transfusions to prevent complications has been controversial. Some
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investigators have used transfusions to simply correct the anaemia and others have 
attempted to reduce the HbS%, whilst others have preferred to avoid transfusion and 
pay careful attention to hydration and oxygenation for successful outcomes (Serjeant 
1997). A randomized transfusion study in patients undergoing cholecystectomy showed 
an overall 1% mortality with a 19% complication rate and 5% mortality in those receiving 
‘no transfusion’. There was no difference in the complication rates between those 
randomized to aggressive or simple transfusion regimens (Haberkern, et al 1997) . 
Vichinsky et al showed that there was no difference in outcome post operatively in 
patients who were randomised to have exchange transfusions and a reduction on the 
HbS to below 30% and those who had a top up transfusion to raise the Hb to 10g/dl. 
(Vichinsky, et al 1995).
In those patients who are deemed to be at high risk of complications post- 
operatively such as those with chronic lung disease or undergoing prolonged surgical 
procedures exchange transfusions may be more beneficial but there is no data from 
prospective clinical trials to confirm this currently.
1.4.5.7. Pregnancy
The use of blood transfusion during pregnancy to affect clinical outcomes is 
controversial with much conflicting evidence in the literature on prophylactic transfusions 
(Charache, et al 1980, Morrison and Wiser 1976, Tuck, et al 1987). In the study by Tuck 
et al no beneficial effect was seen in either maternal or foetal outcome. It is generally felt 
however that pregnant women who develop complications such as pre-eclampsia, 
septicaemia, acute chest syndrome, exacerbation of anaemia, stroke should receive 
transfusion (Koshy and Burd 1991) and most clinicians will also tend towards using 
blood transfusions prophylactically in women with a bad sickle history, bad obstetric 
history or where the obstetric risk is judged to be high e.g. multiple pregnancy or high 
risk medical conditions such as diabetes.
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1.4.5.7 Chronic conditions that may benefit from transfusion support
Conditions that may benefit from supportive transfusion regimes include 
pulmonary hypertension, chronic renal failure and venous ulceration. Pulmonary 
hypertension (PHT) was first reviewed as a complication by Collins and Orringer (Collins 
and Orringer 1982) where three previous cases were described along with three new 
cases and this provided the initial guidance on diagnosis and treatment. The prevalence 
is quoted as being between 30 and 56% (Gladwin, et al 2004, Simmons, et al 1988). The 
exact pathophysiology of PHT is not clear but is likely to be multifactoral and includes 
recurrent chest syndromes, pulmonary emboli, haemolysis and chronic hypoxia (Siddiqui 
and Ahmed 2003). ECHO is a useful for screening and monitoring and a TR jet velocity 
of greater than 2.5m/s is suggestive of PHT, however, the frequency of ECHO 
monitoring is not clear. The gold standard confirmatory test is cardiac catheterisation 
with measurement of right heart pressures. Treatment remains unclear with a variety of 
options being used in most patients including anticoagulation (Gaine 2000) , blood 
transfusion, calcium channel blockers (Rich, et al 1992) continuous nocturnal oxygen if 
responsive on catheter studies , inhaled nitric oxide (Hasuda, et al 2000) , hydroxyurea 
(Castro 1996), vasodilators, prostagladins and endothelin receptor antagonists (Gladwin 
and Kato 2005)
Sickle nephropathy has been recognised for a long time from early reports on 
hyposthenuria (Herrick 1910, Sydenstricker 1924b), tubular dysfunction is well 
documented and has been recently reviewed ((Ataga and Orringer 2000)). Acute renal 
failure is seen in patients who are severely septic, are very febrile or have 
rhabdomyolysis, and is often part of an acute multiorgan failure syndrome. More recently 
concern has been focused on prevention of end stage renal disease and this has
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resulted in regular monitoring of proteinuria and blood pressure in patients at least 
annually. In those patients with significant proteinuria the use of ACE inhibitors (Powars, 
et al 1991) has been of some benefit in reducing the severity of proteinuria. It is 
important to control hypertension and avoid NSAIDs (Kontessis, et al 1992, Nissenson 
and Port 1989). However despite these measures patients will often proceed to renal 
dialysis or renal transplantation. This cohort of patients will often need long term top up 
blood transfusion regimes to support their anaemia.
The management of avascular necrosis and arthropathy (Almeida and Roberts 
2005) and venous ulcers remains difficult (Chung, et al 1996) and are the cause for a 
great deal of morbidity. The healing of sickle venous ulcers may improve with blood 
transfusions but not all ulcers respond. Iron overload may develop insidiously in this 
group as transfusions will be for short periods of time and will occur intermittently 
throughout a patient’s life.
1.4.6. Transfusion regimes used in SCA
The administration of one or two units of blood as a top up transfusion on a three 
or four weekly schedule will reduce the Hb S level to around 30-50%. Exchange 
transfusion performed either manually or automated on a cell separator will result in less 
blood being needed to reduce the HbS% by combining the administration of donor red 
cells with the removal of the patient’s red cells (Cohen, et al 1992). Exchange 
transfusion has been found to be extremely useful in reducing the severity of iron 
overload in patients with SCA on long-term transfusion programs for prevention of stroke 
or other complications. New iron accumulation is stopped or profoundly reduced. A 
single Exchange transfusion is also useful in reducing the Hb S% in patients with 
acute complications or pre-operatively.
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1.4.7. Iron metabolism and iron overload in sickle cell anaemia
Although patients with SCA are anaemic, they rarely develop iron overload 
secondary to increased gastrointestinal iron absorption even when the degree of 
anaemia is significant (O'Brien 1978). This is probably because the anaemia is primarily 
a haemolytic anaemia, although some degree of ineffective erythropoiesis is present 
(Finch, et al 1982, Wu, et al 2005).
Repeated simple blood transfusions will however result in iron overload, but 
exchange transfusions does not result in significant iron overload developing particularly 
if the transfusional iron input is matched with that removed by venesection during the 
exchange (Porter and Huehns 1987) or by automated red cell exchanges (Cohen, et al 
1992). Cohen et al (Cohen, et al 1992) showed in that increasing the pre transfusion 
HbS% to 50% reduced blood requirements in patients by a quarter in those SCA 
patients with no recurrence of stroke and no progressive neurological deterioration 
during at least four years of conventional transfusion.
Even where patients have been heavily transfused, cardiac and endocrine 
manifestations are infrequently seen. It has been proposed that iron distribution may be 
different between patients with SCA and thalassaemia and that this may be due in part 
to the inflammatory response seen in sickle cell disease (Finch, et al 1982, Harmatz, et 
al 2002). There are significant changes in the cytokine profiles in patients with SCA both 
during the acute vaso-occlusive episode and in the steady state when the patient is 
clinically well. It was shown by Taylor et al (Taylor, et al 1997) that type II cytokines such 
as IL4.6, and 10 were raised in SCA during the steady state. Other workers have also
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found raised levels of IL6 but not the other type II cytokines (Bourantas, et al 1998, 
Croizat 1994). More recently Pathare et al (Pathare, et al 2004) has shown increased 
IL1p in the steady state. In addition they looked at the cytokines during acute vaso- 
occlusion and found increased levels of IL6 and IL8.
It is known that IL6 is a potent inducer of hepcidin (Nemeth, et al 2004). Hepcidin 
down regulates iron absorption form the duodenal enterocytes and also simulates 
increased iron uptake by the macrophages (Nicolas, et al 2001). It is therefore possible 
that sequestering of iron in the reticuloendothelial cells such as the macrophages during 
steady state in SCA results in less exposure to toxic forms of iron such as NTBI. This 
would therefore result in fewer complications from the hydroxyl radical generation via the 
Fenton and Haber Weiss reaction (Nicolas, et al 2001).
This interesting observation will be discussed in more detail in chapter 5 where 
the relationship between prohepcidin and anaemia / iron overload in thalassaemia 
syndromes and SCA will be discussed. In addition the distribution of iron overload 
particularly in those patients who have transfusional iron load appears to be different. 
Myocardial iron overload is rarely seen in patients with sickle syndromes, and why this 
may be so will be discussed in chapter 4.
1.6. Conclusions
The advances in our knowledge and the better understanding of the 
thalassaemia and sickle syndromes, the most common of all genetic disorders, has 
allowed better clinical management of patients to the extent that it is now expected that 
the vast majority of optimally treated patients will have near normal life expectancy.
Over the last 100 years advances in transfusion practice such as the use of ABO 
and Rh matched blood, the use of packed cells rather than whole blood, virological
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screening to reduced the risk of transfusion transmitted infections, leucodepletion and /or 
the use of washed cells for transfusion in those with persistent reactions has resulted in 
greatly improved blood safety for the all patients who require transfusion support. The 
advances in chelation therapy have improved the prognosis and reduced morbidity from 
iron overload in the majority of patients.
The relationship between NTBI and iron mediated damage has only been 
assessed in small studies and the time at which NTBI appears in children who have not 
been transfused or have initiated transfusions is not clear. NTBI is known to be 
responsible for cell damage via lipid and protein peroxidation but the role these might 
play in well transfused and chelated patient is unknown. The distribution of iron overload 
is thought to be different in SCA compared to thalassaemia and these patients rarely 
developed iron overload secondary to increased gastrointestinal absorption. All of these 
questions will be reviewed in this thesis to assess what relationship if any exists between 
NTBI and iron mediated damage in the thalassaemia syndromes and SCA.
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Chapter Two
Methods
2.1 Patients
All adult patients gave verbal consent for their samples to be taken and stored for 
the research studies. The consent for the children was written consent from parents or 
guardians. The liver biopsy samples were historical samples form thalassaemia patients 
and where possible verbal consent was taken for the biopsy samples to be used for the 
measurement of hepcidin.
2.1.1 Study sites
The children were from a number of centres. There were 28 children from a 
National Thalassaemia Centre in a town called Kurunegala in Sri Lanka where ethical 
approval had been granted. These patients were managed by the local doctors and 
advice on management provided by Dr Nancy Olivieri and Professor Sir David 
Weatherall. There were 21 children from the Hospital for Sick Children (HSC) in Toronto, 
Canada who were under regular review and 2 children both born at UCLH in the study
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from the main centre. The adult patients in the studies were all patients who were 
regularly treated at UCLH, London.
2.1.2 Patient cohorts
All the children had thalassaemia major or intermedia and numbers were as in 
section 2.1. The adults comprised 26 patients with sickle cell anaemia, 76 TM and 23 
with Tl.
2.1.3 Ethics
The local ethics committee at UCLH gave ethical approval for all the studies. For 
the studies involving children the local ethics committees at HSC, Toronto, Canada and 
the Sri Lanka centre gave the approval for the study enrolment
2.2 Sample Handling
All blood collections were undertaken when the patient had received no 
desferrioxamine for 48 hrs and were clinically well.
2.2.1 Sample Processing
7 mis of blood was collected in haemogard vacutainer tubes (Becton Dickinson). 
All samples were left standing at room temperature for 30 minutes (it was necessary to 
leave them for slightly longer in patients on anticoagulants but not beyond 1h).
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After 30 minutes, samples were centrifuged at 3000 rpm for 10 minutes at 4°C in 
pre-cooled centrifuge. 0.4ml aliquots of serum were frozen in freezing tubes and labelled 
with the date and time of sampling.
2.2.2 Sample Storage
All blood samples were stored at -80°C freezer until ready for analysis. The 
maximal storage of samples prior to analyses was within a year.
2.3 Non Transferrin Bound Iron (NTBI)
2.3.1 Principle
Once transferrin becomes saturated in iron overloaded patients, free iron is 
thought to form oligomeric and monomeric complexes of iron with ligands such as 
citrate, phosphate and albumin resulting in NTBI (Hider 2002, Jacobs, et al 2005). NTBI 
was measured using a method based on iron mobilisation on to NTA followed by 
separation of mobilised iron using ultrafiltration. The NTBI was then detected by HPLC 
using the method described by Singh et al (Singh, et al 1990).
Samples
It is not known if NTBI alters if samples are kept at room temperature, or in a 
normal fridge and for this reason we did not use samples that had been defrosted in 
transit to the UK. Bacterial contamination is a concern and is another reason why 
samples were kept frozen.
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Normal range: for the normal control this value should appear negative. Reference 
interval (95%) for n=29 normal subjects was -0.61+/-0.90
For iron overloaded serum this would have a positive value, reference interval (95%) for 
n=80 iron overloaded subjects was 4.52+/- 3.69
2.3.2 Method
0.18 mL of serum was incubated with 0.02 mL of 800 mM NTA at pH 7.0 for 30 
min at room temperature to form the Fe-NTA complex. Proteins and other higher 
molecular mass materials were removed from the serum by filtration through Whatman 
Microfree Ultracentrifugation devices (molecular mass cut-off 30 K) at 10,500 rpm, 30 
min, 4°C. 25 pl_ of the filtrate was then injected onto a C18 reversed phase HPLC 
column (Varian: glass- no metallic components) equilibrated to 5 mM MOPS containing 
19% acetonitrile and 3 mM 3-hydroxy-1-propyl-2-methylpyridin-4-one (CP22) at pH 7.0. 
The Fe-NTA delivers the iron to the CP22 to give a red coloured complex, which can be 
quantitated by comparison with Fe-NTA standards.
After every 5 samples, the 2 and 8 pM standards were run to check for 
diminution in peak height and all the standards were run again at the end of the 
experiment. Standards and samples were integrated, extracting chromatograms at 430 
nm. The standard peak height versus concentration was plotted and concentration of 
sample was calculated from its peak height using the graph.
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2.4 Transferrin Saturation
2.4.1 Principle
This was determined using urea polyacrylamide gel electrophoresis, which 
resolves all the three forms of iron-loaded transferrin from apotransferrin. The 
percentage saturation was calculated by scanning the bands (Evans and Williams 1978). 
The presence of NTBI, ferritin iron, plasma pigments and high levels of bilirubin can 
results in inaccurate measurements at high transferrin saturations using the routine 
clinical method (al-Refaie, et al 1992a).
2.4.2 Method
25 pL of each serum sample was treated with a solution of rivanol (6.9-diamino- 
2-ethoxyacridine lactate: 94 mg in 25 mL of aqueous 0.1 M tris; 0.01 M borate; 1.6 mM 
EDTA buffer at pH 8.4 containing 8 % glycerol) to precipitate all serum proteins except 
the y-globulins. The protein precipitate was removed by centrifugation at 13,000 rpm for 
5 min after which 55 pL of the supernatant was loaded onto a 6 % acrylamide gel formed 
in 6 M urea and electrophoresed at 110 volts for 20 hours. The colour intensity for the 
four resolved transferrin bands was determined by scanning and the percentage 
saturation was calculated using the formula:
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2  £  ( Id i f e r r ic  I c-mono I N-mono I apo)
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Figure 2.4.2.a: transferrin saturation gel electrophoresis
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2.5 Soluble Transferrin Receptor (sTfR)
2.5.1 Principle
Soluble transferrin receptors can be measured in serum by an 
immunoturbidometric method. The sTfR antibodies are coated onto Latex particles and 
in the presence of sTfR, agglutination occurs in a dose dependant manner. The 
increased turbidity is detected at a wavelength of 600nm on a Cobas MIRA. The results 
are calculated from a reference curve.
2.5.2 Reagents
BioStat IdeA sTfR-IT- Soluble transferrin Receptor (sTfR) Assay Cat. No. 67968
The IdeA sTfR-IT Kit has been standardised against a monoclonal immunoassay (EIA) 
method.
Additional Reagents:
Cat. No. 67976 IdeA sTfR-IT- Control Low
Cat. No. 67975 IdeA sTfR-IT- Control High
Norma range with assay: 0.3-8.5 mg/l
2.5.3 Method
Sample analysis was carried out in duplicate using a Cobas Mira. IdeA sTfR-IT- 
Reagent was reconstituted with 4ml of deionised water, mixed gently and left to stand at 
room temperature for at least 60 minutes. This was mixed once again prior to use and
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was used as start R1. IdeA sTfR-IT-Buffer was used as “reagent”. The calibrators that 
came with the kit were IdeA sTfR-IT-calibrators were used to calibrate and PBS was 
used as standard point 1 (0 mg/l). IdeA sTfR-IT-Controls were used. The results were 
analysed on a Cobas MIRA (Roche Diagnostics) at a wavelength of 600nm and the 
results calculated from a reference graph.
2.6 Serum Protein Carbonyls
Protein carbonyls are derived as a result of hydroxyl radical induced oxidation of 
the amino acid side groups of proteins. This results in the formation of intra-protein 
aldehydes and these can then initiate cross linking by reacting with £-amino groups. 
These are discussed in more detail in chapter 3.
2.6.1 Principle
Protein carbonyls were measured by a modification (Carmine, et al 1995) of the 
original method described by Reznick (Reznick and Packer 1994). Carbonyls react with 
dinitrophenylhydrazine (DNP) dissolved in hydrochloric acid and the protein-carbonyl - 
DNP complex is then precipitated with trichloroacetic acid (TCA). The precipitate is 
extensively washed to remove excess DNP and then dissolved with guanidine 
hydrochloride and its absorbance measured at 380 nm.
Normal range in our lab in healthy adult control subjects 0.72 + 0.27nmol/mg.
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2.6.2 Method
The samples were diluted in PBS and to this was added 10mM DNP dissolved in 
2M HCL. The complex that was formed was precipitated with TCA and washed 3 times 
with ethanol/ethyl acetate mixture (1:1). The pellets were broken up between each 
washing using a spatula and the new pellet reformed by centrifugation. The final pellet 
was dissolved in 6M guanidine HCL and the absorbance at 380 nm was measured. 
Blank controls consisting of the sample and 2M HCL only were taken through the same 
procedure. The absorbance for these at 380 nm was used for controls, and absorbance 
at 280 nm used to measure the protein concentration of the sample. The carbonyls 
values were expressed as nmol/mg of protein.
2.7 Malondialdehyde (MDA)
2.7.1 Principle
MDA analyses were undertaken using the HPLC method as described by 
Halliwell and Chirico (Halliwell and Chirico 1993). Amplification of peroxidation during the 
heating process was prevented by adding the chain breaking antioxidant butylated 
hydroxytoluene (BHT) to the sample before the remaining reagents were added. HPLC 
was used to separate the authentic (TBA)2 -MDA adduct from other chromogens 
absorbing at 532 nm.
Normal range in our lab in healthy adult control subjects was 0.27+ 0.22 uM 
(range 0.03-0.68uM)
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2.7.2 Method
The HPLC column was equilibrated for 2 -3  hours prior to start of assay with the 
mobile phase consisting of 65% 50mM KH2P04 and 35% methanol. 0.2% BHT was 
added to serum and standards and then divided into equal aliquots. These were 
incubated with 0.44M phosphoric acid for 10 minutes following which 0.6% TBA was 
added. The mixture was kept at 90 °C for 30minutes. Once cooled the samples were 
analysed on HPLC using a techsphere 80 ODS2 column and guard. The calibration 
curve from the peak height of standards was used to determine the MDA concentration 
of samples.
2.8 Serum Erythropoietin
2.8.1 Principle
The erythropoietin is measured using a standard ELISA. The wells are pre­
coated with a mouse monoclonal antibody against EPO. Once the unbound serum is 
removed a second incubation with Anti EPO rabbit polyclonal antibody bound to 
horseradish peroxidase is performed. This incubation results in the antibody-enzyme 
conjugate binding to the EPO. Once the complex is formed and unfixed conjugate 
removed, chromogen is added to the wells and is oxidised by the horseradish 
peroxidase. This reaction is stopped by the addition of acid. The colour change is 
directly proportional to the amount of EPO in the sample.
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2.8.2 Reagents
Quantikine®IVD® erythropoietin ELISA; R&D Systems Inc. Catalog Number 
DEPOO
All reagents were bought to room temperature before use.
Wash Buffer was warmed to room temperature and gently mixed until crystals had 
dissolved. 100 ml of wash buffer Concentrate was diluted in deionised water to prepare 
2500 ml of wash buffer.
Substrate Solution 1 and 2 were mixed together in equal volumes within 15 minutes of 
use.
The normal range using serum for this assay is 3.3-16.6 mlU/ml
2.8.3 Method
All reagents and specimens were bought to room temperature before use and 
tests were carried out in duplicate. 1:10 dilutions were used for samples.
Samples were added to each well following which the plate was incubated at 
room temperature for 1 hour on an orbital microplate shaker. The wells were aspirated 
dry and Epo Conjugate was added. A second hour-long incubation was carried out on an 
orbital plate shaker. Each well was washed 4 times and blotted dry. Following this 
Substrate solution was added within 15 minutes of preparation and a short incubation for 
20 minutes performed. At the end of this Stop solution was added and the optical density 
determined using a microplate reader set at 450nm.
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2.8.4 Calculation of results
Duplicate readings were averaged and a standard curve of optical density on the 
y-axis against the concentration on the x-axis was plotted and the value calculated from 
the graph.
2.9 C Reactive Protein (CRP)
2.9.1 Principle
The CRP is measured using an ELISA technique. The wells are coated with 
rabbit antibodies to human CRP. Once the antigen-antibody complex forms following 
incubation with sera, the unbound serum is removed and a second incubation is 
performed using a conjugate of peroxidase with anti human CRP antibody. After 
unbound conjugate is removed the strips are incubated with tertramethybenzidine and 
hydrogen peroxide. A blue colour develops which is proportional to the amount of bound 
complex. The reaction is stopped with sulphuric acid and absorbance read at 450nm.
2.9.2 Reagents 
CRP ELISA, DRG Instruments GmbH, Germany (EIA-1952).
All samples and reagents were bought to room temperature prior to testing.
The normal range using serum for this assay is 1-5 ug/ml
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2.9.3 Method
Samples were diluted 1:1000 for this assay as instructed in manufacture’s 
protocol. The calibrators were diluted to 1:100. Tests were performed in duplicate. 10Oul 
of the diluted calibrators and samples were loaded into each of a pair of wells. The plate 
was covered and incubated for 30 minutes at room temperature. The strips were then 
washed three times with wash solution, leaving the solution in the well for 2 to 3 minutes 
for the first wash. Following this, 100ul of conjugate was added to each well and then 
incubated for another 30 minutes at room temperature. Washing was repeated as 
before and then 10Oul each of solution A and B was added to the wells. Following a 10- 
minute incubation 50ul of 2N sulphuric acid was added and absorbance read at 450nm 
within 30min of adding the acid.
2.9.4 Calculation of results
Duplicate readings were averaged and a standard curve of optical density on the 
y-axis against the concentration on the x-axis was plotted. The value for the CRP was 
read by simple interpolation from the graph.
2.10 Serum Pro-hepcidin
2.10.1 Principle
Pro-hepcidin levels were measured using an ELISA technique. The wells were 
coated with rabbit antihepcidin antibody. Samples and controls were incubated and the 
antigen antibody complexes were detected using a streptavidin-peroxidase with the
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substrate tetramethylbenzidine. The colour reaction was stopped with the addition of 
acid and the colour change read at 450 nm.
2.10.2 Reagents 
DRG Hepcidin Pro-hormone ELISA EIA-40155
The assay is temperature sensitive! The manufacturer advises that the assay is 
performed at room temperature ( 1 8 -2 5  °C) only. In our experience the assay is best 
performed at around 20-22 °C.
Lyophilized contents of the standard /control vials were reconstituted with 1.0 ml bidist. 
Water.
Wash Solution: was prepared by adding deionized water to a final volume of 1200 ml. All 
reagents and samples were brought to room temperature before beginning the test. The 
assay was performed with a 1:1 dilution throughout.
Normal range: 56.1 -156 ng/ml
2.10.3 Method
Pro-hepcidin Standards and Controls were dispensed into appropriate wells and 
duplicate samples were placed into the remaining wells. Biotin Conjugate was added 
and the plate mixed thoroughly followed by Incubation for 60 minutes at room 
temperature. The wells were washed 3 times with diluted Wash Solution and 
Streptavidin HRP Complex was then added to the wells and Incubated for 30 minutes. 
This was followed by repeat washings. Substrate Solution was added to each well and 
incubated for 30 minutes and then Stop Solution was added and the absorbance of each 
well determined at 450±10 nm.
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2.10.4 Calculation of results
The Pro-hepcidin value of each sample was obtained as follows :
Using semi log graph paper, a standard curve was constructed by plotting the 
average absorbance (Y) of each Reference Standard against its corresponding 
concentration (X) in ng/ml.
The average absorbance of each sample was used to determine the 
corresponding Pro-hepcidin value by simple interpolation from this standard curve, 
multiplying by the initial sample dilution, if necessary.
Limitations of this assay:
There are several pitfalls and limitations with this assay. We initially ran the 
assay without any dilution and values were found to be on the non linear portion of the 
curve making the results meaningless. The assay was then repeated using a 1:1 dilution 
and the absorbance results were then on the linear part of the curve. The other limitation 
is the temperature sensitivity. We performed this assay in two batches on two separate 
days and were careful to ensure that the temperature in the lab was around 20-22 °C. 
The results however between the controls which were the same on both days were all 
within the normal range although there is considerable variability within the normal 
range.
2.11 RNA extractions
2.11.1 Principle
Paraffin sections are deparaffinised using xylene and ethanol washes followed by 
protease digestion to release the RNA.
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2.11.2 Reagents
Ambion kit (RNA isolation kit cat. No. 1902)
Proteinase K buffer, proteinase K reagent and linear acrylamide were supplied in the kit. 
All other reagents tubes and pipettes used were RNA free products.
2.11.3 Method
10 X 5pm sections (more for biopsies, fewer for large pieces) were cut and 
placed into a 1.5ml tube. 1 ml of xylene was added to these and they were mixed until all 
the wax dissolved. The mixture was then spun at 7000 rpm for 5min following which the 
xylene was aspirated with a pipette. 1ml 100% ethanol was added to the residue and 
thoroughly mixed. This was then spun at 7000 rpm for 5min and the ethanol removed 
with a pipette and this step repeated again. Once the final ethanol was removed the 
residue was allowed air dry at room temperature or at 65°C. To the dried residue was 
added 100jil proteinase K buffer + 5pl proteinase K, and incubated at 45°C for 2 hours. 
The tubes were spun briefly, 600pl of RNA extraction buffer was added and the tube 
vortexed 5 X 5s. After a 5 minute incubation this was then spun at 7000 rpm for 3 
minutes following which 700pl phenol/chloroform was added to the mixture and vortexed 
5 X 5s. A final spin was performed after 5 minutes incubation. The aqueous phase (top 
layer) was transferred to a fresh tube, 1pl of linear acrylamide added, mixed briefly 
followed by 1 volume (approx. 600jJ) of isopropanol. This mixture was left at -20°C 
overnight following which the sample was spun at 13000 rpm for 15min at 4°C and the 
isopropanol carefully removed. 700pl of 70% ethanol (cooled to -20°C) was added and
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spun again. The ethanol was removed and the tube air dried for about 20min before 
adding 20jil RNA storage solution and storing in a -80 freezer.
PCR was undertaken for hepcidin and this is described in more detail in chapter 5 
section
2.12 Cardio magnetic resonance imaging (CMR)
2.12.1 Principle
Iron is paramagnetic and by virtue of this can be quantified by techniques such 
as MRI. MRI uses either T1 (longitudinal) or T2 (transverse) weighted relaxation times 
and the presence of iron results in a reduction of the signal intensity. T2 relaxation times 
therefore become shorter in the presence of iron. The MRI methodology adopted is that 
used by Anderson et al (Anderson, et al 2001) and is described in more detail in chapter 
4.
2.12.2 Method
For the measurement of myocardial T2*, a single short axis midventricular slice 
was acquired using a gradient echo sequence on a Siemens Sonata 1.5T MRI scanner 
at nine separate Echo times (5.6 -18.0ms.). A gating delay time of 0 ms after the R 
wave was chosen so as to obtain images in a consistent position in the cardiac cycle 
and a full thickness region of the intraventricular septum was analysed. For image signal 
analysis, in house software (CMRtools ©Imperial College) was used.
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For the measurement of liver T2* a single transaxial 10mm slice through the 
center of the liver was acquired using a gradient echo sequence at eight different echo 
times (2.3 - 20.0ms).
2.13 Statistical analysis
All data analyses were carried out using Microsoft Excel 2003. The mean 
median, Standard deviation and Standard Error of the mean were calculated. All results 
were expressed as the mean (SEM). Correlations were expressed as the R value and 
the P value for the correlations was calculated using GraphPad prism version 5. The 
students T test was used to perform paired and unpaired analyses and p values <0.05 
considered significant.
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Chapter Three
The relationship between markers of ineffective erythropoiesis, 
oxidative damage and non transferrin bound Iron in children 
with thalassaemia syndromes
3.1 Introduction
Although the natural history of thalassaemia has been altered with the 
appropriate use of transfusion and chelation therapy as discussed in chapter one, 
patients still suffer serious complications from iron overload such as endocrinopathies 
and cardiac decompensation secondary to iron overload (Borgna-Pignatti, et al 1998, 
Borgna-Pignatti, et al 2004, Zurlo, et al 1989).
Oxidative damage secondary to iron overload is thought to be the key reason 
why fibrosis and cell death occur in organs such as the liver in thalassaemic patients. 
Markers of oxidative damage are increased in adults with iron overload (Cheng, et al 
2005, Cighetti, et al 2002, Livrea, et al 1996). It is however, highly likely that a critical 
level of iron burden is necessary for iron to cause damage (Olivieri and Brittenham 1997) 
and it is quite probable that the duration of exposure to high iron burdens is also 
important (Gabutti and Piga 1996).
Patients with Tl also may develop iron overload secondary to increased 
gastrointestinal iron absorption, although this is at a rate slower than that seen with 
blood transfusion. One can postulate that the driver of this increased absorption is
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hypoxia/anaemia leading to increased erythropoietin with expansion of erythropoiesis. 
However, this does not explain why increased iron absorption is not seen in other 
anaemias where EPO levels are increased such as SCA. It is possible that the ‘leakage’ 
of non-transferrin iron into the plasma compartment secondary to the ineffective 
erythropoiesis (but less so with pure haemolysis) may play a role in increased iron 
absorption and oxidative damage in thalassaemia syndromes.
Iron exists in human sera as transferrin bound ferric iron, however once 
transferrin becomes fully saturated then free iron is found in the form of non-transferrin 
bound iron (NTBI). NTBI species can cause oxidative damage by generation of free 
radicals by the Haber- Weiss reaction (Halliwell and Gutteridge 1990). Reactive oxygen 
species such as superoxide can be derived from electron leakage from the mitochondrial 
electron transport chain.
Haber Weiss Reaction:
0 2 #- + H2O2 ____ ^  O2 + OH ' + HO'
This reaction is catalysed by Iron in two steps (Fenton reaction):
Fe 3+ + 0 2 * '  ► Fe 2+ + 02
Fe 2+ + H2 O2 --------► Fe 3+ + OH' + HO'
Hydroxyl radicals (OH*) can cause lipid peroxidation (Aust, et al 1985, Halliwell 
and Gutteridge 1990), oxidation of cellular proteins, lipoproteins, nucleic acids, and other 
cellular constituents. Cell death results in fibrosis and loss of organ function and hence 
the complications of iron overload (Britton, et al 2002, Fleming and Bacon 2005, 
Houglum, et al 1990, Junge, et al 2001).
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There are a great many markers of oxidative damage that can be assessed but 
in this chapter we will examine the relationship between ineffective erythropoiesis, NTBI 
and malondialdehyde (MDA) and carbonyls.
3.1.1 Non transferrin bound iron (NTBI)
In the healthy physiological state in non-iron overloaded humans, iron is 
transported in the plasma as transferrin bound ferric iron. Transferrin is a key component 
of plasma and is the carrier protein that transports non-heme iron from sites of 
absorption or release to cells where it will be utilised. In health, transferrin is 20-35% 
saturated with iron and this is the only major form of non-heme iron in the plasma. In 
conditions of iron loading such as thalassaemia syndromes, transferrin rapidly becomes 
fully saturated and the plasma transport of additional reticuloendothelial derived iron 
cannot occur via the transferrin pathway. Under these conditions NTBI is formed.
NTBI was first identified by Hershko in thalassaemic patients in whose sera 
chelatable iron was measured in the presence of a fully saturated transferrin. When 
thalassaemic sera was added to normal sera the chelatable iron could no longer be 
detected (Hershko, et al 1978). NTBI was then found to occur in other iron loading 
conditions such as haemochromatosis and was linked to oxidative damage in vitro 
(Gutteridge, et al 1985). NTBI was also found to be present in patients with evidence of 
ineffective erythropoiesis but no iron overload (Cortelezzi, et al 2000, Gafter-Gvili, et al 
2004, Wickramasinghe, et al 1999).
There are two main principles applied for the methods that are in use currently 
for measurement of NTBI. The majority of methods are based on iron mobilisation, using 
shuttle molecules such as nitrilotriacetic Acid (NTA) followed by separation of chelated 
iron by ultrafiltration and detection using methods such as High performance Liquid
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Chromatography (HPLC), atomic absorption, spectroscopy and inductive 
conductiometric plasma spectrometry (ICP) (Gosriwatana, et al 1999, Loreal, et al 2000). 
Other methods are based on the mobilisation and detection of iron without separation 
of it from plasma proteins; such as the use of flourescein probes which are sensitive to 
iron in an ELISA based method (Breuer and Cabantchik 2001) or measurement of 
redox- active iron using Bleomycin (von Bonsdorff, et al 2002).
There is significant variation in NTBI values obtained from the different methods 
used as shown by a recent study (Jacobs, et al 2005).
NTBI has been measured in this study using a method based on iron mobilisation 
on to NTA followed by separation of mobilised iron using ultrafiltration. The NTBI was 
then detected using HPLC using the method first described by Singh (Singh, et al 1990).
From the time that Hershko first described the presence of NTBI in the sera of 
thalassaemic patients, many studies have confirmed the presence of NTBI in patients 
with thalassaemia (al-Refaie, et al 1992a, Cappellini, et al 2000, Cighetti, et al 2002, De 
Luca, et al 1999, Grosse, et al 2005, Pootrakul, et al 2004, Wang, et al 1986) but of 
these studies only Wang and De Luca looked at NTBI in children with established 
transfusional iron overload. Pooktrakul and Cappellini looked at NTBI in Tl and both 
found that levels were raised in the absence of transfusion.
No studies to date have looked at the appearance of NTBI in children very early 
on in the disorder to see if there is NTBI present, which may be related to ineffective 
erythropoiesis. In addition what happens to the NTBI secondary to ineffective 
erythropoiesis once transfusion support is initiated as well as whether there is a critical 
iron burden at which NTBI appears secondary to iron overload has not been studied. In 
this chapter the relationship between NTBI and the degree of transfusional load, as well 
as the effect of transfusion on NTBI in previously untransfused children will be 
discussed.
Page 92 of 278
3.1.2 Markers of oxidative damage
Reactive oxygen species such as the hydroxyl radical and superoxide which can 
be generated in the presence of NTBI (Gutteridge, et al 1990), cause oxidation of 
cellular proteins, lipids etc. and result in the formation of stable end products that can be 
measured (Halliwell and Chirico 1993). Lipid peroxidation products are predominantly in 
the form of very reactive a,(3-unsaturated aldehydes such as malondialdehyde (MDA), 
acrolein, and 4-hydroxy-2(E)-nonenal (HNE) (Picklo, et al 2002). These then go onto 
cause further oxidative damage in the form of protein alkylation, cross linking, 
mitochondrial dysfunction, altered nuclear signalling, inhibition of membrane transporters 
and further generation of reactive oxygen species (Del Rio, et al 2005). Oxidation of 
amino acids within proteins results in the conversion of amino side chains to intra protein 
aldehydes such as glutamic semialdehyde (from peroxidation of lysine and proline) and 
2-amino-3-ketobuytric acid (from peroxidation of threonine) (Picklo, et al 2002). These 
intraprotein aldehydes (protein carbonyls) again can cause further oxidative damage as 
above (Reznick and Packer 1994).
3 .1.2.1 Malondialdehyde ( MDA)
MDA is one of the products of peroxidation of polyunsaturated fatty acids under 
conditions of oxidative stress. At neutral pH, MDA is of low reactivity but is still able to 
react with nucleic acid bases and form a number of toxic adducts such as pyrimido-[1,2- 
a] purine10(3H)-one deoxyribose which can cause sequence dependant frameshift 
mutations and base pair substitutions in mammalian cells. It can also form inter-strand
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DNA cross-links as well as resulting in the formation of DNA- protein cross-links (Del 
Rio, et al 2005). These products damage the DNA and are ‘genotoxic’. MDA like species 
are also thought to be involved in atherogenesis, by impairing the interaction between 
Low density Lipoproteins (LDL) and macrophages (Palinski, et al 1994). The most 
important effect of MDA however remains in its propensity for cross-linking collagen 
(Slatter, et al 2000). This may explain in part why fibrosis and cirrhosis are seen in 
patients with high iron burdens.
MDA exists in free and protein-bound forms. The free forms are not bound to any 
plasma protein and can be detected without any hydrolytic pre-treatment. The bound 
forms however are bound to different protein matrices and need to be liberated prior to 
measurement. Very little is known about the relative pathophysiological effects of the 
free and bound forms.
A number of methods are used for measuring MDA and the majority of them are 
based on derivation with thiobarbituric acid (TBA). The TBA forms an adduct with MDA 
which can then be measured using a spectrophotometric or a HPLC based method. 
Most methods involving TBA will measure total MDA (free and bound) because of the 
strong acidic and high temperature conditions required for the formation of the TBA- 
MDA adduct. The range of values for MDA has varied greatly in different studies and 
this variability is thought to be partly due to differences in the degree of matrix oxidation. 
Methods measuring TBA-MDA adducts without any refinement to overcome the matrix 
oxidation describe the final product as TBA Reactive substances (TBARS) and are 
essentially a global measure of lipid peroxidation.
This problem of matrix oxidation has been overcome to some extent by the 
addition of a step that precipitates the protein prior to oxidation with TBA such as using 
buytlated hydroxytoluene (BHT) (Halliwell and Chirico 1993). A number of workers have 
also tried to overcome the problems of protein matrix oxidation by removing the protein
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precipitation step and using florescence to detect MDA such as the method used by Del 
Rio (Del Rio, et al 2003). Other methods of measuring MDA are without the TBA 
derivation step and can detect both total MDA using strong acidic conditions or free MDA 
if the precipitation step is avoided. Only with gas Chromatography- Mass Spectroscopy 
(GC MS) are reaction conditions relatively mild, however this method still requires strong 
hydrolysis for the measurement of total MDA (Cighetti, et al 1999).
There are a number of studies looking at MDA in thalassaemia patients 
(Cappellini, et al 2000, Cighetti, et al 2002, Livrea, et al 1996, Meral, et al 2000, 
Naithani, et al 2006). Cighetti et al looked at a small number of adult beta thalassaemia 
using GC-MS and found levels to be raised significantly in TM. The study by Cappellini 
assessed adult non-transfused Tl patients and found raised levels of MDA using a TBA 
based spectrophotometric assay. Livrea et al assessed MDA in both adults and children 
but the data was analysed as a single cohort and found that levels were raised. Only 2 
studies (Meral, et al 2000, Naithani, et al 2006) analysed markers of lipid peroxidation in 
children specifically: Meral et al looked at TBARS and Naithani at MDA, both finding 
raised levels in these children. Naithani’s study looked specifically at MDA and although 
the patient groups included children who had received very few transfusions, the data 
was not analysed for this group separately and therefore could not determine if there 
was a critical threshold of iron burden above which lipid peroxidation appears.
In this chapter, oxidative markers in children with thalassaemia disorders have 
been measured to see if damage starts early in life or whether this is a late effect 
occurring only after many years of excess iron loading.
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3.1.2.2 Protein carbonyls
Protein carbonyls are generated when the side chain amino groups of amino 
acids within proteins are oxidised to form various aldehydes, resulting in the formation of 
further reactive species such as peroxides, bromamines and chloramines (Davies 2005). 
Oxidation of protein amino acid side chains can result in unfolding of the protein 
molecule and functional defects then may arise. These are generally not repairable. 
There is some evidence that chelation therapy is protective and may reduce the amount 
of oxidative damage secondary to iron (Cornejo, et al 2001, Reznick, et al 1992).
There are a number of methods for measuring protein carbonyls. The most well 
described is the method developed by Reznick and Packer which uses 
dinitrophenylhydrazine (DNP) to bind carbonyls which can then be detected 
calorimetrically using spectrophotometry (Reznick and Packer 1994). To overcome 
some of the limitations of the original method, this basic principle has been used to 
either detect or quantify protein carbonyls by a variety of techniques such as HPLC 
(Levine, et al 1994) western blot analysis (Shacter, et al 1994), or ELISA (Buss, et al 
1997). Recently chemiluminescence which measure both protein and lipid carbonyls 
has also been used (Shnizer, et al 2003). In this study we used the original method as 
modified by Carmine (Carmine, et al 1995) and described in chapter 2.
There is little published data on carbonyls in patients with thalassaemia (Livrea, 
et al 1996, Ramenghi, et al 1989). It is unclear at which age oxidative damage starts and 
in the Livrea study the number of children was small and the results of the oxidative 
markers analysed as a single group finding that protein carbonyls were raised.
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3.1.3 Markers of ineffective erythropoiesis
3.1.3.1 Erythropoiesis in nomnal and in thalassaemia states:
Erythrogenesis is dependent on a number of factors which when disrupted may
result in ineffective erythropoiesis.
Iron is essential for normal erythropoiesis as discussed in chapter 1. Under 
normal physiological conditions, iron absorbed from the intestine or recycled from red 
cell turnover is transported from the enterocyte to the erythroblasts via transferrin. 
Transferrin binds to the transferrin receptor and iron is taken into the cell by receptor- 
mediated endocytosis. Once iron enters the cell, erythropoiesis can be completed with
the formation of haemoglobin (Conrad, et al 1999).
In p thalassaemia syndromes, globin chain imbalance results in the precipitation 
of unpaired a globin in developing red cells in the bone marrow, causing ineffective 
erythropoiesis and early destruction of red cells in the circulation and the resultant 
haemolysis. The combined effects of ineffective erythropoiesis and haemolysis result in 
anaemia. The kidney detects the hypoxia resulting from anaemia; this then result in 
increased erythropoietin synthesis and secondary proliferation of erythropoiesis and 
erythropoietic tissue, which is reflected, by the increase in transferrin receptors.
The relationship between iron mediated oxidative damage and ineffective 
erythropoiesis is unclear. It has been shown in untransfused Tl patients that NTBI is 
present at measurable levels in the serum (Cappellini, et al 2000, Cighetti, et al 2002). It 
is important to attempt to determine whether NTBI secondary to ineffective 
erythropoiesis plays a role in oxidative damage.
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3.1.3.2 Erythropoietin (EPO)
The vital roles of erythropoietin (EPO) and the erythropoietin receptor (EPO-R), 
the role of stem cell factor (SCF) and its receptor c-Kit, as well as the intracellular 
signalling pathways that these receptors activate and their role on erythroid proliferation 
and survival have been all been clarified in recent years (Munugalavadla and Kapur 
2005).
EPO is a 30,400 Dalton glycoprotein, which belongs to the class 1 cytokine 
family and initiates the signal for erythropoiesis by activating Janus Kinase 2 (JAK2). 
The activated JAK2 then is incorporated onto phosphorylated multiple tyrosine residues 
at various points on the EPO receptor (EPO-R). These then activate a number of 
intracytoplasmic signalling molecules that are involved in cell proliferation and cell 
survival (Munugalavadla and Kapur 2005).
EPO is produced by the peritubular cells in the kidney in adults and the 
hepatocytes in the foetus. It is secreted in response to hypoxia and anaemia (Fisher 
2003). In normal healthy adults who are not anaemic, levels are found to vary between
1.6-34 mill/ml and are raised in those patients with iron deficiency anaemia or 
haemolytic anaemia (Boyd and Lappin 1991, Haddy 1982, Roque, et al 2001) , Patients 
with anaemia secondary to renal insufficiency have low levels of EPO relative to the 
degree of anaemia (de Klerk, et al 1982, McGonigle, et al 1985, McGonigle, et al 1984) 
as do those patients with anaemia of chronic disease (Boyd and Lappin 1991, Gasche, 
et al 2004, Souweine, et al 1995).
Many studies on EPO have been undertaken on thalassaemia carriers and those 
with Tl and TM (Camaschella, et al 1996, Cazzola, et al 1995, Dore, et al 1996, El- 
Nawawy, et al 2002, Galanello, et al 1994, Kalmanti, et al 1991, Nisli, et al 1997, 
Paritpokee, et al 2002). All of these studies have shown that EPO levels are raised in
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transfused TM patients and in intermittently or non-transfused Tl patients. The levels of 
EPO in TM patients tend to be raised despite ‘hyper’ transfusion regimes. Cazzola 
showed the EPO level varied according to the severity of the pre-transfusion anaemia 
and Kalmanti showed that in some patients EPO could be suppressed into the normal 
range. The raised EPO in Tl patients is invariably due to the hypoxia induced by 
anaemia and studies where the HbF% has been used to help determine severity of 
tissue hypoxia such as those by Galanello and Chamaschella have shown that EPO 
levels tend to be higher in those patients with Tl phenotypes associated with high HbF.
There has been much interest over the years in the potential use of EPO to help 
reduce the frequency of transfusions. Some workers have used recombinant human 
EPO (rHuEPO) either alone or with other modifiers of HbF production such as 
hydroxyurea (Chaidos, et al 2004, Makis, et al 2001, Olivieri, et al 1992, Rachmilewitz 
and Aker 1998, Rachmilewitz, et al 1991) with variable benefit. What has been noted is 
that higher doses of rHuEPO are required in thalassaemia patients and the increased 
erythroid drive is reflected by the increase in sTfR levels in those patients who respond 
(Chaidos, et al 2004, Dore, et al 1996).
3.1.3.3 Soluble transferrin receptor (sTfR)
Iron exists in the plasma in normal individuals as transferrin bound iron. 
Transferrin is the plasma protein responsible for transport of iron to various cells 
throughout the body that require iron. Transfer of iron occurs when transferrin binds to 
the transferrin receptors, which are membrane bound glycoproteins, allowing iron to 
enter into the cell by receptor mediated endocytosis of transferrin (Lamb, et al 1983, 
Yamashiro, et al 1984). The vast majority of transferrin receptors are found on the 
erythroid precursors of the bone marrow (80%) but significant numbers are also found
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on the placenta and rapidly dividing cells in S phase (Beguin 2003). Although 
reticulocytes express transferrin receptors, mature red cells do not. The soluble 
transferrin receptor (sTfR) is a truncated monomer of the transferrin receptor lacking the 
initial 100 amino acids circulating in the serum as a complex with transferrin. STfR are 
thought to originate from erythroblasts and to reflect bone marrow activity. The number 
of sTfR in the bone marrow is dependant both on the amount of iron available to cells 
and on the number of erythroid cells (Beutler, et al 2003). Iron deficiency leads to 
increased transferrin expression on developing erythroblasts and this is reflected by 
increased sTfR (Skikne, et al 1990). In hypoplastic erythropoiesis such as renal failure, 
aplastic anaemia or post chemotherapy sTfR is decreased, whereas sTfR is increased in 
conditions where there is an increased erythroid drive or erythropoietic expansion such 
as haemolytic anaemia, megaloblastic anaemia and polycythaemia (Beguin 2003, 
Ponchio, et al 1992, Roque, et al 2001). There is also a close relationship between 
ferrokinetic measurements of erythropoiesis and sTfR levels (Beguin, et al 1993, 
Cazzola, et al 1987). It is now a useful tool in distinguishing between anaemia of chronic 
disease and iron deficiency.
Many groups have looked at the relationship between sTfR and erythroid mass in 
thalassaemia (Camaschella, et al 1996, Cazzola, et al 1999, Cazzola, et al 1995, Dore, 
et al 1996, El-Nawawy, et al 2002, Galanello, et al 1994). All these studies have shown 
increased levels of sTfR in thalassaemia patients and that in patients with TM who follow 
hyper-transfusion regimes; these levels are suppressed into the normal range.
3.2 Study Rationale
It is unclear at which age or at what degree of iron loading, NTBI appears and its 
relationship to the advent of tissue damage is as yet undetermined. It is also unclear
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when and at what iron burden oxidative damage starts: many thalassaemia patients 
develop evidence of pituitary dysfunction such as delayed puberty and primary 
amenorrhea at an early age, which is thought to be secondary to iron overload. Only a 
few investigators have looked into the relationship between iron burden and oxidative 
damage in thalassaemia syndromes.
It was decided to attempt to answer 3 specific questions with this study:
I. Is there a difference in base-line parameters such as Hb, NTBI, EPO, sTfR, 
carbonyls and MDA in patients with thalassaemia disorders based on their 
demographics? These variables were therefore compared in patients treated in 
developed countries (Canada, UK) and patients treated in Sri Lanka.
II. In patients with thalassaemia disorders, either transfused on non-transfused, is 
there a relationship between the markers of iron burden, ineffective 
erythropoiesis and oxidative damage and does this change with time?
III. When does NTBI appear in thalassaemia patients, what is its relationship to 
transfusional iron load?
3.3 Patients and treatment centres
51 patients with TM or Tl were enrolled into the study from three centres. Two 
centres were in countries where optimal treatment was readily available for both 
transfusion and chelation, funded either by the National Health Service or by Private 
Healthcare, the London Centre was University College London Hospitals (UCLH) and 
the other was Hospital for Sick Children, Toronto (HSC). Management at the London 
Centre was lead by Professor John Porter and in Toronto by Dr Melanie Kirby-Allen
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(Sick Kids) and Dr Nancy Olivieri (Toronto General Hospital). These patients were 
recruited from November 1999 and the first samples were taken in March 2000. For this 
study the last patient samples to be included in the analysis were up to March 2004. 
There were 2 patients from London and 17 from HSC Toronto.
The third centre was in Kurunegala, Sri Lanka, where care was provided free of 
charge to the thalassaemic patients. Kurunegala State is in the South of Sri Lanka and 
was found to have the highest prevalence of thalassaemia. Prior to the start of this 
study, thalassaemia care had been undertaken on an ad hoc basis by the medical staff 
working in the State. Patients kept their own records and attendance for transfusion was 
often dependant on symptoms. There was no clear policy on the transfusion 
requirements of patients and very little distinction made between Tl and TM patients by 
junior medical staff. It was decided by the senior clinician Dr Shanitmala de Silva to set 
up a collaboration with the Weatherall Institute in Oxford UK, and a centre was 
established in Kurunegala known as the National Thalassaemia Centre (NTCK) just prior 
to the start of the study, which looked after 300 patients with TM and 200 with E p 
thalassaemia (Premawardhena, et al 2004).
Mutational analysis had shown that a third of the thalassaemia population had E 
p thalassaemia and remainder of the population were either homozygous or compound 
heterozygotes for various p thalassaemia mutations and would have severe transfusion 
dependant anaemia. 24 different p mutations were identified and 4% of the population 
had triplicated or quadruplicated a gene defects.
A dedicated team of doctors comprising Drs Mahinda Arambepola, Ravindra 
Samaranayake, and Uditha Perera looked after the patients on a routine basis. Four 
monthly visits to the centre were carried out. Professor Sir David Weatherall from the 
Weatherall Institute in Oxford, UK, and Professor Nancy Oliveiri, Giulia Muraca and 
Laura Merson (research associates) from the University Health Network based at
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Toronto General Hospital, Canada, comprised the team of international experts. The 
team of local and international experts saw patients and management was reviewed at 
these visits. Patients who had a Tl phenotype (tolerant of anaemia with lower transfusion 
requirements) were weaned of transfusions slowly and those with significant iron 
overload were also chelated. Patients with TM phenotypes (thalassaemic facies, 
enlarged spleen, intolerant of significant anaemia) were started on regular transfusion 
support to maintain appropriate haemoglobin according to international criteria. A total of 
37 patients were recruited from this site with samples dates between the October 2001 
and November 2002 available for analysis.
At this time, patients who had been enrolled into the study had samples taken 
for NTBI and markers of ineffective erythropoiesis. The research associates collected 
samples for the assays from patients and ensured that all sample handling, freezing and 
shipping protocols were followed. The samples were stored at -20° C and transported in 
dry ice with the researchers to Oxford, UK and then couriered to UCLH making sure at 
all times that the cold chain was not broken.
A NIH Grant (DK55462) was awarded for this study and ethical approval was 
obtained for the studies from all the centres from which the patients were enrolled.
TM patients form the UCLH/HSC centres were those who required transfusion at 
3 to 4 weekly intervals. TM patients from NTCK received transfusion support at 3 to 6 
weekly intervals predominantly due to lack of awareness as to the need for regular 
transfusion. Tl patients in the UCLH/HSC cohort were those who were transfusion 
independent or required <8 transfusions/annum. All of the UCLH/HSC Tl (n=4) did 
become transfusion dependent and required transfusion support at 3 to 4 weekly 
intervals. In these patients data was included for the Tl cohort only up to the time they 
required regular transfusion. Their results from post transfusion dependence were 
included in the TM cohort.
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All patients with TM were recruited into the study before the age of 6 and all Tl 
patients before the age of 9 yrs. UCLH/HSC patients comprised 23 patients (19 TM and 
4 Tl) and the NTCK cohort consisted of 28 patients (18 TM and 10 Tl). 9 patients were in 
the study for 3 or more years.
Samples were collected 4 monthly into aluminised vacutainers and processed as 
described in chapter 2. Desferrioxamine was interrupted at least 48 hrs prior to sampling 
and the samples were collected with the pre-transfusion cross match and full blood 
count. Data was collected on transfusion and chelation.
Table 3.3.1.1: Patient characteristics for all groups
Patient characteristics All patients Thalassaemia major #
Thalassaemia 
intermedia *
Age years (mean ± SEM) 3.95 (0.12) 4.62 (0.27) 4.8 (0.25)
Total number UCLH/HSC 23 19 4~
Total number NTCK 28 18 10A
Patients in study <1 yr 19 12 7
Patients in study >1<2 yrs 17 15 2
Patients in study>2< 3 yrs 5 3 2
Patients in study >3 <4 or more yrs 8 6 2
Patients in study >4 or more yrs 1 1 0
Legend: total of 51 patients in the study. 28 patients from NTCK and 23 patients from 
UCLH/HSC, 21 who were treated at Hospital for Sick Children, Toronto, Canada, and 2 at 
University College Hospital London.
if: All UCLH/HSC TM patients transfusion dependant 3 to 4 weekly. All NTCK TM patients 
transfusion dependant but transfused between 3 to 6 weekly
*TI: intermittently transfused or transfusion independent ~ all Tl started transfusion (range 3.5 yrs 
to 7.5 yrs)
A 4 are transfusion independent 2 previously transfused, 2 never transfused
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3.4 Methods
Samples were processed as described in chapter 2 and assays performed for 
NTBI, MDA, carbonyls, serum erythropoietin, and serum transferrin receptor.
Samples at UCLH were collected when the patients attended clinic at four monthly 
intervals, processed as per the protocols described in chapter 2 and frozen at -80 within 
an hour. The samples from HCS were handled similarly and were shipped every 4 
months to UCLH via FedEx in dry ice. The samples are then stored at -80°C with the 
other samples for this study. NTBI and transferrin saturation was measured in all the 
samples within a month of the sample being taken from the patient (UCLH) or arrival at 
UCLH (NTCK and Toronto) and always within 3 months. The sTfR, EPO, Carbonyls and 
MDA measurements were undertaken on samples on a yearly basis using samples that 
had not been defrosted previously. Any samples that were found to be unintentionally 
defrosted on arrival were not used in the analysis.
3.5Statistical analyses
Analysis was undertaken on the patients according to the type of thalassaemia. 
Further sub analysis was carried out in a number of cohorts as described below. The 
first analysis was on all patients from the 3 centres and is described in the text as ‘All 
Patients’. The second analysis of data was according to centre i.e. UCLH/HSC 
compared to NTCK, to see if demographic and socioeconomic issues had an impact on 
levels of NTBI, EPO, sTfR, and markers of oxidative damage. The third set of sub 
analysis was to see if there is a relationship between individual markers of oxidative 
damage or ineffective erythropoiesis. Mean, median, standard deviation, standard error 
of the mean and students T test (unpaired arrays 2 tail and 2 sample equal variance)
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were used to carry out the statistical analysis. All results in the tables are expressed as 
the mean (SEM). Correlations were carried out to see if there was a significant 
relationship between different parameters. P values for the correlations were calculated 
using GraphPad Prism version 5 software.
For section 3.8.3 all patients who were monitored prior to their first ever transfusion were 
separately analysed to look specifically at the appearance of NTBI and what happens to 
NTBI with the initiation of transfusion.
3.6 Overview of variables based on Underlying Disorder and Centres of treatment
3.6.1 Overview of results based on type of thalassaemia
In the first analysis undertaken, the key parameters measured were compared in 
all patients with TM or Tl as defined above, independent of whether they were treated 
primarily in Sri Lanka, London or Toronto. The mean pre transfusion Hb, sTfR, and EPO 
are shown as markers or erythropoiesis. Markers of oxidative damage include protein 
carbonyls and MDA. Markers of iron metabolism include NTBI, transferrin saturation 
and serum ferritin.
Normal range for healthy normal adult controls in our lab were:
EPO: 6.27 mlU/ml ± 2.99 mlU/ml; range 1.07 mlU/ml-10.5 mlU/ml; n=13 
Carbonyls: 0.71 nmol/mg ± 0.08 nmol/mg; range 0.33-1.07 nmol/mg; n=12 
MDA: 0.27 uM ± 0.22uM; range 0.03-0.68uM; n=22 
The sTfR range was 0.3 to 8.5mg/l for the kit used.
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Table 3.6.1.1: Mean values for all parameters in all patients
Parameter (SEM) TM (SEM) 
n=37#
Tl (SEM) 
n=14* P
Pre transfusion Hb g/dl 9.23 (0.12) 7.24 (0.29) <0.0001
ferritin (ng/ml) 1274 (40.1) 491.5(89) <0.0001
Cumulative iron load from 
transfusion (g) 4.55 (0.25) 0.96 (0.31) <0.0001
NTBI (umol/l) 3.92 (0.19) 2.12(0.47) <0.001
transferrin saturation 83.1 (1.54) 62.5(4.01) <0.0001
erythropoietin mlU/ml 422 (64.6) 667 (115.9) ns
MDA (uM) 0.14(0.02) 0.28 (0.06) 0.02
carbonyls (nmol/mg) 0.77 (0.02) 0.75 (0.06) ns
soluble transferrin receptor (mg/l) 7.18(0.4) 17.22 (1.24) <0.0001
Legend:
# :TM; all TM n=37 and + 4 Tl (HSC) once they became transfusion dependant at 4 weekly
intervals. Total samples analysed from TM or transfusion dependant Tl = 222 samples
*: Tl; all Tl n-14 and -4 (HSC) once they became transfusion dependant. Results up to the time
of first blood transfusion were included as Tl and all results from time when they were transfused
4 weekly were included in the TM cohort. Total samples analysed for Tl=40
ns: not significant
As can be seen, when all patients were analysed according to the underlying 
severity (Tl versus TM) there were differences in the ferritin, NTBI, transferrin saturation, 
MDA and soluble transferrin receptors (sTfR).
One would expect the Hb to be lower in the Tl and the ferritin would be higher in 
the TM because of the frequency of blood transfusion and subsequent iron loading. The 
sTfR was higher in the Tl and as previously discussed sTfR is a reflection of the bone 
marrow erythroid mass, and the bone marrow activity is expected to be greater in 
patients who are more anaemic or less frequently transfused.
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It is clear from Table 3.6.1.1 that NTBI and transferrin saturation is higher in TM 
patients than in Tl. Further analysis in this chapter will seek to identify whether the 
presence of NTBI in Tl patients is primarily a consequence of iron load (as suggested by 
raised serum ferritin), or a consequence of a higher degree of ineffective erythropoiesis 
as suggested by higher sTfR in Tl patients.
In addition it is clear that carbonyls and MDA levels are normal in comparison to 
healthy adult controls and although there is a statistically significant difference in the 
MDA levels in the two forms of thalassaemia in young children, these are still within the 
normal range for our lab, accepting the fact that the MDA and carbonyl levels are not 
known for healthy non thalassaemic age matched children. This may suggest that lipid 
and protein peroxidation is a relatively late event developing after a period of prolonged 
exposure to higher iron burdens. In addition the fact that levels are within the normal 
range eliminates the possibility of poor sample handling as a factor. Previous workers 
(Naithani, et al 2006) have found raised levels on MDA’s in children with thalassaemia 
but looked at children up to the age of 18 years with a mean ferritin of >3000ng/ml and 
average years of transfusion of 8.6 years. The children in the study by Naithani had had 
a much longer duration of exposure to iron and a higher iron burden compared to those 
patients in our study.
3.6.2 Overview of differences in variables according to patient treatment 
Centres
Before going on further to analyse the various factors affecting NTBI and other 
variables, it was important to see if there was a significant difference between centres. 
Tables 3.6.2.1 and Table 3.6.2.2 take the data in Table 3.6.1.1 and split it into patients
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treated at UCLH/HSC (Table 3.6.2.1) and those treated at NTCK, Sri Lanka, (Table 
3.6.2.2).
Table 3.6.2.1: Table of parameters for all UCLH/HSC treated patients
Parameter (SEM) TM (n=19) # Tl (n=4) * P
Pre transfusion Hb g/dl 9.4 (0.1) 8.0 (0.24) 0.0004
Ferritin (ng/ml) 1306 (41.4) 217.6 (21.5) 0.0001
Cumulative iron load (g) 5.07 (0.29) 0 <0.0001
NTBI (umol/l) 4.06 (0.21) 1.05 (0.26) <0.0001
Transferrin saturation 81.1 (1.78) 49.2 (2.78) <0.0001
Erythropoietin mlU/ml 219 (41.1) 513(40.84) ns
MDA (uM) 0.07 (0.01) 0.17(0.01) 0.0200
Carbonyls (nmol/mg) 0.74 (0.06) 0.74 (0.06) ns
Soluble transferrin receptor (mg/l) 6.26 (0.37) 19.1 (1.17) <0.0001
Mean liver iron mg/g dw 8.7(0.71) ND NA
Legend:
#: TM; (n-19 TM and +4 Tl whose results are included post start of 4 weekly transfusions) all 
patients were on regular transfusion support at 3 -4 weekly intervals as discussed. Total samples 
analysed for TM-178
*: Tl; All Tl became transfusion dependant at 3 -4 weekly intervals. Tl values are results for 
parameters prior to patient starting regular transfusion. Total samples analysed for Tl =17 
NS: not significant 
ND: not done 
NA not applicable
Chelation therapy was started on 13 of these children at the time of the analyses 
and the median dose was 2.4g ± 2g of desferrioxamine per week. The 6 patients who 
had not started chelation at this time had not fulfilled the clinical criteria required for 
initiation of chelation at that time.
These results show that NTBI is present at relatively high levels in these children 
who have moderate to low iron burdens as reflected by the mean ferritin and liver iron.
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The sTfR remains high in the Tl patients and the markers of oxidative damage remain 
normal.
The Tl patients from HSC were two sets of siblings. The first pair had codon 39 / 
IVS 1-6, aa/aa, and started transfusion support aged at around the age of 3.5 and 4.2 
years at HSC when the Hb fell below 7 g/dl and there was evidence of failure to thrive. 
The second pair had codon 8/9 / IVS 11-1, -a 37/aa, starting transfusion aged 6 and 7.5 
years, they were lost to follow up in the year immediately prior to them starting 
transfusion due to the family moving away from the area, on their return to the clinic at 
HSC for annual review relevant transfusion history was collected, the reason for initiation 
of transfusion at the peripheral hospital remains unclear but is presumed that transfusion 
was initiated due to symptomatic anaemia. It is highly likely that the first pair of siblings 
were potentially TM but had some form of ameliorating factor resulting in the delayed 
development of symptomatic anaemia. The second pair of siblings had less globin chain 
imbalance due to the coinheritance of a single gene deletion alpha thalassaemia.
Interestingly these patients have detectable levels of NTBI in the presence of 
unsaturated transferrin prior to them starting transfusion support and also raised levels 
of sTfR. It is possible that the form of NTBI prior to initiation of transfusion and the 
development of significant iron loading in Tl patients is different to that post transfusion 
or secondary to iron load.
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Table 3.6.2.2: parameters in all NTCK treated patients
Parameter (SEM) TM (n=18)# Tl (n= 10) * P
Pre transfusion Hb g/dl 7.74 (0.33) 6.3 (0.37) 0.03
Ferritin (ng/mi) 1076 (72.6) 866 (111) ns
Cumulative iron load (g) 2.43 (0.26) 1.66 (0.48) ns
NTBI (umol/l) 3.61 (0.39) 3.39 (0.76) ns
Transferrin saturation 90.2 (2.43) 78.1 (5.43) ns
Erythropoietin mlU/ml 1253 (240) 791 (190) ns
MDA (uM) 0.41 (0.06) 0.37 (0.10) ns
Carbonyls (nmol/mg) 0.72 (0.06) 0.78 (0.08) ns
Soluble transferrin receptor (mg/l) 12.83(1.23) 16.02(1.79) ns
— — —
Legend:
#: TM; (n=18) all patients were on regular transfusion support at 3 to 6 weekly intervals as 
discussed. Total samples analysed for TM=42
*: Tl; all patients were either transfused intermittently t >8 week intervals or had never been 
transfused (n=2). 4 had not received transfusion in the last year as per table 3.3.1.1.
All the Tl patients (as defined as less than 8 transfusions /year) had HbE(3 
thalassaemia but the exact beta chain mutation and the presence of any alpha chain 
defect was not available at the time of this analysis. The majority of those patients with 
Tl phenotype were eventually weaned off transfusion. The NTBI, transferrin saturation, 
ferritin, MDA and sTfR are similar between the TM and Tl patients at NTCK. It is 
noticeable that in NTCK the Tl patients receive some transfusion and the TM patients 
receive less transfusion than in UCLH/HSC. Thus the difference between ‘T l’ and ‘TM’ is 
less in the NTCK patients. This may explain why NTBI is relatively raised in the Tl 
patents in NTCK compared with those at UCLH/HSC. The lower transfusion regimen in 
‘TM’ treated at NTCK is reflected in the lower mean Hb values, the higher sTfR (which is
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nearly double that of UCLH/HSC patients) and the higher EPO levels (which are 6 times 
higher than the UCLH/HSC patients.
What can be seen clearly from this table is that the NTBI is present at 
significantly raised levels in both the Tl and TM patients and that Tl patients are similar 
to TM patients with respect to NTBI in Sri Lanka but not at UCLH/HSC. This may be due 
to the cumulative iron load but may also be related to the degree of erythropoietic stress 
as reflected by the greater degree of anaemia and raised levels of EPO and sTfR 
compared to the UCLH/HSC cohorts. As mentioned in section 3.3 transfusions were 
reduced and then stopped in patients with Tl during the course of the study and poorly 
transfused TM patients had their frequency of transfusion increased. Although at the 
time of this interim analysis the cumulative iron burden is similar this should become 
dissimilar as more longitudinal data is obtained.
3.6.3 Discussion of differences between patients at NTCK and UCLH/HSC
There are significant differences between the cohorts in Tables 3.6.2.1 and 
3.6.2.2. Cumulative iron load is higher in the TM patients from UCLH/HSC, the mean 
pre-transfusion Hb is lower in NTCK patients, and the MDA levels although still within in 
the normal range for our assay (range 0.03-0.68uM) (n=22) are significantly raised in the 
NTCK patients.
The cumulative iron load is highest in the TM patients from UCLH/HSC as they 
have been on optimal transfusion regimes while the TM from NTCK had lower 
cumulative iron as they were on less rigorous transfusion schedules. Tl patients from 
NTCK had a higher cumulative iron compared to those from UCLH/HSC because these 
patients prior to the start of the study had been on intermittent transfusion regimes 
primarily due to the lack of knowledge amongst staff treating them at the time.
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The TM NTCK cohorts were considerably more anaemic than those from 
UCLH/HSC with the mean pre-transfusion Hb about 2g below that seen in UCLH/HSC 
patients. Thus, as expected blood transfusion is associated with lower EPO values in 
the hyper-transfused UCLH/HSC patients (219 mlU/ml) than the low transfusion 
frequency patients in NTCK (1253 mlU/ml). This is also reflected in the levels of sTfR, 
which are twice as high in TM patients from NTCK (12.8mg/ml) compared to that in TM 
patients from UCLH/HSC (6.3mg/ml). The apparently small difference in pre-transfusion 
Hb (7.7g/dl) in NTCK TM patients compared with 9.4g/dl in UCLH/HSC patients has a 
two fold effect on stimulating erythroid mass and a five fold difference in erythropoietin.
Transfusion therapy can therefore account for the higher ferritin, NTBI and 
transferrin saturation. The degree of anaemia is quite similar in the two Tl cohorts and 
hence the EPO and sTfR values are similar.
With respect to iron overload and iron mediated oxidative damage, serum ferritin 
and NTBI are similar in NTCK and other TM patients from UCLH/HSC. However, MDA 
appears to be higher in the NTCK patients (p<0.001), while the carbonyls are similar. 
This difference in MDA could reflect differences in chelation therapy as the cumulative 
transfusional iron burden is higher in the UCLH/HSC cohort and the mean MDA was 
much lower in the UCLH/HSC TM (0.07uM) compared to those from NTCK (0.41 uM) 
(p<0.001). The TM patients from UCLH/HSC patients would be on regular and 
consistent chelation regimes whereas the NTCK patients were receiving less frequent 
chelation regimes reflected by the mean cumulative DFO of 189 g in UCLH/HSC versus 
106g in the NTCK TM patients. In the Tl patients the situation is very similar, none of the 
UCLH/HSC patients were transfused but 7 of the 9 Tl from NTCK were transfused 
having a higher cumulative iron, with regards chelation this was given at a much lower 
frequency to the Tl patients compared to the TM patients with only a mean cumulative 
DFO usage of 40g.
Pag© 113 of 278
It is however difficult to be clear about the effect of other factors that may 
influence MDA levels in the cohort from NTCK such as malaria, and nutritional status. 
Recent studies in other countries where similar health problems exist have found low 
levels of antioxidant micronutrients and raised levels of oxidative markers in patients with 
TM and Tl, (Al-Quobaili and Abou Asali 2004, Nasr, et al 2002) and Ep thalassaemia 
(Laksmitawati, et al 2003).
Protein carbonylation appears to be a relatively late effect of iron overload and 
free radical damage and indeed Livrea’s study in TM patients found a positive correlation 
between MDA and ferritin, and a positive trend with carbonyls (Livrea, et al 1996) and 
suggested that good adherence to chelation may help to reduce the appearance of 
these markers of oxidative damage. Our findings support the role of consistent chelation 
in reducing the levels of MDA.
The analysis of patients by demographics above, shows that the patients treated 
at NTCK initially were more anaemic and had a higher erythroid drive whilst those TM 
treated at UCLH/HSC had higher transfusion frequencies and a higher cumulative 
transfusion iron burden. Despite the higher iron load in UCLH/HSC TM patients, the 
levels of MDA were lower suggesting that the regular use of chelation therapy was 
modifying the levels. The NTBI was present in high levels in both cohorts of patients at 
both centres and the levels in Tl patients prior to receiving transfusion therapy were 
raised at a young age before significant siderosis had developed (mean ferritin 217 
ng/ml).
The relationship between markers of anaemia, ineffective erythropoiesis, iron 
burden and oxidative damage is suggested by the preliminary analyses but a more 
detailed analysis of individual parameters and their relationship to each other was 
conducted to confirm and support the preliminary findings.
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3.7 The relationship between Ineffective erythropoiesis, oxidative damage 
and NTBI
3.7.1 Factors affecting serum Erythropoietin
Serum EPO was performed as described in chapter 2 section 2.14.
The normal range for EPO in healthy controls for the EPO kit is 3.3 mlU/ml-16.6 mlU/ml 
and the normal range for healthy adult controls in our lab was 1.07 mlll/ml-10.5 mlU/ml.
3.7.1.1 Relationship between EPO and Hb
In tables 3.6.2.1 and 3.6.2.2 the variability of EPO by patient group was seen. It 
was apparent that in the TM patients EPO was not suppressed to near normal levels 
even in those patients who were on “optimal” transfusion regimes. Those who were 
under transfused as in the NTCK cohort the levels of EPO were higher than those of the 
Tl patients treated at the same centre implying a greater hypoxia drive for erythropoiesis. 
Figure 3.7.1a shows the relationship between EPO and Hb in all patients in this study 
and Figure 3.7.1.b shows the relationship between the LnEPO and Hb.
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Figure 3.7.1a: Haemoglobin versus erythropoietin in all patients
All patients
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E 5000
E 4000
3000o R = 0.64
<D 1000
-1000
haemoglobin (g/dl)
u.o
Legend: Erythropoietin for all patients plotted against the Hb. A good correlation is seen with Hb 
levels.
Total number of tests with simultaneous Hb and erythropoietin measurements n-176 P=<0.0001 
Tl red diamonds; TM black circles
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Figure 3.7.1.b: Relationship of Log Erythropoietin (Ln EPO) to Haemoglobin in all 
patients
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Legend: Log of erythropoietin plotted against Hb shows a good correlation in all patients Number 
of samples with Hb and erythropoietin measured on the same sample n-176. P<0.0001 
Tl red diamonds; TM black circles
Line at 8.5g/dl: showing that majority of patients with Tl in red have a significant anaemia 
associate with a higher LnEPO.
There is a good correlation between haemoglobin and erythropoietin in all 
patients (R=0.64 p<0.0001) and in the UCLH/HSC thalassaemia patients (R=0.53 
p<0.0001) but a much stronger correlation was seen with the more anaemic TM patients 
(R=0.73 p<0.0001) from NTCK. Our study shows a similar correlation to the Hb as 
Cazzola et al (Cazzola, et al 1999).
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A number of studies have shown a relationship between the sTfR and 
erythropoietin levels (Cazzola, et al 1995, Galanello, et al 1994, Roque, et al 2001) and 
this direct relationship was also seen in our patients. If figure.3.7.1b is examined; 
‘abnormal’ EPO values are confined (with the exception of two outliers) to patients with 
Hb values of less than 8.5g/l. This means that patients transfused in UCLH/HSC will 
generally not be sufficiently anaemic to have significantly increased EPO values.
3.7.1.2 Relationship of erythropoietin to sTfR 
Anaemia and the resultant hypoxia stimulate EPO production and this should 
then stimulate erythropoiesis which would be reflected by an increased erythroid mass. 
sTfR reflect the erythroid mass so theoretically should be raised when the EPO levels 
were high. This was confirmed in our study as can be seen from table’s 3.6.2.1 and
3.6.2.2 and figure 3.7.1c.
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Figure 3.7.1.C Relationship between EPO and sTfR in all patients
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Legend: The sTfR plotted against Log Epo in all patients who had Hb, EPO and sTfR measured 
simultaneously (samples analysed n=85) P<0.0001 
Tl red diamonds; TM black circles
Erythropoietin also had a good correlation with sTfR (R=0.67, P<0.0001). Higher 
sTfR levels are found in patients with higher erythropoietin levels and these tend to be 
associated with lower haemoglobins. It can be seen from figure 3.7.1c that ‘abnormal’ 
sTfRs are confined to patients with LnEPO values > 2.4. From inspection of figure 
3.7.1c, it can be seen that LnEPO of 2.4 is roughly equivalent to a Hb value of 8.8g/dl. 
Thus a Hb of <8.5g/dl increases the chance of both an increase in EPO and an 
expansion of the erythroid mass, as measured by sTfR.
Interestingly the use of high intensity transfusion regimes appears to push the 
sTfR into the normal range but the EPO tends to remain raised (table 3.6.2.1)
3.7.1.3 Relationship of erythropoietin to Markers of oxidative damage
All patients
R = 0.67
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♦
%
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Ln EPO
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There appears to be a correlation between EPO and protein carbonyls (R= 0.33 
and P=0.0003; n=82) but with a wide scatter, suggesting that anaemia and ineffective 
erythropoiesis may result in increased formation of protein carbonyls, however this is 
unlikely to be the case as the protein carbonyls in group analysis showed little variation 
despite significantly different EPO levels (tables 3.6.2.1 and 3.6.2.2). There was no 
correlation of MDA with EPO and R=0.04; p=0.80; n=81.
3.7.1.4 Relationship of EPO with ferritin and NTBI
There was a weak correlation seen between LnEPO and ferritin (R=0.27; 
P=0.004; n=104) but with a wide scatter. This could be due to the fact that the more 
anaemic patients would have a lower ferritin and a higher EPO due to the less frequent 
transfusions. There was no correlation between LnEPO and NTBI (R=0.05; p=0.87; 
n=83).
EPO has a good relationship with STfR and Hb as seen in previous studies by 
other groups but is not affected by NTBI and does not appear to have a significant 
relationship with markers of oxidative damage or iron overload.
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3.7.2 Variables affecting Transferrin receptors (sTfR)
3.7.2.1 sTfR and Haemoglobin
Transferrin receptors have been shown to increase in response to anaemia in Tl 
patients by Cazzola (Cazzola, et al 1995) and rose significantly with haemoglobin levels 
below 9g/dl. In this section we examine the relationship between Hb and sTfR in all 
patients and to confirm the relationship shown between EPO and sTfR. The normal 
range of transferrin receptors is 0.3-8.5 mg/l.
With transfusion support, the mean sTfR level for TM comes into the normal range as 
shown in table 3.6.2.1. Levels however remain high for Tl patients on intermittent 
regimes and also for the TM patients from NTCK who are subjected to a low transfusion 
regime as shown in table 3.6.2.2. The relationship between sTfR and Hb for all patients 
is shown in Figure 3.7.2a
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Figure 3.7.2a: Relationship of sTfR to haemoglobin
All patients
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Legend: sTfR in all patients who has simultaneous samples for Hb (n-117) R 0.54 P<0.0001 
Tl red diamonds; TM black circles
There was a good correlation and P<0.0001 but this cannot be confirmed for the 
more anaemic Tl patients as the numbers are too small. As this study continues to 
recruit the relationship will become clearer.
The relationship between EPO and sTfR has already been described in figure
3.7.1c.
3.7.2.2 Relationship of sTfR and markers of oxidative damage
A weak correlation was seen between carbonyls and sTfR as there was a wide 
scatter (R =0.25; p=0.02 n=83). Again it is difficult to say if this is truly significant and
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more data will need to be analysed to confirm these results. It is also imperative that a 
normal range for protein carbonyls in children is ascertained. There was no correlation 
with MDA (R=0.17; p=0.11 n=82) and the level of sTfR.
3.7.2.3 Relationship of sTfR with ferritin and NTBI
In keeping with the erythropoietin data no relationship was seen between NTBI 
and sTfR n=110 samples (R=0.19 p=0.049). Correlations with serum ferritin are shown 
in figure 3.7.2b
Figure 3.7.2b: sTfR and serum ferritin in all patients
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Legend: sTfR in those patients with simultaneous ferritin measurement s available (n-70) 
R-0.41 p=0.0005 for all patients subanalysis. Tl R=0.71; P=0.15 and TM R=0.20 P -0 .11 
Tl= red diamonds and red line; TM- black circles and black line
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There was a correlation of sTfR with ferritin (R=0.41;P=0.0005; n=70) overall for 
all patients. But on subgroup analysis this relationship did not hold. Interestingly 
Cazzola’s group (Cazzola, et al 1999) had shown a positive correlation between ferritin 
and sTfR as well as a relationship between sTfR multiplied by age and ferritin on 
multivariate analysis in patients with Tl, in our patients there was no significant 
relationship as the numbers were too small for a significant P value. All of the patients in 
Cazzola’s study were a mixture of adults and children but were non transfused (15/30) or 
had received less than 12 units of blood in their life time (15/30).
In our transfused patients, the lack of a relationship between sTfR and ferritin is 
likely to result from repeated transfusions decreasing erythroid expansion, but at the 
same time increasing iron overload. In the Tl patients we found that the higher sTfR 
levels were associated with lower ferritin levels contrary to the findings of Cazzola where 
raised ferritin and older age were associated with a higher sTfR. The probable reason for 
this may be that our Tl patients had been transfused (NTCK cohort) some of them 
having received up 8000mls of blood by the age of 8 years. Also our patients were 
children with a mean age of 3.95 years and were probably too young to have developed 
significant iron overload from increased gastrointestinal absorption.
3.7.3 Discussion
Erythropoietin and sTfR both correlate well with haemoglobin and this has been 
well described in a number of studies. Also despite optimal transfusion regimes EPO 
levels are not suppressed to normal levels in TM patients. STfR is however closely 
related to the degree of ineffective erythropoiesis and was suppressed into the normal 
range in our optimally transfused TM patients but not suppressed in the Tl patients or 
the under transfused NTCK TM patients. A relationship was observed between EPO
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and ferritin presumably because the more anaemic patients have less iron loading due 
to lower transfusion rates. No relationship however was seen between sTfR and ferritin 
and there appears to be a suggestion of a relationship between sTfR and carbonyls and 
between EPO and carbonyls although this will need to be confirmed with larger 
numbers.
The relationship of NTBI with anaemia will be discussed later in section 3.8
Iron overload will lead to lipid and protein peroxidation as discussed in section 
3.1. The time of appearance of markers of oxidative damage and their relationship to 
iron burden and NTBI is unclear. Although a number of small studies have assessed 
these parameters in both young and older patients the data has not been analysed in 
very young patients separately to identify when these parameters appear and what their 
relationship may be to the patient’s clinical status. As has already been noted from the 
preliminary analyses in section 3.6.3 and table’s 3.6.2.1 and 3.6.2.2 the MDA levels are 
significantly higher in those patients from NTCK.
3.7.4 Variables affecting Malondialdehyde (MDA)
MDA levels in the normal adult control population used for this study in our 
laboratory was 0.27+ 0.22 uM (range 0.03-0.68uM) (n=22). The patients who were 
treated at NTCK were significantly more anaemic then those at UCLH/HSC. An analysis 
was undertaken of al the patients to see if there was any relationship between MDA and 
anaemia and markers of ineffective erythropoiesis.
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3.7.4.1 MDA and its relationship to Anaemia
There was a weak correlation seen between anaemia and MDA (n=192 R=0.15; 
p=0.03). As can be seen from tables 3.6.2.1 and 3.6.2.2 MDA levels were higher in the 
more anaemic patients. The significance of this is uncertain because the MDA values 
are in the normal range for adults and hence no real conclusions can be made from this 
analysis. It is important that control MDA results are obtained from normal non 
thalassaemic children to ascertain the significance of these results. As discussed above 
in section 3.7.2 and 3.7.3, no correlation was seen with markers of ineffective 
erythropoiesis.
3.7.4.2 MDA and its relationship to NTBI, ferritin and carbonyls
No relationship was seen between MDA and NTBI (R=<0.01; P= 0.81 ;n=187) 
similar to the finding in Livrea’s study. However Cighetti (Cighetti, et al 2002) more 
recently found a relationship with NTBI in adult thalassaemia patients using GC-MS to 
measure free and total MDA. The reason for the difference may that different methods 
were used to quantify MDA and our population of patients were much younger and had 
MDA levels within the normal range.
We saw no correlation between MDA and ferritin (R=0.01; P=0.88; n=111) in our 
study. Cighetti noted a negative correlation with ferritin (R= - 0.3) whilst Livrea found a 
positive correlation with ferritin (R=0.41). Ferritin is affected by the ascorbate status of 
patients and in Livrea’s study there was a 44% reduction in ascorbate levels in patients. 
Cighetti did not measure individual antioxidants but assessed the total peroxyl radical- 
trapping antioxidant parameter (TRAP), which was found to be within the normal range.
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There does not appear to be a clear relationship between MDA and ferritin in our study 
in young patients.
There appears to be a weak correlation between MDA and carbonyls (R=0.24; p=0.006; 
n=134). As both are markers of oxidative damage and both are in the normal range it 
not possible to draw any meaningful conclusions.
3.7.5 Variables affecting Protein Carbonyls
Carbonyls levels for the normal adult control population used in this study were 
0.71+ 0.27nmol/mg (range 0.33-1.09) n=12. Only a few studies have looked at protein 
carbonyls in thalassaemia patients with the definitive study the one done by Livrea which 
showed raised levels of protein carbonyls in adult TM patients.
3.7.5.1 Relationship of carbonyls to anaemia
As has been shown in tables 3.6.2.1 and 3.6.2.2 protein carbonyls do not appear 
to alter in patients when dividing them according to the centres or when separating them 
according to the type of anaemia. There was a relationship with Hb (R=0.28; p=0.009; 
n= 133) with higher carbonyl levels being seen with higher haemoglobin levels. There is 
however a wide distribution on the graph. As has been previously discussed there is a 
relationship between carbonyls and erythropoietin and sTfR.
3.7.5.2 Carbonyls and its relationship to NTBI, ferritin and MDA
There was no relationship between carbonyls and ferritin (R=0.09; P=0.42; n=77) 
or carbonyls and NTBI (R=0.08; P= 0.34; n=133) in the patients as a group or in any of
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the subgroups. No relationship was seen with MDA as mentioned in 3.7.5.2. This is 
probably because the carbonyls were not raised in our patients.
No relationship was seen between MDA, carbonyls and transfusion/ cumulative 
iron load.
3.7.6 Discussion
Our results show that carbonyls and MDA were not raised in thalassaemic 
children who were part of this study. In addition there was no relationship with ferritin or 
NTBI, contrary to the prior studies as discussed earlier where correlations had been 
found with ferritin (Livrea, et al 1996) and NTBI (Cighetti, et al 2002). In particular the 
conflicting results found with correlations between MDA and ferritin by Cighetti and 
Livrea and the lack of correlation with NTBI shown by Livrea raise important questions. 
On reviewing the data by Livrea the plot of the MDA versus ferritin shows a wide 
distribution and the R = 0.41; n=42) shows some correlation but this is still relatively poor 
particularly in view of the distribution. Cighetti’s data again shows a very wide distribution 
and shows a negative correlation of free MDA with ferritin (R=-0.3; n=21). Both of these 
studies were carried out in a mainly adult population of thalassaemia patients. The role 
of chelation therapy is also extremely important in oxidative damage as this removes 
free iron that can initiate hydroxyl radical damage and in both studies patients were 
chelated with DFO so this could not be a cause for the difference.
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Cighetti et al 2002; Eur J Clin Invest, 32 suppl. 1,55-60
Livrea et al 1996, Blood, 88, 3608-3614
It has been well described that when a DF0 infusion is initiated the NTBI 
decreases to very low levels and once the infusion stops NTBI again becomes 
detectable in the blood (Porter, et al 1996). It may be that a consistent and prolonged 
exposure to Iron in the form of NTBI is required for free radical damage to occur. If a
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child were regularly adhering to chelation on 5 to 6 nights a week this would result in 
relatively low exposure to high levels of NTBI. Indeed the cohort of children treated at 
UCLH/HSC is the one expected to have minimal iron overload associated complications 
as supported by data from Borgna-Pignatti (Borgna-Pignatti, et al 2004). The children 
from NTCK were by and large being transfused at variable intervals at the time of this 
analysis as were most of the Tl patients who were being weaned of transfusion regimes. 
Chelation was also variable but most NTCK children had received some and the mean 
DFO given in TM was 106g and Tl was 40g.
Other factors that may affect the results would be poor sample handling and 
storage. However, in the presence of NTBI plasma proteins and lipids would result in 
more oxidation occurring and higher levels of MDA and carbonyls. This was not noted in 
our patients who had levels within the normal range.
It can be concluded that in children with thalassaemia who are adequately 
treated with chelation therapy markers of oxidative damage such as MDA and carbonyls 
tend to remain low.
This is a longitudinal study and it will be interesting to see what happens to these 
markers as the children enter adolescence and if they develop any significant 
complications of iron overload. What is also clear is the NTBI and ferritin in this cohort of 
young children shows no correlation with markers of ineffective erythropoiesis or 
oxidative damage. However, NTBI is present at high levels in those patients who have 
not previously been transfused implying a relationship with ineffective erythropoiesis.
Page 130 of 278
3.8 Factors affecting Non Transferrin Bound Iron (NTBI)
The relationship of NTBI with transfusion and anaemia is an intriguing one. Many 
patients with Tl have detectable NTBI even when they are not transfusion dependant 
(Cappellini, et al 2000, Cighetti, et al 2002, Pootrakul, et al 2003). The question as to 
whether this reflects iron overload, ineffective erythropoiesis or increased iron absorption 
from the gastrointestinal tract is an important one. In addition quite frequently the serum 
transferrin is not fully saturated when NTBI s present (Gosriwatana, et al 1999).
In section 3.8.1 data will be presented on all the patients for NTBI and transferrin 
saturation and its relationship to anaemia discussed. Then a more detailed assessment 
of patients who initiated transfusion therapy after recruitment into this study, and where 
samples were available, pre and post the first transfusion episode will be undertaken. In 
addition an assessment of NTBI and other markers will be carried out in those patients 
who had less than 1000mls of blood.
Of the 51 patients only 7 started transfusion whilst in the study. All of the NTCK 
patients were either already on a transfusion regime or did not required a transfusion at 
the time of this analysis.
3.8.1 NTBI and its relationship with transferrin saturation and anaemia
NTBI is thought to appear once transferrin is fully saturated; however it appears 
that even when transferrin is not saturated NTBI may be present at high levels as shown 
in figure 3.8.1a
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Figure 3.8.1a: Transferrin saturation and NTBI for all patients
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Legend: NTBI and transferrin saturation measured in all patients showing the presence of 
unsaturated transferrin in the presence of NTBI (n=181). 
red diamonds: T l; black circle TM
As can be seen NTBI is present in the presence of unsaturated transferrin. 
However no NTBI is found in patients with transferrin saturation less than one third 
saturated (Figure 3.8.1a). The presence of NTBI even in the absence of completely 
saturated transferrin has previously been identified by (Gosriwatana, et al 1999, 
Gutteridge, et al 1985) in haemochromatosis patients. These patients develop iron 
overload due to increased iron absorption form the gastrointestinal tract. Thalassaemia 
patients develop iron overload due to both increased gastrointestinal iron absorption (Tl) 
and secondary to blood transfusions (TM). It is possible that there are different isoforms 
of NTBI some of which are transferrin accessible and some of which are not. The exact
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nature of NTBI may thus depend on the mechanism and degree of iron loading. 
Interestingly non-transfused TM patients had NTBI and unsaturated transferrin but as 
the transfusion support is increased, transferrin became saturated fully.
On assessing the effect of Hb on NTBI no correlation was found (R=0.1; P=0.17 
n=181). To assess the presence of NTBI in patients prior to the onset of transfusion 
further analyses were undertaken looking specifically at those patients who had very 
little by way of transfusional iron overload.
3.8.2 Relationship of NTBI to blood transfusion
No correlation was found between NTBI cumulative iron load or mis of blood 
transfused (R=0.1) (n=197). Further sub-analysis was undertaken on those who had 
received less then 1000ml of blood.
3.8.3 Patients transfused less than 1000mls
Fifteen patients (5 TM, 10 Tl) had been transfused less than 1000mls and by 
virtue of this were not on chelation therapy and were thought to have a low iron burden. 
Of the patients who were transfused less 1000mls a very good correlation was found 
between NTBI and transferrin saturation as shown in figure 3.8.3a.
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Figure 3.8.3.a: Transferrin saturation for 15 patients transfused less than 1000ml
of blood
8.0
R = 0.81
5.0 -
So
E
3.0 -
COF
z
0.0
100
- 2.0
transferrin saturation %
Legend: 15 patients who had received less than 1000ml of blood. (Sample n=42) shows a good 
correlation of NTBI with transferrin saturation, P<0.0001 
Red diamonds: T l; Black circles TM
Again it can be seen that there are patients with high levels of NTBI and 
unsaturated transferrin. The patients with TM tended to have higher transferrin 
saturations in this small group of patients who had only recently initiated transfusions. 
Correlations were undertaken on these patients to see if there was a relationship 
between anaemia and NTBI or markers of oxidative damage.
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No correlation was found between NTBI and volume of blood transfused 
(R=0.14; P=0.35; n=47), haemoglobin (R=0.21; P=0.15; n=45), MDA (R=0.03; P=0.88; 
n=35) or carbonyls (R=0.24; P=0.22; n=28).
3.8.4 NTBI in patients starting blood transfusions for the first time
Of the 51 patients only 7 started transfusion whilst in the study. All of the NTCK 
patients were either already on a transfusion regime or had not required them at the time 
of this analysis. Hence this group consisted of the patients from UCLH/HSC only. Seven 
(3 TM and 4 Tl) patients were given their first transfusion during the course of the study. 
It was found that NTBI was present prior to transfusion in these patients.
Table 3.8.4.1: NTBI pre-transfusion and post transfusion in those patients 
undergoing their first ever transfusion
Patient Diagnosis Pre transfusion NTBI (umol/l)
Post
transfusion
NTBI
(umol/l)
Interval
between
sample
(months)
Patient 1# TM 5.65 1.77 3.22
Patient 2* TM 4.20 -1.10 0.17
Patient 3* TM 1.20 -0.35 2.07
Patient 4 Tl 0.70 2.20 3.81
Patient 5 Tl -0.12 -1.16 3.68
Patient 6A Tl 2.80 3.00 15.8
Patient 7A Tl 3.60 2.70 15.8
Legend: # Toronto patient Pre transfusion Hb was 5.4g/dl. Post transfusion sample 3 months later 
post 1500 mis of blood.
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*: Patients treated at UCLH. Patient 2; Hb 2.4g/dl at presentation post Hb was 6 days later when 
Hb 10.2. Patient 3; Hb 5.4 g/dl post Hb was 2 months later post 250 ml blood.
A: Siblings with Tl. Started transfusion due to failure to thrive. Baseline NTBI level prior to leaving 
Toronto. Post NTBI result is after <1500 ml of blood had been transfused. Only started 
Transfusion 3 months prior to post sample.
Figure 3.8.4a: NTBI pre-transfusion and post transfusion in those patients 
undergoing their first ever transfusion
6 .0 0  -I
5.00 -
4.00 -
I '  3.00 
E^ 2.00 
CO
Z  1 0 0  ■ 
0.00 
- 1.00 
- 2.00
—♦— patient 1 
patient 2 
patient 3 
-o  patient 4 
— patient 5 
- ♦  patient 6 
patient 7
PRE POST
Legend: Same patients as in table 3.8.4.1. Overall the post transfusion NTBI levels are lower 
(mean 1.01umol/l) than those from pre transfusion (2.58 umol/l).
Once transfusion was administered NTBI generally fell to lower levels in both Tl 
and TM. That NTBI is present at high levels when patients are very anaemic prior to 
their first transfusion and is present in Tl patients at modest degrees of anaemia is an 
interesting observation. It was important to see what happened to NTBI with increasing
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iron load. Three of the Tl patients all had NTBI at first transfusion and this did not alter, 
one of the Tl patients (patient 5) did not have any NTBI at the start of transfusions. In 
view of this the TM patients were analysed because they all had profound anaemia prior 
to first transfusion.
Figure 3.8.4b: NTBI and cumulative iron load in patients with TM who had their 
first transfusion as part of this study
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Legend: cumulative iron load versus NTBI in TM patients undergoing first ever blood transfusion 
Cumulative iron load as calculated by multiplying the mis of blood transfused with the haematocrit 
as per the formula described by Porter (Porter 2001)
As can been from figure 3.8.4b NTBI is present prior to transfusion and then 
decreases with the first transfusion as the anaemia is corrected. Then NTBI reappears
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and fluctuates. As transfusion iron load increases NTBI increases again. The early NTBI 
may be due to ineffective erythropoiesis and increased Gl iron absorption similar to that 
seen in Tl patients. The levels of EPO and sTfR both fell post transfusion in keeping with 
what is expected to happen as the ineffective erythropoietic drive is suppressed.
3.8.5 Relationship of NTBI to ineffective erythropoiesis
It can be seen from section 3.8 that In the case of thalassaemia syndromes, even 
though there are available iron binding sites on transferrin, NTBI is present in plasma. 
An explanation for this may be that as iron is released from macrophages after red cell 
catabolism in the bone marrow (ineffective erythropoiesis) or elsewhere (haemolysis) 
that the rate at which this occurs is too rapid for iron to bind to transferrin and other 
species of NTBI are formed. It is likely that the rate of oxidation of iron (II) to iron (III) is 
more rapid outside the bone marrow than within the bone marrow, where oxygen 
tensions are generally lower. Thus iron (III) binding to transferrin would be slower in the 
bone marrow, favouring NTBI formation when anaemia results more from ineffective 
erythropoiesis than haemolysis. Ineffective erythropoiesis and haemolysis both lead to 
anaemia and secondary expansion of intra and extramedullary erythropoiesis. However 
it is likely that ineffective erythropoiesis leads to a greater intramedullary expansion than 
with simple anaemia.
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3.8.5.1 Relationship between NTBI and sTfR at low cumulative iron load in 
UCLH/HSC patients
Thus it is of interest to examine the relationship between sTfR and NTBI, 
especially in patients who have received relatively little iron loading from transfusion 
(where iron overload could mask a relationship between sTfR and NTBI). The most 
precise data on cumulative iron loading was available in UCL/HSC patients. It was 
decided to analyse the relationship between NTBI and sTfR in patients who had 
received relatively little iron loading (<1g) to see if there was a relationship between a 
marker of erythroid expansion (sTfR) and NTBI. 1g of iron is equivalent to 862 mis of 
pure red cells or 1440 mis of blood with an haematocrit of 0.6 (See TIF guidelines). The 
rate of transfusion in TM is 100-200mls /kg of pure red cells/y (TIF guidelines). Thus in 
young child with TM, 1g will take between 1 and 2 years to accumulate. It can be seen 
that there is a clear trend of increasing NTBI with increased erythroid expansion, 
consistent with the hypothesis that erythroid expansion overload the ability of transferrin 
to bind iron (III) at a sufficient rate to prevent NTBI formation.
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Figure 3.8.5.a: Relationship of sTfR to NTBI in UCLH/HSC patients who had 
received less than 1g of iron from blood transfusion
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Legend: sTfR and NTBI in those patients from UCLH/HSC with cumulative iron less than 1g
3.8.5.2 Relationship between NTBI and sTfR for all patients groups
When NTBI and sTfR were analysed in all patients there was no correlation in 
both Tl and TM patients (figure 3.8.5b)
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Figure 3.8.5.b: sTfR and NTBI in Tl and TM patients
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Legend: NTBI and sTfR in all patients with simultaneous samples showing no correlation between 
these parameters n=110, (TM= 82; Tl=28); P=0.049 
TM black circles; Tl red diamonds
3.8.6. Discussion: factors affecting NTBI
NTBI appears early in TM patients. In this study all the TM patients had 
detectable levels of NTBI regardless of the preceding transfusion history. In addition, 
NTBI was detectable in the TM patients’ prior to start of transfusion and then fell to low 
levels prior to second transfusion at which point the anaemia was less profound. Thus 
ineffective erythropoiesis contributes to NTBI formation even in the absence of 
transfusional iron loading in thalassaemia syndromes.
All patients
%
sTfR mg/l
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Although there is no correlation between anaemia and NTBI, the presence of 
NTBI at this very early pre transfusion period at a time where the patient has profound 
anaemia is important. Two main mechanisms may account for this NTBI.
The first mechanism may be that the anaemia-associated hypoxia drives 
increased iron absorption through the gastrointestinal tract. This would result in 
saturation of the iron transporter binding sites, and iron complexes (NTBI) diffusing 
across the cell membrane and entering the circulation in a transferrin inaccessible form 
such as iron III citrate. This iron would then need to be converted to the ferrous form by 
the macrophages prior to it being able to bind to transferrin (Breuer, et al 2000).
The second possible mechanism may be due to ineffective erythropoiesis and 
impaired erythroid degradation. It has been shown by Moura (Moura, et al 1998) that 
erythroid cell on degradation in macrophages releases iron bound as ferritin, 
haemoglobin and a non protein bound iron complex described as Low molecular weight 
iron (LMW iron). Transferrin when exposed to this LMW iron bound it rapidly. In 
conditions of ineffective erythropoiesis where iron turnover is many times that of normal 
individuals it is conceivable that NTBI would be released from the degraded red cells 
and the rate of binding to transferrin may be to slow too keep up with the rate of efflux 
into the circulation. This is particularly likely in the hypoxic conditions of the bone marrow 
where oxidation of iron (II) to iron (III), and hence binding to transferrin is likely to be 
slower. In the Tl patients NTBI is present at high levels similar to that seen with TM 
patients and the transferrin saturation tends to be lower (table 3.6.2.2). The finding of a 
trend of higher NTBI values in patients with higher sTfR, in patients with low 
transfusional iron loading is consistent with the idea that ineffective erythropoiesis 
contributes to NTBI formation. Probably both ineffective erythropoiesis and iron 
overload play an important role in the appearance of NTBI in both Tl and TM patients 
and in the continued presence of NTBI in Tl patients.
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3.9 Conclusions
In thalassaemic children sTfR and EPO correlate well with the degree of the 
anaemia. There appears to be very little oxidative damage as measured by levels of 
MDA and protein carbonyls in these children who are on the whole well transfused and 
chelated.
There are some concerns regarding sample collection and handling in the Sri 
Lankan cohorts of patients. This is primarily because the sample needs to be collected 
and processed and then shipped to the UK for these markers to be measured. As 
discussed earlier all attempts were made to ensure that samples arrived in a frozen state 
with plenty of dry ice. In cases where this was unsuccessful and samples were not 
frozen, they were discarded. It is possible that the MDA levels are higher, although not 
abnormal in these patients because of sample activation. The assay used for measuring 
MDA measures total MDA as discussed earlier and is a relatively crude test. However 
because the levels are not raised compared to our normal control population we can 
probably assume that the free MDA levels will not be raised. Another concern is that 
there are no normal ranges for MDA or carbonyls in normal healthy children and our 
children results have been compared to those of normal healthy adults. The reason for 
the lack of age matched healthy control children are the difficulty in obtaining ethical 
approval for a blood test that is unnecessary in healthy children.
There is no relationship between markers of ineffective erythropoiesis and 
markers of oxidative damage. In addition neither of these factors have any correlation 
with the presence or absence of NTBI. The relationship between markers of oxidative 
damage and iron burden in children is at best tenuous. Markers of oxidative damage
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have been found to be raised in adult thalassaemic patients. In our study in young 
children who are on regular chelation regimes, markers of oxidative damage were not 
raised. Chelation therapy results in a shorter duration of exposure to toxic forms of iron 
as NTBI is removed from the circulation, in adults however there has been a longer 
duration of exposure to toxic iron species as they received less chelation therapy in 
childhood.
The presence of NTBI early in thalassaemia patients is an important observation 
in this study and has not been described previously. It is likely, based on the analysis of 
data available, that ineffective erythropoiesis is an important contributing factor to NTBI 
formation in patients who have accumulated only small quantities of excess storage iron. 
It will be important to continue with the longitudinal follow-up that is part of this study to 
see if oxidative damage increases with age and prolonged exposure or if a patient 
becomes non adherent to therapy and develops significant iron burden.
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Chapter Four
Relationship of hepatic iron and NTBI to myocardial Iron and LV 
function; contrasts between sickle and thalassaemia disorders
4.1 Introduction
The most serious and frequently fatal consequence of transfusional siderosis in 
thalassaemia major is cardiac failure or dysrhythmia due to iron deposition in the 
myocardium. This is well recognised and documented in the literature for transfusion 
dependant thalassaemia (Aldouri, et al 1990, Brittenham, et al 1994, Davis and Porter 
2000, de Montalembert, et al 1989, Fitchett, et al 1980, Modell, et al 2000). However, 
while transfused patients with SCA are known to have increased iron burdens, as 
measured by liver biopsy, cardiac complications secondary to iron overload are rarely 
described (Batra, et al 2002).
Unlike patients with Tl who may have similar steady state Hb values, in the 
absence of blood transfusions, patients with SCA do not become iron overloaded 
(Harmatz, et al 2002, Vichinsky, et al 2005) However they may require intermittent or 
regular blood transfusions as a part of the management of their disease as discussed in 
chapter one. Indications for transfusion may include rapid onset severe anaemia, chest 
syndromes, sickle stroke syndromes, priapism, and in preparation for surgery (Danielson 
2002, Reed and Vichinsky 1999, Riddington and Wang 2002, Sandoval, et al 2002,
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Simmons, et al 1988, Vichinsky 2002). Transfusion regimens in such cases may either 
be in the form of an exchange transfusion or top up transfusion.
Recognised complications of transfusion regimens in SCA are similar to those 
seen in the general population who may receive blood and are antibody formation 
against red cell blood groups due to the variation between the donor and recipient red 
cell phenotypes, transfusion reactions, transfusion transmitted infections and iron 
overload (Danielson 2002, Ohene-Frempong 2001, Olujohungbe, et al 2001, Sandoval, 
et al 2002). However, there is little published data on the relationship between iron 
overload and its complications, particularly to the myocardium (Wood, et a /2004). This is 
important to understand because blood transfusion in being used increasingly as a 
therapeutic modality, particularly in patients at risk from stroke (Adams, et al 1998a).
There is remarkably little data available on the effects of blood transfusion on iron 
distribution in SCA. Kuple-Faget (Kulpe-Faget, et al 2003) reported iron loading in the 
myocardium at post mortem in patients with SCA and found that three of seven patients 
with severe hepatocellular iron loading had myocardial iron deposition and one other 
patient had moderate or lesser levels of siderosis. In three out of these four patients 
there was also evidence of myocardial fibrosis and cell degeneration compared to five of 
twenty seven patients without myocardial iron loading. In an MRI study using a T2* 
technique (see below) Wood reported normal cardiac T2* in all of 17 patients receiving 
long-term transfusions for SCA (Wood, et al 2004). However, on echocardiography Batra 
did find some evidence of impaired left ventricular diastolic function in chronically 
transfused patients with SCA and suggested that this was one of the early signs of iron 
loading in the myocardium (Batra, et al 2002).
It has been proposed that iron distribution may be differ between patients with 
SCA and thalassaemia and that this may be due in part to the inflammatory response 
seen in SCA (Finch, et al 1982, Harmatz, et al 2002). There are significant changes in
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the cytokine profiles in patients with SCA both during the acute vaso-occlusive episode 
and in the steady state when the patient is clinically well. It was shown by Taylor et al 
(Taylor, et al 1997) that type II cytokines such as IL4, 6, and 10 were raised in SCA 
during the steady state.
It is known that IL6 is a potent inducer of hepcidin (Nemeth, et al 2004). Hepcidin 
synthesis is up-regulated in the anaemia of chronic disease by IL6 and other cytokines 
(Ganz 2006). Furthermore, hepcidin down regulates iron absorption from food by 
decreasing iron release from enterocytes and release of iron from macrophages 
(Nicolas, et al 2001). It is therefore possible that the existence of a chronic inflammatory 
state in SCA, leads to sequestering of iron in the RE cells and consequently a reduced 
transferrin saturation and NTBI, even in the presence of transfusional iron overload. This 
would result in a decreased probability of iron uptake into tissues that possess uptake 
mechanisms for NTBI, such as the myocardium and endocrine tissues.
Tl patients can also develop significant iron overload when minimally transfused 
or even when untransfused, due to increased iron absorption from the gastrointestinal 
tract (Bannerman, et al 1967, Pippard, et al 1979). The signal for this increased iron 
absorption is thought to be related to the degree of ineffective erythropoiesis as 
discussed in chapter 3 and it may be that the severity and type of anaemia override iron 
overload mediated down regulation of iron absorption.
Iron burden has historically been assessed by liver biopsy as liver iron 
concentration (LIC) accurately predicts total body iron stores (Angelucci, et al 2000). 
Studies on the distribution of iron in different tissues have generally been on post 
mortem sampling. Myocardial biopsies in patients with iron overload have not been 
preformed routinely because of the practical difficulties in obtaining tissue samples. More 
recently however, with improvements in image acquisition, MRI has been used to assess 
liver and cardiac iron in patients with haemoglobinopathies in a non-invasive manner.
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This has allowed clinicians to gain an insight into which patients may be at risk of cardiac 
complications due to iron deposition (Anderson, et al 2001, Galia, et al 2003, Jensen, et 
al 2001, Papakonstantinou, et al 1995).
A key objective in this chapter has been to apply the newly available non- 
invasive techniques of liver and heart iron estimation, using the T2* technique, to explore 
whether the relationship between transfusional iron loading and tissue iron accumulation 
is the same for sickle cell and thalassaemia disorders.
4.2 Techniques for estimating myocardial iron
4.2.1 Endomyocardial biopsy
Cardiac biopsies are performed using standard right heart catheterization 
techniques and the biopsy samples are predominantly of the right interventricular 
septum. It is an invasive but relatively safe technique for assessing cardiac pathology 
and has been used extensively over many years (Fowles and Mason 1982, Frustaci, et 
al 2002). The usefulness of endomyocardial biopsy in looking at cardiac iron burden has 
been assessed in a number of studies. An Italian study by Lombardo (Lombardo, et al 
1995) looking at 15 patients with thalassaemia found some correlation between 
myocardial iron grade and ferritin and suggested this was a useful technique in 
assessing transfusional haemosiderosis, It did not however look at the distribution of iron 
throughout the myocardium. An earlier study on 4 severely iron overloaded TM patients 
by Fitchett (Fitchett, et al 1980) showed a raised iron concentration in only one patient 
on endomyocardial biopsy and a patient with cardiac failure secondary to iron overload 
had a normal iron concentration. They concluded that endomyocardial biopsy was an 
insensitive method because of the variability of iron distribution and sampling.
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Endomyocardial biopsies have been performed on patients with sickle cell anaemia 
(Tap, et al 2001) but transfusional haemosiderosis was not assessed.
4.2.2 Post mortem studies
Post mortem studies have provided the most information on the distribution of 
iron in the myocardium. Buja and Roberts (Buja and Roberts 1971) in their classical 
paper, described post mortem review of deaths in patients with chronic anaemia who 
require transfusions and patients with haemochromatosis. They found variability of iron 
distribution throughout the heart, with the iron loading in the ventricular tissue first 
followed by the atrial tissue as iron burden increased. The ventricular iron was primarily 
in the epicardial region, of intermediate concentration in the subendocardial region and 
least in the middle third of the ventricular walls. Iron deposits were found in the cardiac 
myocytes and the interstitial tissue as well as in the conducting bundles. The 
predominant form if iron in the myocardium was haemosiderin. The study of Buja and 
Roberts, in the pre-chelation era, showed that in the adult population of 131 patients 
mainly with acquired bone marrow failure disorders such as leukaemia, that increased 
haemosiderin was seen in 30% of patients who had received 50-75 units of blood, 60% 
of patients who had received 65-200 units, and 100% of patients who had received in 
excess of 200 units. In some of the patients, quantitation of liver and myocardial iron was 
performed. Figure 4.2.2 show the relationship of myocardial iron concentration to LIC 
and to units of blood transfused obtained from data in Buja and Roberts, 1971.
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Figure 4.2.2a: cardiac and LIC correlations from pre-chelation era
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Legend: The relationship between heart iron (mg/g dry wt) and liver iron quantification at post 
mortem with units of blood transfused was (r=0.67) or (r=0.76) respectively as shown for 
patients with mainly acquired anaemia associated with a variety of ‘leukaemia’s ’ (Buja and 
Roberts, 1971).
Tashiro et al showed a reduction in the siderotic granules as well as an 
ultrastructural improvement of myocyte vacuolation and disarray after 3 months of 
intensive chelation with desferrioxamine (Tashiro, et al 1990).
The majority of biopsies studied in SCA have been post mortem myocardial 
biopsies in cases of sudden death and have shown myocardial infarction and myocardial 
necrosis secondary to occlusion of the cardiac microvasculature by sickled red cells 
(Mansi and Rosner 2002, Martin, et al 1996). Kuple-Faget (Kulpe-Faget, et al 2003) 
studied iron loading in the myocardium in patients with SCA and found that out of a total
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of 31 patients seven had severe hepatocellular iron loading and 24 had moderate or mild 
hepatic iron loading. Three of the seven had myocardial iron loading and only one 
patient had myocardial loading out of the twenty four patients with mild to moderate 
hepatocellular iron loading. In three out of these four patients there was also evidence of 
myocardial fibrosis and cell degeneration compared to five of twenty-seven patients 
without myocardial iron loading.
Due to the difficulties of assessing accurately the cardiac iron burden in live 
patients many groups have attempted to find a reliable, accurate and reproducible non- 
invasive method. MRI was first suggested as a suitable method in 1987 (Johnston, et al 
1987).
4.2.3 MRI techniques for assessing myocardial iron
4.2.3.1 Principle
The use of MRI to estimate tissue iron relies on the paramagnetic properties of 
iron ferritin and hemosiderin iron. MRI measures either T1 (longitudinal) or T2 
(transverse) weighted relaxation times of water molecules (H atoms). Iron overload in 
tissues results in shortening in the longitudinal axis (T1) and transverse (T2) tissue 
relaxation times on which magnetic resonance imaging is based and leads to a reduction 
in signal intensity. The decrease in the intensity of spin echo images with iron overload 
results from shortening of the T2 relaxation times (Stark 1991). This shortening is mainly 
due mainly to the paramagnetic properties of ferritin iron.
It is likely that different forms of iron have different effects on T1 and T2 relaxation times. 
While inorganic iron (III) shortens both T1 and T2, this effect is much more pronounced
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when the same amount of iron is present as ferritin (Brown, et al 1985) as ferritin is 
water soluble. By contrast, hemosiderin, a degradation product of ferritin, is water- 
insoluble with a larger cluster which probably explain lack of significant T1-shortening 
effect of this molecule on T1-weighted images (Vymazal, et al 2000). Ferrioxamine, 
which is one of the products of ferric iron binding to DFO, is also paramagnetic, and is 
used as a contrast media using predominantly T1 weighed sequences (Duewell, et al 
1991, Muetterties, et al 1991, Tian, et al 1997, Worah, et al 1988).
4.2.3.2 Image acquisition
MRI has been used for a number of years to assess cardiac function and cardiac 
iron burden using a number of different parameters and techniques (Anderson, et al 
2001, Jensen, et al 2001, Liu, et al 1996, Wood, et al 2004). As MRI methodology has 
become more refined, sensitivity has increased and good correlations are now seen with 
liver MRI assessments and liver biopsy iron quantification. Two different types of echo 
sequences (Spin and Gradient) are used for image acquisition and both have 
advantages and disadvantages (see below).
Spin Echo
This is the most widely used sequence and uses both 90 and 180 flip echo 
sequences. The use of both 90 and 180 0 flip echo results in a reduction in field 
inhomogeneities and return a good echo signal but the acquisition times are longer and 
3D images cannot be acquired.
Gradient Echo
This uses the simplest sequence to obtain an echo signal (alpha flip-gradient 
recalled echo). It is used mainly to acquire T2* decayed based images. The main
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advantage to this technique is that image acquisition is faster and more images can be 
acquired. Artefacts due to wall motion are reduced and 3D images can be taken. The 
disadvantages are that it can be difficult to generate good T2 weighting and magnetic 
field inhomogeneities can cause signal loss.
4.2.3.3 Signal analysis
The echo signals can be analyzed in a variety of ways such as the T2 signal 
alone, as a ratio with a control tissue such as muscle, or using mathematical formulae to 
calculate the T2*. Hence there are a number of combinations that can be used for Iron 
quantification based on these variables and a universal method that is reliable and 
reproducible has yet to be agreed for measuring myocardial iron.
Cardiac T2 and SIR
The first method to be used for assessment of cardiac iron was the T2 
(Perrimond, et al 1991) in which T2 images were acquired using spin echo for both the 
liver and the myocardium. This showed that measuring T2 of the myocardium was 
feasible however the technique needed further refinement due to problems with wall 
motion artefacts and poor signal to noise ratios at longer echo times.
As methodology has become more refined wall motion artefact and gating of 
image acquisition with the cardiac cycle so that images are acquired at the same time in 
each cycle has helped to limit some of the initial problems with measuring cardiac 
relaxation signals and T2 measurements or T2 as a ratio with muscle (SIR). Both 
Jensen and Mavrogeni (Jensen, et al 2001, Mavrogeni, et al 1998) have shown 
correlation of liver T2 with the cardiac T2 or myocardial/ muscle SIR. In addition Jensen 
showed a correlation between number of units of blood given and myocardial iron
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content as calculated by using a modified liver calibration curve in patients who were 
transfused but not chelated.
Cardiac T2*
T2* measured using gradient echo was described by Anderson et al (Anderson, 
et al 2001). Anderson chose gradient echo because of the greater sensitivity to iron and 
the shorter acquisition times resulting in less motion artefact and is thought to be more 
reproducible then SIR. T2* is related to T2 by the summation of the tissue relaxation 
time (T2) and the magnetic inhomogeneity known as T2 prime (T2’) by the formula:
1/T2* = *{[12 + 1/T2’
In this study a strong correlation was found for liver iron quantification and liver 
T2* value (R=0.93 in non fibrotic liver samples). The study could not use myocardial iron 
validation to quantify myocardial iron due to the problems associated with 
endomyocardial biopsy as discussed in section 4.2.1 but found a significant correlation 
with other parameters of myocardial function specifically ejection fraction and end 
systolic volume supporting the fact that cardiac T2* was of prognostic importance.
Magnetic transfer ratio (MTR)
Papanikolaou et al (Papanikolaou, et al 2000) used this method to assess 
cardiac iron burden. This methodology uses gradient echo sequences for image 
acquisition. MTR measures the transfer of magnetization between the tissue being 
imaged and the water molecules in that tissue, a low transfer reflects reduced 
magnetization and hence damage. Papanikolaou found that patients with TM had 
significantly reduced MTR values compared to normal healthy controls.
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4.2.4 Discussion
Recently tissue validation has been undertaken in humans with Mavrogeni et al 
validating T2 with endomyocardial biopsy (Mavrogeni, et al 2005). These patients 
presented with NYHA grade II or III heart failure and the validation showed a good 
relationship between T2 and cardiac iron. There has only been a single case report of 
endomyocardial biopsy and cardiac T2* (Westwood, et al 2005) although studies are 
underway currently to validate T2* with endomyocardial biopsies. There is also some 
recent animal data by Wood et al in iron-overloaded gerbils using T1, T2 and T2* 
confirming a linear increase in cardiac iron burden with increasing iron load (Wood, et al 
2005).
The tissue validation of myocardial iron is becoming clearer due to the above 
studies but concerns remain with the regards the distribution of iron as noted by a recent 
MRI study using T1, T2,T2* and SIR (Macarini, et al 2005). In addition, the effect of 
ferrioxamine that is present in tissues following chelation with desferrioxamine and its 
effect on the signal intensity is as yet unclear.
Advances in MRI methodology have therefore lead to significant advances in our 
understanding of iron distribution. There is however considerable concern over certain 
observations noted in some of the studies. The main concern is the lacks of correlation 
between the traditional parameters of iron overload such as the liver iron burden and the 
serum ferritin seen in Anderson’s study. The lack of correlation of myocardial T2* with 
liver iron in a cohort of well-chelated patients may be due to a number of reasons. Most 
importantly is the effect of chelation history on iron burden. In Jensen’s study the
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patients had been followed from the start of iron chelation therapy and the longitudinal 
response assessed. In Anderson’s study a cross-sectional assessment of the 
parameters was undertaken with no review of prior chelation history.
It is known that serum ferritin reflects hepatic iron burden in iron-loaded 
individuals (Borgna-Pignatti and Castriota-Scanderbeg 1991) but it is also well 
recognized that ferritin is an acute phase protein and not ideal as a monitoring tool in 
patients with chronic conditions. It is most probable that in those patients who had 
myocardial iron loading previous chelation had been poor allowing iron to accumulate in 
the myocardium (Gabutti and Piga 1996). Brittenham (Brittenham, et al 1994) had 
previously shown that patients with liver iron burdens greater than 15 mg/g dry weight 
were at risk of cardiac failure and those patients with a history of poor chelation may iron 
load into the myocardium. These patients would have had high ferritin levels or falling 
ejection fractions initially and this would have prompted intensive chelation to be 
instituted and hepatic siderosis would have improved more rapidly because 
desferrioxamine is an efficient hepatic chelator, the myocardial iron is removed more 
slowly (Porter and Davis 2002). A significant number of the patients in Anderson’s study 
were those undergoing intensive chelation as described by Davis and Porter (Davis and 
Porter 2000). In order to address the concerns raised by the cross-sectional study it was 
decided to assess the longitudinal data from the MRI assessments as outlined in section 
4.3.
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4.3 Aims and Rationale of study
The broad aim of this chapter was to investigate whether transfusional iron 
loading in SCA has different consequences from iron loading in TM or Tl. The recent 
development of MRI techniques to estimate heart and liver iron, as well as left ventricular 
function, allows for the first time an opportunity to examine how total body iron, as 
estimated from liver iron concentration (LIC), impacts on heart iron as estimated from 
myocardial T2* and on heart function as measured by left ventricular ejection fraction 
(LVEF).
Cross sectional analysis of the relationship between liver iron concentration (LIC) 
and myocardial T2* has emphasised the lack of correlation in multi transfused, multi­
chelated patients (Anderson, et al 2001). However it is clear from further studies by the 
same group that chelation therapy with desferrioxamine normalised liver iron as 
estimated by T2* much more rapidly than heart T2* (Anderson, et al 2004) . Furthermore 
studies using MRI in multi-transfused patients naive to chelation therapy show a clear 
relationship between liver iron and myocardial iron using SIR (Jensen, et al 2003). In 
this chapter, an important part of the analysis has been to examine how these variables 
change with time in relation to total iron loading and in relation to chelation therapy.
The only MRI centre quantifying cardiac iron loading in the UK uses the cardiac 
T2* technique and this has been used to monitor patients at UCLH since 1999, allowing 
an analysis of factors which may influence the accumulation or removal of iron from the 
heart in both thalassaemia and sickle patients treated at UCLH.
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There were 3 specific aims in this study.
Specific Aim 1: The first aim was to examine the relationship between heart iron, liver 
iron and heart function in thalassaemia patients by cross sectional analysis.
Specific aim 2: The second aim was to establish factors that affect changes of cardiac 
T2* with time in thalassaemia patients. Factors which have been examined are:
a) The effect of chelation therapy.
b) The influence of body iron burden (LIC) on improvement or worsening of 
cardiac T2* with time, irrespective of the dose or duration of chelation therapy.
Specific aim 3: The third aim was to see if iron distribution between heart and liver in 
multi-transfused SCA patients was different to that seen in TM with similar levels of iron 
loading and if so to identify reasons why this might arise. In principle differences in iron 
distribution to the heart could relate to differences in duration of transfusional overload, 
effects of chelation history or to fundamental differences in iron metabolism between 
sickle and thalassaemia syndromes. One aspect of the latter is whether NTBI is related 
to iron overload differently in SCA compared to thalassaemia syndromes. To address 
this, we compared cardiac T2* in patients matched for liver iron to see if the cardiac T2* 
values were different in the sickle and TM patients and a history of iron associated 
complications noted. NTBI and transferrin saturations were measured in the matched
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pairs and compared. Patients with Tl were assessed separately because it is difficult to 
accurately assess the rate of iron loading due to variable gastrointestinal iron absorption.
4.4 Patients
4.4.1 Patients for specific aim 1
Between July 1999 and November 2002, a total of 98 patients with TM (n=75) or 
Tl (n = 23), followed at UCLH, had at least 1 assessment of cardiac and liver T2* 
together with LVEF estimation by MRI at the Royal Brompton Hospital CMR unit. The 
population of patients was 51 females and 47 males and the mean age was 27.1 years 
(range 6.7- 53.7 yrs). For the purposes of this analysis, TM patients were those who had 
a severe transfusion dependant anaemia requiring blood transfusions at a 2 to 4 weekly 
interval. Tl patients were defined as those with homozygous beta thalassaemia or 
compound heterozygote (Hb E(3 thalassaemia) who were transfused <8 times per year 
or were transfusion independent.
All transfusion dependant patients (TM) were on regular chelation support 
adjusted according to the ferritin and body weight. Only 3 patients form the 98 received 
deferiprone, 2 as part of a combination regime with desferrioxamine and one as 
monotherapy. The remainder of the patients were chelated with desferrioxamine.
4.4.2 Patients for specific aim 2
Retrospective analysis over a 3 year period was undertaken on those patients 
with a low or borderline cardiac T2* on first measurement or on those who subsequently
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developed a low cardiac T2*. 42 patients with TM had a low cardiac T2* (<20ms) on the 
preliminary scan and 1 developed a low cardiac T2* on a subsequent scan. Of these, 13 
patients had had 4 or more CMR assessments at 6 monthly to yearly intervals (12 TM 
and 1 Tl patient). The rate of improvement of cardiac T2* was calculated for these 
patients who were on intensive chelation regimes at severe, moderate and mild levels of 
cardiac iron loading to see if the rate of improvement was altered by levels of loading 
and if there was a relationship between this and liver iron burden. One of the 13 patients 
agreed to undergo sequential CMR assessment on DFO and after stopping DFO to see 
if cardiac T2* or liver iron was significantly affected by delayed elimination of 
ferrioxamine.
4.4.3 Patients for specific aim 3
26 Patients with SCA were studied and included either Hb SS (n=20), Sp 
thalassaemia (n=2) or HbSC (n=2) and HbSD (n=2). These patients, who were receiving 
top up or exchange transfusions or who had been transfused in the past or had a history 
of cardiac arrhythmia, underwent CMR for assessment of iron overload. Transfusion 
history, history of cardiac complications and chest syndrome were collected from a 
review of hospital blood bank records, patient notes and interviews with the patients. Iron 
burden calculation took into account loss of iron by venesection as part of exchange 
transfusion. Most patients were on a 3 units-in 4 units-out regimen for exchange and 
most patients had had a combination of exchange and top up transfusions. These 
patients were matched for age and liver iron with 26 TM patients who were receiving 
blood transfusions at two to four weekly intervals. All of these patients were on regular 
iron chelation therapy with DFO. Only one of the TM patients was on combination 
therapy with Deferiprone. Histories of cardiac abnormalities were collected from patient’s
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notes and interviews. Cumulative iron load was calculated for the matched pairs form the 
units of blood received but the use of iron chelation therapy could not be taken into 
account in the calculation of cumulative iron load.
Thirteen Tl patients had had CMR assessment. Transfusion history was collected 
in a similar manner as above along with history of cardiac and endocrine complications. 
These patients were analyzed separately and were not part of the full matched pair 
study because iron loading can occur independent of transfusion.
4.5 Methods
4.5.1 Cardiac T2*
Patients underwent CMR using a gradient spin echo technique as described by 
Anderson et al for the measurement of myocardial T2*. A single short axis midventricular 
slice was acquired using a gradient echo sequence on a Siemens Sonata 1.5T MRI 
scanner at nine separate Echo times ( TE 5.6 -18.0ms). The signal intensity of this 
region was plotted against the echo time used for each image. The resulting points form 
an assumed exponential decay curve, as the image signal decreases with increasing 
echo time. An exponential function was fitted to the data, with the equation being in the 
form:
y=Ke-TE/T2-
Where K represents a constant, TE represents the echo time and y represents 
the image signal intensity.
For diagnosis of increased cardiac iron burden a T2* of 20ms or greater suggests no 
iron deposition in the myocardium and less then 20ms suggests that iron is present, 
levels less than 8 ms imply severe myocardial iron loading.
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4.5.2 Left Ventricular Ejection Fraction
Manual tracing of epicardial and endocardial borders of contiguous short-axis 
slices at end-diastole (first cine phase of the R-wave-triggered acquisition) and end- 
systole allowed calculation of LV mass, LV end-diastolic volume, and LV end-systolic 
volume, from which LV stroke volume and ejection fraction were derived.
4.5.3 Liver T2*
For the measurement of liver T2* a single transaxial 10mm slice through the 
centre of the liver was acquired using a gradient echo sequence at eight different echo 
times (2.2 - 20.1ms). The echo times were used to calculate the T2* using the same 
formula as in section 4.5.1 and Liver iron in mg/g dry weight was calculated by the 
formula:
Liver iron =EXP(2.66409-(1.06611 * Log(liver T2* ms))
4.5.4 Statistical analysis
The mean, geometric mean standard deviation and standard error of the mean 
were calculated for each cohort of patients. Student T test were used to calculate 
significance. For paired analyses the paired T test was used.
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4.5.4.1 Calculation of cumulative iron burden
Some assumptions were made in the calculation of cumulative iron. During 1980 
to 1986 blood in the UK was gradually changed from whole blood donations to packed 
cells. For the purpose of the analyses it was assumed at all blood was administered in 
the form of packed cells after 1/1/86 and all blood prior to this was whole blood. The 
haematocrit of packed cell units was assumed to be 0.60 and that of whole blood 0.40. 
The mis of blood in a whole blood unit was assumed to be 450 ml and that of a packed 
cell unit 350ml.
Thalassaemia major patients:
The total units of blood transfused was collected from the patient records system 
as far back as the pathology system allowed (1980) with those units transfused prior to 
1/1/86 used to calculate cumulative iron separately. This was done for the majority of 
patients. In those patients who had not been transfused at UCLH or where records did 
not go all the way back to initial transfusions assumptions were made in calculation of 
units of blood transfused based on average blood usage for a child of set ages as 
follows. Assuming that 1 unit of blood was administered monthly form age of first 
transfusion up to the age of 10 yr (this assumption would balance out the smaller 
volumes administered in early childhood with the larger volumes administered in late 
childhood and was born out by the data collected for the children in Chapter 3). Blood 
usage from the age of 10yrs to 16 years was assumed to be 2 units every 4 weeks if 
data was not available and dependent on information provided by patients on direct 
questioning. Cumulative iron load was calculated according to the formula as described 
by Porter (BJH 2001)
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Iron content of transfusion (mg) = volume (ml) x haematocrit x 1.16
The loss of iron via chelation was not included in the assessment of cumulative 
iron load because chelation therapy adherence was variable and clear histories going 
back through the life of the patients were not available. In addition the older 
thalassaemia patients had not started chelation until the mid 1970’s. At that time DFO 
was administered as IM bolus injections and the method of administration was switched 
to subcutaneous treatment in the late 1970s and early 1980’s.
Sickle cell anaemia
The same principles were used to calculate Iron load from blood transfusion and 
transfusion data collected in a similar manner. In addition as SCA patients often present 
to other hospitals a more detailed questioning was undertaken of past transfusion history 
including units of blood administered and if these were as part of exchange transfusions 
or top up transfusions. There are clear limitations to this method of data collection as 
patients were asked to provide information as far back as they could remember. It has to 
be accepted that some transfusions may have been missed. Most patients were on a 3 
units-in 4 units-out regimen for exchange and majority of the patients had had a 
combination of exchange and top up transfusions. It has been standard practice to 
undertake pre and post transfusion HbS% assessments and it was fairly easy to work to 
how many units had been used for exchange transfusion and how many had been used 
for a top up transfusion. Calculation of cumulative iron load was carried out using the 
same formula as for the TM patients but took into account loss of iron by venesection as 
part of exchange transfusion as part of a separated calculation. To calculate the iron lost 
by venesection in exchange transfusions the haematocrit of the unit of blood removed 
was the mean of the pre-transfusion full blood counts. The cumulative iron load was
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calculated by subtracting the iron loss from venesection once the separated calculations 
were done to give the actual transfusional iron load.
4.6 Factors affecting relationship between liver and myocardial T2* and heart 
function in Thalassaemia
4.6.1 Cross sectional analysis of the relationships between liver and heart T2* 
and LVEF in Thalassaemia major and intermedia.
Figure 4.6.1.a Relationship between Ejection Fraction and cardiac T2*
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Legend: Cardiac T2* in 98 patients who underwent 170 assessments for myocardial iron 
assessment from UCLH, using the method described by Anderson et al. Pink squares: patients 
with cardiac T2* between 10 and 20 ms
4.6.1.1 Proportion of patients myocardial T2* <20ms and >20ms
It can be seen from figure 4.6.1a that of 170 assessments that had all results for 
liver iron, cardiac T2*, and ejection fraction available for analysis, 61.1% have T2* 
values <20ms and 29% have T2* values <10ms. A cut off of 20ms was identified by 
Anderson at al (Anderson, et al 2001) as a value below which there was an increased 
chance of a decreased ejection fraction. Table 4.6.1.1 shows the mean values for the 
liver iron mg/g/dw and cardiac T2* for the patients.
Table 4.6.1.1: Baseline characteristics of the study population
cardiac T2* range liver iron mg/g/dw
liver T2* 
ms
cardiac T2* 
ms
ejection fraction
%
<10 (n=50) 7.3(1.04) 5.6(1.02) 6.8 (0.23) 57.0(1.2)
>10<20 (n=54) 5.4 (0.38) 5.7(0.74) 13.5(0.38) 66.2 (0.96)
>20 (n=66) 5.9(0.48) 4.8 (0.74) 35.2 (1.49) 68.8 (0.81)
Legend: value expressed as mean (SEM) for each parameter.
This table shows the mean parameters for all patients and as can be seen the low 
cardiac T2* are associated with a low ejection fraction.
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4.6.1.2 Relationship o f LVEF to cardiac T2* and 1/T2* in Tl and TM
Figure 4.6.1.b: The relationship between LVEF and cardiac T2* in Tl and TM
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Legend: same figure as in 4.6.1a but showing Tl and TM values separately All Tl and TM 
patients with cardiac T2* and LVEF 
Tl; red diamonds TM black squares
It can be seen that the relationship of myocardial T2* to LVEF% differs for Tl and 
TM. In TM patients LVEF <56% is seen mainly in patients with T2* values ^10ms. In Tl 
patients 5 measurements have LVEF £ 60% despite T2* values >20ms (4
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measurements from a patient with pulmonary hypertension and 1 from E(3 thalassaemia 
patient who has not been transfused). Furthermore two Tl patients have T2* values < 
10ms.
Because tissue iron is related linearly to 1/T2* rather than T2* (Anderson, et al 
2001) the same data as above was plotted for 1/T2* or R2*. It can be seen that LVEF of 
less than 53% are confined to patients with R2* values >0.1 (<10ms)) and that all these 
patients have TM rather than Tl.
Figure 4.6.1.c: The relationship between LVEF and R2* in Tl and TM
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Legend: all results for patients converted to R2* showing the Tl in red squares and TM as black 
diamonds. This shows a good correlation with the LVEF R-0.57; P<0.0001;n=163
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4.6.1.3 Relationship o f LIC to LVEF in Tl and TM
Figure 4.6.1.d: The relationship between LIC to LVEF in Tl and TM patients
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It can be seen that neither in Tl or TM patients is there a relationship between 
LIC and LVEF% when analysed in cross section. In order to understand the relationship 
between LIC and LVEF however an analysis of changes in individual patients with time 
in response to chelation therapy is helpful and this is examined in further detail later in 
this chapter.
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4.6.1.4 Relationship o f LIC and liver T2* to cardiac T2* in Tl and TM
Figure 4.6.1.e: The relationship between 1/T2* and LIC
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Legend: all results for patients converted to R2* showing the Tl in red squares and TM as black 
diamonds
There is no relationship between LIC (derived from liver T2*) and R2* in the heart 
(1/CT2*) in the Tl patients or in the TM patients. Both Tl and TM patients had been 
previously treated with chelation therapy, thereby disturbing any relationship which might 
have existed pre- chelation therapy.
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4.6.2 Factors affecting change in cardiac T2* with time
The analyses in section 4.6.1 were cross sectional and did not analyse changes 
in parameters with time. In this section the effect of intervention with desferrioxamine 
(DFO) on these same parameters is examined. The improvement or worsening of 
cardiac T2* with time could in principle be affected by total body iron burden, as 
estimated by LIC, and/or the effects of chelation therapy. These are examined in 
sections 4.6.2.2 and 4.6.2.3. Before this, however, it is important to understand whether 
ferrioxamine could influence the measurements being undertaken. As explained in 
section 4.2.3, ferrioxamine has been used in the past as a contrast agent with T1 
weighed sequences and although this could not have a significant effect on T2 weighted 
sequences such as the T2*, it was important to know that no major effect of acute 
chelation with DFO was observed.
4.6.2.1 The influence of ferrioxamine on T2* values with DFO chelation.
Patients follow a variety of practices when attending for CMR assessment. Some 
attend with the DFO being administered simultaneously; others will not have had DFO 
for 48 hrs or greater prior to the assessment. The other more important concern is the 
effect of ferrioxamine in the cellular compartment on the T2* measurement as discussed 
in section 4.2.3.
One patient under went sequential CMR on day 0, 2, 4, 8, and 10. The day 0 
CMR was with the DFO being administered via a balloon infuser at the time of CMR. The 
DFO was stopped immediately post CMR assessment and the subsequent CMR 
measurements were all taken without any DFO. The aim was to see if cardiac and 
hepatic T2* values would change significantly once the ferrioxamine had cleared from
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the intracellular compartment and whether DFO being administered at the time of the 
scan made any difference to the T2* measurement.
Figure 4.6.2.a: T2* of liver at TO and then 48 hourly intervals post DFO infusion
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There was some correlation between the liver T2* and time off chelation but the 
difference was of little clinical relevance because the liver iron values changed from 0.67 
mg/g/dw to 0.56 mg/g/dw. This patient had a low hepatic iron burden, but it is possible in 
a heavily iron loaded patient the value would alter significantly.
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Figure 4.6.2.b: Cardiac T2* at TO and then up to 10day post DFO infusion
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The cardiac T2* measurements from TO to day 10 showed little variation 
returning an R=0.2. However on further analysis, the T2* difference between these 
points is considerable changing from 9.2 ms on day 2 to 11.9 ms on day 4.
These differences are in keeping with our observations of urinary iron excretion 
of ferrioxamine in patients on DFO infusions where ferrioxamine excretion was seen for 
at least 10 hours after cessation of DFO infusion. This is also very similar to the classical 
study by Roberts and Bomford (Roberts and Bomford 1988) who demonstrated that 
ferrioxamine egress from the intracellular compartment to the extracellular was initially 
rapid but then much slower once equilibrium is reached between the extracellular and 
intracellular compartments at 24 hours (Roberts and Bomford 1988).
Although ferrioxamine may play a role in altering the T2* it is unlikely to change a 
normal T2* value into a severe loading one (conversion of a level of >20 ms to <8 ms)
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and provided that patients follow a similar protocols should not be the cause for great 
deviation in the values.
4.6.2.2 Change in cardiac T2* with chelation treatment over time
It has been observed that patients with very low cardiac T2* it takes a 
considerable amount of time to correct this into the normal range despite optimal 
chelation (Porter and Davis 2002). In addition it has been observed that the hepatic iron 
by and large needs to fall significantly prior to the cardiac T2* improving. In order to see 
if this was a valid observation, 13 patients with TM had 4 or more measurements of 
cardiac T2*, LVEF and liver T2* (LIC) as described in section 4.4. The maximum time 
over which observations were collected was 60 months and the minimum time was 12 
months. All patients were treated with standard DFO regimes according to their ferritin 
and therapeutic index as described below. Table 4.6.2.2 shows the chelation 
characteristics of the patients and the mean rate of improvement of the cardiac T2*. 
Compliance was estimated from patient’s interviews in clinic.
The mean rate of change of cardiac T2* was calculated by dividing the change in 
T2* between consecutive observations by the number of months between those scans. 
This gave the change in T2* per month between consecutive scans. All the individual 
change in T2* per month results were calculated for each patient and this data was used 
to derive figure 4.6.2e. In individual patients the mean of the change in T2* per month 
were calculated.
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Table 4.6.2.2 Change in cardiac T2* with chelation treatment over time
patient diagnosis chelation
Duration 
in hours 
per day
days route
compliance 
following 
initial scan
liver iron 
(mg/g/dw)
lowest
cardiac
T2*(ms)
mean rate 
of change 
of cardiac 
T2*/month
1 TM DFO 24 7 IV 50% 11.3 5.7 0.12
2 TM DFO 24 7 IV 75% 13.2 6.8 0.22
3 TM DFO 24 7 IV 75% 7 8.9 0.26
4 TM DFO 24 7 SC 100% 10 3.2 0.37
5 TM DFO/L1 24 6 SC 100% 4.6 11.8 1.38
6 TM DFO/L1 12 5 SC 50-75% 5.9 5.9 0.33
7 TM DFO 24 7 IV 100% 14 4.9 0.06
8 TM DFO 24 7 IV 100% 1.3 8.4 0.12
9 TM DFO 12 5.5 SC 100% 15 5.7 -0.04
10 TM DFO 12 5 SC 100% 2.1 10.3 0.05
11 TM DFO 24 6 SC 100% 0.6 7.6 0.26
12 TM DFO 24 7 IV 100% 9.3 4 0.13
13 Tl DFO 24 7 IV 50% 3.5 6.9 0.12
The mean rate of change of cardiac T2* was calculated for individual patients in 
this table. In section 4.6.2.3 the rate of change in cardiac T2* shall be assessed for all 
patients analysed above (1 to 13) according to the severity of the myocardial iron load. 
As can bee seen from figure 4.6.2.C, and table 4.6.2.2 the rate of change is extremely 
variable in patients with some showing rapid improvement and others less so. The 
reasons for this will be discussed in more detail in section 4.6.2.3.
Figure 4.6.2c shows the change in cardiac T2* over time in the 13 patients and 
is plotted from sequential CMR results for the individual patients.
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Figure 4.6.2.c: Changes in cardiac T2* over time in patients 1 to 13
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Patient 4 is shown in more detail in figure 4.6.2d. He was initiated on an 
intensive SC DFO regime at 60 mg/kg/day 24 hr infusions following a CMR at TO. The 
adherence to therapy was optimal but he developed cardiac decompensation thought to 
be secondary to an episode of myocarditis. IV chelation was initiated and 4 weeks later 
the ejection fraction had improved significantly. He remained on this regime
Page 176 of 278
subcutaneously until 42 months from first CMR when he started on combination 
treatment with Deferiprone on 7 days a week at a dose of 75mg/kg/day along with 
desferrioxamine at 40mg/kg/day on 5 days a week as 24 hr infusers.
Figure 4.6.2.d: Patient 4 treated with intensive chelation.
— Liver T2*(ms) 
Cardiac T2* (ms) 
- a-  LVEF%
liver iron (mg/g dw)
As can be seen from this graph the cardiac T2* appears to improve rapidly once 
the T2* improves above 10ms and this may be due compliance and dosage of chelator 
used.
While differences in compliance with treatment could explain some variability in 
response seen in table 4.6.2.2, it was decided to examine how trends in LIC and 
absolute LIC values might influence response as this has not been examined previously.
10
1
Months from initial CMR
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4.6.2.3 Effect of hepatic iron burdens on response of cardiac T2*
Patients with impaired LVEF have often been treated with intensification of DFO 
therapy with good results in those who comply with such treatment (Davis and Porter
2000). Due to the increased risk of worsening LVEF in patients with T2* less than 20ms 
(Anderson, et al 2001) in principle intensification of treatment could be applied to 
patients with shortened cardiac T2* with a view to reducing myocardial iron loading and 
therefore decreasing the risk of heart failure. While it has been reported that there is an 
improvement in T2* with intensive DFO (Anderson, et al 2004), it is not known whether 
improvement of T2* is affected by body iron burden (and hence liver iron burden). This is 
addressed in figure 4.6.2e. The patients in table 4.6.2.2 provide the data for this analysis 
and the change in liver iron and the change in cardiac T2* per month between 
sequential scans is used for the analysis as described in section 4.6.2.2
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Figure 4.6.2.e: The relationship between liver iron and change in myocardial T2*
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Legend: change in cardiacT2* per month plotted against the hepatic iron. The rate of change was 
calculated for severe, moderate and mild cardiac iron loading according to the cardiac T2*
Black squares TM patients; Red diamond Tl patient
In Figure 4.6.2e, it can be seen that improvement in myocardial T2* is more likely 
when LIC values were < 10 mg/g dry wt. Statistical analysis was performed on these 
data and these are presented in table 4.6.2.3.
Worsening Improving
&*  *  *  *
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Table 4.6.2.3: The relationship between liver iron and change in myocardial T2*
Worsening 
cardiac T2*(n)
Improving 
cardiac T2*(n)
P
Fischer exact test
LIC >12.5 5 0
LIC< 12.5 15 35 0.002
LIC >10.0 8 2
LIC <10.0 12 33 0.002
LIC>7.5 9 6
LIC<7.5 13 27 ns
LIC>5 11 10
LIC<5 10 24 ns
LIC>2.5 16 17
LIC<2.5 4 18 0.021
Legend. Out of 13 patients with a T2*< 20ms and in whom at least 4 sequential observations of 
liver and heart T2* were made, the change in cardiac T2* was calculated (expressed as change 
in ms/ month) and compared with the mean LIC over that period of observation. The table is 
analysed from Figure 4.6.2.e and shown the number of observations with worsening (T2* 
shortening) or improving (T2* lengthening) over the period of observation in relation to LIC values 
greater or less than those shown. Total number of observations n=55
An LIC > 10 or >12.5mg/g dry wt is associated with a significantly increased risk 
of the cardiac T2* worsening. A LIC <2.5mg/g dry wt is associated with a significant 
decreased probability of the myocardial T2* worsening.
4.7 Iron mediated morbidity, T2* and NTBI at matched ages and levels of 
iron loading.
In order to see whether absolute levels of body iron, as estimated by LIC, were 
predictive of iron redistribution to the heart or elsewhere and whether this effect was the
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same for thalassaemia and sickle syndromes, patients with SCA or TM who had all had 
cardiac and liver MRI and matched for age and liver iron levels, were studied. 26 
patients with SCA who had a history of multiple blood transfusions were matched for 
liver iron and age with 26 TM patients. Patient characteristics were as described in 
section 4.4. Complications of iron overload, heart iron (T2*) and plasma NTBI and 
transferrin saturation were then compared between the sickle and thalassaemia groups.
4.7.1 Characteristics of the two cohorts.
Table 4.7.1.1: Baseline characteristics of the two cohorts
Variable
Age (years)
Gender (males) 
Serum ferritin (pg/l) 
Units transfused 
Cumulative iron load 1 
Chelation therapy with DFO 
Splenectomy
sickle cell 
group (n=26)
34+12
19
1806+2079 
191+ 172
25.2 + 25.5 
5
N/a
Thalassaemia 
group (n=26)
29 + 8 
15
2032 + 1908 
828 +_ 368 
219 + 120 
26 
11
P value
0.59
< 0.00001
<0.00001
Legend Patient characteristics: 1For the calculations of cumulative iron load the units of blood 
venesected was accounted for in the calculations but chelation therapy was not. This is described 
in section 4.4
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Table 4.7.1.2: LIC, cardiac T2*, NTBI and transferrin saturation for all patients
Patient
set
Liver iron 
mg/g dw Cardiac T2* ms NTBI pmol/l
Transferrin
Saturation
%
SCA TM SCA TM SCA TM SCA TM
1 9.8 9.3 29.1 11.3 1.92 0.85 80 95
2 0.5 0.9 39 27.9 -1.08 4.26 20 85
3 1.9 1.5 30 22.4 -0.68 0.18 38 96
4¥ 20 20 22.4 9.2 3.77 5.01 90 100
5¥ 8.4 8 33.8 22.9 0.89 5.75 90 100
6 1.95 1.9 56 14.1 3.3 2.2 80 75
7 2.25 2.4 26.6 5.6 -0.53 4.48 70 70
8¥ 8.8 8.2 33.2 38.3 1.2 4.3 70 85
9 1.2 1.3 34.2 29.3 -0.6 0.4 40 55
10 15.9 13.3 53.2 6.8 -0.9 3.94 20 96
11 1.4 1.7 37.7 17.8 0.8 -0.3 85 45
12¥ 5.7 4.2 29.3 56.8 -0.8 1.72 30 60
13 0.53 0.6 37.6 30.1 -1.2 4.7 27 100
14 1.6 1.9 41.5 7.2 -0.96 5.2 35 100
15 10 9.6 35.9 9.6 5.58 4.64 100 100
16 0.46 0.6 37.7 9.6 -0.94 6.61 37 100
17 0.46 0.5 36.1 27.9 -1.04 3.78 41 99
18 4.45 3.8 36.6 18.9 2.51 4.26 100 96
19 0.75 1.8 41.7 10.2 -0.83 6.4 40 95
20 0.9 0.9 25.4 10.9 -0.35 7.28 47 100
21¥ 8.15 7.7 27.8 7.3 -0.67 -1.9 47 95
22 2.9 3.1 37.6 17.9 -0.95 4.4 30 100
23 3 4 25.6 28.8 -0.63 -0.9 37 43
24 0.5 1 24.6 10.7 -0.98 3.8 30 100
25 0.4 0.9 26.7 20.7 -1.16 3.5 25 100
26 1 0.7 33.1 13.5 -1.22 5.9 33 100
mean 4.3 4.2 34.3 18.7 0.17 3.5 51.6 88.1
median 1.9 1.9 34.0 15.9 -0.68 4.3 40.0 96.0
P value 0.42* 0.00002A 0.00001# 0.00001-
Legend: 26 patients with SCA or TM matched for liver iron are shown:
*: liver iron well matched between SCA and TM patients.
A: mean cardiac T2* in SCA patients 34.3 ms but in TM is lower at 18.7 ms.
#; significant difference between NTBI in SCA and TM
significant difference in transferrin saturation between 2 cohorts.
□ : Sickle cell patients who were on chelation with DFO
Blue text: Sickle cell anaemia patients with high liver iron load but no NTBI and 
unsaturated transferrin
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4.7.2 Complications in Sickle cell anaemia and thalassaemia major
It has been observed that complications secondary to iron overload appear less 
frequently in patients with SCA. To see if this was the case patients were matched for 
liver iron burden because the hepatic iron level is a good refection of total body iron as 
discussed earlier. Table 4.7.2.1 shows the frequency of complications from iron burden.
Table 4.7.2.1: Complications found in SCA and TM cohorts
variable sickle cell thalassaemia
hypothyroid 0 2
hypogonadotrophic hypogonadism 1* 18
hypoparathyroidism 0 5
diabetes mellitus 1A 7
cardiac history 3 # 1 0 -
Legend: *; sickle patient aged 35yrs with premature ovarian dysfunction and intermittent
hypogonadal indices over the course of 6 months.
A: non insulin dependant diabetes in patient above 45 years of age and low iron burden.
#: 1 inferior wall myocardial infarction, 1 small vessel disease documented on cardiac catheter 
and third patient had Atrial Fibrillation requiring medication. All above 45 years of age at 
diagnosis.
Paroxysmal Atrial fibrillation n=4; cardiac failure n=6; All 10 patients below 45 yr.
Table 4.7.2.1 shows clearly that complications that are classically seen 
secondary to iron overload are seen less frequently in SCA with only five out of twenty
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six having a complication and from these only one may have been related to iron burden 
the others were probably age associated complications.
For the following analyses in section 4.7.3 data is taken from table 4.7.1.2.
4.7.3 Myocardial T2* in SCA and TM matched for LIC
The cardiac complications, which are the most serious manifestations of iron 
overload, were not seen in the patients with SCA. The most striking finding when 
matching these patients for hepatic iron burden was the absence of cardiac iron loading 
as measured by T2* in the SCA group (Figure 4.7.3a). There is a statistically significant 
higher myocardial T2* in patients with SCA (34.3 ms + 8.1ms), median 34ms compared 
to TM (18.7 ms + 11.9ms), median 12.4ms, with similar degrees of liver iron loading 
(p=<0.0001) suggesting that there was little or no iron deposition in the myocardium in 
the SCA cohort of patients at similar iron burden
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Figure 4.7.3.a: Cardiac T2* in SCA and TM patients matched for iron loading
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Legend: P value is for the T2* of SCA versus the TM patients using student T test.
The reasons why cardiac iron loading differs between SCA and TM patients 
could have several explanations. Firstly the duration of transfusion differs significantly 
between the SCA and TM patients. The TM cohort began regular transfusion regimes 
within the first few years of life whereas the SCA patients did not. If on regular 
transfusion programmes, SCA patients tend to have exchange transfusions. In this way 
the cumulative iron burden and the duration of exposure to high levels of iron overload is 
less even though the liver iron measurements at time of analysis are similar. A second 
explanation is that the TM patients have been treated with DFO for many years. Patients 
born before the late 1970s were started with chelation therapy in late childhood or 
adolescence and TM children born after this time were generally started at 2-3 years of
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age on DFO. As this drug appears to have preferential iron removing effects from the 
liver compared with the heart (Anderson, et al 2004), then the ratio of heart to liver iron 
would be perturbed by such treatment; and this effect which would be relatively lacking 
in the SCA patients who received relatively little DFO (n=5).
Another important mechanism to consider, as outlined in the introduction is that 
in some way iron is ‘withheld’ in macrophages SCA, even at high levels of iron loading, 
leading to a lower transferrin saturation and NTBI. In order to address this question, 
these variables were measured in the same 26 patients in the TM and SCA groups.
4.7.4 Plasma NTBI and transferrin saturation in SCA and TM matched for LIC.
Table 4.7.1.2 shows NTBI values and transferrin saturation for each of the 26 
patients in each group. It can be seen that NTBI is significantly higher in the TM 
(3.48pM) than in matched SCA patients (0.17pM; p<0.0001). These differences parallels 
lower transferrin saturations in the SCA patients (51.6%) than the TM patients (88.2%;
(p<0.0001).
NTBI is generally found at high iron burdens when transferrin is completely 
saturated. In these patients who were matched for liver iron loading, this difference may 
be explained by the chronic inflammatory response in SCA and its effect in sequestering 
iron in the reticuloendothelial cells. It is thought that NTBI is important for the 
development of complications from iron overload due to the free radical damage and that 
NTBI is responsible for iron deposition in the intracellular compartment (Link, et al 1993, 
Randell, et al 1994). It can be seen from table 4.7.1.2 that NTBI is significantly lower and 
the cardiac T2* is normal in the SCA patients who have been matched closely for liver 
iron with TM.
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4.7.5 Relationship of NTBI to myocardial T2*
Since the presence of plasma NTBI has been clearly linked to cardiac iron in 
animal studies (Oudit, et al 2003), the relationship between myocardial T2* and NTBI 
was examined in the TM and SCA (Figure 4.7.5a) It can be seen that if the overall 
relationship is examined for all patients (Figure 4.7.6a) there is a clear trend of 
decreasing T2* at higher NTBI values.
Figure 4.7.5.a: Relationship of NTBI to myocardial T2*
8
6
4
R=0.42
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0
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Cardiac T2* (ms)
Legend: Relationship between NTBI and cardiac T2* in SCA and TM patients matched for hepatic 
iron. Green Squares: SCA ; TM: black diamonds 
R is for all patients as a single group=0.42; P-0.002
However combining two different groups of patients may confound this analysis. 
When the relationship of NTBI to cardiac T2* is examined for SCA patients only there is
Page 187 of 278
no correlation (R= 0.08; P=0.69) and for the TM this is only (R=0.11; P=0.69). Thus 
within groups NTBI values do not predict or assist with evidence of cardiac iron loading 
suggesting that the apparent association between NTBI and cardiac T2* (Figure 4.7.5a) 
may be the result of association rather than causation. In other words two things which 
are increased more in TM than in SCA are being compared, but they may not be 
causally related.
4.7.6 Relationship of liver iron to NTBI
Figure 4.7.6.a: Relationship of LIC to NTBI in patients matched for liver iron
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Legend: Relationship between NTBI and hepatic iron in SCA and TM patients matched for 
hepatic iron. R=0.55 P=0.004 in SCA. The dotted trend line is the R for SCA.
Green Squares: SCA ; TM: black diamonds
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It can be seen that when SCA and TM patients are analysed together that there 
is no overall relationship between LIC and NTBI (R=0.17; P=0.23; n=26). When the two 
groups are analysed separately, there remains a trend of increasing NTBI with 
increasing LIC in SCA (R=0.55; P=0.004; n=26), but is not seen for the TM patients 
(R=0. 029; P=0.88;n=26).
This observation is of interest when considered in relation to Chapter 3 where it 
was found in young thalassaemia patients that NTBI was present even before iron 
loading. This relative independence of NTBI from body iron loading in thalassaemia 
syndromes compared with sickle syndromes may relate to the ineffective erythropoiesis 
seen in thalassaemia compared with the haemolysis which in the main cause of 
anaemia in SCA. This difference is also likely to be important in the mechanisms, which 
lead to increased dietary iron absorption in thalassaemia syndromes but not in SCA.
4.7.7 Discussion and conclusions of comparisons of SCA and TM
These studies show that if patients with TM and SCA are matched for liver iron, 
there are significant differences in pathology resulting from iron overload, cardiac iron 
accumulation and to plasma NTBI. The duration of iron overload and the age at which 
iron accumulation started may be an important reason for differences in pathology and 
cardiac iron loading. If iron redistribution to tissues outside the liver is a slow process, 
then this would be a logical explanation. However this does not explain the differences in 
NTBI and transferrin saturation in the patients matched for iron loading. As discussed in 
section 4.1 the chronic inflammatory state with raised type II cytokines such as IL6 as 
well as increased IL1p and IL8, would be expected to decrease transferrin saturation 
though the hepcidin mechanism (see chapter 5) and this would explain the lower NTBI in
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SCA at matched levels of iron. A second explanation for the lower transferrin saturation 
and NTBI in SCA patients could be that ineffective erythropoiesis is a driving factor for 
NTBI formation and that this is relatively lacking in SCA compared with thalassaemia 
syndromes. Since there appears to be a relationship between NTBI and cardiac T2*, 
this supports the notion lower NTBI at matched LIC in SCA patients could lead to 
decreased secondary iron redistribution, even at matched levels of transfusional 
overload. In order to answer this question conclusively a prospective study of iron 
distribution comparing children with thalassaemia and sickle syndromes commenced on 
transfusion would be required.
4.8 Relationship between Cardiac T2* and Iron burden in Thalassaemia
Intermedia
Iron overload in Tl occurs due to a combination of factors, which makes it difficult 
to compare them to TM or SCA. Unlike SCA, iron absorption is increased, probably 
because of the greater degree of ineffective erythropoiesis in Tl. The rate of iron 
accumulation dietary iron is variable, presumably depending on the extent of ineffective 
erythropoiesis.
Definitions for Tl was as outlined in section 4.4 thirteen patients with Tl 
underwent CMR assessments and also had NTBI measurements. Patient characteristics 
were as described in section 4.4. Table 4.8.1.1 shows the baseline characteristics of 
this group.
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Table 4.8.1.1: Patient characteristics with thalassaemia intermedia
Variable
Age (years)
Gender (males) 
Serum ferritin (ng/ml) 
Units transfused 
Chelation therapy with DFO
Thalassaemia intermedia (n=13)
34+10
7
1384+1320 
129± 164
8
It can be seen that the Tl patients received less blood and had lower ferritin 
levels compared to the SCA and TM cohorts discussed earlier.
Table 4.8.1.2: Complications in Tl patients
. . . Number of affected
var,able patients
hypothyroid 0
hypogonadothrophic hypogonadism 0
hypoparathyroidism 0
diabetes mellitus 0
cardiac history 2#
Legend: #; 1 rheumatic mitral valve disease; 1 pulmonary hypertension
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Table 4.8.1.3: Liver iron cardiac T2* and LVEF and NTBI for Tl patients
patient unitstransfused
liver iron 
mg/g/dw
cardiac
T2* EF%
ferritin
ng/ml
NTBI
umol/l
1 209 9.8 30.0 77 653 3.99
2* 210 9.1 37.2 56 2303 2.64
3* 79 8.5 46.7 66 243 4.93
4 589 5.6 8.1 70 3814 2.97
5 72 7.7 54.0 74 725 2.65
6 72 5.6 68.0 59 396 1.387 0 3.5 25.7 72 476 3.38
8 0 3.2 43.0 78 414 -0.44
9 209 10.9 12.3 73 3322 0.77
10 210 10.0 28.1 66 1815 4.97
11A 10 10.9 34.9 59 3120 3.00
12 0 1.7 39.5 65 152 -0.51
13A 14 9.6 34.2 56 564 1.38
mean 128.8 7.4 35.5 67 1384 2.39
SD 164.3 3.1 16.0 8 1320 1.79
| SEM 45.6 0.9 4.4 2.1 366.1 0.5
Legend: *; cardiac complications (pulmonary hypertension and rheumatic mitral valve disease) 
A: Efi thalassaemia
It can be seen that transfusion requirements are quite varied amongst the 
patients but some patients have significant iron overload as measured by CMR even 
when transfusion frequency had been minimal. On further analysis no relationship was 
found between NTBI and cardiac T2* or NTBI and units of blood transfused. However 
there was a relationship between units of blood transfused and cardiac T2*
Iron loading in Tl is multi-factorial and increased gastrointestinal iron absorption is 
an important mechanism. These patients are often transfused at various points in their 
lives such as during intercurrent infections, pregnancy, symptomatic anaemia, to aid
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healing of venous ulcers, and to reduce extramedullary haematopoiesis. Patients with Tl 
develop cardiac iron loading similar to the TM patients in the third or fourth decade 
(Pippard and Weatherall 1984) and infrequent transfusions will enhance this rate of iron 
loading. As can be seen from table 4.8.1.3 some Tl patients have a high liver iron even 
when they have had minimal transfusion and tend to have more severe anaemia ( 
mainly E(3 thalassaemia) thereby supporting the role of increased gastrointestinal iron 
absorption. Interestingly patients 11 and 13 were part of the pro-hepcidin Tl cohort and 
both had very low levels of serum pro-hepcidin (46 and 60 ng/ml respectively).
4.9 Conclusions
Myocardial iron loading is an important cause for premature death in transfused 
patients. To date there is no consensus on how best to quantify this with significant 
limitations to endomyocardial biopsies and the limited availability of tissue validation data 
for the different MRI techniques used. In this chapter cardiac T2* has been used as a 
means of quantifying cardiac iron loading. In the absence of suitable tissue validation the 
data presented supports the measurement of T2* as an important prognostic indicator 
with a good correlation below 20ms with LVEF.
Recent publications using this technique have shown no correlation with liver iron 
and documented that patients with low liver iron may have a low T2* (Anderson, et al
2001).
The importance of longitudinal monitoring of patients has been shown in this chapter 
in patients with transfusion associated iron overload. Clearance of myocardial iron is 
slow, particularly when there is a severe degree of hepatic loading in patients. However,
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once the liver iron falls significantly then the cardiac T2* improves into the moderate 
range.
Concern about ferrioxamine altering the cardiac T2* need to be further 
addressed. In our study we only performed sequential monitoring in one patient. The 
degree of change in the T2* over a period of 48 to 84 hours was significant in this 
patient. On this basis, until further data is available on more patients, it is probably best 
to advise patients to have the CMR assessment at the same point in their chelation cycle 
on each occasion i.e. if they normally have the CMR assessment whilst they have their 
DFO infusion, then future CMR assessments should also be undertaken with the DFO 
infusion being administered. This would remove any variability due to slow Ferrioxamine 
clearance from the cells.
CMR (with simultaneous MRI of hepatic iron) assessment is very valuable in 
SCA for assessing the cardiac and liver iron stores. It is apparent that patients with SCA 
do not develop as rapid or as severe iron loading as TM patients. This is because the 
transfusions are predominantly in the form of exchange transfusions with iron being lost 
from the venesected units, in addition, the transfusions are also less frequent, often 
being undertaken intermittently with urgent transfusion being performed for sickle 
complications. There does appear to be a relationship between cardiac T2* and NTBI 
when all patients (SCA and TM) are analysed as a group.
Damage to the myocardium is related to NTBI and free radical damage 
associated with this. Patients with SCA tend to have much lower levels of NTBI at 
matched levels of iron burden compared to TM patients. The NTBI present in sickle 
patients and in TM adult patients will predominantly be due to excess iron secondary to 
transfusion rather than due to ineffective erythropoiesis. It has been shown in SCA that 
even at steady state there are increased inflammatory markers and cytokines such as 
IL1, IL6, IL8 and TNF (Makis, et al 2000a). These cytokines may down regulate the
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levels of NTBI at matched levels of iron loading by causing sequestering of iron in the 
reticuloendothelial system.
The Tl cohort are transfused less frequently than TM patients but they are more 
prone to develop iron loading compared to the SCA patients because of increased 
gastrointestinal iron absorption. The reasons for this difference will be discussed in more 
detail in chapter 5.
CMR is a very valuable tool in the management of iron overload and should be 
offered to all patients on regular transfusion regimes. It has provided a great deal of 
information on the distribution of iron in the body, this has lead to improved management 
of patients by the use of intensification of chelation in those with severe myocardial iron 
loading. Although tissue validation of T2* as a methodology is still awaited, it 
nevertheless measures a clinically important parameter and has prognostic significance.
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Chapter Five
Hepcidin metabolism, iron overload and NTBI in thalassaemia
and sickle disorders
5.1 Introduction
In humans, there is no regulated excretory mechanism for iron, with the only 
means of removal of iron being shedding of the gastrointestinal mucosal cells and skin 
cells at a rate of about 1-2 mg per day. Body iron is therefore usually regulated by the 
amount of iron absorbed from food. Over the last few years, several new regulators of 
iron absorption have been identified. Prominent amongst these has been the discovery 
of hepcidin which is a 25 amino acid peptide expressed in hepatocytes and first 
isolated from human urine by Park et al (Park, et al 2001). This molecule appears to 
inhibit absorption of iron from the enterocyte and iron release from macrophages.
5.1.1 Structure, function and tissue expression of hepcidin
Pigeon et al (Pigeon, et al 2001) found that in carbonyl iron loaded mice, a 225 
base pair cDNA (HEPC1) was over expressed and when the murine full length cDNA 
was isolated, it was found to encode for an 83 AA protein with close homology of its C 
terminus with the human hepcidin isolated in urine by Park et al (Park, et al 2001). It was 
found that the human HEPC1 gene on chromosome 19 showed close homology to the 
mouse HEPC1 with 3 exons and 2 introns as well as a USF2 (upstream stimulating
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factor 2) located at the 5’ end. It encoded for an 84 amino acid protein, which showed a 
54% homology to mouse pro-hepcidin (Kulaksiz, et al 2004).
Hepcidin was found to have antimicrobial activity and its relationship to iron 
metabolism was not noted by Park et al but was first recognised by two other groups 
simultaneously; Nicholas et al and Pigeon et al. Nicholas et al (Nicolas, eta l 2001) found 
that Usf2 knockout mice progressively developed multi-organ iron overload. Using 
subtractive suppressive hybridisation techniques with these mice and wild type mice 
they isolated cDNA encoding for hepcidin. Hepcidin was found to be absent in Usf2 
knockout mice and in a second publication using transgenic mice that constitutively over­
express hepcidin, it was noted that these animals died of severe iron deficiency anaemia 
within a few hours of birth (Nicolas, et al 2002a). Hepcidin was therefore described by 
Nicolas et al as a negative regulator of iron absorption.
Pigeon (Pigeon, et al 2001) whilst working on mice fed iron rich and iron poor 
diets found that hepcidin mRNA increased with the degree of iron loading and decreased 
in iron deficient mice. In murine models hepcidin mRNA expression was primarily in the 
liver with only weak expression in the stomach, intestine, colon, lungs, heart and thymus. 
In human tissues, expression of the mRNA was also strong in the liver but significant 
expression of hepcidin mRNA was also seen in the left atrium and in the spinal cord 
(Pigeon, efa/2001)
Pigeon found that the pro-hepcidin localised to the nucleus and if this 
was masked it localised to the cytoplasm, it was therefore postulated that pro-hepcidin 
may undergo cleavage in the hepatocytes prior to excretion of the mature 25 AA form 
and the other smaller forms of hepcidin. Recent work by Wallace et al (Wallace, et al 
2005) has resulted in the generation of a recombinant mouse pro-hepcidin molecule of
7.5 kDa which localised to the secretory intracellular pathway and further work is
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planned to examine the post Golgi processing of pro-hepcidin and its response to 
stimulants such as IL6.
Kulaksiz et al (Kulaksiz, et al 2004) generated antibodies to the mid portion and 
C terminus of the pro-hepcidin and developed an ELISA assay to look at the presence of 
pro-hepcidin in human sera. It was shown that the antibody identified a single 10 kDalton 
band that co-migrated exactly with immunoreactive hepcidin in tissue extracts of liver 
and HepG2 cells.
5.1.2 Effect of anaemia and hypoxia on hepcidin metabolism
The relationship of hepcidin expression to anaemia was noted by 
Nicholas et al (Nicolas, et al 2002a) when transgenic mice over expressing hepcidin died 
of severe iron deficiency anaemia soon after birth. The relation between anaemia and 
hepcidin was further defined by Nicholas when mice were subjected to anaemia by 
repeated phlebotomies to induce iron deficiency or exposed to phenylhydrazine. The 
phlebotomised mice were found to have an 80% decrease in hepcidin mRNA even in the 
presence of normal liver iron stores and the haemolytic anaemia mouse model was 
found to have a 3 fold reduction of hepcidin mRNA in the presence of an increased liver 
and serum iron (Nicolas, et al 2002b). It was concluded that hypoxia may be overriding 
the liver iron mediated down regulation of hepcidin and therefore the role of hypoxia was 
assessed in mice housed in hypobaric hypoxia chambers. A marked down regulation of 
hepcidin was seen after 2 to 4 days of hypoxia. Tissue hypoxia secondary to anaemia 
may play a major role in hepcidin regulation and result in increased iron absorption. 
Recently Ezah et al showed that samples taken from patients with SCA during steady 
state did not have abnormal levels of pro-hepcidin (Ezeh, et al 2005). A number of
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studies have assessed hepcidin or pro-hepcidin in anaemia of chronic disease and 
found a good association of this with ferritin (Dallalio, et al 2003, Nemeth, et al 2003)
5.1.3 Effect of inflammation on hepcidin metabolism
This observation raised interesting questions as to the role of hepcidin in 
anaemia associated with inflammatory states. Anaemia of chronic disease is 
characterised by increased reticuloendothelial (RE) iron storage and decreased iron 
absorption in the face of the anaemia. Park et al (Park, et al 2001) first noted its 
relationship to inflammation when one of the patients in whom the hepcidin was isolated 
developed an infection and hepcidin increased 100 fold in urine samples taken during 
the acute inflammatory state. In addition Pigeon et al (Pigeon, et al 2001) showed that 
hepcidin expression was upregulated by lipopolysaccharide (LPS) in wild type mice by 4 
fold and 7 fold in mouse hepatocyte cell culture. Further work on the role of inflammation 
on hepcidin levels by Nicholas et al (Nicolas, et al 2002b) using turpentine injections to 
induce inflammation in mice found that hepcidin mRNA increased 6 fold within 16 hrs of 
injection. Nemeth (Nemeth, et al 2003) carried out confirmatory work on the role of 
inflammation in stimulation of hepcidin on hepatocytes that were exposed to IL1a, TNFa 
and IL6, and confirmed that hepcidin is a type II acute phase reactant with upregulation 
in response to stimulation with IL6 but not with IL1a or TNFa.
Further work by Rivera et al (Rivera, et al 2005) showed that when mice were 
injected with hepcidin, hypoferrinaemia was induced within 4 hours of injection and when 
hepcidin excreting xenografts were implanted into NOD-SCID mice, the mice developed 
anaemia associated with increased hepatic iron stores and a low serum iron (anaemia of 
inflammation/chronic disease). This scenario is consistent with the observation in
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anaemia of chronic disease, in which hepcidin expression increases even in the 
presence of anaemia. The increase in hepcidin in chronic inflammatory conditions would 
lead to decreased iron absorption form the duodenal enterocyte and reduced 
release/increased sequestering of RE iron, which would result in low serum iron and 
transferrin bound iron and the development of anaemia due to functional iron 
deficiency.
5.1.4 Relationship of iron overload to hepcidin in humans
Iron loading can occur due to iatrogenic or genetic causes. The most common 
condition causing genetic iron loading is hereditary haemochromatosis (HH) which can 
broadly be divided into 4 main types; type 1 is predominately associated with the HFE 
mutation and has a variable penetrance, type 2 is associated with a severe phenotype 
and presents in young adults, type 3 is associated with mutations in transferrin receptor 
2, type 4 is autosomal dominant and tends to be associated with RE iron loading.
HH types 1, 2 and 3 have predominantly non-RE iron loading. Bridle et al (Bridle, 
et al 2003), Gehrke (Gehrke, et al 2003) and more recent work by Papanikolaou 
(Papanikolaou, et al 2004) have shown reduced hepcidin in these 3 forms of HH. 
Nemeth suggested (Nemeth, et al 2003) that mutations in hepcidin expression may 
contribute to the iron loading seen in HH and indeed this has been shown with the 
discovery of 2 new forms of juvenile HH (HH type 2) due to mutations in the hepcidin 
gene (Biasiotto, et al 2004, Roetto, et al 2003).
The relationship of hepcidin and iron overload in secondary haemochromatosis 
in humans is however unknown. Nemeth (Nemeth, et al 2003) found that in patients with 
transfusional iron loading (n=3) urinary hepcidin (uhepcidin) was increased in amount 
and there was a good correlation between uhepcidin and serum ferritin. However there
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remains a paucity of data on what happens to hepcidin in iron secondary iron overload in 
humans.
The expression of hepcidin is unclear in haemoglobinopathies such as 
thalassaemia and SCA. Patients with (3 thalassaemia syndromes present with anaemia 
at an early age and the severity of the ineffective erythropoiesis and anaemia is a major 
factor underlying the transfusion requirements. Iron overload develops in those who are 
transfusion dependant due to iatrogenic iron via the blood, as well as in those who are 
transfusion independent secondary to increased gastrointestinal iron absorption. The 
sickle haemoglobinopathies are associated with considerable anaemia but no increase 
in iron loading from the gastrointestinal tract has been observed, contrary to the iron 
loading seen in the Tl patients who have a similar degree of hypoxia from anaemia. The 
anaemia of SCA is predominantly driven by haemolysis whereas in Tl, ineffective 
haematopoiesis is much more evident. Thus with Tl red cell destruction is significantly 
greater in the bone marrow than in SCA. These differences could have consequences 
on iron loading onto transferrin, NTBI formation and the regulation of hepcidin.
Only 2 studies from the same group have looked at the relationship between 
thalassaemia and hepcidin expression. Adamsky et al using a Tl mouse that was 
transfusion independent found reduced liver hepcidin mRNA (Adamsky, et al 2004) 
suggesting that the down regulatory effect of anaemia overrides the up regulatory effect 
of iron overload. Follow up work from this group showed decreased hepcidin expression 
in TM mice (Weizer, et al 2004). In addition on exposure of human hepatoma HepG2 
cells to human thalassaemic sera they found that hepcidin expression was an average of 
3 fold lower then that evoked by normal sera. The down regulating effect with 
thalassaemic sera but not with normal sera suggested that there may be a upstream 
factor whose levels may increase in the sera in response to ineffective erythropoiesis 
and that this may override the upregulation of hepcidin in response to iron overload.
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Interestingly Nemeth showed that human hepatoma cells have decreased hepcidin 
mRNA in the presence of NTBI (Nemeth, et al 2003) and this is supported by work in our 
lab (in preparation Rafique et al).
Kearney et al (Kearney, et al 2007) looked at urinary hepcidin in children with 
congenital anaemias and found that in TM children no significant difference in uhepcidin 
was seen however the uhepcidin was significantly lower than control patients for both Tl 
and SCA. In the thalassaemia syndromes there was a good correlation with the ferritin 
and in the sickle syndromes there was an inverse relationship with the erythropoietic 
drive. No studies have been done on plasma hepcidin/ pro-hepcidin or its relationship 
with NTBI in patients with these syndromes.
5.1.5 Relationship of urine and liver hepcidin to plasma hepcidin
It is apparent from the discussion above that clinical studies to date have 
measured either urine hepcidin (Nemeth, et al 2003) or hepatic hepcidin mRNA 
(Detivaud, et al 2005) levels as markers for hepcidin expression and examined changes 
in these in response to iron deficiency, inflammation and other variables. Very little 
evidence exists about serum hepcidin. Dallalio et al (Dallalio, et al 2003) measured 
‘serum hepcidin’ levels in anaemic patients and those with abnormal ferritin 
measurements using western blot analysis, their antibody bound to a 9 kDa molecule 
where the predicated molecular weight of the 25 AA form of hepcidin is 2.7 kDa. Dallalio 
found a good positive correlation between the 9 kDa peptide and ferritin but did not find 
a difference according to the type of anaemia in contrast to Nemeths data (Nemeth, et al 
2003).
Dallalio postulated that there was a free (urinary Hepcidin) and a bound form (9 
kDa peptide). Prior to Dallalio’s publication, the changes in plasma levels have been
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assumed to be the same as changes in urine but to date no simple reliable measure of 
plasma hepcidin has been developed so it is not possible at this stage to say whether 
urine and plasma hepcidin levels truly parallel each other.
5.1.6 Relationship of serum hepcidin to serum pro-hepcidin.
An antibody has been developed however which recognises pro-hepcidin, which 
is the immediate and larger product of the HEPC1 gene which was first identified by 
Pigeon (Pigeon, et al 2001) in mice on chromosome 7. The product of HEPC1 is an 83 
amino acid (mouse) protein, which has close homology between the C terminus and the 
25 amino acid mature chain of human hepcidin. It was found that the human HEPC1 
gene on chromosome 19 showed close homology to the mouse HEPC1 with 3 exons 
and 2 introns as well as a USF2 (upstream stimulating factor 2) located at the 5’ end. 
This encoded for an 84 amino acid protein which showed a 54% homology to mouse 
pro-hepcidin.
Kulaksiz et al (Kulaksiz, et al 2004) generated antibodies to the mid portion and 
C terminus of the pro-hepcidin and developed an ELISA assay to look at the presence of 
pro-hepcidin in human sera. It was shown that the antibody identified a single 10 kDalton 
band that co-migrated exactly with immunoreactive hepcidin in tissue extracts of liver 
and HepG2 cells. Results from the pro-hepcidin ELISA on human sera showed that pro- 
hepcidin was present in reduced amounts in HH sera compared to normal controls 
(Kulaksiz, et al 2004). No information was given in this study on transfusion support that 
patients may have received. Recently Ezah et al showed that samples taken from 
patients with SCA during steady sate did not have abnormal levels of pro-hepcidin 
(Ezeh, et al 2005). No study has been undertaken to assess the relationship between 
pro-hepcidin and iron overload in haemoglobinopathies.
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5.2 Aims and rationale
In this chapter, we explore how iron loading modulates hepcidin 
expression measured as mRNA in liver biopsies and expression of pro-hepcidin in 
plasma in sickle and thalassaemia syndromes. The intention is to gain insight into 
whether the regulation of iron absorption differs between sickle and thalassaemia 
syndromes, and whether this could account for the tendency for thalassaemia 
syndromes to hyperabsorb iron from the gut, as well as the higher levels of NTBI 
compared to the sickle syndromes at matched levels of iron loading, and the different 
patterns of distribution of iron between the two disorders (chapter 4).
There were two main aims:
Aim 1: What is the relationship between hepcidin expression and iron burden in liver 
biopsies in thalassaemia syndromes
Liver biopsy samples have been used for many years in patients with 
thalassaemia syndromes to assess iron burden by the measurement of liver iron 
concentration (LIC). In principle, these biopsy samples can provide the opportunity to 
relate hepcidin synthesis measured as hepcidin mRNA to the liver iron in the same block 
of liver tissue. Ethical approval was therefore requested and obtained from the ethical 
committee at UCL/UCLH to measure hepcidin mRNA in paraffin blocks previously 
obtained for measurement of liver iron. For measurement of hepcidin mRNA using liver
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biopsies prospectively, written consent was obtained for hepcidin measurement in 
addition to liver iron.
Aim 2: What is the relationship of pro-hepcidin with anaemia and iron overload in sickle 
and thalassaemia syndromes
The lack of liver biopsy samples in patients with SCA but the availability 
of serum samples from patients with TM, Tl, and SCA allowed us to examine the 
relationship between anaemia and iron overload in more depth. The LIC was the 
measurement obtained simultaneously during CMR assessment. NTBI, Hb, ferritin 
measurements were from the time of sampling. Liver iron assessment is discussed in 
more detail in section 5.3.3.
5.2.1 Patients for Aim 1
40 liver blocks had RNA extraction performed. RNA was retrieved in sufficient 
quantity in 20 samples. Successful RNA extractions were possible on blocks of biopsies 
from 1993 to 2000. Controls for the first cohort were 5 biopsy samples that had no 
excess liver iron by Peris’ stain, sufficient RNA was extracted in 3 of these. These 
samples were blinded to us and no data is available on the haemoglobin levels or ferritin 
levels of these patients. The controls for the second batch were 10 patients all of whom 
had undergone liver resection for metastatic adenocarcinoma, sufficient RNA was 
retrieved on normal liver tissue in 7 of these blocks all of which were from clear liver 
margins sections with no liver tumour present. Perl’s stain was undertaken on these 
control samples to confirm the absence of iron loading. The patients were 14 TM, 4 
transfused and 2 non-transfused Tl.
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Table 5.2.1.1: Patient characteristics for aim 1
number 
male sex 
Mean age ( range) 
transfusion dependent 
chelation 
HCV Antibody positive 
HCV RNA positive 
abnormal AST
patient characteristics thalassaemia major
25.6 (5.1)
14
8
thalassaemia
intermedia
6
4
30 (10.55)
14
14
t5
3
4
*4
5
1
1
1
Legend:
All TM major patients transfused 3 to 4 weekly.
transfusion dependant Tl on exchange transfusion (2) or top up transfusion (2) at 8 weekly 
intervals
f  HCV antibody positive indicative of infection in the past, one cleared virus with treatment, one 
cleared virus spontaneously. Tl patient HCV positive due to previous transfusions
5.2.2 Patients for Aim 2
A total of 73 patient samples were analysed comprising 21 patients with Tl, 26 
with TM and 26 with SCA. Tl samples were collected either in clinic or immediately pre 
exchange and TM samples were collected when they had been off all chelators for 24 to 
48 hrs and 2 to 8 days prior to blood transfusion. All samples for the sickle patients who 
were transfusion dependant were collected at the start of exchange transfusion. Non­
transfused sickle patient samples were collected in outpatients clinics. Any results from 
patients where samples were taken post transfusion were excluded from the analysis. All 
patients with serum creatinine above 100umol/l, CRP >10 mg/l or HCV RNA positive
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were excluded from the analyses. Any patients who were HCV RNA positive were also 
excluded from the primary analyses (4) but were included in the specific analysis.
After the exclusions 17 patients with TM, 18 patients with Tl of whom 15 Tl 
patients were not currently transfused and 15 patients with SCA were included in the 
final analysis. In the SCA cohort, 12 patients were on exchange transfusions and 3 had 
previously been transfused. Normal healthy controls (n=10).
Table 5.2.2.1: Patient Characteristics for aim 2
patient characteristics thalassaemiaintermedia*
thalassaemia
major~
sickle cell 
anaemia #
number 18 16 15
male sex 10 7 9
transfusion dependant 3 16 121
chelation 4 16 5
ALT>60u/l 2 2 3
Legend: 21 patients with Tl and 26 patients each with TM and SCA were analysed. All 
patients with CRP >10, detectable HCV RNA, creatinine >100umol/l or who donated 
samples post transfusion were excluded from the final analysis. Final numbers are 
shown above.
*77: all patients who require <8 transfusions per annum or are transfusion independent.
-  TM: all patients with transfusion dependant beta thalassaemia.
# SCA: SCA who may or may not require transfusion.
II SCA; transfusion dependants are those who are currently on transfusion programmes. 
Those who are not currently transfused are the remaining patients (3)
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5.3 Methods
RNA extraction and preparation of samples as described in Chapter 2 section
2 . 11 .
5.3.1 PCR methodology
This was performed using previously described methodology ((Laftah, et al 2004, 
Leung, et al 2005).
1pg of total RNA was used for cDNA synthesis with the Abgene Reverse-iT 1st 
Strand Synthesis Kit (ABgene, Surrey, UK). RNA concentration and purity were 
determined by spectrophotometry. The resulting cDNA transcripts of liver mRNA were 
used for real-time PCR amplification using the Roche Lightcycler (Roche diagnostics, 
Germany) and QuantiTect SYBR® Green PCR kit (Qiagen, Sussex, UK) according to 
the manufacturers protocol. Specific primers were designed from the rat sequences for 
hepcidin and the constitutively expressed gene, actin:
Hepcidin:
FORWARD
REVERSE
Actin:
FORWARD
REVERSE
CACGAGGGCAGGACAGAAGGCAAG
CAAGGTCATTGCTGGGGTAGGACAG
GACGGCCAAGTCATCACTATT
CCACAGGATTCCATACCCAAGA
To quantify hepcidin mRNA expression, standard curves were generated with 
known amounts of each gene product. A ratio of relative abundance of the hepcidin gene 
to actin was calculated by the Lightcycler Relative Quantification software version 1.0 
(Roche Diagnostics, Germany).
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5.3.1.1 Calculation of results
The first set of RNA extraction was relatively poor in amount due to smaller 
sample size. The second batch of samples analyses as described above provided a 
greater amount of RNA. To standardise the results between the two batches of 
samples, we normalised the control results of each batch to 100% and then calculated 
the relative value as a percentage of the mean of the control for that batch. The results 
were analysed on the basis of the % of the mean of normal controls for each run. The 
mean, standard deviation and the standard error of the mean was calculated where 
relevant. All p values were derived using the Students T tests and were 2 tailed and of 
equal variance.
All the haemoglobin results were those taken pre-biopsy. The serum ferritin and 
AST were the mean of the results for 6 months prior to the biopsy.
5.3.2 Liver iron quantification in paraffin blocks
The liver iron was obtained from that biopsy sample by drying followed by acid 
digestion as per the method described by Barry (Barry 1974). Mr Gareth Ellis in Special 
Haematology performed these at the Royal Free Hospital. The liver iron concentration 
was calculated by measuring the optical density at 535nm and using the formula:
Iron content of Biopsy pg = OP Digest X [Fe]
OD Standard
Tissue Iron Concentration pg/100mg Dry weight = Iron content of biopsy X 100
Dry weight of Biopsy mg
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5.3.3 Prohepcidin ELISA
Prohepcidin ELISA was performed as described in section 2.10, Chapter 2. The assay 
was performed at a 1:1 dilution throughout.
5.3.3.1 Calculation of results
The pro-hepcidin value of each sample was obtained as follows:
Using linear-linear paper, a standard curve was constructed by plotting the average 
absorbance (Y) of each Reference Standard against its corresponding concentration (X) 
in ng/ml.
The average absorbance of each sample was used to determine the 
corresponding pro-hepcidin value by simple interpolation from this standard curve, 
multiplying by the initial sample dilution.
Normal range: 51.6 -153.9 ng/ml; mean 106 (SEM 32.1 )ng/ml for the kit.
Normal control values in our lab :56-190 ng/ml; mean 119 (14.3) ng/ml
5.3.4 Liver iron measurement by MRI
For the measurement of liver T2* a single transaxial 10mm slice through the 
centre of the liver was acquired using a gradient echo sequence at eight different echo 
times (2.3 - 20.0ms). This was obtained during the same session as the cardiac T2* 
following the method described in Anderson et al (Anderson, et al 2001). This study had 
tissue validation for the liver iron assessments with an R=0.81 for all hepatic biopsies 
and an R of 0.91 P<0.0001 for the non-fibrotic liver biopsies. It is an accurate method
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for calculating hepatic iron burden in no fibrotic liver samples although there is debate 
about the accuracy of results in the non fibrotic samples.
The estimated liver irons values obtained from the CMR were performed within 6 
months of the blood samples. The serum ferritin, AST, haemoglobin, and NTBI were all 
measured on samples taken from the same venepuncture. The mean and the standard 
deviation were calculated and where required Student t tests were performed. All results 
are expressed as the mean (SEM).
5.4 Results: Aim 1: the relationship between hepcidin and LIC in 
thalassaemia
In Table 5.4.1.1 it can be seen that hepcidin mRNA was not significantly different 
in thalassaemia patients from control subjects despite the fact that LIC was between 6 
and 8 fold increased above control liver tissue. This suggests that transfusional (n=18) or 
non transfusional (n=2) iron loading does not result in significant upregulation hepcidin 
synthesis in the liver in thalassaemia patients
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Table 5.4.1.1: Hepcidin mRNA, ferritin, and LIC in patients.
Cohort
Hepcidin mRNA 
(% of mean) 
(SEM)
Ferritin
(ng/ml)
(SEM)
Liver iron 
(mg/g dw) (SEM)
Control
N=10
100
(23.9) 30-400 0.35-1.36
All thalassaemia 114 2448 8.1
N=20 (14.6) (387.2) (1.1)
Transfused patients 110 2640 8.4
N=18 (15.8) (405.6) (1.2)
Non transfused Tl 123.4 719.4 5.7
N=2 (37.6) (21.63) (1.3)
Legend: Results are presented as the mean and (SEM). Liver hepcidin mRNA obtained from
paraffin embedded sections are shown, in liver samples taken from healthy controls (n-10) in all 
iron thalassaemia patients (n=20), and in subgroups of 18 Transfused (14 TM and 4TI) and non 
transfused Tl (n-2) patients. Values of hepcidin mRNA are normalized relative to the control liver 
samples. All controls had normal Perl’s staining on liver biopsy and no evidence of siderosis, 
ferritins and liver iron quantification were not done and the range of ferritin and liver iron for 
normal adults is given. Patient ferritin values were the mean of the preceding 6 months and the 
liver iron result was that from the paraffin block used to perform the mRNA extraction.
5.4.1 Analysis of variables which may modulate hepcidin mRNA
As there appeared to be no difference in hepcidin mRNA in liver biopsies 
between thalassaemia patients, be they TI,TM or controls, an analysis of whether there 
was variability in hepcidin mRNA which could be accounted for by other factors such as
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iron loading, liver function and hepatitis in thalassaemia patients taken as a whole 
(n=20).
The numbers are small however, and the results cannot truly be of any statistical 
significance, but will help to provide some generalisations. It can be seen that hepcidin 
mRNA is lower in patients with LIC values > 10mg/g dry wt than in those with values 
below this. Suggesting that iron overload may down regulated hepcidin. Liver hepcidin 
mRNA is higher in HCV RNA +ve patients (with active hepatitis) than those who are 
HCV RNA -ve suggesting that inflammation from hepatitis C results in increased 
hepcidin synthesis. AST may be increased from with iron overload or from hepatitis so 
for the analysis in Table 5.4.1.2 HCV RNA positive patients were excluded.
Table 5.4.1.2: Analysis of factors which may affect liver hepcidin mRNA levels
Variable
(Units) Category n Hepcidin mRNA (% of control)
sem p value
>10 5 1-85 12 0.3
Liver iron 5-10 8 131 32 0.3
(mg/g dw)
<5 5 131 16 *0.05
>3000 6 1f117 34
Ferritin H
(ng/ml) <1500 7 116 29 ns
>60 4 A67.0 11.9
AST A
(iu/l) <60 12 106.9 15.8 ns
+ 4 182 32.3
0.02
HCV RNA - 16 96.9 12.8
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LEGEND: * Liver iron greater than 10mg/g/dw (n=5) had lower hepcidin mRNA and this 
as significant when compared to those with Liver iron below 5mg/g/dw (n=5) p=0.05. 
P=ns in patients with LIC>10 vrs<10 mg/g/dw
Patients who are HCV + ve have a significantly higher hepcidin mRNA than HCV-ve 
patients (p-0.02). Liver iron quantification was not available on 2 patients with TM who 
were excluded from this analysis.
AAST excludes 4 patients who were HCV RNA positive.
Ferritin >1501 and less than 2999 ng/ml (n=7) not shown on table values hepcidin 
mRNA% similar to levels in table.
5.4.2 Relationship of LIC to liver hepcidin mRNA
When LIC is plotted against hepcidin mRNA, it can be seen that there appears to 
be a weak negative trend between LIC and hepcidin mRNA in all thalassaemia patients, 
although this is not significant P=0.27.
Figure 5.4.2 a: LIC and hepcidin mRNA for all patients
300 !
250 -
R = 0.27
0 20 255 10 15
liver iron mg/g dw
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Legend; The relationship between liver hepcidin (expressed as % of that in control samples) and 
LIC is shown for all thalassaemia patients (n-18). It can be seen that for those patients with LIC 
values £ 10mg/g dry wt that hepcidin mRNA values are close to or less than control values. For 
LIC values < 10mg/g dry with Hepcidin mRNA values show a large spread compared with 
controls ranging from 251% to 21%
Blue diamonds: all patients Orange squares: those with grade 3/4fibrosis
As Table 5.4.1.2 suggested that HCV positivity was a confounding factor 
influencing hepcidin mRNA, an additional analysis of the relationship between LIC and 
hepcidin mRNA was undertaken where HCV +ve patients were excluded from the 
analysis. It can be seen in Figure 5.4.2.b that the negative trend between LIC and 
hepcidin mRNA is more pronounced when these patients (shown in pink) are excluded 
(R=0.38; p=0.16; n=15)
Figure 5.4.2.b: Liver iron and Hepcidin mRNA, excluding HCV RNA positive
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Legend: Black diamonds: liver iron in mg/g/dw compared to hepcidin mRNA (% of mean of 
control) in all patient excluding HCV RNA positive patients (n-15) excluding one patient with no 
liver iron measurement available). 
red squares Tl patients.
Pink squares: HCV RNA positive patients (n-3) AST not available for one HCV RNA positive 
patient. Once those with inflammation have been excluded the liver iron does correlate with 
Hepcidin mRNA with higher iron burdens having lower hepcidin mRNA present.
Figure 5.4.2.c: Hepcidin mRNA subdivided according to LIC
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Legend: Hepcidin mRNA in cohorts subdivided according to hepatic iron load n-18  
Red: liver iron less than 5 mg/g/dw; Orange: liver iron>5<10mg/g/dw; Brown: liver iron 
>10mg/g/dw. In cohort liver iron >10mg/g/d when compared to those with <5 mg/g/dw the 
hepcidin mRNA is significantly lowerp-0.05. HCV RNA positive patients excluded.
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5.4.3 Relationship of Hepcidin mRNA to serum AST
If HCV +ve patients are excluded ( pink squares), there is a trend of decreasing 
hepcidin mRNA with increasing AST (R=0.41; p=0.13;n=15)
Figure 5.4.3.a: Relationship of Hepcidin mRNA to serum AST
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R = 0.01
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Legend: The relationship between AST values and hepcidin mRNA is shown for 19 patients. 
AST not available for 1 patient who was HCV RNA positive. Blue diamonds HCV RNA negative 
thalassaemia patients: pink Square: those patients who were HCV RNA positive. Orange 
squares: those with greater than grade 3/4 fibrosis.
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Some of the variability in AST can be accounted for the tendency for increased 
AST values with increasing LIC as demonstrated by the previously recognised positive 
trend between LIC and AST (r=0.29) when Hep C PCR +ve patients are excluded. Thus 
it appears that increasing liver dysfunction as shown by higher AST values are 
associated with a tendency for decreased hepcidin mRNA unless there is ongoing 
infection with hepatitis C which may lead to an increase in hepcidin mRNA.
5.4.4 Discussion: significance of hepcidin mRNA results
Both cohorts of patients were transfused. The TM patients were on regular 
transfusion programmes at 2 to 4 weekly intervals. Of the 6 Tl patients, 2 were not on 
transfusion programmes, one of them had been heavily transfused in the past and the 
other was only transfused to cover surgical procedures. Of the remaining Tl patients 3 
were on exchange transfusion regimes and one was on 6-8 weekly top up transfusions. 
The relationship between hepcidin mRNA and Hb was not assessed in this analysis as 
the Hb values were not contiguous. Hepcidin mRNA was not significantly altered 
between the 2 cohorts of patients (mean + SD); Tl (123+ 47) compared to (110 + 73) 
p=0.78 in the TM group. This is likely to be due to the majority of patients being 
transfusion dependant. Dallalio found a relationship between hepcidin levels in serum 
using Western blot analysis and ferritin and Nemeth found a good correlation between 
urinary hepcidin and ferritin in 3 non HH iron overloaded patients (2 MDS and 1HbSS).
More recently Aoki et al (Aoki, et al 2005) found hepcidin mRNA correlated well 
with ferritin in patients with HCV infection. We however did not see any relationship 
between the serum ferritin and liver hepcidin mRNA in patients with thalassaemia and 
iron overload (R=0.21; p=0.98; n=18). Those patients with a ferritin greater than 3000
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ng/ml did not have a significant difference in the hepcidin mRNA expression (117%) 
(p=0.99) compared to those with a ferritin of less then 1500ng/ml (116%).
Hepatic iron burden is important in the expression of hepcidin and in keeping with 
the mouse study by Weizer et al (Weizer, et al 2004) we found a trend towards higher 
levels of liver iron burden having lower mean hepcidin mRNA values (85% vrs 131%, 
p=0.05). The reason for this paradoxical down regulation is unknown but one can 
hypothesise that the presence of NTBI at high level may have a role in this as shown in 
recent work by Nemeth on human hepatoma cells. Although NTBI may be an important 
factor in the down regulation of hepcidin it cannot be the only mechanism. Unfortunately 
we do not have contiguous sera samples from these patients to measure their NTBI. The 
patients with liver iron below 10 mg/g dry weight had a higher level of hepcidin mRNA 
expression compared to the controls as one would expect in response to increased iron 
load, this suggests that there is possibly a critical level of iron burden above which 
hepcidin expression becomes dysregulated and fails to increase with further increment 
in the iron burden and paradoxically its production goes down. It is possible that because 
hepcidin is synthesised by hepatocytes, once free iron in the form of the labile iron pool 
reaches a maximum threshold intracellular damage occurs and hepcidin production is 
reduced.
Transaminase levels are thought to be a reflection of liver damage and liver iron 
burden (Olsson, et al 1985). 4 patients with raised AST levels who were not HCV RNA 
positive had low mean hepcidin mRNA levels (67%+ 12%), a higher mean liver iron 
(11.09mg/g/dw+ 24%) and increased levels of fibrosis (intermediate to high) compared 
to those with lower or normal AST levels (n=12) mean hepcidin mRNA (106%+55) mean 
liver iron 7.13 mg/g/ dw and only mild fibrosis; these numbers were too small to gain 
statistical significance but support the suggestion that significant liver damage ( fibrosis 
score intermediate or greater) may lead to down regulation of hepcidin levels and
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indeed this was recently noted Nemeth’s group in patients who had had liver transplants 
or cirrhosis (Detivaud, et al 2005).
Inflammation results in up regulation of hepcidin as discussed earlier. Hepatitis C 
causes a chronic inflammatory mediated hepatitis. The predominant cell type involved in 
this inflammatory response is the T helper cell type 1 (Th1) (Neuman, et al 2001). Th1 
cells release TNFa, IL2 and INFy; these cytokines have the ability to cause ongoing 
cellular immune response. TNFa stimulates macrophages in the liver to release of 
Transforming Growth Factor |3 (TGF p) which then goes on to stimulate the development 
of fibrosis. T helper cell type 2 (Th2) secrete IL4, IL6 and IL10 which in the presence of 
ongoing inflammation suppress the Th1 response and down regulate the TNFa and TGF 
p. There were 4 patients who were HCV RNA positive, all of whom had modestly 
elevated serum AST levels (mean 91.4 iu/l) and mild to high levels of fibrosis on biopsy 
were found to have raised hepcidin mRNA (181% + 79) p=0.01. There was no difference 
in the HCV RNA positive and HCV RNA negative groups for ferritin (2701 ng/ml: 2350 
ng/ml), AST (91.4 iu/l: 58.9 iu/l) or liver iron (7.5 4mg/g/dw versus 8.19 mg/g/dw) p=ns. In 
our patients who had chronic HCV carriage and variable degrees of fibrosis, it is possible 
that the Th2 response with IL4, IL6 and IL10 was the predominant factor in the 
inflammation and hence hepcidin was upregulated in the face of ongoing viraemia. The 
presence of excess iron burden in the presence of HCV infection results in significant 
worsening of liver fibrosis and hastens the onset of cirrhosis (Angelucci, et al 2000, 
Ardalan, et al 2004). It may be that in the presence of HCV infection, hepcidin mRNA 
expression increases more significantly in the presence of moderate iron loading and 
inflammation than it would if either was present alone.
It is however important to appreciate that in transfused thalassaemia patients iron 
overload is predominantly secondary to transfusion, is distributed differently and the role 
of fibrosis and inflammation are probably modified due to this. Transfusional siderosis is
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initially reticuloendothelial and it is possible that a response may not be seen to the 
siderosis until moderate iron loading has occurred when the iron starts to enter 
hepatocytes thereby initiating stimulation of hepcidin synthesis. However as 
transfusional iron loading continues the intracellular labile iron pool continues to increase 
in amount and eventually cell death occurs due to hydroxyl free radical damage and 
hepcidin mRNA decreases in amount.
In conclusion it was noted in thalassaemia syndromes that hepcidin mRNA was 
down regulated at higher iron burdens, with greater levels of fibrosis and with higher 
AST levels. Hepcidin was upregulated with inflammation secondary to hepatitis C over 
riding the suppressive effect of iron and fibrosis on hepcidin mRNA expression.
It was decided to look at a wider population of patients and Kulaksiz et al had 
recently described a pro-hepcidin ELISA that identified a 10 kDa peptide which was 
down regulated in HH and in anaemia similar to that seen with other investigators who 
had used urinary hepcidin or hepcidin mRNA or serum hepcidin measurements using 
western blot analysis.
5.5 Results: Aim 2: pro-hepcidin, anaemia and iron overload in
haemoglobinopathies
The relationship of serum pro-hepcidin to variables which might be predicted to 
influence levels such as iron loading, anaemia, transfusion and hepatitis were analysed, 
first in all patients, sickle and thalassaemia together and subsequently by individual 
patient group to determine whether the relationship of serum pro-hepcidin to these 
variables was different in different patients groups.
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Several relevant differences between the designs of data acquisition occurred in 
the pro-hepcidin analysis compared with the liver mRNA for hepcidin. Firstly LIC was 
estimated from non-invasive measurements obtained during CMR as described in 
section 5.3.4. this method has been validated with liver biopsies. Secondly it was 
possible to include SCA patients in this analysis because LIC values were available and 
lack of liver biopsy tissue had excluded them from the first part of this study. Thirdly it 
was possible to obtain blood samples for analysis of serum pro-hepcidin in a systematic 
way in relation to blood transfusion. This allowed an analysis of the relationship between 
serum pro-hepcidin and anaemia, which was not possible with the liver biopsy analysis 
due to the retrospective nature of the analysis and the arbitrary timing of the liver 
biopsies with respect to transfusion. Finally it was possible to obtain blood samples for 
NTBI measurement on the same day as the serum pro-hepcidin samples, allowing an 
examination of the interrelationship of these variables.
5.5.1 Variables affecting prohepcidin, independent of diagnosis
In all patients grouped together, there a clear relationship between Hb values 
and serum pro-hepcidin with a significant difference in serum pro-hepcidin between 
patients with Hb values < 8 and those >1 Og/dl (p<0.0001).
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Table 5.5.1.1: Variables associated with prohepcidin levels in all patients
Variable
(units)
Category n pro-hepcidin
(ng/ml)
sem p value
>10 19 128.78 7.11
Hb (gldl) 8-10 20 102.1 9.08 <0.0001-
<8 10 65.25 15.55
# Liver iron 
(mg/gdw)
<5
5-10
>10
27
11
4
110
94.73
108
8.26
12.88
22.01
ns
Ferritin <1500 29 101.9 8.87
(M9/L) 1500-3000 7 118.9 9.6 ns
>3000 12 114.5 9.8
Ttransfused
+ 33
16
115
84
6.68
10.9
0.02
NTBI
present
+ 21
24
112
105
8.95
9.37
ns
ALT (iu/l)
>60
<60
6
43
113
107
17.4
6.68
ns
HCVRNA 0
+ 4
49
55
107
18.6
6.3
0.01
Legend: * total of 49 patients were studied and n is the number of patients analyzed for the 
variable shown.
# Liver iron was assessed by MRI (Anderson, et al 2001) in 41 patients
H: Transfused are all patients currently requiring blood transfusion, including; all TM (>8 
transfusions /y), currently transfused Tl (Tl: 1-8 transfusions per annum) and sickle cell patients 
who were on exchange transfusion programmes.
~ is the probability of Hb > 10g/dl compared to Hb <8 g/dl.( <8 vs. all patients >8g/d p =0.23)
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<f : those patients who were HCV RNA positive and were excluded from analysis of Hb, NTBI, and 
liver iron, transfusion status and ALT. Those patients who had previously had HCV and were 
HCV RNA negative were included in the HCV RNA negative cohort
It is also apparent from Table 5.5.1.1 that there is also a tendency to lower serum 
pro-hepcidin in untransfused than transfused patients (p=0.02) the mean Hb at time of 
sample in transfused patients was 10.1 g/dl and in the non-transfused (SCA and Tl) was
8.5 g/dl and also a lower serum pro-hepcidin patients was found in HCV+ patients (n=4 
p=0.01). A further finding in Table 5.5.1.1 is that serum pro-hepcidin appears to be 
lower in the 4 patients who are HCV RNA +ve than in uninfected patients. Surprisingly, 
this is the opposite of what was found for hepcidin mRNA in the liver biopsy samples 
where hepcidin mRNA appeared to be higher in the HCV RNA +ve patients however 
none of these patients were part of the hepcidin mRNA study.
Tables 5.5.1.1 and 5.5.1.2, show that the values for all patients on sub analysis 
were very similar to those when all 3 cohorts studied as a single group. There appears 
to be a significant relationship with transfusion status/anaemia. No relationship is seen 
with iron burden or serum ferritin.
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Table 5.5.1.2: results (mean) for all patients according to type of anaemia
D iagnosis n Pro-hepcidin ng/ml (SEM)
Ferritin
ng/ml
(SEM)
Hb g/dl 
(SEM)
EPO
mlU/ml
(SEM)
Liver iron 
mg/g dw 
(SEM)
NTBI
umol/l
(SEM)
Control 10 119(14.3) 50 (8.9) 13.2 (0.53) 14.7(3.4) ND* 0
SCA(all) 15 129 (9.6) 2304 (409) 9.3 (0.45) 68.6(9.9)
4.75
(1.22) 0.21 (0.48)
SCA not 
currently 
transfused
3 138.7(16.2) 1181 (562) 7.9 (0.64) 74.3(18.9)
2.2
(1.27) 0.26(1.14)
TM (all) 16 122 (8.3) 2824 (575) 10.8(0.27) 50.6(11.8)
4.65
(0.91) 1.48 (0.62)
Tl (all) 18 78 (9.50)~ 562 (193) 8.6 (0.33) 181.4(24)
5.52
(0.83) 1.36 (0.56)
Tl not 
currently 
transfused
15 78.5(10.1) 461 (197) 8.5 (0.36) 114.2(44.6)
4.9
(0.93) 0.8 (0.58)
Legend: Semm pro-hepcidin values, serum ferhtin, LIC and Hb values are shown for 
control subjects and for patients with sickle and thalassaemia disorders. LIC was 
calculated from the relationship between liver T2* and liver LIC as described by 
Anderson.
* Liver iron quantification not done in normal controls, assumed to be within the normal 
range 0.28 -0.44 mg/g/dw (33 ± 7 ms)
~ Tl pro-hepcidin significantly lower than that of TM or SC A despite having similar iron 
burden.
There appeared to be a strong relationship with anaemia in subanalysis and this was 
confirmed on correlations.
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5.5.2 Relationship between pro-hepcidin and anaemia
Further analysis of the relationship between Hb and serum pro-hepcidin in all 
patients, irrespective of diagnosis shows a correlation (R=0.44; P=0.0012; n=49). This is 
consistent with anaemia and hence hypoxia being a key factor in promoting pro-hepcidin 
values in plasma. This is also consistent with the known hypoxia mechanism for hepcidin 
synthesis and suggests that in this respect, serum hepcidin values behave in response 
to anaemia in a similar way to that previously reported for urinary hepcidin and liver 
mRNA (Detivaud, et al 2005).
Figure 5.5.2.a: Relationship of pro-hepcidin and haemoglobin in all patients
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Legend: All patients analysed (n=49) excluding those with high CRP, HCV RNA positivity, renal 
impairment) as described in section 5.2.2
This figure shows a good correlation between Hb and pro-hepcidin (R=0.45; 
P=0.0012; n=49) however it was important to see if there were significant differences in
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the 3 cohorts as they have different transfusion regimes and the degree of ineffective 
erythropoiesis is different in the groups.
When the three groups are assessed separately there is no significant correlation 
within individual cohorts, TM R=0.38 (P=0.14;n=16), Tl R=0.44 (P=0.067,n=18) and SCA 
R=0.25 (P=0.37,n=15).
It is also possible that EPO may be playing an important role in this relationship 
with anaemia and pro-hepcidin and hence this was studied.
Figure 5.5.2.b: Relationship between EPO and pro-hepcidin
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Legend: All patients analysed (n-42) excluding those with high CRP, HCV RNA positivity, renal 
impairment) as described in section 5.2.2
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In the 3 groups when the data was analysed as a single cohort R=0.38; P=0.01; 
n=42. There was no correlation within individual groups; TM R=0.33 (P=0.23; n=14); Tl 
R=0.03 (P=0.9; n=17) and SCA R= 0.22 (P=0.45; n=14). From this figure it can be seen 
that a high EPO levels is associated with a low pro-hepcidin. If pro-hepcidin is the pro 
form of hepcidin found in the plasma this would explain how a high erythropoietic drive 
driven by EPO would cause suppression of pro-hepcidin/hepcidin and a resultant 
increase in the iron absorption in order to increase Hb synthesis. It is possible that the 
EPO driven hypoxia drive overrides the iron driven upregulation in the patients with 
thalassaemia.
When all patients are grouped together in this analysis, there is no obvious 
relationship with serum prohepcidin and markers of iron metabolism such as serum 
ferritin and NTBI. This could be because differences between different classes of 
patients obscure trends within patient groups. Therefore in the subsequent sections, 
analysis of these data is undertaken by diagnosis.
5.5.3 Relationship between pro-hepcidin and LIC
There was no relationship between pro-hepcidin and LIC when all the patients 
were studied as a single cohort (R=0.00; P=0.97;n=42) nor when they were assessed as 
separate groups.
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Figure 5.5.3.a: Pro-hepcidin and LIC in patients
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Legend: Black Squares: TM (n-16) red diamonds: Tl: (n=13) and green squares: SCA (n-13)
All cohorts exclude patients as previously defined. Total patients n-42; 7 patients did not have 
CMR to assess liver iron 57/ and 2 SCA. There was no correlation in any of the groups of pro- 
hepcidin with iron burden. SCA P-0.44, TM P—.0.59, Tl P=0.60
These results were unexpected, as other workers have shown a relationship with 
pro-hepcidin and liver iron and we had seen a relationship between hepcidin mRNA and 
liver iron as discussed earlier in this chapter. Figure 5.5.3a however showed that the 
pro-hepcidin was significantly lower at similar iron burdens in Tl than either the TM or 
SCA groups. We decided to look at the results of patients matched for liver iron in the 3 
cohorts to confirm this observation. Data from table 5.5.3.1 was used.
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Figure 5.5.3.b: pro-hepcidin in 3 cohorts matched for LIC
180
160
140
P=0.04
E 120
O)
c  100
I - P=0.02
jCo
40
20
TM SS
Legend: patients matched for LIC as shown in table 5.5.3.1.
Patient characteristics
Tl n-7  2 exchange transfused, 5 not transfusion dependant. P=0.02 comparing pro-hepcidin 
between Tl and SCA
SCA n-7; 5 transfused 2 not requiring transfusions currently.
TM n-7 all transfusion dependant (p=0.04) comparing pro-hepcidin between Tl and TM.
It is possible the degree of anaemia in Tl patients may override the effect of iron 
burden on pro-hepcidin expression however, the sickle group also had a significant 
degree of anaemia and the mean Hb in SCA patients was 9.3 ( ±1.76g/dl) versus 8.6 (± 
1.42g/dl) in the Tl cohort (p=0.24).
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Table 5.5.3.1 Thalassaemia Intermedia, Major and sickle cell anaemia patients matched for liver iron
matched liver iron mg/g dw Prohepcidin ng/ml NTBI umol/l Haemoglobin g/dl
pair Tl SCA TM Tl SCA TM Tl SCA TM Tl SCA TM
A 1 0 .6 1 0 .0 9.3 116 134 160 3.99 5.58 0.85 9.2 11 .3 11 .5
B 3.5 3.0 3.8 110 170 166 3.38 -0.63 1.71 10.8 13 .4 10 .8
C 6 .8 8 .2 8 .0 100 110 90 2.64 -0.67 4.23 10 .7 9.1 10 .5
D 3.2 2.9 2 .8 110 114 96 -0.44 -0.95 4.60 8.8 8 .8 9 .9
E 9.6 9.3 9.3 60 158 104 1.38 1.17 -0.70 6 9.4 9 .3
F 2 .1 2 .2 2 .6 28 116 130 6 .6 8 -0.53 -0.96 8.9 8 .8 11 .7
G 4.8 4.4 4.1 84 130 140 1.38 2.51 -1.49 9 .0 7 10 .13 10 .62
mean 5.80 5.71 5.70 86 .86 133 .14 126 .57 2.72 0.93 1.18 9.05 9.25 10.65
median 4.80 4.40 4.10 10 0 .00 13 0 .00 13 0 .00 2.64 -0.53 0.85 0.23 0.05
p value 0 .7 4 0.76 0 .0 2 * 0.04* 0.1911 0.35 0 .1 6 - 0 .0 2 #
Legend: *The Tl patients have a significantly lower serum pro-hepcidin compared to sickle (p=0.02) and TM (p=0.04). The 
haemoglobin is not significantly different between the Tl or SCA cohorts #: p value comparing Tl to TM showing significant difference 
in the Hb.]} although the difference in the NTBI is not significant it is 2 time greater then that of the SCA cohort and the TM cohort. 
These patients were not age or sex matched as the aim was to match the liver iron as closely as possible.
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5.5.4 Relationship between pro-hepcidin and NTBI
While figure 5.5.3.a suggests that liver iron stores are not an important regulator 
of serum pro-hepcidin, at least in the iron-overload range, in principle NTBI could 
modulate pro-hepcidin levels. Furthermore in Table 5.5.3.1, Tl patients appear to have 
higher NTBI values than SCA patients despite having similar LIC values. An analysis of 
the relationship between NTBI and serum pro-hepcidin was therefore indicated. It can be 
seen in Figure 5.5.4a, that there is no relationship between pro-hepcidin and NTBI 
however in the Tl cohort there is a trend towards falling pro-hepcidin levels when there is 
a high NTBI (R=0.46; P=0.063;n=17).
Figure 5.5.4.a: NTBI and serum pro-hepcidin in all patients
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Legend:. Tl n=17; TM n=15; SCA n=15
Page 232 of 278
There is a correlation between NTBI and pro-hepcidin in Tl with those patients with the highest 
serum pro-hepcidin having the lowest NTBI (R=0.46). No correlation was seen with the TM and 
SCA patients and NTBI.
An analysis in the different patient groups figure 5.5.4a, show that the 
relationship of serum pro-hepcidin to NTBI appears to differ in the transfused SCA and 
TM patients compared to the Tl. It is possible that the trend that is seen is related to the 
fact that Tl patients have a raised EPO and are more anaemic then TM and SCA 
patients. In this situation the presence of NTBI secondary to ineffective erythropoiesis 
could be playing a role in down regulation of pro-hepcidin.
5.5.5 The relationship between pro-hepcidin and ALT
We had also shown in the study with hepcidin mRNA that there was a 
relationship between the transaminases and hepcidin expression in those patients who 
were negative for the HCV virus. These patients have had higher liver irons and it was 
thought the raised transaminase was associated with increasing liver fibrosis. In this 
section of the study we were unable to assess liver fibrosis with CMR and it was decided 
to look at the transaminase to assess the relationship with liver damage secondary to 
iron overload.
There is no significant correlation in TM patients however there are very few 
patients with TM and raised ALT because the majority are well chelated and have less 
severe iron overload. It is possible that a stronger relationship will be seen when more 
heavily iron overloaded patients are assessed. As iron burden was not causing 
significant alterations in the pro-hepcidin it was decided to study the effect of NTBI in 
these patients on pro-hepcidin expression to see if this may explain some of the 
differences seen.
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5.5.6 Discussion: Factors influencing serum pro-hepcidin levels
As stated in Section 5.1, hepcidin synthesis is known to be positively regulated 
by inflammation and negatively regulated by hypoxia, anaemia and iron deficiency. An in 
vitro study has also suggested NTBI has a negative regulatory effect on hepcidin 
synthesis in cultured hepatocytes . In sickle and thalassaemia syndromes, the potentially 
competing effects of anaemia, iron overload, NTBI and inflammation on hepcidin 
synthesis and hence presumably serum pro-hepcidin are difficult to predict. The 
outcome of these competing effects could determine whether hepcidin is appropriately 
regulated in sickle and thalassaemia syndromes and might explain why thalassaemia 
syndromes are associated with hyper-absorption of dietary iron whereas sickle 
syndromes are typically not.
5.5.6.1 Pro-hepcidin and its relationship to anaemia
It was found that Tl patients (n=18) had a significantly lower serum pro-hepcidin 
(78 + 40.3ng/ml) (p<0.01) compared to those with SCA (n=15) (129 + 38.2 ng/ml), TM 
(n=16) (122.4 + 33.3ng/ml) or control subjects (n=9) (119 + 45ng/ml) (table 5.5.1.2). Hb 
values were not significantly different between Tl (8.6 g/dl) and SCA patients (9.3 g/dl) 
but were higher in the regularly transfused TM patients (10.8g/dl + 1.1). Patients with 
either SCA or Tl who were not transfused had similar serum pro-hepcidin levels 
compared to transfused patients with the similar disorders (table 5.5.1.2). When all 
patients with Hb <8g/dl were compared to those with Hb > 10g/dl serum pro-hepcidin 
remained significantly lower (p=0.001) and this was most evident in the Tl and TM 
cohorts with the SCA patients showing only a poor correlation between Hb and pro- 
hepcidin levels (R=0.25; P=0.37). This supports the role of anaemia as an important
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modulator of serum pro-hepcidin. A high erythropoietic drive driven by EPO would cause 
suppression of pro-hepcidin/hepcidin and a resultant increase in the iron absorption in 
order to increase Hb synthesis. It is possible that the EPO driven hypoxia drive overrides 
the iron driven upregulation in the patients with Tl. In support of this our SCA patients 
both transfused and untransfused had similar EPO levels to the TM cohort and were half 
those found in the Tl group.
In Tl the continued suppression of pro-hepcidin due to anaemia would lead to 
continued iron absorption via the gastrointestinal tract and patients would develop iron 
overload. In SCA the pro-hepcidin does not appear to be down regulated in response to 
anaemia and hence iron overload does not develop secondary to increased Gl 
absorption. This is similar to the findings by Ezeh et al (Ezeh, et al 2005) where the 
expression of pro-hepcidin in SCA patients was found to be similar to that of normal 
controls despite the anaemia.
The reasons for this difference between the 2 different anaemia disorders may 
be the degree of ineffective erythropoiesis. Tl is a disorder of ineffective erythropoiesis 
and SCA is a haemolytic anaemia.
5.5.6.2 Pro-hepcidin and its relationship to Iron
No difference was seen between the three cohorts according to the iron burdens. 
This may be because there were too few patients with liver irons > 10  mg/g/dw (table 
5.4.1.1.) It was shown by Nemeth that NTBI down regulated hepcidin but we did not find 
any correlation between pro-hepcidin and NTBI although there was a trend towards 
suppression of pro-hepcidin levels at higher NTBI levels in Tl figure 5.5.4a although this 
is not a significant correlation. The difference in serum pro-hepcidin between TM, Tl and 
SCA persisted when the 3 groups were matched for liver iron (p < 0.001) (table 5.5.3.1.).
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NTBI was lower in SCA (mean 0.93 + 2.41umol/l; median -0.53 umol/l) 
compared to TM (1.18+ 2.47umol/l median 0.85umol/l) and 2 fold lower than in Tl (2.72 
+ 2.28 umol/l; median 2.64 umol/l) when patients were matched for liver iron.
It is possible that NTBI, present early in Tl secondary to high ineffective 
erythropoiesis, may lead to a similar paradoxical decrease in hepcidin synthesis reported 
in model systems and that this is reflected by reduced serum pro-hepcidin. Although 
levels of NTBI and liver iron did not differ significantly in Tl and TM, transfusion and 
chelation therapy in TM may override NTBI mediated down regulation of pro-hepcidin.
There are several possible factors which need to be considered with regard why 
NTBI may be low in SCA and how this may affect iron loading and pro-hepcidin. The first 
may relate to the effects of inflammation on serum pro-hepcidin. SCA patients exist in 
some respects to ‘a chronic inflammatory state’ due to the nature of microvascular 
occlusion seen in this condition. Indeed it is known that several cytokines including LI-6 
are increased in SCA patients, even in steady state IL6 and IL1 in sickle (Bourantas, et 
al 1998, Taylor, et al 1997). Since IL6 has a central role in hepcidin metabolism, it is 
possible that increased hepcidin synthesis consequent to high IL6 secretion decreases 
iron absorption from the gut and iron release from macrophages. Decreased iron release 
from macrophages may in turn account for the lower NTBI seen in SCA patients 
compared with LIC matched Tl or TM patients (Table 5.5.3.1)
It is not immediately apparent why NTBI levels should be lower in SCA patients 
than Tl at matched iron levels. However, one difference between SCA and Tl patients is 
that in SCA results predominantly from haemolysis whereas in Tl, ineffective 
erythropoiesis. Ineffective erythropoiesis may lead to a greater chance of NTBI 
production due to the relatively hypoxic environment in the bone marrow leading to 
slower binding of iron to transferrin.
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Thus the results in this section show that anaemic patients with Tl have lower 
pro-hepcidin than in SCA patients with similar levels of anaemia and iron loading. 
Furthermore Tl patients have higher NTBI levels than SCA at matched levels of iron 
loading. It is hypothesised that the uptake of NTBI delivered to the hepatocyte may be a 
key factor in determining lower hepcidin synthesis and hence higher iron absorption in Tl 
than SCA.
Fibrosis and ultimately hepatic cirrhosis occurs in thalassaemia patients 
secondary to iron overload. This results in a rise in the transaminases and again unlike 
with the hepcidin mRNA cohort we did not see any correlation with ALT and pro- 
hepcidin. The small number of patients with a significant transaminitis may again 
account for this.
5.6 Conclusion
In conclusion pro-hepcidin is clearly down regulated in response to anaemia and 
raised EPO. Pro-hepcidin shows a downward trend with NTBI in Tl although there is no 
relationship seen with TM or SCA. There was no clear alteration of pro-hepcidin levels in 
the presence of increasing liver iron burden neither (ferritin nor liver iron) however this 
may be due to the small number of patients with a high liver iron. Kulaksiz et al also 
found no significant relationship between pro-hepcidin and ferritin or transferrin 
saturation (Kulaksiz, et al 2004).
Hepcidin mRNA was found to have a downward trend with increasing LIC or 
transaminitis reflecting an increasing iron load. There was no relationship found with the 
ferritin and hepcidin expression.
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Pro-hepcidin measurements using the ELISA need to be interpreted with 
caution. It is important to ensure that the assay is performed at a similar temperature if 
the results between two test series are to be analysed together. It is also important to 
ensure that the results fall in the ‘linear1 portion of the standard curve i.e. between 4- 
400ng/ml. We attempted to overcome these issues by performing the assay on two days 
when the room temperature was similar i.e. between 20-22 °C. We also ran the same 
control samples on each day these showed some variation. It is important to note that in 
our patients most of the results for individual disorders were fairly similar within a group 
as reflected by the low SEM results as seen in table 5.5.1.2.
Further work needs to be undertaken to see if the relationship between NTBI and 
pro-hepcidin is real or if this is a reflection of the anaemia. We plan to perform hepcidin 
measurement on the serum samples once this assay is developed
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Chapter 6
Discussion and Conclusions
The purpose of the work presented in this thesis was to examine the relationship 
between NTBI and iron overload in patients with haemoglobinopathies. Although NTBI 
has historically always been associated with iron overload, we have shown that NTBI is 
present in young children at high levels before they have developed significant iron 
overload. It is probable that this NTBI arises as a consequence ineffective erythropoiesis 
and indeed in the small number of patients examined we saw a fall in the level of NTBI 
post transfusion in previously untransfused children.
It has also been shown in chapter 4 that higher hepatic iron burdens will result in 
a slower rate of improvement of cardiac iron loading. In addition SCA patients rarely 
develop cardiac iron loading. This may be to RE sequestering of toxic iron species and 
indeed NTBI is present at much lower levels in patients with SCA compared to those 
with TM even when matched for liver iron. The role of hepcidin may be important in 
regulation of iron in haemoglobinopathies and it has been shown that in patients with Tl, 
pro-hepcidin levels are significantly lower than in patients with SCA or TM at matched 
levels of hepatic iron.
The results in the individual chapters will be summarised below along with a 
discussion on limitations and clinical application if any.
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6.1 The relationship between markers of ineffective erythropoiesis, oxidative 
damage and NTBI in children with thalassaemia
6.1.1 Important observations:
The presence of NTBI early in childhood in thalassaemia patients is an important 
observation and has not been described previously. It is likely, based on the analysis of 
data available, that ineffective erythropoiesis is an important contributing factor to NTBI 
formation in patients who have accumulated only small quantities of excess storage iron.
It was also observed that in thalassaemic children sTfR and erythropoietin 
correlated well with the degree of the anaemia. There appeared to be very little oxidative 
damage as measured by levels of MDA and protein carbonyls in these children who 
were on the whole well transfused and chelated. There was also no relationship between 
markers of ineffective erythropoiesis and markers of oxidative damage. In addition 
neither of these factors had any correlation with the presence or absence of NTBI.
There does not appear to be any relationship between markers of oxidative 
damage and iron burden in well-chelated children. This is probably due to the duration of 
exposure to toxic forms of iron being less than in the adult patients who had less 
chelation therapy in childhood. Since the examination of this thesis Walter et al (Walter, 
et al 2006) published data showing that MDA levels were raised in SCA and TM and this 
correlated to liver iron burden. It is important to note that the study in this thesis is a 
longitudinal study and once data collection is complete, then the longitudinal analysis will 
provide more accurate information in individual patients on the relationship between 
NTBI and markers of oxidative damage.
6.1.2 Limitations and need for further studies
• Sample collection and handling
Page 240 of 278
This as discussed in chapter 3 has been a concern. Any defrosted samples have 
been discarded and only those that have arrived in a frozen state are used. Samples 
are sent in 0.25ml aliquots and hence only one aliquot is defrosted for analysis, 
samples are not repeated defrosted and frozen. All the markers of oxidative damage 
have been analysed wherever possible on samples that have not previously been 
defrosted although in the case of measurements of EPO and sTfR we have often 
had to use previously defrosted samples.
• Lack of normal range of MDA and carbonyls in children
This has been a significant concern and we have not been able to obtain healthy 
control samples from children for MDA and carbonyl levels. This is due to the 
difficulty in obtaining ethical approval for sample collection in healthy children. 
Attempts are ongoing to address this issue.
• Need for more children re and post first transfusion samples
The data in section 3.8.3 needs to be further validated. Currently there are too few 
numbers of children having their first transfusion although since this analysis has 
occurred, newly diagnosed children with TM have presented both at NTCK, and 
HSC. It is hoped that data from these children will corroborate the preliminary 
findings.
• Cross-sectional analysis
This is a cross-sectional analysis and once more longitudinal data are available, it 
may be possible to ascertain in more detail if there is a relationship between markers 
of oxidative damage and NTBI/ iron overload.
6.1.3 Clinical implications
There are no real studies on the natural history of iron overload in thalassaemic 
children who are chelated looking at the impact of chelation therapy on markers of
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oxidative damage. This study may potentially have significant impact on options for 
treatment and chelation as it is assessing the effect of current standard treatment in 
UCLH/HSC children as well as those who initially were receiving less rigorous treatment 
in NTCK. It will be important to continue with the longitudinal follow-up that is part of this 
study to see if oxidative damage increases with age and prolonged exposure or if a 
patient becomes non adherent to therapy and develops significant iron burden.
6.2 Relationship of hepatic iron and NTBI to myocardial iron and LV function: 
contrasts between SCA and Thalassaemia disorders
Iron deposition occurs progressively but unevenly between different tissues as 
continued transfusion support is provided to children and patients develop 
endocrinopathies and cardiac failure if inadequately chelated. The relationship between 
NTBI and iron loading particularly in the liver and myocardium was assessed in adult 
patients with thalassaemia syndromes and SCA. CMR is a valuable tool in the 
management of iron overload and should be offered to all patients on regular transfusion 
regimes. It has provided a great deal of information on the distribution of iron in the body; 
this has lead to improved management of patients. Although tissue validation of cardiac 
T2* as a methodology is still awaited, it nevertheless assesses a clinically important 
parameter and has likely prognostic significance.
6.2.1 Important observations
In patients with thalassaemia syndromes we found a relationship between 
cardiac T2*, cardiac R2* and cardiac function, as measured by LVEF, consistent with 
previous observations by others. The role of longitudinal monitoring is however 
previously unreported and vital to the interpretation of these measures. We conclude
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from a longitudinal analysis that a liver iron >10 mg/g/dw was associated with a 
significantly increased risk of the cardiac T2* worsening. In addition a liver iron less than 
10mg/g/dw was required prior to seeing an improved in the cardiac T2*.
Ferrioxamine is produced when DFO binds to iron in a 1:1 ratio; if formed within 
cells, it exits only slowly, over 1-2 days. Because, ferrioxamine has been previously 
used as a contrast agent for MRI imaging, we had concerns that ferrioxamine might alter 
the cardiac T2W signal. This issue was addressed using sequential monitoring of T2* in 
one patient. The degree of change in the T2* over a period of 48 to 84 hours is important 
and it is probably best to advice patients to have the CMR assessment at the same point 
in their chelation cycle on each occasion i.e. if they normally have the CMR assessment 
whilst they have their DFO infusion, then future CMR assessments should also be 
undertaken with the DFO infusion being administered. This would remove any variability 
due to slow ferrioxamine clearance from the cells.
It has been suggested that damage to the myocardium may be mediated by 
NTBI (Glickstein, et al 2005), through generation of free radicals (Rachmilewitz, et al 
2005). Whether this is a direct effect or not, NTBI is known to be cleared by myocardial 
cells, leading to increased iron deposition within the myocardium and ultimately to 
increased storage iron as well as increased intracellular labile iron that can be directly 
damaging to myocardial cells. We have found that patients with SCA tend to have much 
lower levels of NTBI at matched levels of iron burden compared to TM patients. The 
NTBI present in SCA and in TM adult patients will predominantly be due to excess total 
body iron, secondary to transfusion, rather than due to ineffective erythropoiesis. It has 
been shown in SCA that, even at steady state, there are increased inflammatory 
markers and cytokines such as IL1, IL6, IL8 and TNF ( Walter, et al 2006, Makis, et al 
2000b). These cytokines may down regulate the levels of NTBI at matched levels of iron 
loading by causing sequestering of iron in the RE system.
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The Tl cohort are transfused less frequently than TM patients but they are more 
prone to develop iron loading compared to the SCA patients because of the role of 
increased gastrointestinal iron absorption.
6.2.2 Limitations and need for further studies.
• MR! methodology and use of the Cardiac T2*
There has been significant debate on the use of this method in the medical 
literature and whether the cardiac T2* measures myocardial iron. This is because 
there in no cardiac tissue validation of the T2* and liver tissue validation was used to 
calibrate the liver T2*. Other workers have carried out successful calibrations using 
endomyocardial biopsy and T2 (Mavrogeni, et al 2005). In section 4.6.1, we have 
confirmed previous observations that there is a relationship between cardiac T2* and 
LVEF. This implies that despite the lack of tissue validation, the cardiac T2* is 
measuring a clinically relevant parameter with prognostic value. Studies are 
currently underway at the Royal Brompton Hospital CMR unit to validate this 
methodology using endomyocardial biopsies and cadavaric hearts from 
thalassaemia patients that have been donated to the unit.
• The use of liver iron for matching patients
We have used hepatic iron load to match our patients working on the assumption the 
hepatic iron is a refection of total body iron (Angelucci, et al 2000). However the 
cumulative iron load is very different in the two groups of patients as the SCA cohort 
have received exchange transfusions predominantly. It is possible that cardiac iron 
loading is seen in SCA when cumulative iron load or the years of exposure to iron is 
examined. There is a clear need for a long term study to assess this.
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• Ferrioxamine and its effect on T2*
We have only studied one patient. This work needs to be carried out in a larger 
group of patients prior to concrete conclusions being made.
• Speciation studies on NTBI
Our studies focussed on the measurement of ‘total NTBI’ using the classic NTA 
assay. However the possibility the proportions of NTBI species differ between SCA 
and other anaemias needs to be explored. In particular it will be of value to examine 
the relationship between total NTBI and labile plasma iron (LPI) a subspecies of 
NTBI that is redox active. It is not clear whether LPI is cleared by tissues in a similar 
way to other NTBI species and this could be important in how iron is distributed in 
SCA compared with thalassaemia syndromes.
6.2.3 Clinical implications
MRI assessment of iron loading is a valuable and clinically relevant technique. It 
should be offered to all patients on transfusion programmes. The cardiac T2* when 
assessed in conjunction with the LVEF is clinically relevant and can be used to change 
the chelation regime given to a patient, with intensification of chelation at low cardiac T2* 
i.e. <10 ms and a falling LVEF.
In addition, in patients where there is already cardiac iron loading, it is important 
to reduce the hepatic iron burden below 10mg/g/dw before any significant improvement 
is seen in the cardiac T2*.It is important to ask patients to have their CMR assessment in 
a standardised chelation routine, i.e. if the assessment is performed off all chelation for 
48 hours then all subsequent scans should occur at a similar time point. Further work is 
needed on the effect of ferrioxamine.
Even though we did not see this in our patients, SCA patients may develop 
cardiac iron loading. Until we have more longitudinal data it will still be important to
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monitor for this complication in SCA. The analysis in this thesis of the relationship 
between liver and heart iron was observational rather than pre-planned. Further 
longitudinal studies are clearly needed to examine the relationship between body iron 
and heart iron, particularly in SCA patients.
6.3 Hepcidin metabolism, iron overload and NTBI in thalassaemia and sickle 
disorders
6.3.1 Important observations
The recent discovery of iron regulatory proteins such hepcidin have provided 
great insight into how gastrointestinal iron absorption and iron release from 
macrophages is modulated. The relationship between hepcidin expression and iron 
burden in liver biopsies in thalassaemia syndromes was examined and we found that 
Hepcidin mRNA showed a downward trend in relation to an increasing liver iron burden 
or transaminitis reflecting an increasing iron load. There was no relationship found with 
the ferritin and hepcidin expression. The numbers are very small and do not reach 
statistical significance.
The relationship between pro-hepcidin and anaemia and iron overload was 
assessed in sickle and thalassaemia syndromes. Pro-hepcidin is clearly down regulated 
in response to anaemia in thalassaemia syndromes but less obviously in SCA. This 
relationship was also seen with high EPO levels associated with a lower pro-hepcidin. 
No relationship was seen between pro-hepcidin and liver iron or serum ferritin. There 
was a significantly lower pro-hepcidin in Tl patients compared to those with SCA or TM 
then matched for liver iron, implying that the down regulatory affect of anaemia overrides 
the upregulatory effect of iron overload. In addition NTBI was having a suppressive 
effective on pro-hepcidin in Tl. Recent publications, since this thesis was examined by
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Kattamis (Kattamis, et al 2006) and Gardenghi (Gardenghi, et al 2007), have both 
suggested that ineffective erythropoiesis is a key driver of hepcidin mediated iron 
absorption, similar to our findings.
6.3.2 Limitations and need for further studies.
• Measurement of Hepcidin mRNA
The study was retrospective and further work should be performed prospectively 
to confirm our findings and allow us to perform a range of measures simultaneously 
to the timing of the biopsy. Recently Jenkins et al (Jenkins, et al 2007) found 
increased hepcidin mNRA levels in liver biopsies of SCA and TM patients. Ideally 
future studies should be undertaken prospectively with simultaneous measurements 
on NTBI, Hb and plasma hepcidin at the time of biopsy. This would allow a closer 
analysis of factors that modulate hepcidin synthesis in the liver and its release into 
plasma. It will be useful to examine to what extent anaemia or hypoxia override the 
effects of iron status. A further factor that needs to be controlled for is the short-term 
effect (if any) of chelation administration on hepcidin synthesis.
• Pro-hepcidin assay and its relationship to hepcidin.
This has been discussed in section 5.1.6. It is be important to ensure that the 
assay is performed in similar conditions. Studies are clearly needed to examine the 
relationship between plasma pro-hepcidin and plasma hepcidin. Hitherto this has not 
been possible because of technical issues surrounding the measurement of hepcidin 
in plasma. However since the initial submission of this thesis, a plasma assay for 
hepcidin has been developed. Matched plasma aliquots have been retained on SCA 
and thalassaemia patients measured in this study and analyses are underway to
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examine how plasma and hepcidin and pro-hepcidin levels relate to each other in 
these patients.
• Need for longitudinal studies to include patients with high iron burdens
None of our patients had very high LICs so the effect of high hepatic iron loading 
on pro-hepcidin were not examined. Future studies should also ideally include 
longitudinal analysis of the effects of progressive iron loading on (pro) hepcidin and 
NTBI.
• Need for study of relationship of inflammatory markers, hepcidin and NTBI in SCA
Our observations are consistent with the notion that NTBI levels are depressed in 
SCA relative to body total iron levels compared with thalassaemia major patients and 
that elevation in (pro) hepcidin may be a mechanism for this effect. Prospective 
studies, designed specifically to examine the relationship between inflammatory 
markers, plasma hepcidin and NTBI levels are indicated in SCA. The question of 
whether a chronic inflammatory state is the key factor responsible for depressed 
levels of NTBI in SCA will require clarification. This may involve the study of the 
relationship between inflammatory markers plasma hepcidin and NTBI levels in 
steady state and during vaso-occlusive episodes.
6.3.3 Clinical implications
Pro-hepcidin appears to be suppressed in our patients with Tl and this appears 
to be related to the degree and severity of the anaemia. This results in increased 
gastrointestinal iron absorption. It appears that the effective of anaemia overrides the 
effect of iron overload in Tl. It is possible that a hepcidin analogue that is orally active 
may be developed in the future and this would at high levels suppress iron absorption in 
these patients, this could have great implications for the management of iron overload in 
Tl. A further possibility is that raised levels of hepcidin in TM could prevent the
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secondary redistribution of iron from macrophages via NTBI to heart, pituitary and other 
tissues. In principle this could be achieved by giving exogenous hepcidin analogue or. 
less appealingly, by the induction of an artificial inflammatory state.
Page 249 of 278
Bibliography
A bboud, M .R . &  A tw eh , G .F . (2 0 0 6 ) Prevention and m anagem ent o f  strokes in patients w ith  
sickle cell disease. C urr Hematol Rep, 5, 15-22 .
A bboud, S. &  H a ile , D .J. (2 0 0 0 ) A  novel m am m alian  iron-regulated  protein  invo lved  in  
in trace llu lar iron m etabolism . J B io l Chem, 275, 19 9 0 6 -1 9 9 1 2 .
Adam s, R.J. &  B ram b illa , D . (2 0 0 5 ) D iscontinu ing  prophylactic  transfusions used to p revent 
stroke in sickle cell disease. N  Engl J  Med, 353, 2 7 6 9 -2 7 7 8 .
A dam s, R .J., M c K ie , V .C .,  B ram b illa , D ., C arl, E ., G allagher, D ., N ich o ls , F .T ., R oach, S.,
A bboud, M . ,  B erm an, B ., D risco ll, C ., F iles, B ., Hsu, L ., H u rle t, A .,  M ille r ,  S., O liv ie r i,  
N ., Pegelow , C ., Scher, C ., V ich in sky , E ., W ang, W ., W oods, G ., K u tla r, A .,  W rig h t, E ., 
H agner, S., T ig h e , F ., W a c la w iw , M .A .  &  et al. (1 9 9 8 a ) Stroke prevention  tr ia l in sickle  
cell anem ia. Control C lin Trials, 19, 110-129 .
A dam s, R .J., M c K ie , V .C .,  Hsu, L ., F iles , B ., V ich in sky , E ., P egelow , C ., A b b ou d , M . ,
G allagher, D ., K u tla r, A ., N ich o ls , F .T ., Bonds, D .R . &  B ram b illa , D . (1 9 9 8 b ) P reventio n  
o f  a first stroke by transfusions in  ch ildren  w ith  sickle cell anem ia and abnorm al results  
on transcranial D o p p le r ultrasonography. N  Engl J  Med, 339, 5 -11 .
A dam sky, K ., W e ize r, O ., A m a rig lio , N . ,  Breda, L ., H a rm e lin , A ., R iv e lla , S., R a c h m ile w itz , E .
&  R echavi, G . (2 0 0 4 ) Decreased hepcidin  m R N A  expression in  thalassem ic m ice . B r J  
Haematol, 124, 123-124.
Aessopos, A ., Farm akis, D ., Deftereos, S., Ts iro n i, M .,  Tassiopoulos, S., M oyssak is , I. &  
Karagiorga, M . (2 0 0 5 ) Thalassem ia heart disease: a com parative eva luation  o f  
thalassem ia m ajor and thalassem ia interm edia . Chest, 127, 15 23 -153 0 .
Aessopos, A ., Farm akis, D ., K aragiorga , M . ,  Vo skarid ou , E ., Loutrad i, A ., H a tz ilia m i, A .,
Joussef, J., Rom bos, J. &  Loukopoulos, D . (2 0 0 1 ) C ard iac invo lvem ent in  thalassem ia  
interm edia: a m u lticenter study. Blood, 97 , 3 4 1 1 -3 4 1 6 .
A h m ed, S., Saleem , M .,  M o d e ll, B . &  Petrou, M . (2 0 0 2 ) Screening extended fam ilies  fo r genetic  
hem oglobin  disorders in Pakistan. N  Engl J  Med, 347, 11 62 -116 8 .
A l-Q u o b a ili, F .A . &  A b o u  A sali, I.E . (2 0 0 4 ) Serum  levels o f  lip ids and lipoprote ins in S yrian  
patients w ith  beta-thalassem ia m ajor. Saudi MedJ, 25 , 8 7 1 -8 7 5 .
a l-R e fa ie , F .N ., Hershko, C ., H o ffb ran d , A .V . ,  Kosaryan, M .,  O liv ie r i,  N .F .,  T o n d ury , P. &  
W onke, B . (1 9 9 5 ) Results o f  long -term  deferiprone ( L I )  therapy: a report by the  
International Study G roup on O ra l Iron  Chelators. B r J  Haematol, 91, 2 2 4 -2 2 9 .
a l-R e fa ie , F .N ., W ickens, D .G ., W o n ke , B ., K ontoghiorghes, G .J. &  H o ffb ran d , A .V .  (1 9 9 2 a )  
Serum  non-transferrin -bound iron in beta-thalassaem ia m a jo r patients treated w ith  
desferrioxam ine and L I .  B r J  Haematol, 82, 4 3 1 -4 3 6 .
a l-R e fa ie , F .N ., W onke, B ., H o ffb ran d , A .V . ,  W ickens, D .G ., N o rte y , P. &  K ontoghiorghes, G .J. 
(1 9 9 2 b ) E fficac y  and possible adverse effects o f  the oral iron  chela tor l ,2 -d im e th y l-3 -  
h yd ro xypyrid -4 -on e ( L I )  in thalassem ia m ajor. Blood, 80 , 5 9 3 -5 9 9 .
A ld o u ri, M .A .,  W onke, B ., H o ffb ran d , A .V . ,  F lynn , D .M .,  W ard , S .E ., A g n ew , J.E. &  H ilso n ,
A .J. (1 9 9 0 ) H ig h  incidence o f  card iom yopathy in beta-thalassaem ia patients rece iv ing  
regular transfusion and iron chelation: reversal by in tensified  chelation. Acta Haematol, 
84, 113-117 .
A lm e id a , A . &  Roberts, I. (2 0 0 5 ) Bone invo lvem ent in sickle cell disease. B r J  Haematol, 129, 
4 8 2 -4 9 0 .
Page 250 of 278
Anderson, L .J ., H o lden , S., D av is , B ., Prescott, E ., C harrier, C .C ., B unce, N .H . ,  F irm in , D .N .,
W on ke , B ., Porter, J., W a lke r, J .M . &  Pennell, D .J. (2 0 0 1 ) C ard io vascu lar T 2 -s ta r ( T 2 * )  
m agnetic resonance fo r the early  diagnosis o f  m yocard ia l iron  overload. Eur Heart J, 22, 
2 1 7 1 -2 1 7 9 .
Anderson, L .J ., W estw ood, M .A . ,  H o lden , S., D av is , B ., Prescott, E ., W o n ke , B ., Porter, J.B ., 
W alke r, J .M . &  Pennell, D .J. (2 0 0 4 ) M yo ca rd ia l iron clearance during  reversal o f  
siderotic card iom yopathy w ith  intravenous desferrioxam ine: a prospective study using  
T 2 *  card iovascular m agnetic resonance. B r J  Haematol, 127, 3 4 8 -3 5 5 .
Anderson, L .J ., W on ke , B ., Prescott, E ., H o lden , S., W a lke r, J .M . &  Pennell, D .J. (2 0 0 2 )  
Com parison  o f  effects o f  oral deferiprone and subcutaneous d esferrio xam ine on  
m yocardial iron concentrations and ventricu la r function in beta-thalassaem ia. Lancet, 
3 6 0 ,5 1 6 -5 2 0 .
A ndrew s, N .C . (1 9 9 9 ) T h e  iron transporter D M T 1 .  In t J  Biochem C ell Biol, 3 1 , 9 9 1 -9 9 4 .
A ngastin iotis , M . &  M o d e ll, B . (1 9 9 8 ) G lo b al ep idem io logy o f  hem oglob in  disorders. Ann N  Y 
AcadSci, 8 5 0 ,2 5 1 -2 6 9 .
A ngastin iotis, M . ,  Pavlides, N .,  A ris tid o u , K ., Kanakas, A ., Y erakaris , M . ,  Eracleous, E . &
Posporis, T . (1 9 9 8 ) Bone pain in thalassaemia: assessment o f  D E X A  and M R I  find ings. J  
Pediatr Endocrinol Metab, 11 Suppl 3, 7 7 9 -7 8 4 .
A n g elucc i, E ., B rittenham , G .M .,  M c L a re n , C .E ., R ip a lti, M .,  B aroncian i, D ., G ia rd in i, C .,
G a lim b e rti, M .,  Polchi, P. &  L u c are lli, G . (2 0 0 0 ) H epatic  iron concentration and to ta l 
body iron stores in  thalassem ia m ajor. N  Engl J  Med, 343, 32 7 -3 3 1 .
A o k i, C .A ., Rossaro, L ., Ram sam ooj, R ., B randhagen, D ., B urritt, M .F .  &  B o w lu s, C .L . (2 0 0 5 )  
L iv e r  hepcidin  m R N A  correlates w ith  iron stores, but not in flam m atio n , in  patients w ith  
chronic hepatitis C . J  C lin Gastroenterol, 39, 71 -74 .
A rau jo , A .S ., S ilva , W .A .,  Leao, S .A ., B andeira , F .C ., Petrou, M ., M o d e ll, B . &  Z ago, M .A .
(2 0 0 3 ) A  d iffe ren t m olecular pattern o f  beta-thalassem ia m utations in  northeast B ra z il. 
Hemoglobin, 27, 2 1 1 -2 1 7 .
A rda lan , F .A ., O squei, M .R .,  Toosi, M .N .  &  Irvan loo , G . (2 0 0 4 ) Synergic e ffect o f  chron ic
hepatitis C in fection  and beta thalassem ia m ajo r w ith  m arked hepatic iron o verload  on 
liv e r fibrosis: a retrospective cross-sectional study. BMC Gastroenterol, 4, 17.
A taga, K .I .  &  O rringer, E .P . (2 0 0 0 ) R enal abnorm alities in sickle cell disease. Am J  Hematol, 63, 
2 0 5 -2 11 .
A tich artakam , V .,  A ngchaisuksiri, P., A ryu rach ai, K ., O npun, S., Chuncharunee, S.,
Thakkinstian , A . &  A tam as iriku l, K . (2 0 0 2 ) R elationsh ip  betw een hypercoagulab le  state 
and erythrocyte phosphatidylserine exposure in splenectom ized haem oglob in  E /b e ta -  
thalassaemic patients. B r J  Haematol, 118, 89 3 -8 98 .
Aust, S .D ., M orehouse, L .A . &  Thom as, C .E . (1 9 8 5 ) R o le  o f  m etals in oxygen radical reactions. J  
Free Radic B io l Med, 1 ,3 -2 5 .
Bannerm an, R .M ., Keusch, G ., K re im e r-B im b a u m , M .,  Vance, V .K .  &  V au g han , S. (1 9 6 7 )  
Thalassem ia interm edia, w ith  iron overload, cardiac fa ilu re , diabetes m ellitus , 
hypopitu itarism  and porphyrinuria. Am J  Med, 42, 4 7 6 -4 8 6 .
Barry , M . (1 9 7 4 ) L iv e r  Iron C oncentration, S tainable Iron, and T ota l B o d y  Iron  Storage Iron.
Gut, 1 5 ,4 1 1 -4 1 5 .
Barry , M .,  F lynn , D .M .,  Letsky, E .A . &  R isdon, R .A . (1 9 7 4 ) L on g -te rm  chelation  therapy in  
thalassaem ia m ajor: e ffect on liv e r  iron concentration, liv e r  h istology, and c lin ica l 
progress. B r Med J, 2, 16-20.
Baruchel, S., Rees, J., Bernstein, M .L .  &  G oodyer, P. (1 9 9 3 ) R e lie f  o f  sickle cell p riap ism  by  
hydralazine. Report o f  a case. Am J  Pediatr Hematol Oncol, 15, 11 5 -1 16 .
Batra, A .S ., A cherm an, R.J., W ong, W .Y .,  W oo d, J.C ., C han, L .S ., R am icone, E ., E b rah im i, M .
&  W ong, P .C . (2 0 0 2 ) C ard iac abnorm alities in ch ild ren  w ith  sickle cell anem ia. Am J  
Hematol, 70, 3 0 6 -3 12 .
Page 251 of 278
Beard, M .E .,  N echeles, T .F . &  A lle n , D .M .  (1 9 6 9 ) C lin ic a l experience w ith  intensive transfusion  
therapy in Cooley's anem ia. Ann N  YAcad Sci, 165, 4 1 5 -4 2 2 .
Beguin , Y . (2 0 0 3 ) S oluble transferrin  receptor fo r the evaluation  o f  erythropoiesis and iron  status. 
Clin Chim Acta, 329, 9 -22 .
Beguin , Y . ,  C lem ons, G .K ., Pootrakul, P. &  F ille t, G . (1 9 9 3 ) Q u an tita tive  assessment o f
erythropoiesis and functional c lassification o f  anem ia based on m easurem ents o f  serum  
transferrin  receptor and erythropoietin . Blood, 81, 10 67 -107 6 .
Bertles, J.F. &  D o b ler, J. (1 9 6 9 ) R eversib le  and irreversib le sickling: a d istinction  by electron  
m icroscopy. Blood, 3 3 , 8 8 4 -8 9 8 .
Beutler, E ., H o ffb ran d , A .V . &  C ook, J.D . (2 0 0 3 ) Iron  d efic iency and overload. Hematology Am 
Soc Hematol Educ Program , 4 0 -6 1 .
B ianco, I., G razian i, B ., Lerone, M .,  Congedo, P., C lem ente, G .F ., Ingrao, G ., C iccone, F ., D i 
N u cc i, G .D ., M a n d e lli, F. &  Isacchi, G . (1 9 8 4 ) A  study o f  the m echanism s and sites o f  
action o f  desferrioxam ine in thalassaem ia m ajor. Acta Haematol, 71 , 10 0 -1 05 .
B iasiotto , G ., Roetto , A ., D ara io , F ., P o lo tti, A ., G erard i, G .M ., G ire lli ,  D ., C rem onesi, L .,
A ros io , P. &  Cam aschella, C . (2 0 0 4 ) Iden tificatio n  o f  new  m utations o f  h epcid in  and  
hem o juvelin  in patients w ith  H F E  C 2 8 2 Y  alle le . Blood Cells M o l Dis, 33, 3 3 8 -3 4 3 .
B lo o m fie ld , S .E ., M arkenson , A .L .,  M ille r ,  D .R . &  Peterson, C .M . (1 9 7 8 ) Lens opacities in  
thalassem ia. J  Pediatr Ophthalmol Strabismus, 15, 154-156 .
B o rg n a-P ign atti, C . &  Castrio ta-Scanderbeg, A . (1 9 9 1 ) M ethods fo r evaluating  iron  stores and  
efficacy  o f  chelation in  transfusional hemosiderosis. Haematologica, 76, 4 0 9 -4 1 3 .
B o rg n a-P ign atti, C ., R ugolo tto , S., D e  Stefano, P., P iga, A ., D i  G regorio , F ., G am b e rin i, M .R . ,  
Sabato, V . ,  M e lev en d i, C ., C a p p e llin i, M .D .  &  V erla to , G . (1 9 9 8 ) S u rv iva l and disease 
com plications in thalassem ia m ajor. Ann N  Y Acad Sci, 850, 22 7 -2 3 1 .
B o rg na-P ignatti, C ., R ugolotto , S., D e  Stefano, P., Zhao, H ., C ap p e llin i, M .D .,  D e l V ec ch io ,
G .C ., Rom eo, M .A .,  F o m i, G .L ., G am b erin i, M .R .,  G h ila rd i, R ., Piga, A . &  C naan, A . 
(2 0 0 4 ) S urvival and com plications in  patients w ith  thalassem ia m ajo r treated w ith  
transfusion and deferoxam ine. Haematologica, 89 , 11 87 -1193 .
Bosm a, P.J., C how dhury, J.R ., B akker, C ., G antla , S., de Boer, A ., Oostra, B .A ., L in d h o u t, D ., 
Tytgat, G .N ., Jansen, P .L ., O ude E lfe rin k , R .P . &  et al. (1 9 9 5 ) T he genetic basis o f  the  
reduced expression o f  b iliru b in  U D P-glucuronosyltransferase 1 in G ilbert's  syndrom e. N  
Engl J  Med, 333, 1 1 71 -1175 .
Bourantas, K .L .,  Dalekos, G .N ., M ak is , A ., Chaidos, A ., Tsiara, S. &  M a v rid is , A . (1 9 9 8 )  A cu te  
phase proteins and interleukins in steady state sickle cell disease. Eur J  Haematol, 61, 4 9 -  
54.
B oyd, H .K . &  Lappin , T .R . (1 9 9 1 ) E ry th rop o ie tin  defic iency in the anaem ia o f  chronic disorders. 
Eur J  Haematol, 46, 198-201 .
Breuer, W . &  Cabantchik , Z .I .  (2 0 0 1 ) A  fluorescence-based one-step assay fo r serum non­
transferrin-bound iron. Anal Biochem, 299, 194-202 .
Breuer, W ., Hershko, C . &  C abantchik , Z .I .  (2 0 0 0 ) T he im portance o f  non-transferrin  bound iron  
in disorders o f  iron m etabolism . Transfus Sci, 23, 185-192 .
B rid le , K .R ., Frazer, D .M .,  W ilk in s , S.J., D ix o n , J .L ., Purdie, D .M . ,  C ra w fo rd , D .H .,
Subram aniam , V .N .,  P o w ell, L .W ., Anderson, G .J. &  R am m , G .A . (2 0 0 3 ) D isrup ted  
hepcidin regulation in H FE-associated  haem ochrom atosis and the liv e r  as a regu lato r o f  
body iron homoeostasis. Lancet, 361, 6 6 9 -6 7 3 .
B rittenham , G .M ., G riff ith , P .M ., N ien h u is , A .W .,  M cL aren , C .E ., Y o u n g , N .S ., T u cker, E .E ., 
A lle n , C .J., Farre ll, D .E . &  H arris , J .W . (1 9 9 4 ) E fficac y  o f  deferoxam in e in preventing  
com plications o f  iron overload in patients w ith  thalassem ia m ajor. N  Engl J  Med, 331, 
5 6 7 -5 73 .
B ritton , R .S ., Leicester, K .L . &  Bacon, B .R . (2 0 0 2 ) Iron  to x ic ity  and chelation therapy. In t J  
Hematol, 7 6 ,2 1 9 -2 2 8 .
Page 252 of 278
B row n , D .W ., H enkelm an , R .M .,  Poon, P .Y . &  Fisher, M .M .  (1 9 8 5 )  N u c le a r m agnetic  resonance  
study o f  iron  overload in liv e r tissue. Magn Reson Imaging, 3 , 2 7 5 -2 8 2 .
B uja, L .M . &  Roberts, W .C . (1 9 7 1 ) Iron  in  the heart. E tio lo g y  and c lin ica l significance. Am J  
Med, 51, 2 0 9 -2 2 1 .
Buss, H ., Chan, T .P ., S luis, K .B ., D o m ig an , N .M .  &  W in te rb o u m , C .C . (1 9 9 7 ) Pro te in  carbonyl 
m easurem ent by a sensitive E L IS A  m ethod. Free Radio B io l Med, 23, 3 6 1 -3 6 6 .
Cam aschella, C ., G on ella , S., Calabrese, R ., V isch ia , F ., R oetto , A ., G raz ia d e i, G ., M a z z a , U . &  
C ap p e llin i, M .D .  (1 9 9 6 ) Serum  erythropoietin  and c ircu la tin g  transferrin  receptor in  
thalassem ia in term edia  patients w ith  heterogeneous genotypes. Haematologica, 81, 3 9 7 -  
403.
C app ellin i, D ., T a v a zz i, D ., D uca, L ., M a re lli,  S. &  F io re lli, G . (2 0 0 0 ) N o n -tran sfe rrin -b o u n d  
iron, iron-related  o x ida tive  stress and lip id  peroxidation in beta-thalassem ia in te rm edia . 
Transfus Sci, 23, 2 4 5 -2 4 6 .
C app ellin i, M .D . ,  Cohen, A ., Piga, A ., B e jaou i, M .,  Perrotta, S., A g ao g lu , L ., A y d in o k , Y . ,
K attam is , A ., K ilin c , Y . ,  Porter, J., Capra, M .,  G alan ello , R ., Fattoum , S., D re lic h m a n ,
G ., M ag n an o , C ., V eriss im o , M .,  A thanassiou-M etaxa , M . ,  G ia rd in a , P ., K o u ra k li-  
Sym eonid is , A ., Janka-Schaub, G ., Coates, T ., V e rm y le n , C ., O liv ie r i, N . ,  T h u re t, I., 
O p itz , H ., R essayre-D ja ffer, C ., M arks , P. &  A lb e rti, D . (2 0 0 6 ) A  phase 3 study o f  
deferasirox ( IC L 6 7 0 ) ,  a o nce-daily  oral iron chelator, in patients w ith  beta-thalassem ia. 
Blood, 107, 3 4 5 5 -3 4 6 2 .
C arm ine, T .C ., Evans, P., B ruchelt, G ., Evans, R ., Handgretinger, R ., N ie th a m m e r, D . &
H a lliw e ll,  B . (1 9 9 5 ) Presence o f  iron catalytic  fo r free radical reactions in  patients  
undergoing chem otherapy: im plications fo r therapeutic m anagem ent. Cancer Lett, 94, 
2 1 9 -2 2 6 .
C aro, J., Huybrechts, K .F . &  G reen, T .C . (2 0 0 2 ) Estim ates o f  the e ffect on hepatic iro n  o f  oral 
deferiprone com pared w ith  subcutaneous desferrioxam ine fo r treatm ent o f  iro n  o verload  
in thalassem ia m ajor: a system atic review . BMC Blood Disord, 2 , 4.
Castro, O . (1 9 9 6 ) System ic fat em bo lism  and pulm onary hypertension in sickle ce ll disease. 
Hematol Oncol C lin North Am, 10, 12 89 -130 3 .
C azzo la , M .,  Beguin, Y . ,  Bergam aschi, G ., G uam one, R ., C erani, P., B are lla , S., C ao , A . &  
G alanello , R . (1 9 9 9 ) S oluble transferrin  receptor as a potential d eterm inant o f  iron  
loading in congenital anaem ias due to ine ffective  erythropoiesis. B r J  Haematol, 106, 
75 2 -7 55 .
C azzo la , M .,  D e  Stefano, P., Ponchio, L ., L o cate lli, F ., B eguin, Y . ,  Dessi, C ., B a re lla , S., C ao , A . 
&  G alan ello , R . (1 9 9 5 ) R elationsh ip  betw een transfusion reg im en  and suppression o f  
erythropoiesis in beta-thalassaem ia m ajor. B r J  Haematol, 89, 4 7 3 -4 7 8 .
C azzola , M .,  Pootrakul, P., Huebers, H .A .,  Eng, M .,  Eschbach, J. &  F inch , C .A . (1 9 8 7 )  E ry th ro id  
m arrow  function in anem ic patients. Blood, 69, 2 9 6 -3 0 1 .
Ceci, A ., F elis i, M .,  D e  Sanctis, V . &  D e  M a ttia , D . (2 0 0 3 ) Pharm acotherapy o f  iron  o verload  in  
thalassaemic patients. Expert Opin Pharmacother, 4, 17 6 3 -1 7 7 4 .
Celada, A . (1 9 8 2 ) Iron  overload in a non-transfused patient w ith  thalassaem ia in te rm edia . ScandJ  
Haematol, 28, 169-174 .
Chaidos, A ., M ak is , A ., H a tz im ich ae l, E ., Tsiara, S., G ouva, M . ,  T zo u vara , E. &  Bourantas, K .L .  
(2 0 0 4 ) Treatm ent o f  beta-thalassem ia patients w ith  recom binant hum an erythropo ietin : 
effect on transfusion requirem ents and soluble adhesion m olecules. Acta Haematol, 111, 
189-195 .
Charache, S., Scott, J.P., N ie b y l, J. &  Bonds, D .R . (1 9 8 0 ) M an ag m e n t o f  sickle cell disease in 
pregnant patients. Obstet Gynecol, 55 , 4 0 7 -4 1 0 .
Charache, S., T errin , M .L . ,  M o ore , R .D ., D o ver, G .J ., B arton, F .B ., Eckert, S .V ., M c M a h o n , R .P . 
&  Bonds, D .R . (1 9 9 5 ) E ffec t o f  h ydroxyurea on the frequency o f  p a in fu l crises in  sickle
Page 253 of 278
cell anem ia. Investigators o f  the M u ltic e n te r Study o f  H y d ro x y u re a  in  S ick le  C e ll  
A n em ia . TV Engl J  Med, 332, 13 17 -132 2 .
C hatterjee, R ., Shah, F .T ., Byers, M .,  Sooranna, S., B a jo ria , R ., P ring le , J. &  Porter, J.B . (2 0 0 3 a )  
Prospective Study o f  H is to m o rm om etry , B io ch em ica l B one M arke rs  and B one  
D ensitom etric  Response T o  Pam idronate in -Thalassaem ia Presenting w ith  Osteoporosis. 
ASH Annual Meeting Abstracts, 103, abstract 939.
C hatte ijee , R ., Shah, F .T . &  Porter, J.B. (2 0 0 3 b ) Prospective Study o f  Spinal and F em o ra l B one  
D ensitom etric  Response to Pam idronate in B eta Thalassaem ia M a jo r. . Conference 
proceedings
The 9th International Conference on Thalassaemia andHaemoglobinopathies, Palermo, , P I 69.
Cheng, M .L . ,  H o , H .Y . ,  Tseng, H .C ., Lee, C .H ., Shih, L .Y .  &  C h iu , D .T . (2 0 0 5 ) A n tio x id a n t  
d efic it and enhanced susceptibility to ox ida tive  dam age in  ind iv iduals  w ith  d iffe ren t  
form s o f  alpha-thalassaem ia. Br J  Haematol, 128, 119-127 .
Chung, C ., C ackovic , M . &  Kerste in, M .D .  (1 9 9 6 ) Leg  ulcers in patients w ith  sickle cell disease. 
Adv Wound Care, 9, 46 -50 .
C ighetti, G ., D eb ias i, S., Paroni, R . &  A lle v i, P. (1 9 9 9 ) Free and total m a londia ldehyde
assessment in  b io log ica l m atrices by gas chrom atography-m ass spectrom etry: w h a t is 
needed fo r an accurate detection. Anal Biochem, 266, 2 2 2 -2 2 9 .
C ig hetti, G ., D uca , L ., B ortone, L ., Sala, S., N a va , I., F io re lli, G . &  C a p p e llin i, M .D .  (2 0 0 2 )
O x id a tiv e  status and m alondialdehyde in beta-thalassaem ia patients. E ur J  C lin  Invest, 32 
Suppl 1, 55 -60 .
C lark , B .E . &  T he in , S .L . (2 0 0 4 ) M o le c u la r diagnosis o f  haem oglobin  disorders. Clin Lab 
Haematol, 26, 159-176 .
Cohen, A ., M a rtin , M .B .,  S ilber, J .H ., K im , H .C ., O hene-Frem pong, K . &  Schw artz, E . (1 9 9 2 )  A  
m o d ified  transfusion program m e fo r prevention o f  stroke in sickle cell disease. Blood, 79, 
16 57 -1661 .
Cohen, A .R ., G alan ello , R ., Piga, A ., D ip a lm a , A .,  V u llo , C . &  T ric ta , F. (2 0 0 0 ) Safety  p ro file  o f  
the oral iron chelator deferiprone: a m u lticentre study. B r J  Haematol, 108, 3 0 5 -3 1 2 .
Cohen, A .R ., M iza n in , J. &  Schw artz, E. (1 9 8 9 ) R ap id  rem oval o f  excessive iron  w ith  d a ily , 
high-dose intravenous chelation therapy. J  Pediatr, 115, 151-155 .
C o llins, F .S . &  O rringer, E .P . (1 9 8 2 ) P u lm onary hypertension and cor pulm onale  in the s ickle  
hem oglobinopathies. Am J  Med, 73, 8 1 4 -8 2 1 .
Conrad, M .E .,  U m bre it, J.N . &  M o o re , E .G . (1 9 9 9 ) Iron  absorption and transport. Am J  M ed Sci, 
3 1 8 ,2 1 3 -2 2 9 .
C oo ley, T .B . &  Lee, P. (1 9 2 5 ) A  series o f  cases o f  splenom egaly in ch ildren  w ith  anaem ia  and  
peculiar bone changes. Transactions o f  the American Pediatric Society, 3 7 , 29 .
C o m ejo , P., T ap ia , G ., Puntarulo, S., G alleano , M .,  V id e la , L .A . &  Fernandez, V .  (2 0 0 1 )  Iro n -
induced changes in n itric  oxide and superoxide radical generation in rat liv e r  a fte r lindane  
or thyro id  horm one treatm ent. Toxicol Lett, 119, 87 -93 .
C orte lezz i, A ., Cattaneo, C ., C ris tian i, S., D uca, L ., Sarina, B ., D e lilie rs , G .L .,  F io re lli, G . &  
C app ellin i, M .D .  (2 0 0 0 ) N o n -tran sferrin -bo u nd  iron in m yelodysplastic  syndrom es: a 
m arker o f  ine ffective erythropoiesis? Hematol J, 1, 153-158 .
C ro izat, H . (1 9 9 4 ) C ircu la tin g  cytokines in sickle cell patients during  steady state. B r J  Haematol, 
87, 59 2 -5 97 .
D aar, S., Hussein, H .M . ,  M erghoub , T . &  K rishnam oorthy, R . (1 9 9 8 ) Spectrum  o f  beta- 
thalassem ia m utations in O m an . Ann N  Y Acad Sci, 850, 4 0 4 -4 0 6 .
D acie , J .V . (1 9 6 0 ) The Haemolytic Anaemias. C h u rch ill.
D a lla lio , G ., F leury, T . &  M eans, R .T . (2 0 0 3 ) Serum  hepcid in  in  c lin ica l specimens. B r J  
Haematol, 122, 9 9 6 -1 0 0 0 .
Danielson, C .F . (2 0 0 2 ) The ro le o f  red b lood cell exchange transfusion in  the treatm ent and  
prevention o f  com plications o f  sickle cell disease. Ther Apher, 6 , 2 4 -3 1 .
Page 254 of 278
D avies , M .J . (2 0 0 5 ) The o x ida tive  en vironm ent and protein dam age. Biochim Biophys Acta,
1703, 93 -1 0 9 .
D avis , B .A ., O 'S u llivan , C ., Jarritt, P .H . &  Porter, J.B. (2 0 0 4 ) V a lu e  o f  sequential m o n ito rin g  o f  
le ft ventricu la r ejection fraction  in the m anagem ent o f  thalassem ia m ajor. Blood, 104, 
2 6 3 -2 6 9 .
D avis , B .A . &  Porter, J.B. (2 0 0 0 ) L on g -te rm  outcom e o f  continuous 2 4 -h o u r d eferoxam in e
infusion v ia  in d w ellin g  intravenous catheters in h ig h -risk  beta-thalassem ia. Blood, 95 , 
1229 -123 6 .
D avis , B .A . &  Porter, J.B. (2 0 0 2 ) Results o f  long term  iron chelation treatm ent w ith  
deferoxam ine. Adv Exp Med Biol, 509, 91 -125 .
de K lerk , G ., W ilm in k , J .M ., Rosengarten, P .C ., V e t, R.J. &  G oudsm it, R . (1 9 8 2 )  Serum
erythropoietin  (E S F ) titers in anem ia o f  chronic renal fa ilu re . J  Lab C lin Med, 100, 7 2 0 -  
734.
D e  Luca, C ., Filosa, A ., G randinetti, M .,  M ag g io , F ., Lam ba, M . &  Passi, S. (1 9 9 9 ) B lo o d
antioxidant status and urinary levels o f  catecholam ine m etabolites in beta-thalassem ia. 
Free Radic Res, 30, 4 5 3 -4 6 2 .
de M o nta lem b ert, M .,  L lados, A ., Hannedouche, T . &  G iro t, R . (1 9 8 9 ) T rea tm ent o f  post­
transfusion iron  overload by deferoxam ine. Arch F r Pediatr, 46, 9 9 -1 0 5 .
D e  V irg iliis , S., A rg io lu , F ., Sanna, G ., C om acchia , G ., Cossu, P., Cao, A ., M a lla rd i, V . &
Puxeddu, P. (1 9 7 9 ) A u d ito ry  invo lvem ent in thalassem ia m ajor. Acta Haematol, 6 1 , 2 0 9 -  
215.
D e  V irg iliis , S., C ongia , M .,  Frau, F ., A rg io lu , F ., D ian a , G ., Cucca, F ., V ars i, A ., Sanna, G ., 
Podda, G ., Fodde, M . &  et al. (1 9 8 8 ) D efero xam in e-ind u ced  grow th  retardation  in  
patients w ith  thalassem ia m ajor. J  Pediatr, 113, 6 6 1 -6 6 9 .
D e l R io , D ., P e llegrin i, N ., C o lo m b i, B ., B ianch i, M .,  S erafm i, M .,  Torta, F ., T eg on i, M . ,  M u sc i, 
M . &  B righenti, F. (2 0 0 3 ) R ap id  flu o rim etric  m ethod to detect total plasm a  
m alondialdehyde w ith  m ild  d erivatiza tion  conditions. Clin Chem, 49, 6 9 0 -6 9 2 .
D e l R io , D ., Stew art, A .J. &  P e lleg rin i, N . (2 0 0 5 ) A  rev iew  o f  recent studies on m a lo n d ia ld eh yd e  
as toxic m olecule and b io log ical m arker o f  o xidative  stress. Nutr Metab Cardiovasc Dis, 
1 5 ,3 1 6 -3 2 8 .
D etivau d , L ., N em eth , E ., Boudjem a, K ., T u rlin , B ., Troadec, M .B .,  Leroyer, P., R opert, M .,
Jacquelinet, S., Courselaud, B ., G anz, T ., Brissot, P. &  L orea l, O . (2 0 0 5 ) H e p c id in  levels  
in humans are correlated w ith  hepatic iron stores, hem oglobin  levels, and hepatic  
function. Blood, 106, 7 4 6 -7 4 8 .
D iggs, L .W . &  C h ing , R .E . (1 9 3 4 ) P athology o f  sickle cell anaem ia. Southern Med. J., 27, 8 3 9 -  
845.
D ore , F., B o n fig li, S., G aviano , E ., P ard in i, S. &  L on g inotti, M . (1 9 9 6 ) Serum  transferrin  receptor 
levels in  patients w ith  thalassem ia in term edia  during rH u E P O  adm in istration. 
Haematologica, 81, 3 7 -39 .
D resner Pollack, R ., R ach m ilew itz , E ., B lu m en fe ld , A ., Idelson, M . &  G o ld farb , A .W . (2 0 0 0 )  
B one m ineral m etabolism  in adults w ith  beta-thalassaem ia m a jo r and in term edia . B r J  
Haematol, 111, 9 0 2 -9 07 .
D u ew e ll, S., W uthrich , R ., von Schulthess, G .K ., Jenny, H .B ., M u lle r , R .N ., M o e rk e r, T . &
Fuchs, W .A . (1 9 9 1 ) N o n io n ic  polyethylene g ly co l-fe rrio xa m in e  as a renal m agnetic  
resonance contrast agent. Invest Radiol, 26 , 50 -57 .
E l-N a w a w y , A ., M assoud, M .N . ,  E l-B o rd in y , M . &  H egazya, S. (2 0 0 2 ) E va lua tio n  o f  serum  
soluble transferrin  receptors and erythropoietin  levels as indicators fo r erythropo ietic  
activ ity  am ong m ulti-transfused beta-thalassem ic patients. J  Trop Pediatr, 48, 3 3 -3 8 .
Em ond, A .M .,  C o llis , R ., D a rv ill, D ., H iggs, D .R ., M au d e, G .H . &  Serjeant, G .R . (1 9 8 5 ) A cute  
splenic sequestration in hom ozygous sickle cell disease: natural h istory and m anagem ent. 
J  Pediatr, 107, 20 1 -2 06 .
Page 255 of 278
Em ond, A .M .,  H o lm an , R ., Hayes, R.J. &  Seijeant, G .R . (1 9 8 0 ) P riapism  and im potence in  
hom ozygous sickle cell disease. Arch Intern Med, 140, 14 3 4 -1 4 3 7 .
E ngle, M .A .  (1 9 6 4 ) C ard iac Invo lvem ent in Cooley's A n em ia . Ann N  Y Acad Sci, 119, 6 9 4 -7 0 2 .
Evans, R .W . &  W illia m s , J. (1 9 7 8 ) Studies o f  the b ind ing  o f  d iffe ren t iron  donors to hum an  
serum transferrin  and isolation o f  iro n -b ind in g  fragm ents fro m  the N -  and C -te rm in a l 
regions o f  the protein. BiochemJ, 173, 5 4 3 -5 52 .
Ezeh, C ., U g o ch ukw u , C .C ., W einstein , J. &  O kp ala , I. (2 0 0 5 ) H e p c id in , h aem oglob in  and  
fe rritin  levels in sickle cell anaem ia. Eur J  Haematol, 74, 8 6 - 8 8 .
Finch, C .A ., Lee, M .Y .  &  Leonard, J .M . (1 9 8 2 ) Continuous R B C  transfusions in a patien t w ith  
sickle cell disease. Arch Intern Med, 142, 27 9 -2 8 2 .
Fisher, J .W . (2 0 0 3 ) Erythropo ietin : physiology and pharm acology update. Exp B io l Med  
(Maywood), 2 2 8 , 1-14.
Fitchett, D .H .,  C o ltart, D .J ., L ittle r , W .A ., Leyland , M .J ., T ruem an, T ., G o zzard , D . I .  &  Peters,
T.J. (1 9 8 0 ) C ard iac invo lvem ent in secondary haem ochrom atosis: a catheter b iopsy study  
and analysis o f  m yocardium . Cardiovasc Res, 14, 7 1 9 -7 24 .
F lem ing , R .E . &  B acon, B .R . (2 0 0 5 ) O rchestration o f  iron homeostasis. N  Engl J  Med, 3 5 2 ,
1741-1744.
F lin t, J., H ard in g , R .M ., Boyce, A .J. &  C legg, J.B. (1 9 9 8 ) T h e  population genetics o f  the  
haem oglobinopathies. Baillieres C lin Haematol, 11, 1-51.
F lynn , D .M .,  F a im ey , A ., Jackson, D . &  C layton , B .E . (1 9 7 6 ) H o rm on al changes in thalassaem ia  
m ajor. Arch Dis Child, 51, 8 2 8 -8 3 6 .
Fow les, R .E . &  M ason , J .W . (1 9 8 2 ) E ndom yocard ia l biopsy. Ann Intern Med, 97, 8 8 5 -8 9 4 .
Frustaci, A ., P ieroni, M . &  C h im en ti, C . (2 0 0 2 ) T h e  ro le o f  endom yocardial b iopsy in  the  
diagnosis o f  cardiom yopathies. Ita l Heart J, 3, 34 8 -3 53 .
G abutti, V . &  Piga, A . (1 9 9 6 ) Results o f  long -term  iron-chela ting  therapy. Acta Haematol, 95, 
2 6 -36 .
G a fte r-G v ili, A ., P rokocim er, M .,  B reuer, W ., C abantchik , I .Z . &  Hershko, C . (2 0 0 4 )  N o n ­
transferrin-bound serum iron ( N T B I )  in m egaloblastic anem ia: e ffect o f  v ita m in  B (1 2 )  
treatm ent. Hematol J, 5, 32 -34 .
G aine , S. (2 0 0 0 ) P ulm onary hypertension. Jama, 284, 3 1 6 0 -3 1 6 8 .
G alanello , R ., B are lla , S., Turco, M .P ., G iagu , N ., Cao, A ., D o re , F ., L iberato , N .L .,  G u a m o n e , R. 
&  Barosi, G . (1 9 9 4 ) Serum  eryth ropo ietin  and erythropoiesis in h igh - and lo w -fe ta l 
hem oglobin  beta-thalassem ia in term edia  patients. Blood, 83, 5 6 1 -5 6 5 .
G alia , M .,  M id ir i ,  M .,  B arto lo tta, V ., M o rab ito , A ., R izzo , M ., M an g ia g li, A ., M a liz ia , R ., 
B orsellino, Z ., Capra, M .,  D 'A sco la , D .G ., M agnano, C ., G erard i, C ., R ig an o, P. &  
M ag g io , A . (2 0 0 3 ) Potentia l m yocard ia l iron content evaluation  by m agnetic  resonance  
im aging  in thalassem ia m ajo r patients treated w ith  D e fero xam in e  or D e fe rip ro n e  d urin g  a 
random ized m ulticenter prospective c lin ica l study. Hemoglobin, 27, 6 3 -7 6 .
G anz, T . (2 0 0 6 ) M o le c u la r pathogenesis o f  anem ia o f  chronic disease. Pediatr Blood Cancer, 46, 
5 5 4 -5 57 .
G ardenghi, S., M aron g iu , M .F .,  Ram os, P., G uy , E ., Breda, L ., C h ad b um , A .,  L iu , Y . ,  A m a rig lio , 
N ., Rechavi, G ., R a ch m ilew itz , E .A ., B reuer, W ., C abantchik , Z .I . ,  W rig h tin g , D .M .,  
A ndrew s, N .C ., de Sousa, M .,  G ia rd in a , P.J., G rady, R .W . &  R iv e lla , S. (2 0 0 7 )
Ine ffective  erythropoiesis in beta-thalassem ia is characterized by increased iron  
absorption m ediated by d ow n-regu la tion  o f  hepcidin and up-regu lation  o f  ferroportin . 
Blood, 109, 5 0 2 7 -5 0 3 5 .
Gasche, C ., Lom er, M .C .,  C a v ill, I. &  W eiss, G . (2 0 0 4 ) Iron, anaem ia, and in flam m a to ry  bow el 
diseases. Gut, 53 , 1190 -1197 .
G ehrke, S .G ., K u laks iz , H ., H errm ann , T ., R iedel, H .D .,  Bents, K ., V e ltk a m p , C . &  S trem m el, W .
(2 0 0 3 ) Expression o f  hepcidin in hereditary hem ochrom atosis: evidence fo r a regu lation
Page 256 of 278
in response to the serum transferrin  saturation and to non-transferrin -bound  iron. Blood, 
102, 3 7 1 -3 7 6 .
G la d w in , M .T .  &  K ato , G .J. (2 0 0 5 ) C ard io p u lm o n ary  com plications o f  s ickle cell disease: ro le o f  
n itric  oxide and hem olytic  anem ia. Hematology Am Soc Hematol Educ Program , 51 -57 .
G la d w in , M .T . ,  Sachdev, V . ,  Jison, M .L . ,  Sh izukuda, Y . ,  P lehn, J .F ., M in te r , K ., B ro w n , B .,
Coles, W .A ., N ich o ls , J.S., Ernst, I., H unter, L .A ., B lac kw eld er, W .C ., Schechter, A .N .,  
Rodgers, G .P ., Castro, O . &  O gnibene, F .P . (2 0 0 4 ) P u lm onary hypertension as a risk  
factor fo r death in patients w ith  sickle cell disease. N  Engl J  Med, 350, 8 8 6 -8 9 5 .
G lickste in , H ., E l, R .B ., Shvartsm an, M . &  C abantchik , Z .I .  (2 0 0 5 ) In trace llu la r lab ile  iron  pools  
as direct targets o f  iron chelators: a fluorescence study o f  chelator action in liv in g  cells. 
Blood, 106, 32 4 2 -3 2 5 0 .
G ordeuk, V . ,  Bacon, B .R . &  B rittenham , G . (1 9 8 7 ) Iron  overload: causes and consequences.
Annu Rev Nutr, 1987, 4 8 5 -5 0 8 .
G osriw atana, I., L orea l, O ., L u , S., Brissot, P., Porter, J. &  H id er, R .C . (1 9 9 9 ) Q u a n tific a tio n  o f  
non-transferrin -bound iron in the presence o f  unsaturated transferrin . Anal Biochem, 273, 
212- 220 .
G raham , G .S . (1 9 2 4 ) Case o f  sickle cell anaem ia w ith  necropsy. Arch Intern Med, 34, 7 7 8 -8 0 0 .
Grosse, R ., Lund , U ., Caruso, V . ,  Fischer, R ., Janka, G .E ., M agnano, C ., E ngelhardt, R ., D u rk en , 
M . &  N ie lsen , P. (2 0 0 5 ) N o n -transferrin -bound  iron during b lood transfusion cycles in  
beta-thalassem ia m ajor. Ann N  Y Acad Sci, 1054, 4 2 9 -4 32 .
G unshin, H ., M ac ke n z ie , B ., B erger, U .V . ,  G unshin, Y . ,  Rom ero, M .F .,  B oron, W .F ., Nussberger, 
S., G o llan , J.L . &  H ediger, M .A .  (1 9 9 7 ) C lo n in g  and characterization o f  a m a m m alia n  
proton-coupled m eta l-io n  transporter. Nature, 3 8 8 , 4 8 2 -4 88 .
G utteridge, J .M ., M a id t, L . &  Poyer, L . (1 9 9 0 ) Superoxide dismutase and Fenton chem istry .
R eaction  o f  fe r r ic -E D T A  co m p lex  and fe rric -b ip y rid y l com plex w ith  hydrogen p eroxide  
w ith o ut the apparent fo rm ation  o f  iro n (II) .  Biochem J, 269, 169-174 .
G utteridge, J .M ., R o w le y , D .A .,  G riffith s , E . &  H a lliw e ll,  B . (1 9 8 5 ) L o w -m o le c u la r-w e ig h t iron  
com plexes and oxygen radical reactions in  id iopath ic haem ochrom atosis. Clin Sci (Lond), 
6 8 , 4 6 3 -4 6 7 .
H aberkem , C .M .,  N eu m ayr, L .D ., O rrin ger, E .P ., Earles, A .N .,  Robertson, S .M ., B lac k , D .,  
Abboud, M .R .,  Koshy, M ., Ido w u, O . &  V ich in sky , E .P . (1 9 9 7 ) C ho lecystectom y in  
sickle cell anem ia patients: perioperative outcom e o f  364  cases fro m  the N a tio n a l 
Preoperative Transfusion Study. Preoperative Transfusion in  S ick le  C e ll D isease Study  
Group. Blood, 8 9 ,15 33 -154 2 .
H add y, T .B . (1 9 8 2 ) E rythropo ietin  in sickle cell disease: relation o f  eryth ropo ietin  levels to crisis  
and other com plications. Am J  Pediatr Hematol Oncol, 4, 191-196 .
H a lliw e ll,  B . &  C h irico , S. (1 9 9 3 ) L ip id  peroxidation: its m echanism , m easurem ent, and  
significance. Am J  C lin Nutr, 57, 71 5S -7 24 S ; discussion 72 4S -7 25 S .
H a lliw e ll,  B . &  G utteridge, J .M . (1 9 9 0 ) R o le  o f  free radicals and catalytic  m etal ions in  hum an  
disease: an overv iew . Methods Enzymol, 186, 1-85.
H arm atz, P., Butensky, E ., Fung, E ., L o u ie , L ., T h e il, E ., Ferre ll, L ., W illia m s , R . &  V ic h in s k y , 
E.P. (2 0 0 2 ) O rgan In ju ry  in C h ro n ic a lly  Transfused Patients w ith  beta Tha lassem ia  or 
S ick le  C e ll Disease. ASH Annual Meeting Abstracts, abstract 8 8 8 .
Hasuda, T ., Satoh, T ., Shim ouchi, A ., S akam aki, F ., K yo tan i, S., M atsum oto , T ., G oto , Y . &  
N akanish i, N . (2 0 0 0 ) Im pro vem en t in exercise capacity w ith  n itr ic  o x ide  inh alatio n  in 
patients w ith  p recap illary pulm onary hypertension. Circulation, 101, 2 0 6 6 -2 0 7 0 .
H e rrick , J.B. (1 9 1 0 ) Peculiar elongated and sickle-shaped red b lood corpuscles in  a case o f  severe  
anaem ia. Arch Intern Med, 6 , 51 7 -5 2 1 .
Hershko, C ., C app ellin i, M .D . ,  G alan ello , R ., Piga, A ., T og n on i, G . &  M asera, G . (2 0 0 4 ) Purging  
iron from  the heart. B r J  Haematol, 125, 5 4 5 -5 5 1 .
Page 257 of 278
Hershko, C ., G raham , G ., Bates, G .W . &  R a ch m ilew itz , E .A . (1 9 7 8 )  N o n -sp ec ific  serum  iron in 
thalassaemia: an abnorm al serum iron fraction  o f  potential to x ic ity . B r J  Haematol, 40, 
2 5 5 -2 6 3 .
Hershko, C ., L in k , G . &  K o n ijn , A .M .  (2 0 0 2 ) C ard iopro tective effect o f  iron chelators. Adv Exp 
Med Biol, 509, 77 -89 .
Hershko, C . &  R a ch m ilew itz , E .A . (1 9 7 8 ) Iron  chelation in thalassem ia: m echanism  o f  
desferrioxam ine action. Is r J  Med Sci, 14, 11 11 -1115 .
H ickm an , M ., M o d e ll, B ., Greengross, P., C hapm an, C ., Layton , M .,  Falconer, S. &  D avies , S .C . 
(1 9 9 9 ) M a p p in g  the prevalence o f  sickle cell and beta thalassaem ia in  E ngland: 
estim ating and va lid ating  ethnic-specific  rates. B r J  Haematol, 104, 8 6 0 -8 6 7 .
H id er, R .C . (2 0 0 2 ) N a ture  o f  nontransferrin-bound iron. Eur J  C lin Invest, 32 Suppl 1, 5 0 -5 4 .
Hodges, F.J. &  H o lt, J.F. (1 9 5 1 ) E d ito ria l com m ent. The 1951 year book o f  radiology , 89 .
H o ffb ran d , A .V . ,  G orm an , A ., L au lich t, M .,  G arid i, M .,  E conom idou, J., G eo rg ip o u lo u , P.,
Hussain, M .A .  &  F lynn , D .M . (1 9 7 9 ) Im provem ent in iron status and liv e r  fu nctio n  in  
patients w ith  transfusional iron overload w ith  long-term  subcutaneous desferrio xam ine . 
Lancet, 1, 9 4 7 -9 4 9 .
H o uglum , K ., F ilip , M . ,  W itz tu m , J.L . &  C h o jk ie r, M . (1 9 9 0 ) M alo n d ia ld eh yd e  and 4 -
hydroxynonenal protein adducts in  plasm a and liv e r o f  rats w ith  iron overload. J  C lin  
Invest, 8 6 , 1991 -199 8 .
Hughes, J .G ., D iggs, L .W . &  G illesp ie , C .E . (1 9 4 0 ) T h e  involvem ent o f  the nervous system  in  
s ickle-ce ll anaem ia. J  Pediatr, 17, 166-184 .
Jacobs, E .M ., H endriks , J.C ., van T its , B .L ., Evans, P.J., Breuer, W ., L iu , D .Y . ,  Jansen, E .H .,  
Jauhiainen, K ., Sturm , B ., Porter, J.B ., Scheiber-M ojdehkar, B ., von B onsdorff, L ., 
Cabantchik , Z .I . ,  H id er, R .C . &  S w inkels, D .W . (2 0 0 5 ) Results o f  an in ternational round  
robin  fo r the quantification  o f  serum non-transferrin -bound iron: N e ed  fo r d e fin in g  
standardization and a c lin ica lly  re levant isoform . Anal Biochem, 341, 2 4 1 -2 5 0 .
Jenkins, Z .A .,  Hagar, W ., B ow lus, C .L ., Johansson, H .E ., H arm atz, P., V ich in sk y , E .P . &  T h e il, 
E .C . (2 0 0 7 ) Iron  homeostasis during  transfusional iron overload in beta-thalassem ia and 
sickle cell disease: changes in iron regu latory protein, hepcidin, and fe rritin  expression. 
Pediatr Hematol Oncol, 24, 2 3 7 -2 4 3 .
Jensen, P .D ., Jensen, F .T ., Christensen, T ., E isk jaer, H ., Baandrup, U . &  N ie lsen , J .L . (2 0 0 3 )  
E valuation  o f  m yocardial iron by m agnetic resonance im ag ing  during  iron chela tion  
therapy w ith  deferrioxam ine: ind ication  o f  close relation betw een m yocard ia l iron  content 
and chelatable iron pool. Blood, 101, 4 6 3 2 -4 6 3 9 .
Jensen, P .D ., Jensen, F .T ., Christensen, T ., H e icken d o rff, L ., Jensen, L .G . &  E llegaard , J. (2 0 0 1 )  
Ind irect evidence fo r the potential ab ility  o f  m agnetic resonance im ag ing  to  evaluate  the  
m yocardial iron content in patients w ith  transfusional iron overload. Magma, 12, 153-
166.
Johnston, D .L ., R okey, R . &  O kada, R .D . (1 9 8 7 ) N u c lea r m agnetic resonance im ag in g  o f  the  
cardiovascular system. Herz, 12, 51 -67 .
Junge, B ., C arrion, Y . ,  Bosco, C ., G alleano , M .,  Puntarulo, S., T ap ia , G . &  V id e la , L .A . (2 0 0 1 )  
Effects o f  iron overload and lindane intoxication  in re lation  to o x ida tive  stress, K u p ffe r  
cell function, and liv e r in ju ry  in the rat. Toxicol Appl Pharmacol, 170, 2 3 -2 8 .
K a lm an ti, M .,  K alm antis , T ., L iacopoulou , T ., Tsoum akas, K ., Ladis, V . &  K attam is , C . (1 9 9 1 )  
Serum  erythropoietin  in regu larly  transfused thalassem ic patients. Haematologia 
(Budap), 24, 129-134 .
Kattam is, A ., Papassotiriou, I., Palaio logou, D ., A posto lakou, F ., G a lan i, A ., Lad is , V .,
Sakellaropoulos, N . &  P apanikolaou, G . (2 0 0 6 ) T he effects o f  erythropoetic ac tiv ity  and 
iron burden on hepcidin expression in patients w ith  thalassem ia m ajor. Haematologica, 
9 1 ,8 0 9 -8 1 2 .
Page 258 of 278
K earney, S .L ., N em eth , E ., N e u fe ld , E .J., Thapa, D ., G anz, T ., W einste in , D .A . &  C u n nin gh am , 
M . J. (2 0 0 7 ) U rin a ry  hepcidin  in  congenital chronic anem ias. Pediatr B lood Cancer, 48, 
57 -63 .
K hattak, M .F . &  Saleem , M . (1 9 9 2 ) Prevalence o f  heterozygous beta-thalassem ia in  northern  
areas o f  Pakistan. J  Pak Med Assoc, 42, 32 -34 .
K in ney , T .R ., Sleeper, L .A .,  W ang, W .C ., Z im m erm an , R .A ., P egelow , C .H ., O hene -Frem po ng , 
K ., W ethers, D .L .,  B e llo , J .A ., V ich in sky , E .P ., M o ser, F .G ., G allagh er, D .M . ,  D eB au n , 
M .R .,  P latt, O .S . &  M ille r , S .T . (1 9 9 9 ) S ilent cerebral infarcts in  sickle cell anem ia: a risk  
factor analysis. T h e  C ooperative Study o f  S ick le  C e ll Disease. Pediatrics, 103, 6 4 0 -6 4 5 .
K irk h a m , F.J., L em er, N .B .,  N o etze l, M .,  D eB aun , M .R .,  Datta, A .K .,  Rees, D .C . &  A d am s, R.J. 
(2 0 0 6 ) T ria ls  in sickle cell disease. Pediatr Neurol, 3 4 , 4 5 0 -4 5 8 .
Kontessis, P., M ay o p o u lo u -S ym vo u lid is , D ., S ym vou lid is , A . &  K o n to p o u lo u -G riva , I. (1 9 9 2 )  
Renal invo lvem ent in sickle cell-beta  thalassem ia. Nephron, 61, 10-15.
Kontoghiorghes, G .J., A ld o u ri, M .A . ,  H o ffb ran d , A .V .,  Barr, J., W on ke , B ., K o u ro uc laris , T . &  
Sheppard, L . (1 9 8 7 a ) E ffec tive  chelation o f  iron in beta thalassaem ia w ith  the oral 
chelator l,2 -d im e th y l-3 -h y d ro x y p y rid -4 -o n e . Br Med J  (Clin Res Ed), 295, 1 5 0 9 -1 5 1 2 .
Kontoghiorghes, G .J ., B artle tt, A .N .,  H o ffb ran d , A .V . ,  G oddard, J.G ., Sheppard, L ., B a rr, J. &  
N o rte y , P. (1 9 9 0 ) Lon g -te rm  tria l w ith  the oral iron chelator l ,2 -d im e th y l-3 -  
h yd ro xyp yrid -4 -o n e  ( L I ) .  I. Iron  chelation and m etabolic studies. B r J  Haematol, 76, 
2 9 5 -3 0 0 .
Kontoghiorghes, G.J. &  Evans, R .W . (1 9 8 5 ) Site specific ity  o f  iron rem oval fro m  transferrin  by 
alp ha -ke tohydroxypyrid ine chelators. FEBS Lett, 189, 141-144 .
Kontoghiorghes, G .J., Sheppard, L ., H o ffb ran d , A .V . ,  Charalam bous, J., T ik erp a e , J. &  P ippard, 
M .J . (1 9 8 7 b ) Iron  chelation studies using desferrioxam ine and the potentia l oral chelator, 
l ,2 -d im e th y l-3 -h y d ro x y p y rid -4 -o n e , in norm al and iron loaded rats. J  C lin Pathol, 40, 
4 0 4 -4 0 8 .
Koshy, M . &  Burd, L . (1 9 9 1 ) M anagem ent o f  pregnancy in sickle cell syndrom es. Hematol 
Oncol C lin North Am, 5, 5 8 5 -5 9 6 .
Koshy, M ., W einer, S.J., M ille r ,  S .T ., S leeper, L .A .,  V ich in sky , E ., B row n, A .K .,  K h ak o o , Y .  &  
K in ney, T .R . (1 9 9 5 ) Surgery and anesthesia in sickle cell disease. C o o perative  S tudy o f  
Sick le  C e ll Diseases. Blood, 8 6 , 3 6 7 6 -3 6 8 4 .
K u laks iz , H ., G ehrke, S .G ., Janetzko, A ., Rost, D ., Bruckner, T ., K a llin o w s k i, B . &  S trem m el, W .
(2 0 0 4 ) Pro-hepcidin: expression and cell specific localisation in  the liv e r and its 
regulation in hereditary haem ochrom atosis, chronic renal insuffic iency, and renal 
anaem ia. Gut, 53, 7 3 5 -7 43 .
K u lpe-Faget, P., G ordeuk, V .R . &  Castro, O . (2 0 0 3 ) Association o f  increased iron  status w ith
m yocardial pathology in sickle cell disease. Bioirons, Washington, DC. 2003, Poster 24 .
Laftah , A .H .,  Ram esh, B ., S im pson, R .J., S olanky, N .,  B ahram , S., Schum ann, K ., D eb n am , E .S . 
&  Srai, S .K . (2 0 0 4 ) E ffec t o f  hepcidin  on intestinal iron absorption in m ice. Blood, 103, 
3 9 4 0 -3 9 4 4 .
L aksm itaw ati, D .R ., H andayan i, S., U dyaningsih -F reis leben , S .K ., K u m ia ti, V . ,  A d h iy an to , C ., 
H id aya t, J., Kusnandar, S., D illo n , H .S ., M u nth e , B .G ., W ira w a n , R ., Soegianto , R .R ., 
Ram elan, W . &  Freisleben, H .J. (2 0 0 3 ) Iron status and o x ida tive  stress in  beta- 
thalassem ia patients in Jakarta. Biofactors, 19, 53 -62 .
Lam b, J.E., R ay, F., W ard , J .H ., Kushner, J.P. &  K aplan , J. (1 9 8 3 ) In te rn a liza tio n  and subcellu lar 
localiza tion  o f  transferrin  and transferrin  receptors in H e L a  cells. J  B io l Chem, 258, 
8 7 5 1 -8 7 5 8 .
Landau, H ., Spitz, I .M . ,  C iv id a lli, G . &  R a ch m ilew itz , E .A . (1 9 7 8 ) G onadotroph in , thyro tro p hin  
and prolactin  reserve in beta thalassaem ia. Clin Endocrinol (Oxfi, 9, 1 6 3-1 73 .
Lassman, M .N .,  O 'B rien , R .T ., Pearson, H .A .,  W ise, J .K ., D onabed ian , R .K ., F e lig , P. &  G enel, 
M . (1 9 7 4 ) Endocrine evaluation  in thalassem ia m ajor. Ann N  Y Acad Sci, 232, 226-237.
Page 259 of 278
Lee, A ., Thom as, P., Cupidore, L ., Serjeant, B . &  Serjeant, G . (1 9 9 5 )  Im p ro ved  surv ival in  
hom ozygous sickle cell disease: lessons from  a cohort study. Bmj, 311, 1 6 0 0 -1 6 0 2 .
Lehm ann, H . &  Huntsm an, R .G . (1 9 6 6 ) Man's Haemoglobins. N o rth  H o lla n d  Publish ing  
C om pany.
Leung, P .S., Srai, S .K ., M ascarenhas, M . ,  C h u rch ill, L.J. &  D ebn am , E .S . (2 0 0 5 ) Increased
duodenal iron uptake and transfer in a rat m odel o f  chronic h yp ox ia  is accom panied  by 
reduced hepcidin  expression. Gut, 54, 1391 -139 5 .
L evine, R .L ., W illia m s , J .A ., Stadtm an, E .R . &  Shacter, E. (1 9 9 4 ) C arb on yl assays fo r
determ ination  o f  o x ida tive ly  m o d ified  proteins. Methods Enzymol, 233, 3 4 6 -3 5 7 .
L in k , G ., Pinson, A . &  H ershko, C . (1 9 9 3 ) Iron  loading o f  cultured cardiac m yocytes m o d ifies  
sarcolem m al structure and increases lysosom al frag ility . J  Lab C lin Med, 121, 1 2 7 -1 34 .
L iu , P., H enkelm an, M .,  Joshi, J., H ard y , P., B utany, J., Iw anochko, M .,  C lauberg , M . ,  D h ar, M .,  
M a i, D ., W aien , S. &  O liv ie r i, N . (1 9 9 6 ) Q uantificatio n  o f  cardiac and tissue iron  by  
nuclear m agnetic resonance re laxom etry  in a novel m urine thalassem ia-card iac iron  
overload m odel. Can J  Cardiol, 12, 155-164 .
L iv rea , M .A . ,  Tesoriere, L ., P intaudi, A .M .,  Calabrese, A ., M ag g io , A ., Freis leben, H .J ., D 'A rp a ,  
D ., D 'A n n a , R . &  B o n g io m o , A . (1 9 9 6 ) O x id a tiv e  stress and antiox idant status in  beta- 
thalassem ia m ajor: iron overload  and depletion o f  lip id -so lu b le  antioxidants. Blood, 8 8 , 
36 0 8 -3 6 1 4 .
Lom bardo, T ., T am b u rino , C ., B arto lo n i, G ., M o rro n e , M .L . ,  F ro ntin i, V . ,  Ita lia , F ., C o rd aro , S., 
P riv ite ra , A . &  C a lv i, V . (1 9 9 5 ) C ard iac iron overload in thalassem ic patients: an 
endom yocard ia l b iopsy study. Ann Hematol, 71, 135-141 .
L oreal, O ., G osriw atana, I., G uyader, D ., Porter, J., Brissot, P. &  H id er, R .C . (2 0 0 0 )
D eterm inatio n  o f  non-transferrin -bound iron in genetic hem ochrom atosis using a n ew  
H P L C -b ased  method. J  Hepatol, 32, 72 7 -7 3 3 .
M aa n , Z ., A rya , M . &  Patel, H .R . (2 0 0 3 ) P riap ism —a rev iew  o f  the m edical m anagem ent. Expert 
Opin Pharmacother, 4, 2 2 7 1 -2 2 7 7 .
M ac arin i, L ., M a r in i, S., Pietrapertosa, A ., Scardapane, A . &  Ettorre, G .C . (2 0 0 5 ) N o n
cardiopatic and cardiopatic beta thalassem ic patients: quantitative and q u a lita tive  card iac  
iron deposition evaluation w ith  M R I .  Radiol Med (Torino), 109, 7 7 -9 0 .
M ag g io , A ., D A m ic o , G ., M o rab ito , A ., C apra, M .,  C iaccio , C ., C ia n c iu lli, P., D i  G reg o rio , F ., 
G arozzo, G ., M a liz ia , R ., M ag n an o, C ., M an g ia g li, A ., Q uarta, G ., R izzo , M . ,  D A s c o la ,  
D .G ., R izzo , A . &  M id ir i ,  M . (2 0 0 2 ) D e ferip ro ne versus d eferoxam ine in  patients w ith  
thalassem ia m ajor: a random ized  c lin ica l tria l. Blood Cells M o l Dis, 28 , 19 6 -2 0 8 .
M ahachoklertw attana, P., C huansum rit, A ., S irisriro , R ., C houbtum , L ., S riphrapradang, A . &  
R ajatanavin , R . (2 0 0 3 ) Bone m inera l density, b iochem ical and horm onal p ro files  in  
suboptim ally  treated children and adolescents w ith  beta-thalassaem ia disease. Clin  
Endocrinol (Oxf), 58, 2 7 3 -2 7 9 .
M ak is , A .C ., Chaliasos, N ., H a tz im ic h a e l, E .C . &  Bourantas, K .L . (2 0 0 1 ) R eco m b in ant hum an  
erythropoietin  therapy in a transfusion-dependent beta-thalassem ia m a jo r patient. Ann 
Hematol, 80, 4 9 2 -4 9 5 .
M ak is , A .C ., H a tz im ich ae l, E .C . &  Bourantas, K .L . (2 0 0 0 a ) T h e  ro le o f  cytokines in s ickle  cell 
disease. Ann Hematol, 7 9 ,4 0 7 -4 1 3 .
M ak is , A .C ., H a tz im ichael, E .C . &  Bourantas, K .L . (2 0 0 0 b ) T he role o f  cytokines in sickle cell 
disease. Annals o f  Hematology, 79 , 4 0 7 -4 1 3 .
M an si, I. A . &  Rosner, F. (2 0 0 2 ) M yo ca rd ia l infarction in sickle cell disease. J  Natl Med Assoc, 
9 4 , 4 4 8 -4 5 2 .
M artin , C .R ., Johnson, C .S ., Cobb, C ., T atter. D . &  H ayw o o d , L .J. (1 9 9 6 ) M y o c a rd ia l in fa rctio n  
in sickle cell disease. J  Natl Med Assoc, 8 8 , 4 2 8 -4 3 2 .
M avro g en i, S .I., Gotsis, E .D ., M arkussis, V .,  Tsekos, N .,  P o litis , C ., V re to u , E. &  Kerm astinos, 
D . (1 9 9 8 ) T 2  re laxation  tim e study o f  iron overload  in  b-thalassem ia. Magma, 6 , 7 -1 2 .
Page 260 of 278
M avro gen i, S .I., M arkussis, V .,  K ak lam an is , L ., Tsiapras, D ., Paraskevaid is, I., K aravo lias , G ., 
K aragiorga , M ., Douskou, M .,  C okk inos, D .V .  &  Krem astinos, D .T .  (2 0 0 5 )  A  
com parison o f  m agnetic resonance im ag ing  and cardiac biopsy in the eva lu ation  o f  heart 
iron overload in patients w ith  beta-thalassem ia m ajor. Eur J  Haematol, 75, 2 4 1 -2 4 7 .
M cC ro ry , W .W ., G oren, N . &  G o m fe ld , D . (1 9 5 3 ) D em onstra tion  o f  im p a irm en t o f  u rinary
concentration ab ility , or the 'petressin resisitance' in ch ild ren  w ith  sickle cell anaem ia. Am 
J D is  Child, 8 6 , 51 2 -5 13 .
M cG o n ig le , R.J., Boineau, F .G ., B eckm an, B ., O hene-Frem pong, K ., L e w y , J .E ., Shadduck, R .K .  
&  Fisher, J .W . (1 9 8 5 ) E rythropo ietin  and inhibitors o f  in v itro  erythropoiesis in the  
developm ent o f  anem ia in ch ildren  w ith  renal disease. J  Lab C lin Med, 105, 4 4 9 -4 5 8 .
M cG o n ig le , R.J., W a llin , J .D ., Shadduck, R .K . &  Fisher, J .W . (1 9 8 4 ) E ry th ro p o ie tin  d e fic ien cy  
and inh ib ition  o f  erythropoiesis in renal insuffic iency. Kidney Int, 25 , 4 3 7 -4 4 4 .
M cIn tosh , N . (1 9 7 6 ) Endocrinopathy in thalassaem ia m ajor. Arch Dis Child, 51 , 1 9 5 -2 01 .
M c K ie , A .T .,  B arro w , D ., L atunde-D ada, G .O ., R o lfs , A ., Sager, G ., M u d a ly , E ., M u d a ly , M .,  
Richardson, C ., B a rlo w , D ., B o m fo rd , A ., Peters, T .J ., R a ja , K .B ., S h ira li, S., H e d ig er, 
M .A .,  Farzaneh, F. &  Sim pson, R.J. (2 0 0 1 ) A n  iron-regulated ferric  reductase associated  
w ith  the absorption o f  dietary iron. Science, 291, 17 55 -1759 .
M c K ie , A .T .,  L atu nde-D ada, G .O ., M ire t, S., M cG re g o r, J .A ., Anderson, G .J ., V u lp e , C .D .,
W rigg lesw o rth , J .M . &  Sim pson, R.J. (2 0 0 2 ) M o le c u la r evidence fo r the ro le o f  a fe rric  
reductase in iron  transport. Biochem Soc Trans, 30 , 7 2 2 -7 2 4 .
M c K ie , A .T .,  M a rc ia n i, P., R o lfs , A ., B rennan, K ., W ehr, K ., B arro w , D ., M ire t, S., B o m fo rd , A .,  
Peters, T .J ., Farzaneh, F ., H ed ig er, M .A . ,  H entze , M .W . &  Sim pson, R .J. (2 0 0 0 )  A  novel 
duodenal iron-regulated  transporter, IR E G 1 , im plicated  in the basolateral transfer o f  iron  
to the circulation. M ol Cell, 5, 2 9 9 -3 0 9 .
M e ra l, A ., T uncel, P., Surm en-G ur, E ., O zb ek , R ., O zturk , E. &  G unay, U . (2 0 0 0 ) L ip id
peroxidation and antioxidant status in beta-thalassem ia. Pediatr Hematol Oncol, 17 , 6 8 7 -  
693.
M ille r , S .T ., Rao, S.P., D unn, E .K . &  Glassberg, K .I .  (1 9 9 5 ) Priapism  in ch ildren  w ith  sickle cell 
disease. J  Urol, 154, 84 4 -8 4 7 .
M o d e ll, B . (1 9 7 6 ) M anagem ent o f  thalassaem ia m ajor. B r Med Bull, 32 , 2 7 0 -2 7 6 .
M o d e ll, B . (1 9 7 9 ) Advances in the use o f  iron-chelating  agents fo r the treatm ent o f  iron overload . 
Prog Hematol, 11, 2 6 7 -3 1 2 .
M o d e ll, B ., K han, M . &  D arlison, M . (2 0 0 0 ) S u rv iva l in beta-thalassaem ia m a jo r in the U K :  data  
from  the U K  Thalassaem ia Register. Lancet, 3 5 5 , 2 0 5 1 -2 0 5 2 .
M oeschlin , S. &  Schnider, U . (1 9 6 4 ) T rea tm ent o f  P rim ary  and Secondary H em ochrom atosis  and  
Acute Iron  Poisoning w ith  a N e w  Potent Iron  E lim in a tin g  A g en t (D e s fe rrio x a m in e  B -  
D fo m ). Ned Tijdschr Geneeskd, 108, 16 48 -165 3 .
M o lliso n , P .L . (1 9 7 9 ) Blood transfusion in c lin ica l medicine 6th edition. B la c k w e ll S c ien tific  
Publications.
M o rab ito , N .,  Lasco, A ., G audio , A ., C ris a fu lli, A ., D i  Pietro, C ., M e o , A . &  F ris ina , N .  (2 0 0 2 )  
Bisphosphonates in the treatm ent o f  thalassem ia-induced osteoporosis. Osteoporos Int,
13, 6 4 4 -6 4 9 .
M orrison , J. &  W iser, W . (1 9 7 6 ) T he use o f  prophylactic  partia l exchange transfusion in
pregnancies associated w ith  sickle cell haem oglobiopathies. Obstet Gynecol, 48, 51 6 -  
520.
M o ura , E ., N oorderm eer, M .A .,  V erhoeven , N .,  V erheu l, A .F .M . &  M a rx , J .J .M . (1 9 9 8 ) Iron
Release F rom  H um an M onocytes A fte r  Erythrophagocytosis In V itro : A n  Investigation  in 
N o rm a l Subjects and H ered itary  H em ochrom atosis Patients. Blood, 92, 2 5 1 1 -2 5 1 9 .
M ourad , F .H ., H o ffb ran d , A .V .,  S h eikh -Taha , M ., Koussa, S., K h o ria ty , A . I .  &  Tah er, A . (2 0 0 3 )  
Com parison between desferrioxam ine and com bined therapy w ith  d esferrioxam ine and  
deferiprone in iron overloaded thalassaem ia patients. B r J  Haematol, 121, 18 7-1 89 .
Page 261 of 278
M uetterties, K .A .,  H oener, B .A ., Engelstad, B .L ., Ton g o l, J .M ., W ik s tro m , M .G .,  W an g , S .C ., 
Eason, R .G ., M o seley , M .E . &  W h ite , D .L . (1 9 9 1 ) F err io x am in e  B  d erivatives as 
hepatobilia ry  contrast agents fo r m agnetic resonance im ag ing . Magri Res on Med, 22, 8 8 - 
100.
M u nugalavad la , V . &  K apur, R . (2 0 0 5 ) R o le  o f  c -K it  and erythropo ietin  receptor in  
erythropoiesis. C rit Rev Oncol Hematol, 54, 63 -75 .
M u ru ve , N . &  H osking , D .H . (1 9 9 6 ) Intracorporeal phenylephrine in  the treatm ent o f  priap ism . J  
Urol, 155, 141-143 .
N a ith an i, R ., Chandra, J., Bhattachaijee, J., V e rm a , P. &  N arayan , S. (2 0 0 6 ) P erox ida tive  stress 
and antioxidant enzym es in children w ith  beta-thalassem ia m ajor. Pediatr B lood Cancer, 
46, 7 8 0 -7 8 5 .
N asr, M .R .,  A li ,  S., Shaker, M . &  E lgabry, E. (2 0 0 2 ) A n tio x id an t m icronutrients in ch ild ren  w ith  
thalassaem ia in Egypt. East M editerr Health J, 8, 4 9 0 -4 9 5 .
N em eth , E ., R ivera , S., G abayan, V .,  K e lle r, C ., Taudorf, S., Pedersen, B .K . &  G an z, T . (2 0 0 4 )  
IL -6  m ediates h ypoferrem ia o f  in flam m atio n  by inducing the synthesis o f  the iron  
regulatory horm one hepcidin. J  C lin Invest, 113, 1271 -1276 .
N em eth , E ., V a lo re , E .V .,  T errito , M .,  S ch iller, G ., L ichtenstein, A . &  G anz, T . (2 0 0 3 )  H e p c id in , 
a putative m ediato r o f  anem ia o f  in flam m atio n , is a type I I  acute-phase protein . Blood, 
101, 2 4 6 1 -2 4 6 3 .
N eum an, M .G .,  B enham ou, J.P., M a lk ie w ic z , I .M . ,  A k re m i, R ., Shear, N .H .,  Asselah, T .,
Ib rah im , A ., B oyer, N .,  M artin o t-P e ig n o u x , M .,  Jacobson-Brow n, P., K a tz , G .G ., L e  
Breton, V .,  L e  G uludec, G ., Suneja, A . &  M arce llin , P. (2 0 0 1 ) C ytok ines as predictors fo r  
sustained response and as m arkers fo r im m unom odulation  in patients w ith  chronic  
hepatitis C . Clin Biochem, 34, 173-182 .
N ico las , G ., Bennoun, M .,  D evau x , I., Beaum ont, C ., G randcham p, B ., K ahn , A . &  V a u lo n t, S.
(2 0 0 1 ) L ack  o f  hepcidin gene expression and severe tissue iron overload in  upstream  
stim ulatory factor 2 (U S F 2 ) knockout m ice. Proc Natl Acad Sci USA,  98, 8 7 8 0 -8 7 8 5 .
N ico las , G ., Bennoun, M .,  Porteu, A ., M a tiv e t, S., Beaum ont, C ., G randcham p, B ., S irito , M . ,  
Sawadogo, M .,  K ahn, A . &  V au lo n t, S. (2 0 0 2 a ) Severe iron defic iency an em ia  in  
transgenic m ice expressing liv e r hepcidin. Proc Natl Acad Sci USA,  99, 4 5 9 6 -4 6 0 1 .
N ico las, G ., Chauvet, C ., V ia tte , L ., D anan, J .L ., B igard , X .,  D evaux , I., B eaum ont, C ., K a h n , A . 
&  V au lon t, S. (2 0 0 2 b ) T he gene encoding the iron regulatory peptide hepcid in  is 
regulated by anem ia, hypoxia , and in flam m atio n . J  C lin Invest, 110, 1 0 3 7 -1 0 4 4 .
N isb et-B ro w n , E ., O liv ie r i, N .F ., G ia rd in a , P.J., G rady, R .W ., N e u fe ld , E .J., Sechaud, R ., K reb s- 
B row n, A .J ., Anderson, J.R., A lb e rti, D ., S izer, K .C . &  N athan , D .G . (2 0 0 3 )
E ffectiveness and safety o f  IC L 6 7 0  in iron-loaded patients w ith  thalassaem ia: a 
random ised, double-b lind , p lacebo-controlled , dose-escalation tria l. Lancet, 3 6 1 , 15 97 -  
1602.
N is li, G ., K a v a k li, K ., A y d in o k , Y . ,  O ztop , S. &  C etin g u l, N . (1 9 9 7 ) Serum  eryth ro po ietin  levels  
in patients w ith  beta thalassem ia m ajo r and interm edia. Pediatr Hematol Oncol, 14, 161-
167.
Nissenson, A .R . &  Port, F .K . (1 9 8 9 ) O utcom e o f  end-stage renal disease in patients w ith  rare  
causes o f  renal fa ilure. I. Inherited  and m etabolic disorders. Q J  Med, 73, 1 0 5 5 -1 0 6 2 .
O 'B rien , R .T . (1 9 7 8 ) Iron burden in sickle cell anem ia. J  Pediatr, 9 2 , 5 7 9 -5 8 2 .
O hene-Frem pong, K . (2 0 0 1 ) Indications fo r red cell transfusion in sickle cell disease. Semin 
Hematol, 3 8 , 5 -13 .
O hene-Frem pong, K ., W einer, S.J., S leeper, L .A ., M ille r ,  S .T ., E m b u ry , S., M o o h r, J .W .,
W ethers, D .L ., Pegelow, C .H . &  G il l ,  F .M . (1 9 9 8 ) C erebrovascular accidents in sickle  
cell disease: rates and risk factors. Blood, 91, 2 8 8 -2 9 4 .
O ld , J .M ., K han, S .N ., V erm a , I., Fucharoen, S., K leanthous, M ., Ioannou, P., K o tea , N .,  F isher,
C ., R iazuddin , S., Saxena, R ., W in ich ag oo n , P., K yriaco u , K ., A l-Q u o b a ili,  F. &  K h an ,
Page 262 of 278
B. (2 0 0 1 ) A  m ulti-cen ter study in order to fu rther define the m o lec u lar basis o f  beta- 
thalassem ia in Tha ilan d , Pakistan, Sri Lanka, M au ritiu s , Syria, and Ind ia , and to  develop  
a sim ple m olecular diagnostic strategy by am p lifica tio n  re fracto ry  m u tation  system - 
polym erase chain reaction. Hemoglobin, 25, 3 9 7 -4 0 7 .
O liv ie ri, N .F . &  B rittenham , G .M . (1 9 9 7 ) Iro n -che la tin g  therapy and the treatm ent o f  
thalassem ia. Blood, 89 , 7 3 9 -7 61 .
O liv ie ri, N .F ., Freedm an, M .H . ,  Perrine, S .P., D o ver, G .J ., Sheridan, B ., Essentine, D .L .  &  N a g e l, 
R .L . (1 9 9 2 ) T ria l o f  recom binant hum an erythropoietin: three patients w ith  thalassem ia  
interm edia. Blood, 80, 3 2 5 8 -3 2 6 0 .
O liv ie ri, N .F ., Koren, G ., H erm ann, C ., Bentur, Y .,  Chung, D ., K le in , J., St Lou is, P., Freedm an, 
M .H .,  M c C le lla n d , R .A . &  T em pleton , D .M . (1 9 9 0 ) Com parison  o f  oral iron  ch ela tor L I  
and desferrioxam ine in  iron-loaded patients. Lancet, 336, 12 75 -127 9 .
Olsson, K .S ., R itter, B . &  Lund in , P .M . (1 9 8 5 ) L iv e r  affection  in iron overload  studied w ith  
serum ferritin  and serum am inotransferases. Acta Med Scand, 217, 7 9 -8 4 .
O lu johungbe, A ., H am b le ton , I., Stephens, L ., Seijeant, B . &  Serjeant. G . (2 0 0 1 )  R ed  ce ll
antibodies in patients w ith  hom ozygous sickle cell disease: a com parison o f  patients in 
Jam aica and the U n ited  K in gd o m . Br J  Haematol, 113, 66 1 -6 6 5 .
O udit, G .Y .,  Sun, H ., T r iv ie r i, M .G .,  K och , S .E ., D aw o o d , F ., A ckerley , C ., Y azd anp an ah , M .,  
W ilso n , G .J ., Schw artz, A ., L iu , P.P. &  B ackx, P .H . (2 0 0 3 ) L -typ e  C a 2 +  channels  
provide a m a jo r pathw ay fo r iron entry into cardiom yocytes in iro n -o verload  
card iom yopathy. Nat Med, 9, 1187 -119 4 .
Palinski, W ., O rd , V .A . ,  P lum p, A .S ., B res low , J.L ., Steinberg, D . &  W itz tu m , J.L. (1 9 9 4 )  A p o E -  
defic ien t m ice are a m odel o f  lipoprote in  oxidation  in atherogenesis. D em o nstra tio n  o f  
oxidation -specific  epitopes in lesions and high titers o f  autoantibodies to  
m alondia ldehyde-lys ine in serum. Arterioscler Thromb, 14, 6 0 5 -6 1 6 .
Papakonstantinou, O .G ., M aris , T .G ., K ostaridou, V .,  G ouliam os, A .D .,  K outou las, G .K .,
K a lovidouris , A .E ., Papavassiliou, G .B ., Kordas, G ., K attam is , C ., V lah os , L .J. &  et al. 
(1 9 9 5 ) Assessment o f  liv e r iron overload  by T 2 -q u an tita tive  m agnetic resonance  
im aging: correlation o f  T 2 -Q M R I measurem ents w ith  serum ferritin  concentration  and  
histologic grading o f  siderosis. Magn Reson Imaging, 13, 9 6 7 -9 7 7 .
Papanikolaou, G ., Samuels, M .E .,  L u d w ig , E .H ., M ac D o n a ld , M .L . ,  F ranchin i, P .L ., D u b e , M .P .,  
Andres, L ., M acFarlan e , J., Sakellaropoulos, N ., Po litou, M ., N em eth , E ., Tho m p so n , J., 
Risler, J .K ., Zaborow ska, C ., B ab aka iff, R ., R adom ski, C .C ., Pape, T .D .,  D a v id as , O ., 
Christakis, J., Brissot, P., L ockitch , G ., G anz, T ., H ayden , M .R . &  G o ld berg , Y .P . (2 0 0 4 )  
M utations in H F E 2  cause iron overload in chrom osom e lq -lin k e d  ju v e n ile  
hem ochrom atosis. Nat Genet, 36 , 77 -82 .
Papanikolaou, N .,  G hiatas, A ., K attam is , A ., Ladis, C ., K ritiko s , N . &  K attam is , C . (2 0 0 0 )  N o n -  
invasive m yocardial iron assessment in thalassaem ic patients. T 2  re laxo m etry  and  
m agnetization transfer ratio  measurements. Acta Radiol, 41, 3 4 8 -3 5 1 .
Paritpokee, N ., W iw a n itk it, V . ,  Bhokaisaw an, N .,  B oonchalerm vich ian, C . &  Preechakas, P.
(2 0 0 2 ) Serum erythropoietin  levels in pediatric patients w ith  beta- 
thalassem ia/hem oglobin  E . Clin Lab, 48, 6 3 1 -6 3 4 .
Park, C .H ., V a lo re , E .V .,  W arin g , A .J . &  G anz, T . (2 0 0 1 ) H ep c id in , a u rinary an tim icro b ia l 
peptide synthesized in the liver. J  B io l Chem, 276, 7 8 0 6 -7 8 1 0 .
Parkes, J.G ., Hussain, R .A ., O liv ie r i, N .F . &  Tem pleton , D .M . (1 9 9 3 ) E ffects o f  iron loading  on 
uptake, speciation, and chelation o f  iron in cultured m yocard ia l cells. J  Lab C lin Med,
122, 36 -47 .
Pathare, A ., A l K in d i, S., A ln aq dy , A .A .,  D aar, S., K n o x -M a c a u la y , H . &  Dennison, D . (2 0 0 4 )  
C ytok in e  p ro file  o f  sickle cell disease in O m an. Am J  Hematol, 77, 3 2 3 -3 2 8 .
Page 263 of 278
Pattison, J.R ., Jones, S .E ., Hodgson, J., D av is , L .R ., W h ite , J .M ., Stroud, C .E . &  M u rta za , L .
(1 9 8 1 ) Parvovirus infections and hypoplastic crisis in s ick le -ce ll anaem ia. Lancet, 1, 6 6 4 -  
665.
Perrim ond, H ., Chagnon, C ., M o u lan ie r, I., M ic h e l, G ., G u id ic e lli, H . &  B ernard, P.J. (1 9 9 1 )  [T h e  
value o f  nuclear m agnetic resonance in  the study o f  iron overload  in thalassem ia  
patients]. Ann Pediatr (Paris), 38, 175-184 .
Perrotta, S., C ap p e llin i, M .D .,  Berto ldo , F ., Servedio, V . ,  Iolascon, G ., D 'A g ru m a , L ., G asparin i, 
P., S ic ilian i, M .C . &  Iolascon, A . (2 0 0 0 ) Osteoporosis in beta-thalassaem ia m a jo r  
patients: analysis o f  the genetic background. B r J  Haematol, 111, 4 6 1 -4 6 6 .
P icklo , M .J ., M o n tin e , T .J ., A m am ath , V . &  N e e ly , M .D . (2 0 0 2 ) C arbonyl to x ico lo g y  and  
A lzheim er's  disease. Toxicol Appl Pharmacol, 184, 187-197 .
Piga, A ., G alanello , R ., Foschini, M .L . ,  Zappu, A ., Bordone, E ., Longo, F., F o m i, G .-L . ,
Lavagetto, A ., Bertrand, Y . ,  M aseruka, H ., Latham , N . &  A lb e rti, D . (2 0 0 4 )  O n c e -D a ily  
Treatm ent w ith  the O ra l Iron  C helator IC L 6 7 0  (E x ja d e (R )): Results o f  a Phase I I  S tudy in  
Pediatric Patients w ith  {b eta}-T h a lassem ia  M a jo r. ASH Annual Meeting Abstracts, 104, 
3614 -.
P igeon, C ., Ily in , G ., Courselaud, B ., Leroyer, P., T u rlin , B ., Brissot, P. &  Lorea l, O . (2 0 0 1 )  A  
new  mouse liver-sp ecific  gene, encoding a protein  hom ologous to hum an an tim ic ro b ia l 
peptide hepcidin, is overexpressed during iron overload. J  B io l Chem, 276, 7 8 1 1 -7 8 1 9 .
P io m e lli, S., D a n o ff, S.J., B ecker, M .H . ,  L ipera, M .J . &  Travis, S .F. (1 9 6 9 ) P revention  o f  bone  
m alfo rm ations and card iom egaly in Cooley's anem ia by early  hypertransfusion reg im en . 
Ann N  Y Acad Sci, 165, 4 2 7 -4 3 6 .
P io m elli, S., K arp atk in , M .H . ,  A rzan ian , M .,  Z am an i, M .,  B ecker, M .H .,  G eneiser, N . ,  D a n o ff,
S.J. &  Kuhns, W .J . (1 9 7 4 ) H ypertransfusion regim en in patients w ith  C ooley's anem ia. 
Ann N  Y Acad Sci, 232, 186-192 .
P ippard, M .J . (1 9 8 9 ) D esferrioxam ine-induced  iron excretion in humans. Baillieres C lin  
Haematol, 2, 32 3 -3 43 .
Pippard, M .J ., C allender, S .T . &  F inch, C .A . (1 9 8 2 ) Ferrio xam in e excretion in iro n -lo ad ed  m an. 
Blood, 60, 2 8 8 -2 9 4 .
Pippard, M .J ., C allender, S .T ., W arn er, G .T . &  W eatherall, D .J. (1 9 7 9 ) Iron  absorption and  
loading in beta-thalassaem ia interm edia . Lancet, 2, 8 1 9 -8 21 .
P ippard, M .J ., C allender, S .T . &  W eath era ll, D .J. (1 9 7 8 a ) Intensive iron-chela tion  th erapy w ith  
desferrioxam ine in  iron-load ing  anaemias. Clin Sci M o l Med, 54, 9 9 -1 0 6 .
P ippard, M .J ., Letsky, E .A ., C a llender, S .T . &  W eatherall, D .J. (1 9 7 8 b ) P revention  o f  iron  
loading in transfusion-dependent thalassaemia. Lancet, 1, 11 78 -118 1 .
P ippard, M .J . &  W eatherall, D .J. (1 9 8 4 ) Iron  absorption in non-transfused iron load ing  anaem ias: 
prediction o f  risk fo r iron loading, and response to iron chelation treatm ent, in  beta  
thalassaem ia interm edia and congenital sideroblastic anaemias. Haematologia (Budap), 
17, 17-24.
Pippard, M .J . &  W eatherall, D .J. (1 9 8 8 ) Iron  balance and the m anagem ent o f  iron o verload  in 
beta-thalassem ia interm edia. Birth Defects O rig Artie  Ser, 2 3 , 29 -3 3 .
P ittm an, A .K . (1 9 6 4 ) D esferrio xam in e and A cute  Iron  Poisoning. C  R Seances Soc B io l F il, 15 87 , 
1135.
Ponchio, L ., Beguin, Y ., Farina, G ., Pedrazzo li, P., Pedrotti, C ., Poggi, G ., Rosti, V . ,
Bergam aschi, G ., Battistel, V . &  C azzo la , M . (1 9 9 2 ) E va lua tio n  o f  ery th ro id  m arrow  
response to recom binant hum an erythropoietin  in patients w ith  cancer anaem ia. 
Haematologica, 77 , 4 9 4 -5 0 1 .
Pootrakul, P., Breuer, W ., Sam etband, M .,  S irankapracha, P., H ershko, C . &  C abantch ik , Z .I .
(2 0 0 4 ) L ab ile  plasm a iron (L P I)  as an ind icator o f  chelatab le plasm a redox ac tiv ity  in 
iron-overloaded beta-thalassem ia/H bE  patients treated w ith  an oral chelator. Blood, 104, 
1504 -1510 .
Page 264 of 278
Pootrakul, P., K itcharoen, K ., Yansukon, P., W asi, P., Fucharoen, S., C haroen larp , P.,
B rittenham , G ., P ippard, M . &  F inch , C . (1 9 8 8 ) T h e  e ffect o f  e ry th ro id  hyperp las ia  on 
iron blalance. Blood, 71 (4), 1124 -112 9 .
Pootrakul, P., Sirankapracha, P., Sankote, J., K ach in to m , U ., M aungsub , W ., Sriphen, K .,
Thakem p ol, K ., A tisuk, K ., Fucharoen, S., C hantra luksri, U ., Shalev, O . &  H o ffb ran d ,
A .V .  (2 0 0 3 ) C lin ica l tria l o f  deferiprone iron chelation therapy in  beta- 
thalassaem ia/haem oglobin E patients in T ha ilan d . B r J  Haematol, 122, 3 0 5 -3 1 0 .
Porter, J. &  Huehns, E .R . (1 9 8 7 ) Transfusion and exchange transfusion in sickle cell anaem ias, 
w ith  particu lar reference to iron m etabolism . Acta Haematol, 78 , 19 8 -2 05 .
Porter, J., V ich in sky, E ., Rose, C ., Piga, A ., O liv ie r i, N ., G atterm ann, N .,  M aertens, J., R abault,
B ., G athm ann, I. &  A lb erti, D . (2 0 0 4 ) A  Phase I I  Study w ith  IC L 6 7 0  (E x ja d e (R )) , a 
O n c e -D a ily  O ra l Iron  C helator, in Patients w ith  V arious T ran sfu s io n -D ep en dent A n em ias  
and Iron  O verload. ASH Annual Meeting Abstracts, 104, 3193 -.
Porter, J.B. (2 0 0 1 ) Practical m anagem ent o f  iron overload. B r J  Haematol, 115, 2 3 9 -2 5 2 .
Porter, J.B ., Abeysinghe, R .D ., M arsh a ll, L ., H id er, R .C . &  Singh, S. (1 9 9 6 ) K in e tics  o f  rem o va l 
and reappearance o f  non-transferrin -bound plasm a iron w ith  deferoxam in e therapy.
Blood, 88, 7 0 5 -7 1 3 .
Porter, J.B. &  D av is , B .A . (2 0 0 2 ) M o n ito r in g  chelation therapy to achieve o p tim a l outcom e in  the  
treatm ent o f  thalassaem ia. Best Pract Res C lin Haematol, 15, 3 2 9 -3 6 8 .
Porter, J.B ., Jaswon, M .S ., Huehns, E .R ., East, C .A . &  H a ze ll, J .W . (1 9 8 9 ) D e s fe rrio xam in e  
ototoxicity: evaluation  o f  risk  factors in thalassaemic patients and guidelines fo r safe 
dosage. B r J  Haematol, 7 3 ,4 0 3 -4 0 9 .
Powars, D ., W eidm an , J .A ., O d o m -M a ry o n , T ., N ila n d , J.C. &  Johnson, C . (1 9 8 8 ) S ick le  cell 
chronic lung disease: p rio r m o rb id ity  and the risk o f  pulm onary fa ilu re . Medicine 
(Baltimore), 67, 66 -76 .
Powars, D .R ., E llio tt-M ills , D .D .,  Chan, L ., N ila n d , J., H it i,  A .L ., Opas, L .M . &  Johnson, C . 
(1 9 9 1 ) C hron ic  renal fa ilu re  in sickle cell disease: risk factors, c lin ica l course, and  
m orta lity . Ann Intern Med, 115, 6 1 4 -6 2 0 .
Prem awardhena, A ., D e  S ilva, S., A ram b epo la , M .,  O liv ie ri, N ., M erson, L ., M u rac o , J., A lle n ,
A ., Fisher, C ., Peto, T ., V ich in sky , E. &  W eatherall, D . (2 0 0 4 ) Thalassem ia in Sri Lanka: 
a progress report. Hum M ol Genet, 13 Spec No 2, R 2 0 3 -2 0 6 .
Prem awardhena, A ., S, D .E .S ., A ram bepo la , M .,  O liv ie r i, N .F ., V ich in sky , E .P ., M erso n , L ., 
M u raco , G ., A lle n , A ., F isher, C ., Peto, T . &  W eath era ll, D .J. (2 0 0 5 ) H e m o g lo b in  E -  
{ beta}-Thalassem ia: Progress R eport from  the International Study G roup . Ann N  YAcad  
Sci, 1054, 33 -39 .
Race, R .R . &  Sanger, R . (1 9 7 5 ) Blood Groups in Man 6th edition. B la c k w e ll S c ien tific  
Publications.
R ach m ilew itz , E .A . &  A k er, M . (1 9 9 8 ) T he ro le o f  recom binant hum an eryth ro po ietin  in  the  
treatm ent o f  thalassem ia. Ann N  Y Acad Sci, 850, 129-138.
R ach m ilew itz , E .A ., G o ld farb , A . &  D o ver, G . (1 9 9 1 ) A d m in is tra tio n  o f  ery th ro po ietin  to
patients w ith  beta-thalassem ia interm edia: a p re lim inary  tria l. Blood, 78 , 1 1 4 5 -1 1 4 7 .
R ach m ilew itz , E .A ., W e ize r-S te m , O ., A dam sky, K ., A m a rig lio , N . ,  R ech av i, G ., B reda, L ., 
R ive lla , S. &  Cabantchik , Z .I .  (2 0 0 5 ) R o le  o f  iron in inducing  o x id a tive  stress in 
thalassemia: can it be prevented by inh ib ition  o f  absorption and by antioxidants? Ann N  Y 
Acad Sci, 1054, 118-123.
R ackoff, W .R ., O hene-Frem pong, K ., M o n th , S., Scott, J.P., N e ah rin g , B. &  Cohen, A .R . (1 9 9 2 )  
N euro lo g ic  events after partial exchange transfusion fo r priap ism  in sickle cell disease. J  
Pediatr, 120, 88 2 -8 85 .
Ram enghi, U ., D a v id , O ., D ian zan i, I., Sacchetti, L ., B iasi, F ., C h iarp o tto , E. &  P o li, G . (1 9 8 9 )  
A nalysis o f  the carbonyl com pounds produced in beta thalassaem ic erythrocytes by 
o xidative stress. Haematologica, 74 , 5 3 1 -5 3 5 .
Page 265 of 278
Rana, S., Houston, P .E ., Surana, N .,  S halaby-R ana, E .I. &  Castro, O .L . (1 9 9 7 ) D iscon tinu atio n  o f  
long-term  transfusion therapy in patients w ith  sickle ce ll disease and stroke. J  Pediatr, 
131, 7 5 7 -7 6 0 .
R andell, E .W ., Parkes, J.G ., O liv ie r i, N .F . &  Tem p leto n , D .M . (1 9 9 4 ) U p tak e  o f  n on -transferrin - 
bound iron by both reductive and nonreductive processes is m odulated  by in trace llu la r  
iro n . J  B io l Chem, 269, 1604 6 -16 05 3 .
Reed, W .F . &  V ich in sky , E .P . (1 9 9 9 ) Transfusion practice fo r patients w ith  sickle ce ll disease. 
Curr Opin Hematol, 6 , 4 3 2 -4 3 6 .
Rees, D .C ., Luo , L .Y . ,  T he in , S .L ., S ingh, B .M . &  W ickram asinghe, S. (1 9 9 7 ) N o n tran sfu s io na l 
iron overload  in thalassem ia: association w ith  hereditary hem ochrom atosis. Blood, 90, 
3 2 3 4 -3 2 3 6 .
Rees, D .C ., Styles, L ., V ich in sky , E .P ., C legg , J.B. &  W eatherall, D .J. (1 9 9 8 ) T h e  h em o g lo b in  E  
syndromes. Ann N  Y Acad Sci, 850, 3 3 4 -3 43 .
R eznick , A .Z .,  Cross, C .E ., H u , M .L . ,  S uzuki, Y .J ., K h w aja , S., Safadi, A ., M o tc h n ik , P .A .,
Packer, L . &  H a lliw e ll,  B . (1 9 9 2 ) M o d ific a tio n  o f  plasm a proteins by cigarette sm oke as 
measured by protein  carbonyl form ation . Biochem J, 286 ( Pt 2), 6 0 7 -6 1 1 .
R ezn ick , A .Z . &  Packer, L . (1 9 9 4 ) O x id a tiv e  dam age to proteins: spectrophotom etric m ethod  fo r  
carbonyl assay. Methods Enzymol, 233, 35 7 -3 63 .
R ich , S., K au fm an n , E . &  L evy , P.S. (1 9 9 2 ) T he effect o f  high doses o f  ca lc ium -ch an ne l b lockers  
on survival in  prim ary pu lm onary hypertension. N  Engl J  Med, 327, 7 6 -8 1 .
R idd ington , C . &  W ang, W . (2 0 0 2 ) B lo o d  transfusion fo r preventing stroke in  people w ith  sickle  
cell disease. Cochrane Database Syst Rev, C D 0 0 3 1 4 6 .
R ivera , S., N em eth , E ., G abayan, V . ,  Lopez, M .A . ,  Farshidi, D . &  G anz, T . (2 0 0 5 ) S ynthetic  
hepcidin causes rapid dose-dependent hypoferrem ia and is concentrated in  fe rro p o rtin - 
containing organs. Blood, 106, 2 1 9 6 -2 1 9 9 .
Roberts, S. &  B om ford , A . (1 9 8 8 ) C h ela tio n  o f  transferrin  iron by desferrioxam ine in  K 5 6 2  cells. 
The partition  o f  iron between ferrio xam in e  and ferritin . Biochem J, 254, 8 6 9 -8 7 5 .
Roetto, A ., Papanikolaou, G ., Politou, M . ,  A lb e rti, F ., G ire lli, D ., C hristakis, J., Lou ko p ou lo s , D . 
&  Cam aschella, C . (2 0 0 3 ) M u ta n t an tim icrob ia l peptide hepcidin is associated w ith  
severe ju v e n ile  hem ochrom atosis. Nat Genet, 3 3 , 21 -22 .
Rogers, D .W ., V a id ya , S. &  Serjeant, G .R . (1 9 7 8 ) E arly  splenom egaly in hom ozygous s ick le -ce ll 
disease: A n  indicator o f  susceptibility to infection. Lancet, 2, 9 6 3 -9 6 5 .
Roque, M .E .,  Sandoval, M .J . &  A g g io , M .C . (2 0 0 1 ) Serum  erythropoietin  and its re la tion  w ith
soluble transferrin  receptor in patients w ith  d iffe ren t types o f  anaem ia in  a lo c a lly  d efined  
reference population. Clin Lab Haematol, 23 , 2 9 1 -2 9 5 .
Rund, D . &  R a ch m ilew itz , E . (1 9 9 5 ) Advances in the pathophysio logy and treatm ent o f  
thalassem ia. C rit Rev Oncol Hematol, 2 0 , 2 3 7 -2 5 4 .
S adeghi-N ejad , H . &  Seftel, A .D . (2 0 0 2 ) T he etio logy, diagnosis, and treatm ent o f  priap ism :
rev iew  o f  the A m erican  Foundation fo r U ro lo g ic  Disease Consensus Panel R eport. C urr 
Urol Rep, 3 , 4 9 2 -4 9 8 .
Sandoval, C ., S tringel, G ., O zkayn ak, M .F .,  T ug al, O . &  Jayabose, S. (2 0 0 2 ) P erioperative
m anagem ent in children w ith  sickle cell disease undergoing laparoscopic surgery. Jsls, 6 , 
29 -33 .
S am aik , S., Soorya, D ., K im , J., Ravindranath , Y . &  Lusher, J. (1 9 7 9 ) Period ic  transfusions for 
sickle cell anem ia and C N S  infarction. A m J D i s  Child, 133, 12 5 4 -1 2 5 7 .
Serjeant, G .R . (1 9 9 7 ) Chron ic transfusion program m es in sickle cell disease: p roblem  or 
panacea? B r J  Haematol, 97, 2 5 3 -2 5 5 .
Shacter, E ., W illia m s , J .A ., L im , M . &  L ev in e , R .L . (1 9 9 4 ) D iffe re n tia l susceptibility  o f  p lasm a  
proteins to o xidative m o d ification : exam ination  by w estern  b lo t im m unoassay. Free 
Radic B io l Med, 1 7 ,4 2 9 -4 3 7 .
Page 266 of 278
Shinar, E. &  R ach m ilew itz , E .A . (1 9 9 0 ) O x id a tiv e  denaturation o f  red b lood cells in thalassem ia. 
Semin Hematol, 27, 7 0 -82 .
Shnizer, S., K agan, T ., L an ir, A ., M a o r, I. &  R ezn ick , A .Z . (2 0 0 3 ) M o d ific a tio n s  and o x id a tio n  o f  
lip ids and proteins in hum an serum detected by therm ochem ilum inescence.
Luminescence, 18, 90 -96 .
S iddiqui, A .K . &  A h m ed, S. (2 0 0 3 ) P u lm onary m anifestations o f  s ickle cell disease. Postgrad 
MedJ, 79, 3 8 4 -3 90 .
Siegel, J.F., R ich, M .A . &  B rock, W .A . (1 9 9 3 ) Association o f  sickle cell disease, priap ism , 
exchange transfusion and neurological events: A S P E N  syndrom e. J  Urol, 150, 1480 - 
1482.
S im m ons, B .E ., Santhanam , V .,  Castaner, A ., Rao, K .R ., Sachdev, N . &  C ooper, R . (1 9 8 8 )  S ick le  
cell heart disease. T w o -d im en sion al echo and D o p p ler u ltrasonographic find ings in the  
hearts o f  adult patients w ith  sickle cell anem ia. Arch Intern Med, 148, 1 5 2 6 -1 5 2 8 .
Singer, K ., M o tu lsk y , A .G . &  W ile , S .A . (1 9 5 0 ) A p lastic  crisis in sickle cell anem ia; a study o f  
its m echanism  and its relationship  to other types o f  hem olytic  crises. J  Lab C lin  Med, 35, 
7 2 1 -7 3 6 .
Singh, S., H id er, R .C . &  Porter, J.B. (1 9 9 0 ) A  direct m ethod fo r q uantification  o f  n on -tran s ferrin - 
bound iron. Anal Biochem, 186, 3 2 0 -3 23 .
Skikne, B .S ., F low ers , C .H . &  C ook, J .D . (1 9 9 0 ) Serum  transferrin  receptor: a q uantita tive  
m easure o f  tissue iron deficiency. Blood, 75 , 1870 -1876 .
Slatter, D .A .,  B o lton , C .H . &  B a ile y , A .J. (2 0 0 0 ) T he im portance o f  lip id -d erived  
m alondialdehyde in  diabetes m ellitus. Diabetologia, 43, 55 0 -5 57 .
Sm ith , R .S . (1 9 6 2 ) Iron  excretion in  thalassaem ia m ajo r after adm in istration  o f  chela ting  agents. 
Br Med J, 2, 1 5 77 -1580 .
Sousa, C .M ., Catoe, B .L . &  Scott, R .B . (1 9 6 2 ) Studies in sickle cell anem ia. X I X .  P riap ism  as a 
com plication  in children. J  Pediatr, 60 , 52 -54 .
Souw eine, B ., Serre, A .F ., Ph ilippe, P., C on io , N ., A u m a itre , O . &  M arc h e ix , J.C. (1 9 9 5 )  Serum  
erythropoietin  and reticulocyte counts in in flam m ato ry  process. Ann Med Interne (Paris), 
146, 8-12.
Stark, D .D . (1 9 9 1 ) H epatic  iron overload: param agnetic pathology. Radiology, 179, 3 3 3 -3 3 5 .
Summers, J.B., G unn, B .P ., M a rtin , J .G ., M azd iyasn i, H ., Stew art, A .O ., Y o u n g , P .R ., G oetze ,
A .M .,  Bouska, J.B ., D yer, R .D ., Brooks, D .W . &  et al. (1 9 8 8 ) O ra lly  ac tive  h yd ro xam ic  
acid inhibitors o f  leukotriene biosynthesis. J  Med Chem, 31, 3-5 .
Sydenstricker, V.P. (1 9 2 4 a ) Further observations on sickle cell anem ia. J  Am Med Ass, 83, 12-15 .
Sydenstricker, V .P . (1 9 2 4 b ) S ick le  cell anaem ia. Southern Med. J., 17, 17 7 -1 81 .
Sydenstricker, V .P ., M u lh erin , W .A . &  Houseal, R .W . (1 9 2 3 ) S ick le  cell an aem ia .R epo rt o f  tw o  
cases in children, w ith  necropsy in one case. Am J  Dis Child, 26, 1 3 2 -1 54 .
Tap, San, M .,  M e te , U .O . &  K aya , M . (2 0 0 1 ) U ltrastructura l alterations in the m y o card iu m  o f  
patients w ith  sickle cell anem ia. J  Submicrosc Cytol Pathol, 33, 15 1 -1 56 .
Tashiro, A ., Satodate, R . &  Segawa, I. (1 9 9 0 ) H isto log ical changes in  cardiac hem ochrom atosis  
im proved by an iron-chela ting  agent. A  biopsy case. Acta Pathol Jpn, 40, 2 8 8 -2 9 2 .
T ay lo r, S .C ., Shacks, S.J., Q u, Z . &  W ile y , P. (1 9 9 7 ) T yp e 2 cytok ine serum levels in healthy  
sickle cell disease patients. J  N atl Med Assoc, 89, 7 5 3 -7 5 7 .
Thein , S .L . (2 0 0 4 ) G enetic insights into the c lin ica l d iversity  o f  beta thalassaem ia. B r J  
Haematol, 124, 2 6 4 -2 7 4 .
Thong, M .K .,  Tan, J.A ., Tan , K .L . &  Y a p , S .F. (2 0 0 5 ) Characterisation  o f  beta-g lob in  gene  
m utations in M alays ian  children: a strategy fo r the control o f  beta-thalassaem ia in a 
developing country. J  Trop Pediatr, 51, 3 2 8 -3 3 3 .
T ian , G ., Shen, J., Su, S., K o z lo w sk i, P., Sun, J., X ia n g , B ., Saunders, J .K . &  Deslauriers, R .
(1 9 9 7 ) E va luation  o f  h yd ro xyeth y l-s tarch -ferrioxam in e as an intravascular M R  contrast 
agent fo r assessment o f  m yocardial perfusion. Acta Radiol Suppl, 412, 8 5 -90 .
Page 267 of 278
Toccafondi, R ., M a io li,  M . &  M e lo n i, T . (1 9 7 0 ) Plasm a insulin  response to oral carbohydrate in  
Cooley's anaem ia. Riv C rit C lin Med, 70, 9 6 -1 0 1 .
Tom linson, W .J. (1 9 4 5 ) A b d om in al crises in  uncom plicated sickle cell anem ia. A  c lin ic o -
pathologic study o f  o f  11 cases w ith  a suggested explanation  o f  th e ir cause. Am. J. Med. 
Sci., 209, 7 2 2 -7 4 1 .
Top ley , J .M ., Rogers, D .W ., Stevens, M .C . &  S eijeant, G .R . (1 9 8 1 ) A cute  splenic sequestration  
and hypersplenism  in the first five  years in hom ozygous sickle cell disease. Arch Dis 
Child, 56, 7 6 5 -7 6 9 .
T uck, S., James, C ., B rew ster, E ., Pearson, T . &  Studd, J. (1 9 8 7 ) P rophylactic  b lood transfusion  
in m aternal sickle syndromes
Br J  Obstet Gynaecol, 94, 121-125.
V ich in sky, E . (2 0 0 2 ) N e w  therapies in sickle cell disease. Lancet, 360, 6 2 9 -6 3 1 .
V ich in sky, E ., Butensky, E ., Fung, E ., Hudes, M .,  T h e il, E ., Ferrell, L ., W illia m s , R ., L o u ie , L ., 
Lee, P .D . &  H a rm a tz , P. (2 0 0 5 ) Com parison o f  organ dysfunction in transfused patients  
w ith  S C D  or beta thalassem ia. Am J  Hematol, 80, 70 -74 .
V ich in sky, E  P., H a b erkem , C .M ., N eu m ayr, L ., Earles, A .N .,  B lack , D ., K oshy, M . ,  P eg e lo w , C ., 
A bboud, M .,  O hene-Frem pong, K . &  Iyer, R .V . (1 9 9 5 ) A  com parison o f  conservative  
and aggressive transfusion regim ens in the perioperative m anagem ent o f  s ick le  cell 
disease. T he Preoperative Transfusion in  S ickle C e ll Disease Study G roup . N  Engl J  Med, 
333, 2 0 6 -2 1 3 .
V ich in sky , E .P ., N eu m ayr, L .D .,  Earles, A .N .,  W illia m s , R ., Lennette, E .T ., D ean , D .,  N ickerso n ,
B ., O rringer, E ., M c K ie , V . ,  B e llevu e, R ., Daeschner, C . &  M an c i, E .A . (2 0 0 0 )  Causes  
and outcomes o f  the acute chest syndrom e in sickle cell disease. N a tio n a l A c u te  Chest 
Syndrom e Study G roup. N  Engl J  Med, 342, 1855 -1865.
V ich in sky , E .P ., Styles, L .A .,  C o langelo , L .H ., W rig h t, E .C ., Castro, O . &  N ickerso n , B . (1 9 9 7 )  
A cute chest syndrom e in sickle cell disease: c lin ica l presentation and course. C o o p era tive  
Study o f  S ickle C e ll Disease. Blood, 89, 1787 -1792 .
V ira g , R ., B ach ir, D ., Lee, K . &  G alacteros, F. (1 9 9 6 ) Preventive treatm ent o f  p riap ism  in sickle  
cell disease w ith  oral and self-adm inistered  intracavem ous in jection o f  e tile frin e .
Urology, 47, 77 7 -7 81 ; discussion 781.
von Bonsdorff, L ., L indeberg, E ., Sahlstedt, L ., Lehto, J. &  Parkkinen, J. (2 0 0 2 ) B le o m y c in -
detectable iron assay fo r non-transferrin -bound iron in hem atologic m alignancies. Clin  
Chem, 48, 30 7 -3 14 .
V ym aza l, J., U rgosik , D . &  B u lte , J .W . (2 0 0 0 ) D iffe ren tia tio n  betw een h em osiderin - and fe rr it in -  
bound brain iron using nuclear m agnetic resonance and m agnetic resonance im ag ing . Cell 
M ol B io l (Noisy-le-grand), 46, 83 5 -8 42 .
W allace , D .F ., Jones, M .D . ,  Pedersen, P., R ivas, L ., S ly, L .I .  &  Subram aniam , V .N .  (2 0 0 5 )  
P urification  and partia l characterisation o f  recom binant hum an hepcidin . Biochimie.
W alsh, J.R., M ass, R .E ., Sm ith , F .W . &  Lange, V . (1 9 6 4 ) D esfe rrio xam in e  E ffe c t on Iro n  
E xcretion  in Hem ochrom atosis. Arch Intern Med, 113, 4 3 5 -4 4 1 .
W alter, P .B ., Fung, E .B ., K illi le a , D .W .,  Jiang, Q ., Hudes, M .,  M ad d en , J., Porter, J., Evans, P., 
V ich in sky, E. &  H arm atz, P. (2 0 0 6 ) O x id a tive  stress and in flam m a tio n  in iro n -  
overloaded patients w ith  beta-thalassaem ia or sickle cell disease. B r J  Haematol, 135, 
25 4 -2 6 3 .
W ang, W .C ., A hm ed, N . &  Hanna, M . (1 9 8 6 ) N o n -tran sferrin -bo u nd  iron in lon g -te rm  
transfusion in children w ith  congenital anem ias. J  Pediatr, 108, 5 5 2 -5 5 7 .
W ang, W .C ., K ovnar, E .H ., T o n k in , I.L ., M u lh e m , R .K ., Langston, J .W ., D a y , S .W ., S chell, M .J . 
&  W ilim as , J.A . (1 9 9 1 ) H ig h  risk o f  recurrent stroke a fte r discontinuance o f  fiv e  to 
tw e lve  years o f  transfusion therapy in patients w ith  sickle cell disease. J  Pediatr, 118, 
37 7 -3 82 .
Page 268 of 278
W ap nick , A .A .,  Lynch, S .R ., C harlton , R .W ., Seftel, H .C . &  B o th w e ll, T .H . (1 9 6 9 ) T h e  effect o f  
ascorbic acid defic iency on desferrioxam ine-induced urinary  iron excretion . B r J  
Haematol, 17, 56 3 -5 68 .
W ashburn, R .E . (1 9 1 1 ) Peculiar elongated and elongated red blood corpuscles in a case o f  severe  
anaem ia. Virgina Med. Semi Monthly, 15, 4 9 0 -4 9 3 .
W axm an, H .S . &  B row n , E .B . (1 9 6 9 ) C lin ica l usefulness o f  iron chelating  agents. Prog Hematol, 
6 , 33 8 -3 7 3 .
W ayne, A ., K evy , S. &  N athan, D .G . (1 9 9 3 ) Transfusion m anagem ent o f  s ickle cell disease. 
Blood, 81, 1109 -112 3 .
W eatherall, D .J. &  C legg , J.B. (1 9 7 2 ) The Thalassaemia Syndromes 2nd edition.
W eatherall, D .J. &  C legg , J.B. (1 9 8 1 ) The Thalassaemia Syndromes 3rd Edition. B la c k w e ll 
S cientific  Publications
W eatherall, D .J. &  C legg , J.B. (2 0 0 1 ) Inherited  haem oglobin  disorders: an increasing g lobal 
health problem . B ull World Health Organ, 79 , 7 0 4 -7 12 .
W einer, M .,  K arp atk in , M .,  H art, D ., Seaman, C ., V o ra , S .K ., H enry , W .L . &  P io m e lli, S. (1 9 7 8 )  
C o o ley  anem ia: h igh transfusion regim en and chelation therapy, results, and perspective. 
J  Pediatr, 92, 6 5 3 -6 5 8 .
W e ize r, O ., A dam sky, K ., B reda, L ., Cabantchik , I., R ach m ilew itz , E ., B reuer, W ., H a rm e lin , A ., 
L ev in , C ., K oren , A .,  A m a rig lio , N .,  R ive lla , S. &  G ., R . (2 0 0 4 ) H e p c id in  E xpression  in  
C ultured  L iv e r  C e lls  Responds D iffe re n tly  to Iron  O verloaded Sera D e riv e d  fro m  
Patients w ith  Thalassem ia and Hem ochrom atosis. ASH Annual Meeting Abstracts, 31 96 .
W estw ood, M .A . ,  Sheppard, M .N . ,  A w ogbade, M .,  E llis , G ., Stephens, A .D . &  P ennell, D .J .
(2 0 0 5 ) M yo ca rd ia l biopsy and T 2 *  m agnetic resonance in heart fa ilu re  due to  
thalassaemia. Br J  Haematol, 128, 2.
W ickram asinghe, S .N ., T he in , S .L ., S richairatanakool, S. &  Porter, J.B. (1 9 9 9 ) D e term inants  o f  
iron status and b iliru b in  levels in congenital dyserythropoietic anaem ia type I. Br J  
Haematol, 107, 52 2 -5 25 .
W in trobe, M .M .  (1 9 4 6 ) Clin ica l Hematology. H e n ry  K im p to n .
W o lfe , L ., O liv ie ri, N ., Sallan, D ., C o lan , S., Rose, V .,  Propper, R ., Freedm an, M .H .  &  N a th an ,
D .G . (1 9 8 5 ) Prevention o f  cardiac disease by subcutaneous deferoxam ine in patients w ith  
thalassem ia m ajor. N  Engl J  Med, 312, 1 6 00 -1603 .
W olm an , I.J. (1 9 6 4 ) Transfusion Therap y in Cooley's A nem ia : G ro w th  and H e a lth  as R e la ted  to 
Long-R ange H em o glo b in  Levels, a Progress Report. Ann N  YAcad Sci, 119, 7 3 6 -7 4 7 .
W olm an , I.J. &  O rto lan i, M . (1 9 6 9 ) Som e c lin ica l features o f  Cooley's anem ia patients as related  
to transfusion schedules. Ann N  Y Acad Sci, 165, 4 0 7 -4 1 4 .
W ood, J.C ., O tto-D uessel, M . ,  A g u ila r, M .,  N ic k , H ., N elson , M .D . ,  Coates, T .D .,  P o llack , H . &  
M oats, R . (2 0 0 5 ) C ard iac iron determ ines cardiac T 2 * ,  T 2 , and T l  in  the g erb il m odel o f  
iron cardiom yopathy. Circulation, 112, 5 3 5 -5 43 .
W ood, J.C., Tyszka, J .M ., Carson, S., N elson , M .D .  &  Coates, T .D . (2 0 0 4 ) M y o c a rd ia l iron
loading in transfusion-dependent thalassem ia and sickle cell disease. Blood, 10 3 , 1934 - 
1936.
W orah , D ., Berger, A .E ., Burnett, K .R ., C o ck rill, H .H .,  K ana l, E ., K en d a ll, C ., Leese, P .T .,
Lyons, K .P ., Ross, E ., W o lf, G .L . &  et al. (1 9 8 8 ) Ferrio xam in e as a m agnetic  resonance  
contrast agent. P reclin ical studies and phase I and I I  hum an c lin ica l trials. Invest Radiol, 
23 Suppl 1, S 2 8 1-285.
W u, C .J., K rishnam urti, L ., K u to k , J .L ., B iem ac k i, M .,  Rogers, S., Zhang , W ., A n tin , J.H . &  R itz , 
J. (2 0 0 5 ) Evidence fo r ine ffective  erythropoiesis in severe sickle cell disease. Blood, 106, 
3 6 3 9 -3 6 4 5 .
Page 269 of 278
W u , K .H .,  Chang, J.S., Tsai, C .H . &  Peng, C .T . (2 0 0 4 ) C om bined  therapy w ith  deferiprone and 
desferrioxam ine successfully regresses severe heart fa ilu re  in patients w ith  beta- 
thalassem ia m ajor. Ann Hematol, 83, 4 7 1 -4 7 3 .
Y am ashiro , D .J., Tycko , B ., Fluss, S .R . &  M a x fie ld , F .R . (1 9 8 4 ) Segregation o f  transferrin  to a 
m ild ly  acidic (p H  6 .5 ) p ara -G o lg i com partm ent in the recycling  pathway. Cell, 3 7 , 7 8 9 -  
800.
Z a ino , E .C ., Kuo, B . &  Roginsky, M .S . (1 9 6 9 ) G ro w th  retardation in thalassem ia m ajor. Ann N  Y 
Acad Sci, 165, 3 9 4 -3 99 .
Z urlo , M .G .,  D e  Stefano, P., B orgna-P ignatti, C ., D i Palm a, A ., Piga, A ., M e lev en d i, C ., D i 
G regorio , F ., B urattin i, M .G . &  T e rzo li, S. (1 9 8 9 ) S urvival and causes o f  death in 
thalassaem ia m ajor. Lancet, 2, 27 -30 .
Page 270 of 278
Page 271 of 278
Appendix 1
Children from UCLH/HSC
patient
cum ulative
iron
(gram s)
cum ulative
D F O
N TB P I
Serum
transferrin
rcptr
Serum
E P O
carbonyls M D A
1 2 .3 7 19 .5 3 .7 2 3 .0 8 1841 .0 5 0 .67 0 .200
2 .6 4 41.1 13 .64 4 4 .5 7 9 4 4 0 .75 0 .2 30
2 .9 0 70 .0 4 .5 0 .05 0 .73 0 .1 40
3 .2 0 105 .4 2 6 .3 2 -0 .12 6
3 .2 0 115 .0 -0 .8 33 31 .27 -0 .0 9 9
4 .3 0 189 .0 9 0 0 .62 -0 .07 0
2 1.01 0.0 3 .0 7 53.71 0 .96 0.0.
1.77 0.0 4 .3 173 .9 1.43 0 .200
2 .5 9 0.0 10 .4 17 7 .84 75 0 .0 03
3 .65 2 8 .5 0.6 9 8 .1 8 6 4 4 0.001
4 .5 3 91 .5 8.1
5 .1 7 145.5 9 0 .9 8 3 0 5 -0 .0 5 7
3 9 .50 73 .9 4 .2 3.81 2 7 .8 9 0 .67 0 .2 90
10 .20 127.9 3 .3 6 .5 4 77 .75701 0.62 0 .1 70
11 .35 2 1 1 .4 3.2 4 1 .9 8 -0 .04 2
12 .55 2 9 5 .0 6 .5 2 1 .3 6 0 .0 45
12 .79 3 1 3 .0 5 .2 5 6 .7 4 5 7 6 -0 .0 1 9
13 .57 3 5 4 .5 4 .3
15 .13 4 3 5 .0 14 .6 6 3 .1 8 6 4 4 0 .0 42
4 3.08 0.0 4 .3 7 .88 4 0 0 .2 6 0 .82 0 .1 60
3 .7 0 0.0 4 15 .24 4 0 3 .2 4 0.65 0 .3 60
4 .5 7 4 0 .0 7 .6 4 346 0.73 0 .3 30
5 .4 9 88 .7 0 .2 4 6.22 1.03 0 .2 40
6.41 150.4 5 .7 195.3051 0 .0 42
6 .6 9 164.7 2 .8 1 92 .678 0 .0 3 6
7 .94 2 5 3 .7 8 .4
8 .9 8 32 8 .7 7 4 .5 4 2 3 7 -0 .0 0 6
5 0 .2 4 0.0 6 .6 4 2 8 9 .2 0 3 4 -0 .1 0 8
0 .39 0.0 4 .4
0 .77 0.0 9 8 .6 9 4 9 2 -0 .041
6 0.00 0.0 -0 .2 6 7 .6 7 3 2 76 0 .3 2 0 .0 9 0
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0 .0 9 0 .0 5 .6 5 19 .4 5 2 1 5 0 .8 2 0 .1 6 0  I
1 .23 0 .0 1 .77 4 .6 8 0.81 -0 .0 3 0
2 .1 2 0 .0 0 .5 4 .1 3 2 1 3 .4 0.51 0 .0 5 0
2 .8 0 0 .0 1.7 6.91 2 2 1 .4 0 .6 9 0 .0 6 0  i
3 .6 0 0 .0 -1 .5 5 .8 7 2 0 7 .0 3 0 .6 9 -0 .1 0 0
4 .7 6 0 .0 5 10 7 .2 -0 .0 8 8
5.01 2 1 .0 3 .9 1 4 6 .8 5 -0 .0 5 9
5 .2 6 3 4 .5 3 .8 5
7 2 .1 7 0 .0 6 .8 6 .4 2 2 5 .5 2 insuff
2 .8 2 0 .0 5 .3 8 1 9 2 .5 4 0 .7 0 0 .0 3 0
3.71 3 2 .6 7 .4 9 3 .5 8 106.41 0 .3 7 0 .1 5 0
4 .91 9 9 .9 5 .02 2 .4 7 2 4 .9 5 3 2 7 0 .7 0 0 .0 1 0
5 .7 0 1 5 1 .9 5.71 1 .68 3 2 .7 6 0 .6 2 0 .0 9 0
6 .7 9 1 9 1 .9 2 .0 9 7 6 .8 2 2 4 3 0 .7 7 0 .1 0 0
8.81 3 4 1 .9 9 .7 7 0 .3 8 9 8 3 -0 .0 8 5
9.11 3 6 5 .9 12.1 5 2 .1 6 9 4 9 -0 .171
1 0 .3 6 4 6 7 .9 4 .9
1 0 .6 9 4 9 7 .9 6 .8
r
11 .68 5 8 8 .9 5 5 .1 3 5 5 9 -0 .0 8 7
8 2.21 0 .0 5 .3 3 .7 4 1 9 7 .6 3 0 .1 8 0 .1 1 0
2 .7 5 7 .5 8 .5 2 4 .7 4 2 1 2 .0 6 0.71 0 .0 9 0
3 .46 5 7 .5 5.61 4.1 2 0 9 .0 7 0 .5 8 0 .1 6 4
1 4 .0 0 1 0 1 .5 ? 8 .82 7 .0 3 2 2 9 .4 3 0 .8 4 0 .0 8 0
f
4 .7 4 16 7 .2 5 .6 3 .3 2 1 5 .4 1 .14 0 .1 8 2
5 .53 2 3 3 .5 5 .6 4.1 8 8 .2 7 1 1 9 0 .8 2 0 .0 8 0
6 .2 9 3 0 1 .5 5.1
6 .6 6 3 3 5 .8 7 14 5 .30 51 -0.101
t------ -------
7 .4 4 3 9 1 .8 5
7 .6 6 4 0 3 .8 3 .6
8 .4 8 4 6 7 .8 8 1 .2 3 7 2 9 -0 .0 8 7
9 0 .0 8 0 .0 0 .3 7 4 .0 3 3 9 -0 .1 2 4
0 .1 7 0 .0 3 .7 3 8 .1 8 6 4 4 -0.101
0 .3 5 0.0 -0 .3 4 6 8 .0 1 6 9 5 -0 .0 8 3  1
0 .4 4 0 .0 -1 .5 j
0 .5 3 0 .0 1
10 0 .9 9 0.0 -0 .5 0 .3 8 in suff
1 .23 0.0 5.51 3 .9 1 2 0 .7 2 1 .29 in suff
1.88 4 .4 6.1 1
2 .1 4 11 .9 6 0 .4 2 0 .3 3 0
2 .7 0 3 6 .0 5 .2 4 .1 5 0 .6 2 in suff
3 .3 2 7 0 .9 -0 .3 3 4 .1 5 4 9 .6 2 0.61 0 .0 4 0
5 .1 0 1 9 4 .9 5 .7 2 .0 9 3 0 .5 6 0 7 5 0 .8 4 0 .1 7 0  ;
5 .5 6 2 2 7 .9 3 2 .3 5 41 .71 1 .13 0 .1 4 0  j
Page 273 of 278
6 .0 5 2 6 3 .5 -0 .2 3 .2 2 8 .2 2 4 3 0 .8 3 0 .2 4 0
6.91 3 3 0 .4 9 4 6 2 .2 4 -0 .0 3 8
7 .8 6 3 9 1 .9 8.8 1 0 0 .8 1 3 6 -0 .0 3 3
8 .0 5 4 0 3 .4 3 .8 9 3 .1 8 6 4 4 0 .0 3 3
8 .8 4 4 5 5 .9 5 .4
9 .6 4 5 0 8 .4 7 0 .8 9 8 3 1 -0 .1 2 4
11 2 .5 5 14 .0 -0 .5 8 insuff insuff
2.71 2 2 .0 5 .6 8 .9 9 1 .4 4 1 .1 3 0 .1 9 0
3 .0 5 3 6 .0 0 .6 1 .58 0 .2 8 0
3 .7 6 6 6 .9 0 .9 7 1 .26 0 .2 0 0
5 .2 9 1 3 5 .8 6.1 5 .8 4 4 .1 2 1 .0 4 0 .1 9 0
5 .8 7 1 7 0 .2 5 6 .6 5 7 2 .0 6 0 .4 5 0 .1 2 0
7 .0 5 2 3 5 .8 0 .5 6 4 .2 4 6 1 .3 5 0 .3 8 0 .2 7 0
8 .3 2 3 2 0 .9 6 .5 4 .9 3 96 7 0 .9 6 0 .2 0 0
9 .1 6 3 7 0 .8 3 .2 5 .0 9 7 4 .6 1. 15 0 .3 2 0
9 .8 3 4 0 2 .6 3 .5 5 .3 0 .9 0 .9 3 0 .1 0 0
1 1 .0 0 4 8 3 .8 6 .6 8 2 .9 3 2 2 0.131
1 1 .98 5 5 1 .3 5 .2
1 2 .23 5 7 3 .8 3 .9 5 6 .8 3 0 5 1 0 .0 5 2
12 0 .5 8 0 .0 -0 .9 5 1 9 0 .0 5 0 8 -0 .1 2 8
0 .68 0 .0 5 .2 11 9 .9661 -0 .1 1 0
0 .7 9 0 .0 2 .6 1 0 9 .5 4 2 4 -0 .1 1 3
1 .13 0 .0 6 .9
1 .63 0 .0 6 3 .4 4 0 6 8 -0 .0 9 6
13 9 .8 6 3 6 4 .4 0.2 1 .2 9 1 3 3 .0 9 0 .9 2
11 .42 5 0 2 .4 -0 .0 8 0 .5 5 0 .1 9 0
13 .08 600 .1 4 .9 5 .5 104 .81 0 .8 6 0 .3 5 0
15 .92 740.1 3 .4 8 1.9 83 .01 0 .6 0 0 .1 9 0
17 .19 8 2 8 .6 1 .6 3 1.21 9 4 .0 3 0 .5 8 0 .1 1 0
?0 3 .9 1.41 1 .66 0 .0 8 0
-0 .5 0 .0 1 6
1.3
14 4 .2 6 4 8 .9 3 .1 4 0 .8 8 insuff
4 .5 6 6 1 .4 5 .8 6 .1 2 5 8 .8 1 .22 0 .1 5 0
5.81 1 3 0 .5 4 1 .37 insuff
6 .4 5 172.1 2.1 7 .6 5 0 .5 2 0 .3 7 0
7 .2 3 2 2 9 .5 5 .2 4 .3 8 3 3 .8 3 1 7 8 0 .5 8 0 .2 0 0
8 .0 4 2 8 1 .8 5 .4 7 4 .2 9 9 1 .6 7 0 .1 8 -0 .0 8 0
8 .8 7 349.1 4 .4 4 5 .1 6 7 9 .9 0 .7 7 0 .1 1 0
9 .5 4 3 9 1 .5 3 5 .6 2 66 .71 0.91 0 .2 5 0
1 0 .23 4 3 2 .0 1.3 5 .4 9 2 6 .4 0 .8 9 0 .1 0 0
1 1 .4 7 5 0 5 .5 5 .6 6 2 .3 3 8 9 8 -0 .0 6 7
12 .22 5 5 4 .5 4 .5 8 0 .3 0 5 0 8 -0 .0 6 2
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1 2 .60 5 7 9 .0 4 .4 7 4 .4 5 7 6 3 -0 .0 5 6
15 0 .0 0 0 .0 4 .2
0 .0 6 0 .0 - 1.1 1 0 7 .4 3
0 .5 4 0 .0 1.73 2 .8 4 1 0 8 .9 9 0 .6 8 0
0 .8 4 0 .0 3 .4 2 4 .2 5 528 .51 0 .5 4 0
0 .9 3 0 .0 -0 .22 4.01 16 .19 0 .0 3 0
1 .03 0 .0 2 .4 6 3 .4 7 2 3 5 .41 0 .4 3 0.000
1.52 0 .0 5.1 5 .8 4 4 0 1 .3 3 1.12 0 .2 7 0
1 .9 8 0 .0 5 5 .2 4 2 9 0 0 .8 5 0 .2 2 0
2 .0 4 0 .0 5 .7 3 2 3 3 0 .6 2 -0 .1 3 0
2 .4 7 4 4.11 1 .04 0 .2 0 0
2 .7 9 4 .9 1 4 0 .4 8 0 .0 8 7
3 .1 2 15 .0 4 .9 2 7 0 .0 4 -0 .0 4 7
4 .0 0 4 6 .5 6 .6 6 5 .8 8 0 .0 5 6
4 .7 3 7 2 .0 84 .81 0 .0 8 8
16 0 .0 0 0 .0 -0.2 1 .6 5 2 9 4 .1 9 0 .7 2 0 .1 2 0
0 .0 0 0 .0 -0.1 4 8 0 .8 6 0 .9 4 0.000
0 .0 4 0 .0 1.2 7 .2 3 0 .6 7 0 .2 3 0
0 .2 0 0 .0 -0 .3 5 3.71 1 7 4 .9 0 .6 7 0 .1 1 0
0 .4 4 0 .0 -1 .2 3 6 .6 8 1.27 0 .0 4 0
0.61 0 .0 1.2 9 1 .1 9 -0 .0 2 7
0 .8 0 0 .0 4 .8
1.20 0 .0 8 .3 6 2 5 .4 0 .0 4 4
17 1.80 18 .0 6.1 2 .2 8 14 0 .2 6 0 .8 3 0 .2 0 0
2 .2 8 4 0 .4 1 .3 5 3 .4 1.22 0 .2 8 0
2 .9 7 9 1 .9 8 .6 0 .5 4
3.61 1 4 0 .7 11 .4 4 .3 3 2 0 5 .2 5 0 .4 8 0 .0 4 0
4 .1 6 1 7 6 .7 5 .4 2.21 5 7 .6 5 0 .5 9 0.000
4 .9 8 2 8 4 .2 5 .0 8 3 .9 4 6 0 .3 4 0 .7 9 0 .0 2 0
5 .38 3 4 1 .4 4 .9 5 .0 5 3 2 .9 0 .8 4 0 .0 8 0
6 .3 6 4 4 6 .4 6 .9 1 4 1 .7 7 5 7 0 .5 2 0 .1 0 0
6.91 5 1 1 .4 6 .3 9 2 .2 5 4 2 4 -0 .0 9 3
7 .4 7 5 6 6 .4 6 .6 6 2 .4 2 3 7 3 -0 .0 4 7
7 .6 8 5 8 6 .4 5 .3 6 0 .2 2 0 3 4 -0 .0 5 6
8 .5 8 6 6 5 .4 9 .2
18 7.21 1 1 6 .0 4 .9 5 .2 7 191.81 1 .05 0 .1 20
7 .8 0 3 7 6 .0 2 .5
8 .88 4 3 8 .0 1.27 2 7 2 .1 6 9 5 -0 .0 7 4
10 .67 5 5 3 .0
11.91 6 2 8 .0 5 3 .1 8 6 4 4 -0 .0 9 8
19 9.91 5 0 8 .4 9 .3 8 6 .1 5 2 5 4 0 .0 2 9
11 .06 5 8 3 .0 5 5 .0 5 0 8 5 -0 .0 1 8
20 0 .0 0 0 .0 -0 .3 4 0.91 insuff
Pag© 275 of 278
0 .0 0 0 .0 -0 .6 1 7 .8 8 0 .7 3 0 .1 3
0 .0 0 0 .0 -0 .1 4 1 .23 0 .1 6
0 .0 0 0 .0 2 .8 5 1.41 insuff
0 .0 0 0 .0 0 .7 19 .8 0 .7 2 0 .2 7
0.61 0 .0 2 .2 7 .4 1 3 6 .2 0 .1 8 0 .0 9
0 .9 9 0 .0 -0 .3 3 6 .9 2 2 2 1 .4 0 .4 6 0 .1 2
1.21 0 .0 3 .2 9 7 .0 6 3 0 2 .6 0 .7 2 0.11
1 .90 0 .0 3 .9 5 7 .3 2 1 9 8 .0 0 .7 2 0 .2 0
3 .0 7 3 5 .0 1.8 8.01 2 7 3 .9 1 .03 0 .2 4
4 .2 2 1 0 3 .0 2 .9 6 .2 3 0 .5 7 0 .2 3
5 .2 9 1 6 0 .7 2 .6
5 .5 5 1 7 5 .6 0 .4 3 1 1 9 .2 0 .0 0
5 .8 0 1 9 2 .7 5 .7 3 1 4 .7 0.01
6 .31 2 2 7 .7 7 .2 3 1 2 .3 -0 .0 4
7 .7 5 3 4 0 .4 12 .4 1 6 1 .9 -0 .0 7
21 0 .0 0 0.0 -0.1 1 .1 7 insuff
0 .0 0 0 .0 0 .6 7 .4 4 0 .7 5 0.21
0 .00 0.0 0 .4 2 0 .9 9 0 .1 7
0 .00 0 .0 2 .4
0 .00 0 .0 -0.1 1 1 2 .7 5 2 7 1 .4 0 .7 6 0 .2 4
0 .00 0 .0 0 .2 4 2 9 .4 5 7 0 0 .2 0 .4 2 0 .1 5
0 .00 0 .0 -0 .1 2 2 4 .8 4 8 3 7 .5 0 .4 4 0 .1 5
0 .00 0.0 -1 .1 6 7 .0 7 4 3 .4 0 .5 8 0 .1 6
0 .62 0.0 5 .5 2 5 .5 6 9 1 .8 0 .5 7 0.11
1 .48 0 .0 4 .6 6 .7 1 0 0 .9 0 .7 4 0 .1 6
2 .9 6 0 .0 4 .7 4 9 .3 0 .1 9
3 .96 0 .0 0 .0 3 80.1
4 .6 6 3 5 .0 4 .9 1 2 7 .9 -0 .0 4
5 .9 5 1 5 9 .7 12 .8 10 2 .8 -0.11
22 0 .00 0 .0 -0 .7 15 .9 4 6 0 .2 0 .6 6 0 .1 7
0 .00 0 .0 2 .8 2 3 .5 8 1 3 .7 0 .4 7 0.22
1 .05 0.0 3 6 .4 5 8 8 .9 1 .02 0 .12
3 .97 0 .0 11 .8 5 6 .2 -0 .0 4
23 0 .00 0 .0 4.1 2 3 .4 4 3 4 .7 insuff insuff
0 .00 0 .0 3 .6 2 1 .1 5 4 5 2 .4 0 .22 0 .0 9
1 .26 0.0 2 .7 6 .6 5 8 8 .4 0 .8 5 0 .12
1 .50 0.0 5.1 17 .2 2 4 .0 -0 .12
M ea n 4 .6 3 1 5 9 .3 4 3 .65 8 .6 5 234.41 0 .7 8 0 .08
M ed ian 3 .7 4 4 7 .6 8 3 .98 5 .73 9 8 .4 4 0 .73 0 .0 9
S D 3 .9 9 2 0 1 .2 2 2 .86 1 2 .3 5 5 3 9 .9 4 0 .3 0 0 .1 4
sem 0 .28 1 4 .3 4 0 .20 0 .88 3 8 .4 7 0 .02 0.01
Pag© 276 of 278
0.00 0.0 -0.6 17 .88 0 .7 3 0 .13
0 .00 0.0 -0 .14 1.23 0 .16
0 .00 0.0 2 .8 5 1.41 insuff
0 .00 0.0 0 .7 19 .8 0 .72 0 .27
0.61 0.0 2.2 7 .4 136.2 0 .18 0 .09
0 .99 0 .0 -0 .33 6 .9 2 2 2 1 .4 0 .4 6 0.12
1.21 0.0 3 .29 7 .0 6 30 2 .6 0 .7 2 0.11
1.90 0 .0 3 .95 7 .32 198.0 0 .7 2 0.20
3 .07 35 .0 1.8 8.01 2 7 3 .9 1.03 0 .24
4 .2 2 10 3 .0 2 .9 6 .2 3 0 .5 7 0 .23
5 .29 160 .7 2.6
5 .55 17 5 .6 0 .43 119 .2 0 .00
5 .80 19 2 .7 5.7 31 4 .7 0.01
6.31 2 2 7 .7 7 .2 31 2 .3 -0 .04
7 .7 5 34 0 .4 12 .4 161 .9 -0 .0 7
21 0 .00 0.0 -0.1 1.17 insuff
0 .00 0.0 0.6 7 .4 4 0 .7 5 0.21
0.00 0.0 0 .42 0 .99 0 .17
0.00 0.0 2 .4
0.00 0.0 -0.1 112 .75 27 1 .4 0 .76 0 .24
0.00 0.0 0 .24 2 9 .4 5 70 0 .2 0 .42 0 .1 5
0.00 0.0 -0 .12 2 4 .8 4 83 7 .5 0.44 0 .1 5
0.00 0.0 -1 .1 6 7 .07 43 .4 0 .58 0 .16
0.62 0 .0 5 .52 5 .56 91 .8 0 .57 0.11
1.48 0.0 4 .6 6 .7 100 .9 0 .7 4 0 .1 6
2 .96 0.0 4 .7 4 9 .3 0 .1 9
3 .96 0.0 0 .03 80.1
4 .66 35 .0 4 .9 127 .9 -0 .04
5.95 159.7 12.8 102 .8 -0.11
22 0.00 0.0 -0 .7 15 .9 4 6 0 .2 0.66 0.17
0.00 0.0 2.8 23 .5 81 3 .7 0 .47 0.22
1.05 0.0 3 6 .4 5 88 .9 1.02 0.12
3.97 0.0 11.8 56 .2 -0 .04
2 3 0.00 0.0 4.1 23 .4 4 3 4 .7 insuff insuff
0 .00 0.0 3 .6 2 1 .1 5 4 5 2 .4 0 .22 0 .09
1.26 0.0 2 .7 6 .6 5 8 8 .4 0 .85 0.12
1.50 0.0 5.1 17 .2 24 .0 -0 .12
M ean 4 .6 3 1 5 9 .34 3 .6 5 8 .65 234.41 0 .78 0 .08
M edian 3.74 4 7 .6 8 3 .98 5 .73 9 8 .44 0 .73 0 .09
SD 3.99 201 .22 2 .86 12 .35 5 3 9 .9 4 0 .30 0 .14
sem 0.28 14 .34 0.20 0 .88 38 .47 0 .02 0.01
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All NTCK patients
Iro n  load d fo  g ra m s N T B P I E p o
Sol
transferrin
rcptr
mda carbonyls
1 1.66 9 5 .0 7.81 2 7 5 8 .4 7 .9 7 0 .0 3 0 .2 5
3 .3 4 1 9 6 .0 4 .9 0 0 .5 2 1 .5 6
3 .8 0 2 1 4 .0 1 .30 0 .0 0 0 .7 4
2 1 .9 0 3 0 .0 6 .9 9 5 0 1 .3 1 5 .52 0 .2 3 0 .4 8
3 1 .07 11 .5 8 .3 6 4 6 1 .3 5 .1 3 0 .1 4 1 .92
2 .6 4 5 9 .0 3 .8 0 4 1 0 .9 0 .3 9 0 .8 9
4 1 .07 2 4 .0 6 .31 5 2 4 .2 6 .6 8 0 .2 9 0 .1 9
2 .4 9 9 1 .5 1 2 2 9 .4
2 .9 4 1 .3 3 0 .2 8 0 .5 9
4.31
5 0.71 0 .0 6 .8 2 1 0 0 7 .0 0 .2 5 0 .0 5
1 .07 2 4 .0 1 .5 0 4 1 5 .4 4 .2 9 0 .0 7 0 .5 8
1 .67 2 .7 0 2 4 3 .3 0.51 0 .9 4
2 .0 8 0 .6 9 2 5 .4 0 .2 3 0 .7 0
6 1 .16 0 .0 2 .1 3 5 7 0 5 .4 2 3 .4 4 0 .22 0 .2 5
1.66 0 .0 -0 .61 6 3 8 .3 2 1 .9 2 0 .0 3 0 .3 9
2 .5 3 4 .5 2 .6 0 4 3 6 9 .0 0 .4 4 0 .6 3
2 .9 8
7 0 .2 5 8 .6 5 4 3 4 6 .5 2 5 .2 4 0 .3 6 0.31
0.31 4 .5 4 6 1 8 .8 1 4 .92 0 .0 3 0 .9 2
0 .4 9 3 .4 0 2 2 0 .9 0 .5 5 1 .18
0 .6 2 1 .26 1 3 1 .4 0 .5 5 0 .9 5
8 2 .9 8 4 2 .5 12 .16 4 8 6 .9 8 .0 7 0 .0 6 0.51
2 .5 7 7 .4 0 60 5 .1 1 .8 4  ^ 0 .9 4
9 0.81 1 0 .04 5 3 1 .5 8 .0 9 0.21
10 0.41 1.61 3 6 8 0 .8 32 0 .0 5
0.71 - 1 .00 1 6 3 3 .2 1 4 .32 -0 .0 2 0 .2 7
1 .59 4 .7 0 6 9 3 .4 8 .3 0 .3 6 1 .07
2 .2 5 2 .0
10.61 2 3 9 .0
11 0.41 1.71 5 0 7 .2 14 .2 0 .2 6
0.41 0 .3 0 7 0 2 .3
12 1 .32 3 6 .5 -0 .2 5 4 4 .2 0 .2 6 1.01
13 0 .2 0 4 .8 6 5 4 7 .2 0 .1 0 0 .1 0
0 .6 0 1 0 1 8 .5 0.21 0 .7 7
0 .7 6 0 .8 7 0 .0 0 0 .9 0
14 2 15 9 3 .0 6 .8 0 5 0 4 5 .6 1 9 .92 0 .2 5 0 .1 3
3 22 1 1 5 .5 0 .6 5 1 1 8 .8 3 .0 2 0 .0 7 0 .5 9
4 .1 3 1 3 7 .5 3 .5 0 9 7 9 .0 0 .5 9 1 .30
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5 .25 169.0 1.52 170.7 0.48 0 .70
7 .1 8 23 4 .5 6 .3 0
15 0 .32 6.81 4 5 9 .3 5 .83 0.22 0.36
1.04 3 .20 51 .9 0 .84
1.44 8.0 1.93 95 .9 0 .46 0.66
16 4 .0 2 167.5 3 .68 4 9 1 .6 4 .0 7 0.21 0 .59
6.66 29 5 .5 1.82 0 .35 0 .63
17 3 .7 6 159.5 1 .39 -
5.43 26 8 .0 3 .70 44.1 0 .53 1.18
5 .8 9 30 5 .5 3.91 22 5 4 .9 0 .26 0 .47
18 5 .85 2 1 7 .0 2 .69 -
7 .0 7 36 7 .0 2 .6 0 23 8 .0 0 .77 1.36
7 .0 7 38 5 .0 4 .0 6
19 0 .3 6 1.61 82 0 .7 13 .76 0.20 0.75
0.91 3 .30 18 .2 0 .3 3 1.22
20 3 .2 5 36 .5 1653 .6 2 .0 6
21 1.83 91 .0 7 .40 2 7 0 3 .9 1 .19
22 0.20 0.62 2 1 .7 2 0 .29 0 .99
23 0.00 - 96 .9 0 .83
24 1.27 5 .40 146.4 0.41
25 1.12 -0 .32 19 .3 0 .53
26 1.83 4 .6 0 34 6 6 .5 1.57
27 0.00 0 .14 2 8 2 .5
M ean 2.38 124.8 3 .5 9 6 1 1 6 1 1 0 8 .6 4 6 13 .25762 0 .40 0 .7 348 03
M edian 1.67 93 .0 3 .25 51 5 .73 13 .76 0 .27 0 .6 968 65
S D 2.22 115.0 2 .9 2 9 6 1 4 1 4 45 .8 48 8 .1 8 5 3 7 4 0.43 0 .4 0 9 5 1 4
S E M 0 .2 7 14.2 0.360611 1 7 7 .9 7 1 5 1 .00755 0 .05 0 .050408
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